WO2017095428A1

WO2017095428A1 - Modulators of activin and methods for modulating immune responses and t follicular helper cells

Info

Publication number: WO2017095428A1
Application number: PCT/US2015/063827
Authority: WO
Inventors: Andrew Todd MILLER; Shane Crotty; Michela LOCCI
Original assignee: Novartis AG; La Jolla Institute for Allergy and Immunology
Current assignee: Novartis AG; La Jolla Institute for Allergy and Immunology
Priority date: 2014-12-02
Filing date: 2015-12-03
Publication date: 2017-06-08
Anticipated expiration: 2018-06-02
Also published as: WO2016090035A3; WO2016090035A2; US20180111991A1

Abstract

The invention provides methods and uses for stimulating, inducing, increasing or enhancing Tfh (follicular helper) cell differentiation, germinal center B cell development or an antibody response, and an immune response by administering activin or a subsequence thereof, or an activator of activin receptor, in an amount effective to stimulate, induce, increase or enhance Tfh (follicular helper) cell differentiation, germinal center B cell development or an antibody response, and an immune response, respectively. Also provided are peptides comprising or consisting of a subsequence of human activin sequence, in which the activin sequence or subsequence stimulates, induces, increases or enhances development of Tfh (follicular helper) cell differentiation, germinal center B cell development, an antibody response, an immune response and/or an immune response induced by a vaccine.

Description

MODULATORS OF ACTIVIN AND METHODS FOR MODULATING IMMUNE RESPONSES AND T FOLLICULAR HELPER CELLS

[0001] This invention was made with government support under contract/grant number UM1-AI100663 awarded by NIH. The government has certain rights in the invention.

BACKGROUND

[0002] Follicular helper T cells (Tfh) are the specialized providers of T cell help to B cells, and are essential for germinal centers, affinity maturation, and the development of most high affinity antibodies and memory B cells. Because of their important role regulating B cells and antibody responses, Tfh appear to be critical components of many protective immune responses against pathogens, as well as being positively associated with protective responses against multiple cancers. As such, there is strong interest in harnessing Tfh cell biology to enhance new vaccines. Tfh cell responses also are major components of a number of autoimmune diseases associated with autoantibody responses.

BRIEF SUMMARY OF THE INVENTION

[0003] The invention is based at least in part on our finding that modulation of activin (activin A, activin AB or activin B), which is able to modulate various immune responses (e.g., stimulate induce, increase or enhance, or inhibit, decrease or reduce an immune response). For example activin can stimulate, induce, increase or enhance an immune response. Activin can also stimulate, induce, increase, or enhance Tfh (follicular helper) cell differentiation, germinal center B cell development or an antibody response. Therefore, provided are activators of activin A for use in methods to enhance Tfh and thereby improve vaccines against pathogens, or improve cancer immunotherapy. Additionally, we have found that inhibitors of activin can inhibit or reduce immune responses, such as inflammatory and autoimmune responses and inflammation. Thus provided are methods for blocking activin activity with inhibitors for treatments of autoimmune diseases that have a Tfh component, such as, for example, lupus, Sjogrens Syndrome, rheumatoid arthritis, and others.

[0004] In certain embodiments, the invention provides for a method for stimulating, inducing, increasing or enhancing Tfh (follicular helper) cell differentiation comprising contacting a cell with activin or a subsequence thereof or an activator of activin Receptor effective to stimulate, induce, increase or enhance Tfh (follicular helper) cell differentiation. In additional embodiments, the invention provides for a method for stimulating, inducing, increasing or enhancing Tfh (follicular helper) cell differentiation, germinal center B cell development or an antibody response, comprising administering activin or a subsequence thereof or an activator of activin receptor to a subject in amount effective to stimulate induce, increase or enhance Tfh (follicular helper) cell differentiation, germinal center B cell development or an antibody response in the subject. In further embodiments, the invention provides for a method for stimulating, inducing, increasing or enhancing an immune response, comprising administering activin or a subsequence thereof or an activator of activin receptor to a subject in an amount effective to stimulate, induce, increase or enhance an immune response in the subject. In still further embodiments, the invention provides for a method for stimulating or increasing an immune response induced by a vaccine, comprising administering activin or a subsequence thereof or an activator of activin receptor to a subject in an amount effective to stimulate, induce or increase an immune response induced by the vaccine in the subject. In particular aspects, the immune response comprises a cell-mediated or humoral immune response. In additional aspects, the immune response stimulated, induced or increased is against a bacterial, viral, fungal or parasite pathogen. In further aspects, the immune response stimulated, induced or increased is against cancer. In additional aspects, the vaccine comprises a bacterial, viral, fungal, parasite or cancer antigen. In additional aspects, the vaccine is administered prior to, during or following administration of an activator of activin receptor or activin or subsequence thereof. In further aspects, the subject is immunosuppressed or immunocompromised or has an immunodeficiency syndrome.

[0005] In additional embodiments, the invention provides a method for vaccinating a subject against a pathogen or cancer, comprising administering activin or a subsequence thereof or an activator of activin receptor and a pathogen or pathogen antigen or cancer antigen to a subject in an amount effective to vaccinate the subject against the pathogen or cancer. In particular aspects, the pathogen comprises a bacterial, viral, fungal or parasite pathogen. In additional aspects, the method provides the subject with protection against one or more physiological conditions, disorders, illness, diseases or symptoms caused by or associated with pathogen infection or pathology or cancer. In further aspects, the activator of activin or a subsequence thereof, or activin receptor is administered prior to, substantially contemporaneously with or following administration of the subject with the pathogen or pathogen antigen or cancer antigen. In additional aspects, the activator of activin or a subsequence thereof, or activin receptor is administered within 2-72 hours, 2-48 hours, 4-24 hours, 4-18 hours, or 6-12 hours of administration of the subject with the pathogen or pathogen antigen or cancer antigen.

[0006] In additional embodiments, the invention provides for a method for inhibiting, decreasing or reducing Tfh (follicular helper) cell differentiation, germinal center B cell development or an antibody response, comprising administering an inhibitor of activin or activin receptor to a subject in an amount effective to inhibit, decrease or reduce Tfh (follicular helper) cell differentiation, germinal center B cell development or an antibody response in the subject. In further aspects, the invention provides for a method for inhibiting or reducing an undesirable or aberrant immune response, comprising administering an inhibitor of activin or activin receptor to a subject in an amount effective to inhibit or reduce an undesirable or aberrant immune response in the subject. In further embodiments, the invention provides a method for inhibiting or reducing an undesirable or aberrant inflammatory response or inflammation, comprising administering an inhibitor of activin or activin receptor to a subject in an amount effective to inhibit or reduce an undesirable or aberrant inflammatory response or inflammation in the subject. In particular aspects, the inhibitor binds to activin or activin receptor. In further aspects, the inhibitor comprises FoUistatin. In additional aspects, the inhibitor comprises an antibody or a fragment thereof that binds to activin or activin receptor, or an antisense nucleic acid sequence of activin or activin receptor. In further aspects, the antibody or fragment thereof comprises an Fab, Fab', F(ab')₂, Fv, Fd, single-chain Fv (scFv), disulfide-linked Fvs (sdFv), V, VH, trispecific (Fab₃), bispecific (Fab₂), diabody ((V_L-V_H)₂ or (V_H-V_L)₂), triabody (trivalent), tetrabody (tetravalent), minibody ((scF_v -C_H3)₂), bispecific single-chain Fv (Bis-scFv), IgGdeltaCH2, scFv-Fc or (scFv)₂-Fc fragment. In additional aspects, the antibody is human or humanized. In further aspects, the antibody comprises one or more of M244B, M248, LS Bio LS- C195902, R&D Systems Clone 132815, R&D Systems Clone 69403, R&D Systems AF338, Novus Biologicals MM0074-7L18, GeneTex 7L18, or Ray Biotech ACVR1B. In further aspects, the antisense binds to a nucleic acid encoding a mammalian activin or activin receptor. In further aspects, the antisense binds to a nucleic acid encoding a human activin or activin receptor. In additional aspects, the antisense binds to a nucleic acid encoding all or a portion of a human activin sequence. In further aspects, the antisense binds to a nucleic acid encoding all or a portion of a human activin receptor sequence. In additional aspects, the undesirable or aberrant immune response or undesirable or aberrant inflammatory response or inflammation is acute or chronic. In additional aspects, the undesirable or aberrant immune response or undesirable or aberrant inflammatory response or inflammation comprises an autoimmune disease. In further aspects, the autoimmune disease comprises: rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, diabetes mellitus, multiple sclerosis, encephalomyelitis, myasthenia gravis, systemic lupus erythematosus (SLE), autoimmune thyroiditis, atopic dermatitis, eczematous dermatitis, psoriasis, Sjogren's Syndrome, Crohn's disease, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis, asthma, allergic asthma, cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis, erythema nodosum leprosum, autoimmune uveitis, allergic encephalomyelitis, acute necrotizing hemorrhagic encephalopathy, idiopathic bilateral progressive sensorineural hearing loss, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome, idiopathic sprue, lichen planus, Graves' disease, sarcoidosis, primary biliary cirrhosis, uveitis posterior, interstitial lung fibrosis, Hashimoto's thyroiditis, autoimmune polyglandular syndrome, insulin-dependent diabetes mellitus, insulin-resistant diabetes mellitus, immune-mediated infertility, autoimmune Addison's disease, pemphigus vulgaris, pemphigus foliaceus, dermatitis herpetiformis, autoimmune alopecia, Vitiligo, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, pernicious anemia, Guillain-Barre syndrome, acute rheumatic fever, sympathetic ophthalmia, Goodpasture's syndrome, systemic necrotizing vasculitis, antiphospholipid syndrome or an allergy. In further aspects, the undesirable or aberrant immune response or undesirable or aberrant inflammatory response or inflammation comprises a cell mediated or humoral immune response. In additional aspects, production or one or more antibodies is reduced, decreased, inhibited or suppressed. In particular aspects, the subject is a mammal. In further aspects, the subject is a human. In additional aspects, the activin inhibitor binds to a mammalian activin or activin receptor. In additional aspects, the activin inhibitor binds to a human activin or activin receptor sequence. In further aspects, the activin comprises a dimer comprising two polypeptides each selected from inhibin-βΑ or inhibin-βΒ. In additional aspects, the activin is mammalian. In further aspects, the activin is human. In additional aspects, the activin comprises all or a portion of a human activin sequence. In further aspects, the activin receptor comprises one of ActRIIA or ActRIIB. In additional aspects, the activin receptor further comprises one of ALK2 or ALK4.

[0007] In additional embodiments of the present invention, the invention provides a peptide comprising or consisting of a subsequence of human activin sequence wherein the subsequence stimulates, induces, increases or enhances development of Tfh (follicular helper) cell differentiation, germinal center B cell development, an antibody response, an immune response or an immune response induced by a vaccine. In particular aspects, the polypeptide is isolated or purified. In additional aspects, the subsequence is from about 5 to 425 amino acids in length provided that the subsequence is at least one amino acid less in length than the full length activin sequence. In additional aspects, the subsequence is from 5 to 15, 20 to 25, 25 to 50, 50 to 100, 100 to 150, 150 to 200, 200 to 300 or 300 to 425 amino acids in length provided that the subsequence or portion is at least one amino acid less in length than a full length activin sequence.

[0008] In additional embodiments, the invention provides a pharmaceutical composition comprising the peptide of the above embodiments. In particular aspects, the composition is a vaccine. In additional aspects, the composition further comprises an adjuvant.

BRIEF DESCRIPTION OF THE DRAWINGS

[0009] Figure 1A-D: Inhibin beta A (INHBA) emerged from the screen as potent regulator of human Tfh differentiation. (A) Schematic of primary screen. Purified human naive CD4 T cells from a leukapheresis donor were stimulated by anti-CD3/CD28 beads on 384 well plates on day 0. The GNF secretomics recombinant proteins were added at the beginning of the stimulation. Each secretomics protein was tested in duplicate. After 5 days of in vitro culture, cells were evaluated by automated FACS analysis for the expression of Tfh signature markers, including CXCR5 and PD-1. (B) Primary screen results. Relative enrichment of PD-1⁺CXCR5⁺ cell induction is reported as Z score for each recombinant protein. INHBA gene product is shown in red.(C) CXCR5 and PD-1 expression from repeat experiment in which INHBA gene product was tested again for its capacity to induce Tfh-like differentiation. (D) Confocal microscopy of INHBA expression in human tonsils. Tonsil sections were stained with anti-INHBA (red) anti-BCL6 (blue) and anti-CD3 (green) Abs. An overlay from one donor representative of six is shown on the left panel. Enlarged images on the right panels are representative INHBA expression on (I) germinal center, (II) T-B border and (III) T cell areas.

[0010] Figure 2A-0: Activin A plays a synergic role with IL-12 and molds the human Tfh gene program. (A-B) Bead purified naive CD4 T cells from multiple healthy subjects were stimulated by anti CD3/CD28 beads on 96 well plates, in the presence of commercial human recombinant activin A, with or without IL-12. PD-1 and CXCR5 expression was analyzed after 5 days by FACS. A representative donor is shown in (A). Data from 12 donors from 6 independent experiments are shown in (B). The dotted line shows the average basal induction of PD-1⁺CXCR5⁺ cells induced by beads from 13 donors. (C) The expression of PD-1 and CXCR5 was monitored by flow cytometry at 0, 1, 2, 3, 5, 7 and 10 days on live cells following in vitro differentiation. Data from one experiment representative of two are depicted (n=3). (D) Cells were cultured in vitro with different doses of activin A combined with a fixed amount of IL-12 for 5 days in the presence of anti-activin A mAb MOR8806 (block) or isotype control mAb (isotype). Graphs show mean and SEM from 3 independent experiments (n=8). Dotted lines indicate the average percentages of PD- 1⁺CXCR5⁺ cells induced by IL-12 with isotype control mAb from 8 donors. (E) CCR7 MFI on day 5 in vitro differentiated cells. The graph shows mean and SEM of 8 donors from 4 independent experiments. * p<0.05, ** p<0.01 (F) BCL6 intranuclear expression was measured by FACS on day 5 of the in vitro culture. Data are cumulative of 3 experiments (n=7). * p<0.05 (G-I) Gene Set Enrichment Analysis (GSEA) showing enrichment of tonsil GC Tfh signature genes (done from previously publish tonsil gene expression data) in genes upregulated by activin A + IL-12 cultured cells in comparison to beads only (G), IL-12 (H) or activin A only (I) stimulated cells. (J) RNA-seq analysis on day 3 in vitro differentiated cells. The "Volcano" plots show the absolute gene expression data set (RPKM) from cells differentiated with activin A and IL-12 versus cells differentiated with beads only. Genes up and downregulated in cells differentiated with activin A and IL-12 versus beads only are represented in red and blue, respectively (red, activin A + IL-12 versus beads > 2; blue, activin A + IL-12 versus beads < -2). (K) Heat- map showing absolute expression (RPKM) of selected Tfh signature genes on cells differentiated with beads only, IL-12, activin A or activin A + IL12. (L and N) Relative expression (2^A-ACt) of LIF and PRDM1 was determined by qPCR. (M and O) SLAMF1 and ΙΤΟβ7 expression by flow cytometry. In (L) to (O) all the data were obtained from day 3 in vitro differentiated cells and are from at least 3 or more independent experiments (n=9 or higher). Bars show mean and SEM. * p<0.05, ** p<0.01 and *** p<0.001.

[0011 ] Figure 3A-E: CD4 T cells differentiated with activin A and IL-12 acquire functional signature molecules of Tfh cells. (A) Naive CD4 T cells from 9 donors were stimulated by plate bound anti-CD3 mAb and hrlCOS-L chimera for 5 days. CXCL13 released in the supernatant was determined by ELISA. Data are individual values, mean and SEM from 3 independent experiments (n=9). ** p<0.01 (B) Day 5 in vitro differentiated cells were stimulated with PMA/Ionomycin and the intracellular expression of CD40L and IL-21 was measured by FACS. One representative donor is depicted. The graph on the right shows individual data, mean and SEM from 3 independent experiments (n=7 donors). * p<0.05. (C) Day 3 differentiated cells were stimulated with PMA/Ionomycin to test intracellular expression of TNF-oc and LT-oc by FACS. One representative donor is shown. (D) Quantification of (C). * p<0.05, ** p<0.01 and *** p<0.001.(E) Day 3 in vitro differentiated CD4 T cells were cocultured with fresh autologous memory B cells in the presence of SEB for 7 days. B cells (CD19+ live cells) and plasmablast (CD19⁺CD20^loCD38⁺ cells) were analyzed by flow cytometry. IgG released in the culture supernatants were measured by ELISA. In all graphs n=8. Data are cumulative from 4 experiments. Mean and SEM are shown. Statistical significance was evaluated by one-tailed Wilcoxon matched-pairs signed ranked test. * p<0.05 and ** p<0.01.

[0012] Figure 4A-I: Activin A and TGF act independently from each other to drive in vitro Tfh differentiation. (A-B) RNAseq data from day 3 differentiated cells. (A) Absolute expression (RPKM) values in cells differentiated with TGF + IL-12 and activin A + IL-12. (B) "Volcano" plots showing genes differentially regulated in cells differentiated with activin A + IL-12 versus beads only condition. Genes upregulated in cells differentiated with TGF + IL-12 (TGF + IL-12 versus beads, fold change > 2) are shown in red, while genes downregulated in TGF +IL-12 (TGF +IL-12 versus beads, FC <-2) are depicted in blue. (C) Day 5 in vitro differentiation with TGF , alone or with IL-12, in the presence of anti-activin A mAb or isotype control mAb (n=8, 3 independent experiments). (D-E) TGF was blocked by anti-TGF mAb in cells cultured in vitro with TGF and TGF +IL-12 (D) or activin A and activin A + IL-12 (E). (F) Representative PD-1 and CXCR5 expression after 5 days of in vitro culture. (G) Quantification of (F). Data are from 3 independent experiments (n=6). (H-I) FoxP3 induction in day 5 in vitro differentiated cells was determined by FACS. Data are cumulative from 4 experiments. In (D), (G) and (H), * p<0.05, ** p<0.01 and *** p<0.001.

[0013] Figure 5A-C: IL-2 antagonizes activin A driven Tfh cell differentiation. (A-

C) Day 5 in vitro differentiation with anti-IL-2 blocking mAbs, or isotype controls. PD-1 and CXCR5 expression were measured by FACS. Data are cumulative from 3 independent experiments (n=10). ** p<0.01

[0014] Figure 6A-D: The role of activin A in Tfh differentiation is conserved for non-human primate CD4 T cells, but not mouse CD4 T cell. (A-B) Splenic naive CD4 T cells from BALB/c or C57BL/6 mice were cultured in vitro for 5 days with IL-12, activin A, activin A and IL12 or medium only, in the presence of plate-bound anti-CD3 and anti-CD28 mAbs. PD-1 and CXCR5 expression from one representative mouse samples are shown in (A). Data from 4 or more independent experiments were combined in (B) as mean and SEM. (C-D) Day 5 in vitro differentiation of FACS sorted naive CD4 T cells (live CD4⁺CD45RA⁺CD95^~CD28⁺CCR7⁺ cells) from rhesus macaque PBMCs. Cells were activated by plate bound anti-CD3 and anti-CD28 mAbs in the presence of human recombinant proteins. (C) Representative PD-1 and CXCR5 expression. (D) is the quantification of (C). Data are from 5 independent experiments (n=7). * p<0.05.

[0015] Figure 7A-G: Activin A activity is mediated by SMAD2/3 pathway. (A-B) Expression of phosphorylated-SMAD2/3 (P-SMAD) by human naive CD4 T cells (CD4⁺C45RA⁺) was measured by flow cytometry following stimulation with activin A (red), activin A + SB 431542 (blue) and in unstimulated cells (grey). (A) P-SMAD expression on one representative donor at 1 hour following stimulation (B) Data are cumulative from 3 independent experiments (n=8). ** p<0.01. (C-D) Human naive CD4 T cells were differentiated for 5 days in the presence of SB 431542 or vehicle (DMSO). (C) Representative PD-1 and CXCR5 expression following 5 days culture with vehicle or SB 431542 (50μΜ) is shown. (D) Data are from 4 independent experiments (n=6 or more). * p<0.05 and ** p<0.01.(E) Naive CD4 T cells were culture for 5 days with activin A + IL-12 in the presence of Galunisertib or vehicle (DMSO). The graph shows combined data from 3 independent experiments (n=6). * p<0.05(F-G) P-SMAD expression from tonsillar naive CD4 T cells (CD4⁺CD45RO-), mTfh (CD4⁺CD45RO⁺PD-l^intCXCR5^int) and GC Tfh cells (CD4⁺CD45RO⁺PD-l^hiCXCR5^hi) following stimulation with activin A (red), activin A + Galunisertib (blue) and in unstimulated cells (grey). (A) P-SMAD expression on one representative donor at 1 hour following stimulation (B) Data are cumulative from 3 independent experiments (n=6).

[0016] Figure 8A-D: Activin A promotes the differentiation of human Tfh cells.

Human naive CD4 T cells were stimulated with anti CD3/CD28 coated beads alone (or in combination with human recombinant IL-12, activin A or both cytokines. The induction of PD-1+CXCR5+ Tfh-like cells was measured by flow cytometry. A representative donor is shown. It was found that activin A alone was able to drive a massive PD-1 induction and some CXCR5 expression. Moreover, in combination with IL-12, activin A caused a dramatic increase in the coexpression of PD-1 and CXCR5, a feature of bona fide Tfh cells. B. Titration of recombinant activin A, with or without recombinant IL-12, and its effect on the induction of PD-1+CXCR5+ cells. Data are mean and SEM from 4 independent experiments. C. Induction of Bcl6 protein expression was measured by FACS intranuclear staining. The percentage of Bcl6 expressing cells from 7 donors is shown. D. The downregulation of CCR7 induced by activin A was measured by FACS as CCR7 Mean Fluorescence Intensity (MFI). The graph displays mean and SEM from 8 donors.

[0017] Figure 9. Human naive CD4 T cells were stimulated with anti CD3/CD28 coated beads and titration of recombinant activin A with or without 11-2, and its effect on the induction of PD1+CXCR5+ cells was measured by flow cytometry. It was found that activin A has a synergistic effect with IL-12.

[0018] Figure 10. Titration of recombinant activin A, with or without recombinant IL- 12,and its effect on the induction of CCR7+CXCR5+ cells was measured by flow cytometry. The effect of recombinant TGF with or without recombinant IL-12 was also measured. It was found that both activin A and TGF influence CCR7 downregulation.

[0019] Figure 11. Titration of recombinant activin A, with or without recombinant IL- 12, and its effect on the induction of BC16+CXCR5+ cells was measured by flow cytometry. The effect of recombinant TGF with or without recombinant IL-12 was also measured. No detectable induction of Bcl6 was found.

[0020] Figure 12. Blocking of activin activity by various activin inhibitors including follistatin and anti-activin antibodies was tested. FACS analysis

[0021] Figure 13. To determine if activin A was responsible for the TGF induced Tfh- like phenotype, human naive CD4 T cells were stimulated with anti CD3/CD28 coated beads in combination with TGF , IL-12 and an anti-activin A blocking antibody. The induction of Tfh-like cells was measured by flow cytometry. (A) activin was found to be potently inhibited by blocking a blocking antibody. (B) It was found that the anti-activin A antibody alone did not affect TGFP activity.

[0022] Figure 14. To determine if TGFP was responsible for the activin A induced Tfh- like phenotype, human naive CD4 T cells were stimulated with anti CD3/CD28 coated beads and combinations of activin A, IL-12 and/or an anti-TGFP blocking antibody. The induction of Tfh-like cells was measured by flow cytometry. It was found that the anti-TGFP Ab neutralizes hrTGFp at 1 ng/ml but does not significantly affect the activin A induced phenotype.

[0023] Figure 15. The synergies between different interleukins and TGFP or activin A were examined by measuring the induction of CXCR5+ cells or CXCR5+PD1+ cells by flow cytometry. It was found that: (1) IL-27 does not act in synergy with TGFP or activin A, (2) IL-23 synergizes with TGFP or activin A but less potently than IL-12 (3) IL-35 does not synergize with TGFP or activin.

[0024] Figure 16. The IL-21 production of Tfh cells in vitro was determined after stimulating cells with plate bound anti-CD3 and CD28 and either activin A, with or without IL-12, TGFP with or without IL-12 or IL-12 alone.

[0025] Figure 17. The CXCL13 production of Tfh cells in vitro was determined after simulating cells with plate bound anti-CD3 and recombinant ICOS ligand and either activin A, with or without IL-12, TGFP with or without IL-12 or IL-12 alone.

[0026] Figure 18A-B: Activin A is responsible for induction of the Tfh signature markers CXCR5 and PD-1. Fig. 18A shows flow cytometry analysis of bead purified naive CD4 T cells from a representative healthy donor subject that were stimulated by dynabeads on 96 well plates, in the presence of commercial human recombinant activin A, with IL-12 ("activin A + IL-12") or without IL-12 ("activin A") as indicated at the top of each panel. PD-1 (y-axis) and CXCR5 (x-axis) expression were analyzed after 5 days by FACS. Results were similar for multiple healthy donors (data not shown). Fig. 18B shows the percentage of naive CD4 T cells from 6 donors that were differentiated (PD1⁺ CXCR5⁺ double positive cells) with activin A and IL-12, or IL-12 only (horizontal dotted line, average value), in the presence of anti-ACVR2 pan mAb MOR8806 (labelled as CDD861 in the figure), or isotype control mAb (Isotype). Data are cumulative of 2 experiments.

DETAILED DESCRIPTION OF THE INVENTION

[0027] The invention is based at least in part on our finding that activin (e.g., activin A, activin AB or activin B), is able to modulate various immune responses (e.g., stimulate, induce, increase or enhance, or inhibit, decrease or reduce an immune response). Activin has been found to have roles in cell proliferation, differentiation, apoptosis, metabolism, homeostasis, immune response, wound repair and endocrine function. Activin is a dimer composed of two identical or very similar beta subunits expressed by the Inhibin beta gene. Activin can comprise two subunits of beta-A (activin A), two subunits of beta-B (activin B) or one subunit of beta-A and one subunit of beta-B (activin AB). Activin receptor comes in two types activin type 1 receptor and activin type 2 receptor. Activin binds to the type 2 receptor and initiates a cascade reaction that leads to the recruitment, phosphorylation and activation of type 1 receptor, which then phosphorylates SMAD2 and SMAD3.

[0028] For example, activin can stimulate, induce, increase or enhance an immune response. Activin can also stimulate, induce, increase or enhance Tfh (follicular helper) cell differentiation, germinal center B cell development or an antibody response. Activin can furthermore stimulate, induce, increase or enhance an immune response, for example, a response induced by a vaccine. Accordingly, activin and activators of activin receptor are useful for and the invention provides, among other things, methods for stimulating, inducing or increasing an immune response, such as an immune response induced by a vaccine. In respective embodiments, a method includes administering activin or an activator of activin receptor to a subject in an amount effective to stimulate, induce, increase or enhance an immune response in the subject, administering activin or an activator of activin receptor to a subject in an amount effective to stimulate, induce, increase or enhance Tfh (follicular helper) cell differentiation, germinal center B cell development and/or an antibody response, and administering activin or an activator of activin receptor to a subject in an amount effective to stimulate, induce, increase or enhance an immune response, such as a response induced by the vaccine in the subject.

[0029] Inhibitors of activin receptor can inhibit, decrease and/or reduce Tfh (follicular helper) cell differentiation, germinal center B cell development and/or an antibody response. Inhibitors of activin receptor can furthermore inhibit, decrease and/or reduce an undesirable or aberrant immune response. Activin receptor inhibitors can additionally inhibit, decrease and/or reduce an undesirable or aberrant inflammatory response or inflammation in the subject. Accordingly, activin receptor inhibitors are useful for and the invention provides, among other things, methods for inhibiting, decreasing and/or reducing such cell differentiation, germinal center B cell development, antibody response(s), undesirable and aberrant immune response(s), and undesirable and aberrant inflammatory response(s) and inflammation. In respective embodiments, a method includes administering an inhibitor of activin receptor to a subject in an amount effective to inhibit, decrease and/or reduce Tfh (follicular helper) cell differentiation, germinal center B cell development or an antibody response in the subject, administering an inhibitor of activin receptor to a subject in an amount effective to inhibit, decrease and/or reduce an undesirable or aberrant immune response in the subject, and administering an inhibitor of activin receptor to a subject in an amount effective to inhibit, decrease and/or reduce method for inhibiting or reducing an undesirable or aberrant inflammatory response or inflammation in the subject.

[0030] Inhibitors and activators of activin receptor "modulate" activin activity, function or expression. Modulate can mean any increase, stimulation, promotion, or enhancement, or decrease, reduction, inhibition, or prevention, in activin activity, function or expression. For example, modulating an immune response means that activity or function or an effect is that the immune response is detectably changed, e.g., an increase, stimulation, promotion, or enhancement, or decrease, reduction, inhibition, or prevention, of any immune function, such as inflammation, humoral or cell mediated immunity, activity, function or numbers of T and B cells, cytokine or chemokine production, antibody production, mitogen responsiveness, or symptoms thereof, which can be measured by a variety of methods disclosed herein or known to one of skill in the art.

[0031] Exemplary activators of activin receptor detectably induce, increase, promote, stimulate or enhance an activity, function or expression of activin or activin receptor. Thus, an activin receptor activator detectably induces, increases, promotes, stimulates or enhances one or more activin receptor activities or functions or activin or activin receptor expression, which can include, for example, modulation of an immune response, as set forth herein or otherwise one that one of skill in the art would know.

[0032] An activin receptor activator may act directly upon activin receptor. Such activators of activin receptor need not bind to activin receptor provided that they induce, increase, promote, stimulate or enhance one or more activin receptor activities or functions. For example, an activin receptor activator may indirectly interact with activin receptor, for example, by acting through an intermediary, for example, the activator binds to or modulates a molecule that in turn binds to or modulates activin receptor.

[0033] Exemplary inhibitors of activin receptor detectably reduce, decrease, inhibit, prevent or abrogate an activity or function of activin or activin receptor. Thus, an activin receptor inhibitor detectably reduces, decreases, inhibits, prevents or abrogates one or more activin receptor activities or functions. Activin receptor activities and functions can include, for example, binding of activin receptor to a ligand, activin receptor mediated signaling or expression, and/or an immune response, as set forth herein or otherwise one that one of skill in the art would know.

[0034] An activin receptor inhibitor may act directly upon activin receptor. Such inhibitors of activin receptor need not bind to activin receptor provided that they inhibit, reduce, suppress or in any way interfere with activin or activin receptor function or activity. For example, an activin receptor inhibitor may indirectly interact with activin receptor, for example, by acting through an intermediary, for example, the inhibitor binds to or modulates a molecule that in turn binds to or modulates activin or activin receptor.

[0035] Activin receptor activators and inhibitors include ligands that bind to activin receptor or a subsequence thereof (e.g., SEQ ID NO: 3-10). Non-limiting examples of ligands include polypeptides that bind to activin receptor, such as antibodies and activin. Additional exemplary activin receptor activators and inhibitors include antisense RNA and inhibitory nucleic acid against activin or activin receptor.

[0036] The term "bind," or "binding," means a physical interaction at the molecular level (directly or indirectly). Typically, binding is that which is specific or selective for activin receptor, i.e., is statistically significantly higher than the background or control binding for the assay. The term "specifically binds" refers to the ability to preferentially or selectively bind to activin receptor. Specific and selective binding can be distinguished from nonspecific binding using assays known in the art (e.g., immunoprecipitation, ELISA, flow cytometry, and Western blotting).

Antibodies and antigen binding fragments thereof

[0037] As used herein, the terms "activin Receptor antibody," "anti-activin Receptor" and "anti-activin Receptor antibody" refer to an antibody that specifically binds to activin Receptor. As used herein, the terms "activin antibody," "anti-activin " and "anti-activin antibody" refer to an antibody that specifically binds to activin. Antibodies include monoclonal or polyclonal immunoglobulin molecules that belong to any class such as IgM, IgG, IgA, IgE, IgD, and any subclass thereof. Exemplary subclasses for IgG are IgGl, IgG2, IgG3 and IgG4.

[0038] A "monoclonal" antibody refers to an antibody that is based upon, obtained from or derived from a single clone, including any eukaryotic, prokaryotic, or phage clone. A "monoclonal" antibody is therefore defined structurally, and not the method by which it is produced.

[0039] Antibodies include full-length antibodies that include two heavy and two light chain sequences. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as V_H) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CHI, CH2 and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as V_L) and a light chain constant region. The light chain constant region is comprised of one domain, C_L- The V_H and V_L regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each V_H and V_L is composed of three CDRs and four FRs arranged from amino- terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g. effector cells) and the first component (Clq) of the classical complement system.Antibodies can have kappa or lambda light chain sequences, either full length as in naturally occurring antibodies, mixtures thereof (i.e., fusions of kappa and lambda chain sequences), and subsequences/fragments thereof. Naturally occurring antibody molecules contain two kappa or two lambda light chains.

[0040] Antibodies include antigen binding fragments of antibodies comprising subsequences of a full native antibody complex. The term "antigen-binding portion" of an antibody (or simply "antigen portion"), as used herein, refers to full length or one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g. a portion of ActRII). It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Subsequences include all or a portion of a full- length antibody heavy or light chain, or a heavy or light chain variable region, which includes one or more CDRs of a heavy or light chain variable region sequence. In various aspects, a subsequence of a full length antibody heavy or light chain, or a heavy or light chain variable region, has a length from about 20-30, 30-50, 50-100, 100-150, 150-200, 200-250, 250-300, 300-400, or 400-500, amino acid residues. Examples of binding fragments encompassed within the term "antigen-binding portion" of an antibody include a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; a F(ab)₂ fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consisting of the VH and CHI domains; a Fv fragment consisting of the VL and VH domains of a single arm of an antibody; a dAb fragment (Ward et al., 1989 Nature 341 :544-546), which consists of a VH domain; and an isolated complementarity determining region (CDR).

[0041 ] Non- limiting representative antigen binding fragments of antibodies comprising antibody subsequences include but are not limited to Fab, Fab', F (ab')₂, Fv, Fd, single-chain Fv (scFv), disulfide-linked Fvs (sdFv), V_L, V_H, Camel Ig, V-NAR, VHH, trispecific (Fab₃), bispecific (Fab₂), diabody ((VL-VH)₂ or (VH-VL)₂), triabody (trivalent), tetrabody (tetravalent), minibody ((scFv -CH3)₂), bispecific single-chain Fv (Bis-scFv), IgGdeltaCH2, scFv-Fc, (scFv)2-Fc, affibody, aptamer, avimer or nanobody, or other antigen binding subsequences of an intact immunoglobulin. Antibodies include those that bind to more than one epitope (e.g., bispecific antibodies), or antibodies that can bind to one or more different antigens (e.g., bi- or multi- specific antibodies).

[0042] Antibodies include antibodies and antigen binding fragments of antibodies subsequences capable of binding to activin or activin receptor in solution or in solid phase, present on one or more cells in vitro, in primary cell isolates, passaged cells, cultured cells and immortalized cells, or in vivo. Specific non-limiting cell types that can express activin or activin receptor include pituitary, macrophages, osteoblasts, fibroblasts, testis, thyroid, prostate, lung, pancreatic islet cells, bronchial epithelial cells, smooth muscle cells, cardiac myocytes, placenta, uterus and ovary.

[0043] Antibodies include mammalian, primatized, humanized, fully human antibodies and chimeras. A mammalian antibody is an antibody which is produced by a mammal, transgenic or non-transgenic, or a non-mammalian organism engineered to produce a mammalian antibody, such as a non-mammalian cell (bacteria, yeast, insect cell), animal or plant.

[0044] The term "human" when used in reference to an antibody, means that the amino acid sequence of the antibody is fully human, i.e., human heavy and human light chain variable and human constant regions. Thus, all of the amino acids are human or exist in a human antibody. An antibody that is non-human may be made fully human by substituting the non-human amino acid residues with amino acid residues that exist in a human antibody. Amino acid residues present in human antibodies, CDR region maps and human antibody consensus residues are known in the art (see, e.g., Kabat, Sequences of Proteins of Immunological Interest, 4th Ed.US Department of Health and Human Services. Public Health Service (1987); Chothia and Lesk (1987). A consensus sequence of human VH subgroup III, based on a survey of 22 known human VH III sequences, and a consensus sequence of human VH kappa-chain subgroup I, based on a survey of 30 known human kappa I sequences is described in Padlan Mol. Immunol. 3: 169 (1994); and Padlan Mol. Immunol. 28:489 (1991). Human antibodies therefore include antibodies in which one or more amino acid residues have been substituted with one or more amino acids present in any other human antibody. [0045] The term "humanized" when used in reference to an antibody, means that the amino acid sequence of the antibody has non-human amino acid residues (e.g., mouse, rat, goat, rabbit, etc.) of one or more complementarity determining regions (CDRs) that specifically bind to the desired antigen in an acceptor human immunoglobulin molecule, and one or more human amino acid residues in the Fv framework region (FR), which are amino acid residues that flank the CDRs. Such antibodies typically have reduced immunogenicity and therefore a longer half-life in humans as compared to the non-human parent antibody from which one or more CDRs were obtained or are based upon.

[0046] Antibodies referred to as "primatized" are "humanized" except that the acceptor human immunoglobulin molecule and framework region amino acid residues may be any primate amino acid residue (e.g., ape, gibbon, gorilla, chimpanzees orangutan, macaque), in addition to any human residue. Human FR residues of the immunoglobulin can be replaced with corresponding non-human residues. Residues in the CDR or human framework regions can therefore be substituted with a corresponding residue from the non-human CDR or framework region donor antibody to alter, generally to improve, antigen affinity or specificity, for example. A humanized antibody may include residues, which are found neither in the human antibody nor in the donor CDR or framework sequences. For example, a FR substitution at a particular position that is not found in a human antibody or the donor non-human antibody may be predicted to improve binding affinity or specificity human antibody at that position. Antibody framework and CDR substitutions based upon molecular modeling are well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions (see, e.g., U.S. Patent No. 5,585,089; and Riechmann et al., Nature 332:323 (1988)).

[0047] The term "chimeric" and grammatical variations thereof, when used in reference to an antibody, means that the amino acid sequence of the antibody contains one or more portions that are derived from, obtained or isolated from, or based upon two or more different species. For example, a portion of the antibody may be human (e.g., a constant region) and another portion of the antibody may be non-human (e.g., a murine heavy or murine light chain variable region). Thus, an example of a chimeric antibody is an antibody in which different portions of the antibody are of different species origins. Unlike a humanized or primatized antibody, a chimeric antibody can have the different species sequences in any region of the antibody.

[0048] Methods of producing polyclonal and monoclonal antibodies are known in the art. For example, activin, activin receptor or an immunogenic fragment thereof, optionally conjugated to a carrier such as keyhole limpet hemocyanin (KLH) or albumin (e.g., BSA), or mixed with an adjuvant such as Freund's complete or incomplete adjuvant, and used to immunize an animal. Using hybridoma technology, splenocytes from immunized animals that respond to activin or activin receptor can be isolated and fused with myeloma cells. Monoclonal antibodies produced by hybridomas can be screened for reactivity with activin, activin receptor or an immunogenic fragment thereof. Hybridoma, recombinant, and phage display methods are known in the art (see, for example, U.S. Patent Nos. 4,902,614, 4,543,439, and 4,41 1,993; see, also Monoclonal Antibodies. Hybridomas: A New Dimension in Biological Analyses. Plenum Press, Kennett, McKearn, and Bechtol (eds.), 1980, and Harlow et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 2nd ed. 1988).

[0049] Animals that may be immunized include primates, mice, rats, rabbits, goats, sheep, cattle, or guinea pigs. Initial and any optional subsequent immunization may be through intravenous, intraperitoneal, intramuscular, or subcutaneous routes. Additionally, to increase the immune response, antigen can be coupled to another protein such as ovalbumin or keyhole limpet hemocyanin (KLH), thyroglobulin and tetanus toxoid, or mixed with an adjuvant such as Freund's complete or incomplete adjuvant. Initial and any optional subsequent immunization may be through intraperitoneal, intramuscular, intraocular, or subcutaneous routes. Subsequent immunizations may be at the same or at different concentrations of antigen, and may be at regular or irregular intervals.

[0050] Animals include those genetically modified to include human gene loci, which can be used to produce human antibodies. Transgenic animals, such as human trans- chromosomic mice with one or more human immunoglobulin genes, are described, for example, in U.S. Patent No. 5,939,598, WO 02/43478, and WO 02/092812. In brief, animals are immunized with activin, activin receptor or cells that express activin or activin receptor antigen. Using conventional hybridoma technology, splenocytes from immunized mice that are high responders to the antigen can be isolated and fused with myeloma cells. Antibodies that bind to activin or activin receptor can thereby be obtained. [0051] Humanized antibodies can be produced using techniques known in the art including, for example, CDR-grafting (EP 239,400; W091/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunol. 28:489 (1991); Studnicka et al., Protein Engineering 7:805 (1994); Roguska. et al., Proc. Natl Acad. Sci. USA 9 1:969 (1994)), and chain shuffling (U.S. Patent No. 5,565,332). Human consensus sequences (Padlan, Mol. Immunol. 31:169 (1994); and Padlan, Mol. Immunol. 28:489 (1991)) have previously used to produce humanized antibodies (Carter et al., Proc. Natl. Acad. Sci. USA 89:4285 (1992); and Presta et al., J. Immunol. 151:2623 ( 1993)). Additional methods for producing human polyclonal antibodies and human monoclonal antibodies are described (see, e.g., Kuroiwa et al., Nat. Biotechnol. 20:889 (2002); WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598).

[0052] Methods for producing chimeric antibodies are known in the art (e.g., Morrison, Science 229: 1202 (1985); Oi et al., BioTechniques 4:214 (1986); Gillies et al., J. Immunol. Methods 125:191 (1989); and U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397). Chimeric antibodies in which a variable domain from an antibody of one species is substituted for the variable domain of another species are described, for example, in Munro, Nature 312:597 (1984); Neuberger et al., Nature 312:604 (1984); Sharon et al., Nature 309:364 (1984); Morrison et al., Proc. Natl Acad. Sci. USA 81:6851 (1984); Boulianne et al., Nature 312:643 (1984); Capon et al., Nature 337:525 (1989); and Traunecker et al., Nature 339:68 (1989).

[0053] Activin or activin receptor protein suitable for generating antibodies can be produced by any of a variety of standard protein purification or recombinant expression techniques. Forms of activin or activin receptor suitable for generating an immune response include activin or activin receptor subsequences, such as an immunogenic fragment. Additional forms of activin or activin receptor include activin or activin receptor expressing cells, activin or activin receptor containing preparations or extracts or fractions, partially purified activin or activin receptor. For example, an activin or activin receptor sequence can be produced by standard peptide synthesis techniques, such as solid-phase synthesis. A portion of the protein may contain an amino acid sequence such as a T7 tag or polyhistidine sequence to facilitate purification of expressed or synthesized protein. The protein may be expressed in a cell and purified. The protein may be expressed as a part of a larger protein (e.g., a fusion or chimera) by recombinant methods.

[0054] Suitable techniques that additionally may be employed in antibody generation methods include activin or activin receptor based affinity purification, non-denaturing gel purification, HPLC or RP-HPLC, size exclusion, purification on protein A column, or any combination of these techniques. Antibody isotype can be determined using an ELISA assay, for example, a human Ig can be identified using mouse Ig- absorbed anti-human Ig.

[0055] Non-limiting representative examples of antibodies that specifically bind to activin or activin receptor include antibodies denoted as M244B, M248, LS Bio LS-C195902, R&D Systems Clone 132815, R&D Systems Clone 69403, R&D Systems AF338, Novus Biologicals MM0074-7L18, GeneTex 7L18, or Ray Biotech ACVR1B.

[0056] In some embodiments, methods comprise use of antibodies comprising VH amino acid sequences of isolated antibodies shown in SEQ ID NOs: 106-119 and VL amino acid sequences of isolated antibodies shown in SEQ ID NOs: 120-133 respectively. Examples of preferred full length heavy chain amino acid sequences of antibodies of use in methods of the invention are shown in SEQ ID NOs: 167-171 and 177-181. Examples of preferred full length light chain amino acid sequences of antibodies of use in the methods of the invention are shown in SEQ ID NOs: 162-166 and 172-176 respectively. Other antibodies of use in the methods of the invention include amino acids that have been mutated by amino acid deletion, insertion or substitution, yet have at least 85, 90, 95, 96, 97, 98 or 99 percent identity in the CDR regions with the CDR regions depicted in the sequences described above. In some embodiments, methods comprise use of antibody compositions provided herein which include mutant amino acid sequences wherein no more than 1, 2, 3, 4 or 5 amino acids have been mutated by amino acid deletion, insertion or substitution in the CDR regions when compared with the CDR regions depicted in the sequence described above.

[0057] In some embodiments, methods comprise use of antibodies or antigen binding fragments comprising variable heavy chain parental nucleotide sequences shown in SEQ ID NOs: 148-161 and variable light chain parental nucleotide sequences shown in SEQ ID NOs: 134-147. In certain embodiments methods comprise use of ull length light chain nucleotide sequences optimized for expression in a mammalian cell shown in SEQ ID NOs: 182-186 and 192- 196, and full length heavy chain nucleotide sequences optimized for expression in a mammalian cell are shown in SEQ ID NOs: 187- 191 and 197-201. Other embodiments provide for use of antibodies in methods of the invention including amino acids or nucleic acids that have been mutated, yet have at least 85 or more (e.g. 90, 95, 96, 97, 98, 99 or more) percent identity to the sequences described above. In some embodiments, it includes mutant amino acid sequences wherein no more than 1, 2, 3, 4 or 5 amino acids have been mutated by amino acid deletion, insertion or substitution in the variable regions when compared with the variable regions depicted in the sequence described above.

[0058] In some embodiments, the VH, VL, full length light chain, and full length heavy chain sequences (nucleotide sequences and amino acid sequences) can be "mixed and matched" to create other anti-ActRII binding molecules of the invention. ActRII binding of such "mixed and matched" antibodies can be tested using the binding assays described above and in the Examples (e.g. ELISAs), and others know in the art. When these chains are mixed and matched, a VH sequence from a particular VH/VL pairing should be replaced with a structurally similar VH sequence. Likewise a full length heavy chain sequence from a particular full length heavy chain / full length light chain pairing should be replaced with a structurally similar full length heavy chain sequence. Likewise, a VL sequence from a particular VH VL pairing should be replaced with a structurally similar VL sequence. Likewise a full length light chain sequence from a particular full length heavy chain / full length light chain pairing should be replaced with a structurally similar full length light chain sequence. Accordingly, in one aspect, the invention provides methods using an isolated recombinant anti-ActRII antibody or antigen binding region thereof having: a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 106-119; and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 120- 133.

In another embodiment, the invention provides methods of use of an isolated recombinant anti-ActRII antibody or antigen binding fragment thereof having: a full length heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 106- 119; and a full length light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 120- 133.

[0059] In another embodiment, the invention provides methods of use of an isolated recombinant anti-ActRII antibody or antigen binding fragment thereof having a full length heavy chain encoded by a nucleotide sequence that has been optimized for expression in the cell of a mammalian selected from the group consisting of SEQ ID NOs: 148-161, and a full length light chain encoded by a nucleotide sequence that has been optimized for expression in the cell of a mammalian selected from the group consisting of SEQ ID NOs: 134- 147.

[0060] In particular embodiments, provided methods comprise use of antibodies described herein, for example: the amino acid sequences of the VH CDRls of the antibodies are shown in SEQ ID NOs: 22-35; the amino acid sequences of the VH CDR2S of the antibodies are shown in SEQ ID NOs: 36-49; the amino acid sequences of the VH CDR3S of the antibodies are shown in SEQ ID NOs: 50-63; the amino acid sequences of the VL CDRls of the antibodies are shown in SEQ ID NOs: 64-77; the amino acid sequences of the VL CDR2s of the antibodies are shown in SEQ ID NOs: 78-91; the amino acid sequences of the VL CDR3S of the antibodies are shown in SEQ ID NOs: 92-105. CDR regions are delineated using the Kabat system (Kabat, E. A., et al., 1991 Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242).

[0061 ] In one embodiment, provided methods comprise use of antibodies wherein an isolated recombinant anti-ActRII antibody, or antigen binding region thereof has: a heavy chain variable region CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 22-35; a heavy chain variable region CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 36-49; a heavy chain variable region CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 50-63; a light chain variable region CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 64-77; a light chain variable region CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 78-91 ; and a light chain variable region CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 92-105.

[0062] In one embodiment, provided methods comprise use of antibodies wherein the antibody comprises: a heavy chain variable region CDR1 of SEQ ID NO: 22; a heavy chain variable region CDR2 of SEQ ID NO: 36; a heavy chain variable region CDR3 of SEQ ID NO: 50; a light chain variable region CDR1 of SEQ ID NO: 64; a light chain variable region CDR2 of SEQ ID NO: 78; and a light chain variable region CDR3 of SEQ ID NO: 92.

[0063] In one embodiment, provided methods comprise use of antibodies wherein the antibody comprises: a heavy chain variable region CDRl of SEQ ID NO: 23 a heavy chain variable region CDR2 of SEQ ID NO: 37; a heavy chain variable region CDR3 of SEQ ID NO: 51; a light chain variable region CDRl of SEQ ID NO: 65; a light chain variable region CDR2 of SEQ ID NO: 79; and a light chain variable region CDR3 of SEQ ID NO: 93.

[0064] In one embodiment, provided methods comprise use of antibodies wherein the antibody comprises: a heavy chain variable region CDRl of SEQ ID NO: 24; a heavy chain variable region CDR2 of SEQ ID NO: 38; a heavy chain variable region CDR3 of SEQ ID NO: 52; a light chain variable region CDRl of SEQ ID NO: 66; a light chain variable region CDR2 of SEQ ID NO: 80; and a light chain variable region CDR3 of SEQ ID NO: 94.

[0065] In one embodiment, provided methods comprise use of antibodies wherein the antibody comprises: a heavy chain variable region CDRl of SEQ ID NO: 25; a heavy chain variable region CDR2 of SEQ ID NO: 39; a heavy chain variable region CDR3 of SEQ ID NO: 53; a light chain variable region CDRl of SEQ ID NO: 67; a light chain variable region CDR2 of SEQ ID NO: 81; and a light chain variable region CDR3 of SEQ ID NO: 95.

[0066] In one embodiment, provided methods comprise use of antibodies wherein, the antibody comprises: a heavy chain variable region CDRl of SEQ ID NO: 26; a heavy chain variable region CDR2 of SEQ ID NO: 40; a heavy chain variable region CDR3 of SEQ ID NO: 54; a light chain variable region CDRl of SEQ ID NO: 68; a light chain variable region CDR2 of SEQ ID NO: 82; and a light chain variable region CDR3 of SEQ ID NO: 96.

[0067] In one embodiment, provided methods comprise use of antibodies wherein the antibody comprises: a heavy chain variable region CDRl of SEQ ID NO: 27; a heavy chain variable region CDR2 of SEQ ID NO: 41; a heavy chain variable region CDR3 of SEQ ID NO: 55; a light chain variable region CDRl of SEQ ID NO: 69; a light chain variable region CDR2 of SEQ ID NO: 83; and a light chain variable region CDR3 of SEQ ID NO: 97.

[0068] In one embodiment, provided methods comprise use of antibodies wherein the antibody comprises: a heavy chain variable region CDRl of SEQ ID NO: 28; a heavy chain variable region CDR2 of SEQ ID NO: 42; a heavy chain variable region CDR3 of SEQ ID NO: 56; a light chain variable region CDRl of SEQ ID NO: 70; a light chain variable region CDR2 of SEQ ID NO: 84; and a light chain variable region CDR3 of SEQ ID NO: 98.

[0069] In one embodiment, provided methods comprise use of antibodies wherein the antibody comprises: a heavy chain variable region CDRl of SEQ ID NO: 29; a heavy chain variable region CDR2 of SEQ ID NO: 43; a heavy chain variable region CDR3 of SEQ ID NO: 57; a light chain variable region CDRl of SEQ ID NO: 71 a light chain variable region CDR2 of SEQ ID NO: 85; and a light chain variable region CDR3 of SEQ ID NO: 99.

[0070] In one embodiment, provided methods comprise use of antibodies wherein the antibody comprises: a heavy chain variable region CDRl of SEQ ID NO: 30; a heavy chain variable region CDR2 of SEQ ID NO: 44; a heavy chain variable region CDR3 of SEQ ID NO: 58; a light chain variable region CDRl of SEQ ID NO: 72; a light chain variable region CDR2 of SEQ ID NO: 86; and a light chain variable region CDR3 of SEQ ID NO: 100.

[0071] In one embodiment, provided methods comprise use of antibodies wherein the antibody comprises: a heavy chain variable region CDRl of SEQ ID NO: 31; a heavy chain variable region CDR2 of SEQ ID NO: 45; a heavy chain variable region CDR3 of SEQ ID NO: 59; a light chain variable region CDRl of SEQ ID NO: 73; a light chain variable region CDR2 of SEQ ID N087; and a light chain variable region CDR3 of SEQ ID NO: 101.

[0072] In one embodiment, provided methods comprise use of antibodies wherein the antibody comprises: a heavy chain variable region CDRl of SEQ ID NO: 32; a heavy chain variable region CDR2 of SEQ ID NO: 46; a heavy chain variable region CDR3 of SEQ ID NO: 60; a light chain variable region CDRl of SEQ ID NO: 74; a light chain variable region CDR2 of SEQ ID NO: 88; and a light chain variable region CDR3 of SEQ ID NO: 102.

[0073] In one embodiment, provided methods comprise use of antibodies wherein the antibody comprises: a heavy chain variable region CDRl of SEQ ID NO: 33; a heavy chain variable region CDR2 of SEQ ID NO: 47; a heavy chain variable region CDR3 of SEQ ID NO: 61; a light chain variable region CDRl of SEQ ID NO: 75; a light chain variable region CDR2 of SEQ ID NO: 89; and a light chain variable region CDR3 of SEQ ID NO: 103.

[0074] In one embodiment, provided methods comprise use of antibodies wherein the antibody comprises: a heavy chain variable region CDRl of SEQ ID NO: 34; a heavy chain variable region CDR2 of SEQ ID NO: 48; a heavy chain variable region CDR3 of SEQ ID NO: 62; a light chain variable region CDRl of SEQ ID NO: 76; a light chain variable region CDR2 of SEQ ID NO: 90; and a light chain variable region CDR3 of SEQ ID NO: 104.

[0075] In one embodiment, provided methods comprise use of antibodies wherein the antibody comprises: a heavy chain variable region CDRl of SEQ ID NO: 35; a heavy chain variable region CDR2 of SEQ ID NO: 49; a heavy chain variable region CDR3 of SEQ ID NO: 63; a light chain variable region CDRl of SEQ ID NO: 77; a light chain variable region CDR2 of SEQ ID NO: 91; and a light chain variable region CDR3 of SEQ ID NO: 105.

[0076] In one embodiment, provided methods comprise use of antibodies wherein the antibody comprises: : (a) the variable heavy chain sequence of SEQ ID NO: 120 and variable light chain sequence of SEQ ID NO: 106; (b) the variable heavy chain sequence of SEQ ID NO: 121 and variable light chain sequence of SEQ ID NO: 107; (c) the variable heavy chain sequence of SEQ ID NO: 122 and variable light chain sequence of SEQ ID NO: 108; (d) the variable heavy chain sequence of SEQ ID NO: 123 and variable light chain sequence of SEQ ID NO: 109; (e) the variable heavy chain sequence of SEQ ID NO: 124 and variable light chain sequence of SEQ ID NO: 110; (f) the variable heavy chain sequence of SEQ ID NO: 125 and variable light chain sequence of SEQ ID NO: 111; (g) the variable heavy chain sequence of SEQ ID NO: 126 and variable light chain sequence of SEQ ID NO: 112; (h) the variable heavy chain sequence of SEQ ID NO: 127 and variable light chain sequence of SEQ ID NO: 113; (i) the variable heavy chain sequence of SEQ ID NO: 128 and variable light chain sequence of SEQ ID NO: 114; (j) the variable heavy chain sequence of SEQ ID NO: 129 and variable light chain sequence of SEQ ID NO: 115; (k) the variable heavy chain sequence of SEQ ID NO: 130 and variable light chain sequence of SEQ ID NO: 116; (1) the variable heavy chain sequence of SEQ ID NO: 131 and variable light chain sequence of SEQ ID NO: 117; (m) the variable heavy chain sequence of SEQ ID NO: 132 and variable light chain sequence of SEQ ID NO: 118; or (n) the variable heavy chain sequence of SEQ ID NO: 133 and variable light chain sequence of SEQ ID NO: 119.

[0077] In one embodiment, provided methods comprise use of antibodies wherein the antibody comprises: : (a) the heavy chain sequence of SEQ ID NO: 167 and light chain sequence of SEQ ID NO: 162; (b) the heavy chain sequence of SEQ ID NO: 168 and light chain sequence of SEQ ID NO: 163; (c) the heavy chain sequence of SEQ ID NO: 169 and light chain sequence of SEQ ID NO: 164; (d) the heavy chain sequence of SEQ ID NO: 170 and light chain sequence of SEQ ID NO: 165; (e) the heavy chain sequence of SEQ ID NO: 171 and light chain sequence of SEQ ID NO: 166; (f) the heavy chain sequence of SEQ ID NO: 177 and light chain sequence of SEQ ID NO: 172; (g) the heavy chain sequence of SEQ ID NO: 178 and light chain sequence of SEQ ID NO: 173; (h) the heavy chain sequence of SEQ ID NO: 179 and light chain sequence of SEQ ID NO: 174; (i) the heavy chain sequence of SEQ ID NO: 180 and light chain sequence of SEQ ID NO: 175; or (j) the heavy chain sequence of SEQ ID NO: 181 and light chain sequence of SEQ ID NO: 176.

[0078] In certain embodiments, methods of the invention utilize an antibody having full length heavy and light chain amino acid sequences; full length heavy and light chain nucleotide sequences, variable region heavy and light chain nucleotide sequences, or variable region heavy and light chain amino acid sequences that are homologous to the amino acid and nucleotide sequences of the antibodies described herein, and wherein the antibodies retain the desired functional properties of the anti-ActRII antibodies of the invention. For example, the invention provides use of an isolated recombinant anti-ActRII antibody (or a functional protein comprising an antigen binding portion thereof) comprising a heavy chain variable region and a light chain variable region, wherein: the heavy chain variable region comprises an amino acid sequence that is at least 85%, or at least 90% (preferably at least 95, 97 or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 106-119; the light chain variable region comprises an amino acid sequence that is at least 85%, or at least 90% (preferably at least 95, 97 or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 120-133; and the antibody exhibits at least one of the following functional properties: (i) it inhibits activin binding in vitro or in vivo and/or (ii) decreases an immune response.

[0079] In a further embodiment, the invention methods provide for use of an isolated recombinant anti-ActRII antibody, (or a functional protein comprising an antigen binding portion thereof) comprising a full length heavy chain and a full length light chain, wherein: the full length heavy chain comprises an amino acid sequence that is at least 85%, or at least 90% (preferably at least 95, 97 or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 167-171 and 177-181; the full length light chain comprises an amino acid sequence that is at least 85%, or at least 90% (preferably at least 95, 97 or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 162- 166 and 172- 176; and the antibody exhibits at least one of the following functional properties: (i) it inhibits activin binding in vitro or in vivo and/or (ii) decreases an immune response.

[0080] In another embodiment, the invention methods provide for use of an isolated recombinant anti-ActRII antibody (or a functional protein comprising an antigen binding portion thereof), comprising a full length heavy chain and a full length light chain, wherein: the full length heavy chain is encoded by a nucleotide sequence that is at least 85%, or at least 90% (preferably at least 95, 97 or 99%) identical to a nucleotide sequence selected from the group consisting of SEQ ID NOs: 187-191 and 197-201 ; the full length light chain is encoded by a nucleotide sequence that is at least 85%, or at least 90% (preferably at least 95, 97 or 99%) identical to a nucleotide sequence selected from the group consisting of SEQ ID NOs: 182-186 and 192- 196; and the antibody exhibits at least one of the following functional properties: (i) it inhibits activin binding in vitro or in vivo and/or (ii) decreases an immune response.

[0081 ] In various embodiments, an antibody may exhibit one or more, two or more, or three of the functional properties discussed herein. The antibody can be, for example, a human antibody, a humanized antibody or a chimeric antibody. Preferably the antibody is a fully human IgGl antibody.

[0082] In other embodiments, the VH and/or VL amino acid sequences may be 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the sequences set forth above. In other embodiments, the VH and/or VL amino acid sequences may be identical except an amino acid substitution in no more than 1, 2, 3, 4 or 5 amino acid position. An antibody having VH and VL regions having high (i.e. 85% or greater) identity to the VH and VL regions of SEQ ID NOs 120- 133 and SEQ ID NOs: 106-1 19 respectively, can be obtained by mutagenesis (e.g. site-directed or PCR-mediated mutagenesis) of nucleic acid molecules SEQ ID NOs: 148-161 and 134-147 respectively, followed by testing of the encoded altered antibody for retained function (i.e. the functions set forth above) using the functional assays described herein.

[0083] In other embodiments, the full length heavy chain and/or full length light chain amino acid sequences may be 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the sequences set forth above. An antibody having a full length heavy chain and full length light chain having high (i.e. 85% or greater) identity to the full length heavy chains of any of SEQ ID NOs: 167-171 and 177-181 and full length light chains of any of SEQ ID NOs: 162-166 and 172-176 respectively, can be obtained by mutagenesis (e.g. site-directed or PCR- mediated mutagenesis) of nucleic acid molecules SEQ ID NOs: 187-191 and 197-201 and SEQ ID NOs: 182-186 and 192-196 respectively, followed by testing of the encoded altered antibody for retained function (i.e. the functions set forth above) using the functional assays described herein.

[0084] As used herein, the percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e. % identity = # of identical positions/total # of positions x 100), taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm, as described below. The percent identity between two amino acid sequences can be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci., 4: 11-17, 1988) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. In addition, the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (J. Mol, Biol. 48:444-453, 1970) algorithm which has been incorporated into the GAP program in the GCG software package (available at http://www.gcg.com), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.

[0085] In another embodiment, the invention methods provide for use of an isolated recombinant anti-ActRII antibody (or a functional protein comprising an antigen binding portion thereof), comprising an antibody having a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences, wherein one or more of these CDR sequences have specified amino acid sequences based on the antibodies described herein or conservative modifications thereof, and wherein the antibodies retain the desired functional properties of the anti-ActRII antibodies of the invention. Accordingly, the invention provides an isolated recombinant anti- ActRII antibody, or a functional protein comprising an antigen binding portion thereof, consisting of a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences, wherein: the heavy chain variable region CDR1 amino acid sequences are selected from the group consisting of SEQ ID NOs: 22-35, and conservative modifications thereof; the heavy chain variable region CDR2 amino acid sequences are selected from the group consisting of SEQ ID NOs: 36-49, and conservative modifications thereof; the heavy chain variable region CDR3 amino acid sequences are selected from the group consisting of SEQ ID NOs: 50-63, and conservative modifications thereof; the light chain variable regions CDR1 amino acid sequences are selected from the group consisting of SEQ ID NOs: 64-77, and conservative modifications thereof; the light chain variable regions CDR2 amino acid sequences are selected from the group consisting of SEQ ID NOs: 78-91, and conservative modifications thereof; the light chain variable regions of CDR3 amino acid sequences are selected from the group consisting of SEQ ID NOs: 92-105, and conservative modifications thereof. Preferably the antibody exhibits at least one of the following functional properties: (i) it inhibits activin binding in vitro or in vivo and/or (ii) decreases an immune response.

[0086] In various embodiments, the antibody may exhibit one or both of the functional properties described herein. Such antibodies can be, for example, human antibodies, humanized antibodies or chimeric antibodies.

[0087] As used herein, the term "conservative sequence modifications" is intended to refer to amino acid modifications that do not significantly affect or alter the binding characteristics of the antibody containing the amino acid sequence. Such conservative modifications include amino acid substitutions, additions and deletions. Modifications can be introduced into an antibody of the invention by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are ones in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g. lysine, arginine, histidine), acidic side chains (e.g. aspartic acid, glutamic acid), uncharged polar side chains (e.g. glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g. alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g. threonine, valine, isoleucine) and aromatic side chains (e.g. tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues within the CDR regions of an antibody of use in the methods of the invention can be replaced with other amino acid residues from the same side chain family, and the altered antibody can be tested for retained function using the functional assays described herein.

[0088] Activin or activin receptor antibodies and functional (e.g., binding) subsequences, can have substantially the same, greater or less relative activity for than a reference antibody. For example, an activin or activin receptor antibody can have substantially the same, greater or less relative binding affinity or avidity for activin or activin receptor than a reference antibody. Such antibodies having measurable affinity for activin or activin receptor compete for binding of the reference antibody to activin or activin receptor. Activin or activin receptor antibodies and subsequences therefore include those that do not compete with a reference antibody for binding to activin or activin receptor, and those that compete with a reference antibody for binding to activin or activin receptor, and have substantially the same, greater or less relative binding affinity or avidity for binding to activin or activin receptor as compared to a reference antibody. In particular embodiments, a activin or activin receptor antibody competes for binding of antibody denoted as M244B, M248, LS Bio LS-C195902, R&D Systems Clone 132815, R&D Systems Clone 69403, R&D Systems AF338, Novus Biologicals MM0074-7L18, GeneTex 7L18, or Ray Biotech ACVR1B

[0089] Activin or activin receptor antibodies and subsequences can have a binding affinity for binding to activin or activin receptor within about K_<j 10^~2 M to about 10^"1 M, or within about K_<j 10^"6 M to about 10^~2 M. In particular embodiments, binding affinity is less than 5xl0^"2 M, 10^"2 M, 5xl0^"3 M, 10^"3 M, 5x 10^"4 M, 10^"4 M, 5xl0^"5 M, 10^"5 M, 5xl0^"6 M, 10^"6 M, 5xl0^"7 M, 10^"7 M, 5xl0^"8 M, 10^"8 M, 5xl0^"9 M, 10^"9 M, 5xl0^"10 M, 10^"10 M, 5xl0^"n M, 10^"11 M 5xl0^"12 M, 10^"12 M, 5xl0^"13 M, 10^"13 M, 5xl0^"14 M, 10^"14 M, 5xl0^"15 M, and 10^"15 M.

[0090] Activin or activin receptor antibodies and subsequences can have a greater or less than 2-5, 5-10, 10-100, 100-1000 or 1000-10,000-fold binding affinity for binding to activin or activin receptor, or any numerical value or range within or encompassing such values, than a reference antibody. In one embodiment, an antibody or a functional subsequence thereof has a binding affinity within about 1-5000 fold (more or less than) of a reference antibody for binding to activin or activin receptor.

[0091] In certain embodiments, useful compositions in provided methods include an antibody that "specifically binds to ActRII polypeptide" which is intended to refer to an antibody that binds to human ActRII polypeptide with a KD of a ΙΟΟηΜ or less, ΙΟηΜ or less, InM or less. An antibody that "cross-reacts with an antigen other than ActRII" is intended to refer to an antibody that binds that antigen with a KD of 10 x 10^~9 M or less, 5 x 10^~9 M or less, or 2 x 10^"9 M or less. An antibody that "does not cross-react with a particular antigen" is intended to refer to an antibody that binds to that antigen, with a KD of 1.5 x 10^~8 M or greater, or a KD of 5-10 x 10^~8 M, or 1 x 10^"7 M or greater. In certain embodiments, such antibodies that do not cross-react with the antigen exhibit essentially undetectable binding against these proteins in standard binding assays. KD may be determined using a biosensor system, such as a Biacore^® system.

[0092] Activin or activin receptor antibodies and subsequences can have substantially the same binding affinity for activin or activin receptor as a reference antibody. In particular embodiments, a activin or activin receptor antibody has substantially the same binding affinity or avidity for activin or activin receptor as antibody denoted as M244B, M248, LS Bio LS-C195902, R&D Systems Clone 132815, R&D Systems Clone 69403, R&D Systems AF338, Novus Biologicals MM0074-7L18, GeneTex 7L18, or Ray Biotech ACVR1B.

[0093] The term "substantially the same" when used in reference to antibody or functional subsequence binding affinity or avidity for antigen, means that the binding affinity is within 100 fold of the binding affinity of a reference antibody for activin or activin receptor or a subsequence thereof. Binding affinity can be determined by association (Ka) and dissociation (Kd) rate. Equilibrium affinity constant, K, is the ratio of Ka/Kd. Association (Ka) and dissociation (Kd) rates can be measured using surface plasmon resonance (SPR) (Rich and Myszka, Curr. Opin. Biotechnol. 11:54 (2000); Englebienne, Analyst. 123 : 599 ( 1998)). Instrumentation and methods for real time detection and monitoring of binding rates are known and are commercially available (BiaCore 2000, Biacore AB, Upsala, Sweden; and Malmqvist, Biochem. Soc. Trans. 27:335 (1999)). Thus, for example, if binding of a reference antibody to activin or activin receptor has a Kd 10^"9 M, than an antibody which has substantially the same binding affinity as the reference activin or activin receptor antibody will have a Kd from 10^"7 M to 10^~n M for binding to activin or activin receptor.

Polypeptides

[0094] Activin or activin receptor polypeptides and subsequences thereof, and amino acid substitutions thereof, can be used to practice invention methods and uses. Such activin or activin receptor polypeptides and subsequences thereof can exhibit sequence identity to a reference activin or activin receptor polypeptide or subsequence thereof. Activin comprises two subunits selected from an Inhibin- a polypeptide and an Inhibin- b polypeptide. An exemplary human Inhibin- a polypeptide sequence is set forth as: MPLLWLRGFLLASCWIIVRSSPTPGSEGHSAAPDCPSCALAALPKDVPNSQPEMVEA VKKHILNMLHLKKRPDVTQPVPKAALLNAIRKLHVGKVGENGYVEIEDDIGRRAEM NELMEQTSEIITFAESGTARKTLHFEISKEGSDLSVVERAEVWLFLKVPKANRTRTKV TIRLFQQQKHPQGSLDTGEEAEEVGLKGERSELLLSEKVVDARKSTWHVFPVSSSIQR LLDQGKSSLDVRIACEQCQESGASLVLLGKKKKKEEEGEGKKKGGGEGGAGADEEK EQSHRPFLMLQARQSEDHPHRRRRRGLECDGKVNICCKKQFFVSFKDIGWNDWIIAP SGYHANYCEGECPSHIAGTSGSSLSFHSTVINHYRMRGHSPFANLKSCCVPTKLRPMS MLYYDDGQNIIKKDIQNMIVEECGCS (SEQ ID NO: 1).

[0095] An exemplary human Inhibin- fib polypeptide sequence is set forth as:

MDGLPGRALGAACLLLLAAGWLGPEAWGSPTPPPTPAAPPPPPPPGSPGGSQDTCTS

CGGFRRPEELGRVDGDFLEAVKRHILSRLQMRGRPNITHAVPKAAMVTALRKLHAG

KVREDGRVEIPHLDGHASPGADGQERVSEIISFAETDGLASSRVRLYFFISNEGNQNLF

VVQASLWLYLKLLPYVLEKGSRRKVRVKVYFQEQGHGDRWNMVEKRVDLKRSGW

HTFPLTEAIQALFERGERRLNLDVQCDSCQELAVVPVFVDPGEESHRPFVVVQARLG

DSRHRIRKRGLECDGRTNLCCRQQFFIDFRLIGWNDWIIAPTGYYGNYCEGSCPAYL

AGVPGSASSFHTAVVNQYRMRGLNPGTVNSCCIPTKLSTMSMLYFDDEYNIVKRDV

PNMIVEECGCA (SEQ ID NO: 2).

[0096] Activin receptor comprises two subunits selected from one of ActRIIA or

ActRIIB and one of ALK2 or ALK4. An exemplary human ActRIIA polypeptide sequence is set forth as one of:

MG A A AKL AFA VFLIS CSS G AILGRSETQECLFFN AN WEKDRTNQTG VEPC YGD KD K RRHCFATWKNISGSIEIVKQGCWLDDINCYDRTDCVEKKDSPEVYFCCCEGNMCNE KFSYFPEMEVTQPTSNPVTPKPPYYNILLYSLVPLMLIAGIVICAFWVYRHHKMAYPP VLVPTQDPGPPPPSPLLGLKPLQLLEVKARGRFGCVWKAQLLNEYVAVKIFPIQDKQ SWQNEYEVYSLPGMKHENILQFIGAEKRGTSVDVDLWLITAFHEKGSLSDFLKANVV SWNELCHIAETMARGLAYLHEDIPGLKDGHKPAISHRDIKSKNVLLKNNLTACIADF GLALKFEAGKSAGDTHGQVGTRRYMAPEVLEGAINFQRDAFLRIDMYAMGLVLWE LASRCTAADGPVDEYMLPFEEEIGQHPSLEDMQEVVVHKKKRPVLRDYWQKHAGM AMLCETIEECWDHDAEARLSAGCVGERITQMQRLTNIITTEDIVTVVTMVTNVDFPP KESSL (SEQ ID NO: 3),

[0097] MCNEKFSYFPEMEVTQPTSNPVTPKPPYYNILLYSLVPLMLIAGIVICAFW

VYRHHKMAYPPVLVPTQDPGPPPPSPLLGLKPLQLLEVKARGRFGCVWKAQLLNEY

VAVKIFPIQDKQSWQNEYEVYSLPGMKHENILQFIGAEKRGTSVDVDLWLITAFHEK

GSLSDFLKANVVSWNELCHIAETMARGLAYLHEDIPGLKDGHKPAISHRDIKSKNVL

LKNNLTACIADFGLALKFEAGKSAGDTHGQVGTRRYMAPEVLEGAINFQRDAFLRID

MYAMGLVLWELASRCTAADGPVDEYMLPFEEEIGQHPSLEDMQEVVVHKKKRPVL

RDYWQKHAGMAMLCETIEECWDHDAEARLSAGCVGERITQMQRLTNIITTEDIVTV

VTMVTNVDFPPKESSL (SEQ ID NO: 4) or

[0098] MGAAAKLAFAVFLISCSSGAILGRSETQECLFFNANWEKDRTNQTGVEPC

YGDKDKRRHCFATWKNISGSIEIVKQGCWLDDINCYDRTDCVEKKDSPEVYFCCCE

GNMCNEKFSYFPEMEVTQPTSNPVTPKPPYYNILLYSLVPLMLIAGIVICAFWVYRHH

KMAYPPVLVPTQDPGPPPPSPLLGLKPLQLLEVKARGRFGCVWKAQLLNEYVAVKIF

PIQDKQSWQNEYEVYSLPGMKHENILQFIGAEKRGTSVDVDLWLITAFHEKGSLSDF

LKANVVSWNELCHIAETMARGLAYLHEDIPGLKDGHKPAISHRDIKSKNVLLKNNLT

ACIADFGLALKFEAGKSAGDTHGQVGTRRYMAPEVLEGAINFQRDAFLRIDMYAMG

LVLWELASRCTAADGPVDEYMLPFEEEIGQHPSLEDMQEVVVHKKKRPVLRDYWQ

KHAGMAMLCETIEECWDHDAEARLSAGCVGERITQMQRLTNIITTEDIVTVVTMVT

NVDFPPKESSL (SEQ ID NO: 5).

[0099] An exemplary human ActRIIB polypeptide sequence is set forth as:

MTAPWVALALLWGSLCAGSGRGEAETRECIYYNANWELERTNQSGLERCEGEQDK

RLHCYASWRNSSGTIELVKKGCWLDDFNCYDRQECVATEENPQVYFCCCEGNFCNE

RFTHLPEAGGPEVTYEPPPTAPTLLTVLAYSLLPIGGLSLIVLLAFWMYRHRKPPYGH

VDIHEDPGPPPPSPLVGLKPLQLLEIKARGRFGCVWKAQLMNDFVAVKIFPLQDKQS

WQSEREIFSTPGMKHENLLQFIAAEKRGSNLEVELWLITAFHDKGSLTDYLKGNIITW

NELCHVAETMSRGLSYLHEDVPWCRGEGHKPSIAHRDFKSKNVLLKSDLTAVLADF

GLAVRFEPGKPPGDTHGQVGTRRYMAPEVLEGAINFQRDAFLRIDMYAMGLVLWEL

VSRCKAADGPVDEYMLPFEEEIGQHPSLEELQEVVVHKKMRPTIKDHWLKHPGLAQ

LCVTIEECWDHDAEARLSAGCVEERVSLIRRSVNGTTSDCLVSLVTSVTNVDLPPKES

SI (SEQ ID NO: 6) [00100] An exemplary ALK2 polypeptide sequence is set forth as:

MVDGVMILPVLIMIALPSPSMEDEKPKVNPKLYMCVCEGLSCGNEDHCEGQQCFSSL

SINDGFHVYQKGCFQVYEQGKMTCKTPPSPGQAVECCQGDWCNRNITAQLPTKGKS

FPGTQNFHLEVGLIILSVVFAVCLLACLLGVALRKFKRRNQERLNPRDVEYGTIEGLIT

TNVGDSTLADLLDHSCTSGSGSGLPFLVQRTVARQITLLECVGKGRYGEVWRGSWQ

GENVAVKIFSSRDEKSWFRETELYNTVMLRHENILGFIASDMTSRHSSTQLWLITHYH

EMGSLYDYLQLTTLDTVSCLRIVLSIASGLAHLHIEIFGTQGKPAIAHRDLKSKNILVK

KNGQCCIADLGLAVMHSQSTNQLDVGNNPRVGTKRYMAPEVLDETIQVDCFDSYK

RVDrWAFGLVLWEVARRMVSNGIVEDYKPPFYDVVPNDPSFEDMRKVVCVDQQRP

NIPNRWFSDPTLTSLAKLMKECWYQNPSARLTALRIKKTLTKIDNSLDKLKTDC

(SEQ ID NO: 7).

[00101] An exemplary ALK4 polypeptide sequence is set forth as one of:

MAESAGASSFFPLVVLLLAGSGGSGPRGVQALLCACTSCLQANYTCETDGACMVSIF

NLDGMEHHVRTCIPKVELVPAGKPFYCLSSEDLRNTHCCYTDYCNRIDLRVPSGHLK

EPEHPSMWGPVELVGIIAGPVFLLFLIIIIVFLVINYHQRVYHNRQRLDMEDPSCEMCL

SKDKTLQDLVYDLSTSGSGSGLPLFVQRTVARTIVLQEIIGKGRFGEVWRGRWRGGD

VAVKIFSSREERSWFREAEIYQTVMLRHENILGFIAADNKDNGTWTQLWLVSDYHEH

GSLFDYLNRYTVTIEGMIKLALSAASGLAHLHMEIVGTQGKPGIAHRDLKSKNILVK

KNGMCAIADLGLAVRHDAVTDTIDIAPNQRVGTKRYMAPEVLDETINMKHFDSFKC

ADIYALGLVYWEIARRCNSGGVHEEYQLPYYDLVPSDPSIEEMRKVVCDQKLRPNIP

NWWQSYEALRVMGKMMRECWYANGAARLTALRIKKTLSQLSVQEDVKI (SEQ ID

NO: 8).

[00102] MVSIFNLDGMEHHVRTCIPKVELVPAGKPFYCLS SEDLRNTHCCYTD Y

CNRIDLRVPSGHLKEPEHPSMWGPVELVGIIAGPVFLLFLIIIIVFLVINYHQRVYHNRQ

RLDMEDPSCEMCLSKDKTLQDLVYDLSTSGSGSGLPLFVQRTVARTIVLQEIIGKGRF

GEVWRGRWRGGDVAVKIFSSREERSWFREAEIYQTVMLRHENILGFIAADNKDNGT

WTQLWLVSDYHEHGSLFDYLNRYTVTIEGMIKLALSAASGLAHLHMEIVGTQGKPG

IAHRDLKSKNILVKKNGMCAIADLGLAVRHDAVTDTIDIAPNQRVGTKRYMAPEVL

DETINMKHFDSFKCADIYALGLVYWEIARRCNSGGVHEEYQLPYYDLVPSDPSIEEM

RKVVCDQKLRPNIPNWWQSYEALRVMGKMMRECWYANGAARLTALRIKKTLSQL

SVQEDVKI (SEQ ID NO: 9) [00103] MAESAGASSFFPLVVLLLAGSGGSGPRGVQALLCACTSCLQANYTCET

DGACMVSIFNLDGMEHHVRTCIPKVELVPAGKPFYCLSSEDLRNTHCCYTDYCNRID

LRVPSGHLKEPEHPSMWGPVELVGIIAGPVFLLFLIIIIVFLVINYHQRVYHNRQRLDM

EDPS CEMCLS KD KTLQDLV YDLS TS GS GS GLPLFVQRTV ARTI VLQEIIGKGRFGEVW

RGRWRGGDVAVKIFSSREERSWFREAEIYQTVMLRHENILGFIAADNKADCSFLTLP

WEVVMVSAAPKLRSLRLQYKGGRGRARFLFPLNNGTWTQLWLVSDYHEHGSLFDY

LNRYTVTIEGMIKLALSAASGLAHLHMEIVGTQGKPGIAHRDLKSKNILVKKNGMCA

IADLGLAVRHDAVTDTIDIAPNQRVGTKRYMAPEVLDETINMKHFDSFKCADIYALG

LVYWEIARRCNSGGVHEEYQLPYYDLVPSDPSIEEMRKVVCDQKLRPNIPNWWQSY

EALRVMGKMMRECWYANGAARLTALRIKKTLSQLSVQEDVKI (SEQ ID NO: 10).

[00104] A non-limiting exemplary activin or activin receptor polypeptide or subsequence thereof includes or consists of a sequence at least 60% or more (e.g., 65%, 70%, 75%, 80%, 85%, 90%, 95%, etc.) identical to any one of SEQ ID NO: 1-10, wherein the activin or activin receptor polypeptide or subsequence stimulates, induces, increases or enhances an immune response, Tfh (follicular helper) cell differentiation, germinal center B cell development, an antibody response, or an immune response, such as a response induced by a vaccine.

[00105] In accordance with the invention, there are also provided activin and subsequences thereof that exhibit sequence identity to a reference activin subunit polypeptide or subsequence thereof, and which have an ability to modulate an immune response, for example, stimulates, induces, increases or enhances an immune response, Tfh (follicular helper) cell differentiation, germinal center B cell development, an antibody response, or an immune response, such as a response induced by a vaccine, in vitro or in vivo. In one embodiment, an activin or subsequence thereof includes or consists of a sequence at least 60% or more (e.g., 65%, 70%, 75%, 80%, 85%, 90%, 95%, etc.) up to 100% identical to any activin or activin receptor polypeptide or subsequence thereof (e.g., SEQ ID NOs: 1-10)

[00106] In another embodiment, activin or subsequence thereof includes or consists of a activin or subsequence thereof set forth as SEQ ID NO: 1-2, wherein the activin subunit polypeptide or subsequence thereof has one or more amino acid additions, deletions or substitutions of any of SEQ ID NO: 1-2. In particular aspects, activin subunit or subsequence is at least 80% or more, e.g., 80-85%, 85-90%, 90-95%, 95-100% identical to a activin subunit polypeptide or subsequence thereof set forth in SEQ ID NO: 1-2.

[00107] Activin comprises two subunits selected from an Inhibin- a polypeptide and an Inhibin- b polypeptide. An exemplary human Inhibin- a polypeptide sequence is set forth as (SEQ ID NO: 1).

[00108] An exemplary human Inhibin- fib polypeptide sequence is set forth as (SEQ ID NO: 2).

[00109] The invention provides isolated activin polypeptides, including or consisting of a activin subsequence, which exhibits sequence identity to a reference activin polypeptide or subsequence thereof (e.g., SEQ ID NO: 1-2), and which has one or more functions or activities of full length activin.

[00110] Such activin subsequences can be from about 5 to 300 amino acids in length, for example, from 5 to 15, 20 to 25, 25, to 50, 50 to 100, 100 to 150, 150 to 200, or 200 to 300 amino acids in length, provided that said subsequence or portion is at least one amino acid less in length than a full-length activin sequence (e.g., SEQ ID NO: 1-2).

[00111] In particular embodiments, a subsequence of an activin sequence or subsequence inhibits, decreases or reduces Tfh (follicular helper) cell differentiation, germinal center B cell development or an antibody response, inhibits, inhibits, decreases or reduces an undesirable or aberrant immune response, inhibits, decreases or reduces an undesirable or aberrant inflammatory response or inflammation. In additional embodiments, an activin subsequence stimulates, induces or increases an immune response, or stimulates, induces or increases Tfh (follicular helper) cell differentiation, germinal center B cell development, an antibody response, or stimulates, induces or increases an immune response, such as a response induced by a vaccine (e.g., elicits, promotes or enhances an immune response against a vaccine antigen in vitro or in vivo).

[00112] The term "isolated," when used as a modifier of a composition (e.g., activin polypeptides and subsequences thereof, etc.), means that the compositions are made by the hand of man or are separated, completely or at least in part, from their naturally occurring in vivo environment.

[00113] Generally, isolated compositions are substantially free of one or more materials with which they normally associate with in nature, for example, one or more protein, nucleic acid, lipid, carbohydrate, cell membrane. The term "isolated" does not exclude alternative physical forms of the composition, such as fusions/chimeras, multimers/oligomers, modifications (e.g., phosphorylation, glycosylation, lipidation) or derivatized forms, or forms expressed in host cells produced by the hand of man.

[00114] An "isolated" composition (e.g., activin or subsequence thereof) can also be "substantially pure" or "purified" when free of most or all of the materials with which it typically associates with in nature. Thus, isolated activin or subsequence thereof, that also is substantially pure or purified does not include polypeptides or polynucleotides present among millions of other sequences, such as peptides of an peptide library or nucleic acids in a genomic or cDNA library, for example. A "substantially pure" or "purified" composition can be combined with one or more other molecules. Thus, "substantially pure" or "purified" does not exclude combinations of compositions, such as combinations of activin or subsequence thereof and adjuvants, vaccines (e.g., antigens), agents, drugs or therapies.

[00115] The term "chimeric" and grammatical variations thereof, when used in reference to a sequence, means that the amino acid sequence contains one or more portions that are derived from, obtained or isolated from, or based upon two or more different proteins. For example, a portion of the sequence may be activin or subsequence thereof, and another portion of the sequence may be from a different peptide sequence, or a non-activin polypeptide sequence.

[00116] Activin and subsequences thereof of the invention include those having at least partial sequence identity to one or more exemplary activin sequences or a subsequence thereof (e.g., SEQ ID NO: 1-2). The percent identity of such sequences can be as little as 60%, or can be greater (e.g., 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, etc.). The percent identity can extend over the entire sequence length or a portion of the sequence. In particular aspects, the length of the sequence sharing the percent identity is 2, 3, 4, 5 or more contiguous amino acids, e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, etc. contiguous amino acids. In additional particular aspects, the length of the sequence sharing the percent identity is 20 or more contiguous amino acids, e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, etc. contiguous amino acids. In further particular aspects, the length of the sequence sharing the percent identity is 35 or more contiguous amino acids, e.g., 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 45, 47, 48, 49, 50, etc., contiguous amino acids. In yet further particular aspects, the length of the sequence sharing the percent identity is 50 or more contiguous amino acids, e.g., 50-55, 55-60, 60-65, 65-70, 70-75, 75-80, 80-85, 85-90, 90-95, 95-100, 100-1 10, etc. contiguous amino acids.

[00117] The term "identity" and grammatical variations thereof, mean that two or more referenced entities are the same. Thus, where two activin polypeptides or subsequences thereof are identical, they have the same amino acid sequence. The identity can be over a defined area (region or domain) of the sequence. "Areas, regions or domains" of homology or identity mean that a portion of two or more referenced entities share homology or are the same. The extent of identity between two sequences can be ascertained using a computer program and mathematical algorithm known in the art. Such algorithms that calculate percent sequence identity (homology) generally account for sequence gaps and mismatches over the comparison region or area. For example, a BLAST (e.g. , BLAST 2.0) search algorithm (see, e.g., Altschul et al., J. Mol. Biol. 215:403 (1990), publicly available through NCBI) has exemplary search parameters as follows: Mismatch -2; gap open 5 ; gap extension 2 . For polypeptide sequence comparisons, a BLASTP algorithm is typically used in combination with a scoring matrix, such as PAM100, PAM 250, BLOSUM 62 or BLOSUM 50. FASTA (e.g., FASTA2 and FASTA3) and SSEARCH sequence comparison programs are also used to quantitate the extent of identity (Pearson et al., Proc. Natl. Acad. Sci. USA 85:2444 (1988); Pearson, Methods Mol Biol. 132: 185 (2000); and Smith et al., J. Mol. Biol. 147:195 (1981)).

[00118] Programs for quantitating protein structural similarity using Delaunay-based topological mapping have also been developed (Bostick et al., Biochem Biophys Res Commun. 304:320 (2003)).

[00119] In accordance with the invention, there are provided activin subunit polypeptides and subsequences thereof that include modified and variant forms. As used herein, the terms "modify" or "variant" and grammatical variations thereof, mean that activin subunit polypeptides or subsequence thereof deviates from a reference activin sequence (e.g., SEQ ID NO: 1-2). Modified and variant activin subunit polypeptides and subsequences thereof may therefore have greater or less activity or function than a reference activin subunit polypeptide, or subsequence thereof, but at least retain partial activity or function of the reference sequence (e.g., SEQ ID NO: 1-2). Thus, activin subunit polypeptides and subsequences thereof include sequences having substantially the same, greater or less relative activity or function as SEQ ID NO: 1-2, for example, an ability to stimulate, induce or increase Tfh (follicular helper) cell differentiation, germinal center B cell development or an antibody response in vitro or in vivo, an ability to stimulate, an ability to inhibit, decrease or reduce an undesirable or aberrant immune response in vitro or in vivo, an ability to inhibit, decrease or reduce an undesirable or aberrant inflammatory response or inflammation in vitro or in vivo, an ability to stimulate, induce or increase an immune response in vitro or in vivo, or an ability to stimulate, induce or increase an immune response induced by a vaccine in vitro or in vivo (e.g., elicit, promote or enhance an immune response against a vaccine antigen in vitro or in vivo).

[00120] Non-limiting examples of modifications include one or more amino acid substitutions (e.g., 1-3, 3-5, 5-10, 10-15, 15-20, 20-25, or more residues), additions (e.g., insertions or 1-3, 3-5, 5-10, 10-15, 15-20, 20-25, or more residues) and deletions (e.g., subsequences or fragments) of a reference activin subunit polypeptide or subsequence thereof. In particular embodiments, a modified or variant sequence retains at least part of a function or an activity of unmodified sequence. Such modified forms and variants can have less than, the same, or greater, but at least a part of, a function or activity of a reference sequence, for example, as described herein.

[00121] Specific non- limiting examples of substitutions include conservative and non- conservative amino acid substitutions. A "conservative substitution" is the replacement of one amino acid by a biologically, chemically or structurally similar residue. Biologically similar means that the substitution does not destroy a biological activity. Structurally similar means that the amino acids have side chains with similar length, such as alanine, glycine and serine, or a similar size. Chemical similarity means that the residues have the same charge or are both hydrophilic or hydrophobic.

[00122] Particular examples include the substitution of one hydrophobic residue for another (e.g., isoleucine, valine, leucine or methionine), or the substitution of one polar residue for another, (e.g., substitution of arginine for lysine, glutamic for aspartic acids, or glutamine for asparagine, serine for threonine, and the like).

[00123] A modification also includes one or more D-amino acids substituted for L- amino acids (and mixtures thereof), structural and functional analogues, for example, peptidomimetics having synthetic or non-natural amino acids or amino acid analogues and derivatized forms. Accordingly, polypeptides and peptides described herein further include compounds having amino acid structural and functional analogues, for example, peptidomimetics having synthetic or non-natural amino acids or amino acid analogues, so long as the mimetic has one or more functions or activities of a native polypeptide set forth herein. Non-natural and non-amide chemical bonds, and other coupling means can also be included, for example, glutaraldehyde, N-hydoxysuccinimide esters, bifunctional maleimides, or N, N'-dicyclohexylcarbodiimide (DCC). Non-amide bonds can include, for example, ketomethylene aminomethylene, olefin, ether, thioether and the like (see, e.g., Spatola (1983) in Chemistry and Biochemistry of Amino Acids. Peptides and Proteins, Vol. 7, pp 267-357, "Peptide and Backbone Modifications," Marcel Decker, NY).

[00124] Modifications include cyclic structures such as an end-to-end amide bond between the amino and carboxy-terminus of the molecule or intra- or inter-molecular disulfide bond.

[00125] Polypeptides, peptides and peptidomimetics can be produced and isolated using methods known in the art. Peptides can be synthesized, whole or in part, using chemical methods known in the art (see, e.g., Caruthers (1980). Nucleic Acids Res. Symp. Ser. 15; Horn (1980); and Banga, A.K., Therapeutic Peptides and Proteins, Formulation, Processing and Delivery Systems (1995) Technomic Publishing Co., Lancaster, PA). Peptide synthesis can be performed using various solid phase techniques (see, e.g., Roberge Science 269:202 (1995); Merrifield, Methods Enzymol. 289:3(1997)) and automated synthesis may be achieved, e.g., using the ABI 431 A Peptide Synthesizer (Perkin Elmer) in accordance with the manufacturer's instructions. Peptides and peptide mimetics can also be synthesized using combinatorial methodologies. Synthetic residues and polypeptides incorporating mimetics can be synthesized using a variety of procedures and methodologies known in the art (see, e.g., Organic Syntheses Collective Volumes, Oilman, et al. (Eds) John Wiley & Sons, Inc., NY). Modified peptides can be produced by chemical modification methods (see, for example, Belousov, Nucleic Acids Res. 25:3440 (1997); Frenkel, Free Radic. Biol. Med. 19:373 (1995); and Blommers, Biochemistry 33:7886 (1994)

[00126] An addition can be the covalent or non-covalent attachment of any type of molecule to the sequence. Specific examples of additions include glycosylation, acetylation, phosphorylation, amidation, formylation, ubiquitination, and derivatization by protecting/blocking groups and any of numerous chemical modifications. Additional specific non-limiting examples of an addition include one or more additional amino acid residues. In particular embodiments, an addition is a fusion (chimeric) sequence, an amino acid sequence having one or more molecules not normally present in a reference native (wild type) sequence covalently attached to the sequence. A particular example is an amino acid sequence of another sequence to produce a chimera. Another particular example of a modified sequence having an amino acid addition is one in which a second heterologous sequence, i.e., heterologous functional domain is attached (covalent or non-covalent binding) that confers a distinct or complementary function. Heterologous functional domains are not restricted to amino acid residues. Thus, a heterologous functional domain can consist of any of a variety of different types of small or large functional moieties. Such moieties include nucleic acid, peptide, carbohydrate, lipid or small organic compounds, such as a drug (e.g., an antiviral), a metal (gold, silver), radioisotope. Thus, in other embodiments the invention provides activin subunit polypeptides and subsequences thereof and a heterologous domain, wherein the domain confers a distinct function, i.e. a heterologous functional domain.

[00127] Further non-limiting examples of additions are detectable labels. Thus, in another embodiment, the invention provides activin subunit polypeptides and subsequences thereof that are detectably labeled. Specific examples of detectable labels include fluorophores, chromophores, radioactive isotopes (e.g., S35, P32, 1125), electron-dense reagents, enzymes, ligands and receptors. Enzymes are typically detected by their activity. For example, horseradish peroxidase is usually detected by its ability to convert a substrate such as 3,3-',5,5-'-tetramethylbenzidine (TMB) to a blue pigment, which can be quantified.

[00128] Another non-limiting example of an addition is an insertion of an amino acid within any sequence of activin subunit polypeptides and subsequences thereof (e.g., SEQ ID NO: 1-2). In a particular embodiment, an insertion is of one or more amino acid residues in an activin subunit polypeptide or subsequence thereof (e.g., SEQ ID NO: 1-2). [00129] Modified activin subunit polypeptides and subsequences thereof also include one or more D-amino acids substituted for L-amino acids (and mixtures thereof), structural and functional analogues, for example, peptidomimetics having synthetic or non- natural amino acids or amino acid analogues and derivatized forms.

[00130] Activin subunit polypeptides and subsequences thereof including modified forms can be produced by any of a variety of standard protein purification or recombinant expression techniques. For example, an activin subunit polypeptide or subsequence thereof can be produced by standard peptide synthesis techniques, such as solid-phase synthesis. A portion of the protein may contain an amino acid sequence such as a T7 tag or polyhistidine sequence to facilitate purification of expressed or synthesized protein. The protein may be expressed in a cell and purified. The protein may be expressed as a part of a larger protein (e.g., a fusion or chimera) by recombinant methods.

[00131] Activin subunit polypeptides and subsequences thereof including modified forms can be made using recombinant DNA technology via cell expression or in vitro translation. Polypeptide sequences including modified forms can also be produced by chemical synthesis using methods known in the art, for example, an automated peptide synthesis apparatus (see, e.g., Applied Biosystems, Foster City, CA).

[00132] In accordance with the invention, there are provided host cells that express activin subunit polypeptides and subsequences thereof. Host cells include but are not limited to prokaryotic and eukaryotic cells such as bacteria, fungi (yeast), plant, insect, and animal (e.g., mammalian, including primate and human, CHO cells and hybridomas) cells. For example, bacteria transformed with recombinant bacteriophage nucleic acid, plasmid nucleic acid or cosmid nucleic acid expression vectors; yeast transformed with recombinant yeast expression vectors; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid); insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus); and animal cell systems infected with recombinant virus expression vectors (e.g., retroviruses, adenovirus, vaccinia virus), or transformed animal cell systems engineered for stable expression. The cells may be a primary cell isolate, cell culture (e.g., passaged, established or immortalized cell line), or part of a plurality of cells, or a tissue or organ ex vivo or in a subject (in vivo). [00133] The term "transformed" or "transfected" when used in reference to a cell (e.g., a host cell) or organism, means a genetic change in a cell following incorporation of an exogenous molecule, for example, a protein or nucleic acid (e.g., a transgene) into the cell. Thus, a "transfected" or "transformed" cell is a cell into which, or a progeny thereof in which an exogenous molecule has been introduced by the hand of man, for example, by recombinant DNA techniques.

[00134] An activin subunit nucleic acid or protein can be stably or transiently transfected or transformed (expressed) into the host cell and progeny thereof. The cell(s) can be propagated and the introduced protein expressed, or nucleic acid transcribed. A progeny of a transfected or transformed cell may not be identical to the parent cell, since there may be mutations that occur during replication.

Nucleic Acids

[00135] Additional activin or activin receptor inhibitors include inhibitory and antisense nucleic acid sequences. Inhibitory, antisense and RNAi nucleic acids can modulate expression of activin or activin receptor. Antisense includes single, double or triple stranded polynucleotides and peptide nucleic acids (PNAs) that bind RNA transcript or DNA (e.g., genomic DNA). For example, a single stranded nucleic acid can target activin or activin receptor transcript (e.g., miRNA). Oligonucleotides derived from the transcription initiation site of activin or activin receptor gene, e.g., between positions -10 and +10 from the start site, are another particular example. Triplex forming antisense can bind to double strand DNA thereby inhibiting transcription of the gene. "RNAi" is the use of double stranded RNA sequences for inhibiting gene expression (see, e.g., Kennerdell et al., Cell 95: 1017 (1998); and Fire et al., Nature . 391 :806 (1998)). Double stranded RNA sequences from an activin or activin receptor coding region may therefore be used to inhibit or prevent activin or activin receptor expression in accordance with the methods and uses of the invention. Antisense and RNAi can be produced based upon genes encoding activin or activin receptor sequences subunits (e.g., SEQ ID NOs: 1-10), such as nucleic acid encoding mammalian and human Inhibin- a, Inhibin- b, ActRIIA, ACTRIIB, ALK2 or ALK4. An exemplary human Inhibin- a mRNA sequence is set forth as:

AGTACAGTATAAAACTTCACAGTGCCAATACCATGAAGAGGAGCTCAGACAGCT CTTACCACATGATACAAGAGCCGGCTGGTGGAAGAGTGGGGACCAGAAAGAGA ATTTGCTGAAGAGGAGAAGGAAAAAAAAAACACCAAAAAAAAAAATAAAAAAA

TCCACACACACAAAAAAACCTGCGCGTGAGGGGGGAGGAAAAGCAGGGCCTTTT

AAAAAGGCAATCACAACAACTTTTGCTGCCAGGATGCCCTTGCTTTGGCTGAGAG

GATTTCTGTTGGCAAGTTGCTGGATTATAGTGAGGAGTTCCCCCACCCCAGGATC

CGAGGGGCACAGCGCGGCCCCCGACTGTCCGTCCTGTGCGCTGGCCGCCCTCCCA

AAGGATGTACCCAACTCTCAGCCAGAGATGGTGGAGGCCGTCAAGAAGCACATT

TTAAACATGCTGCACTTGAAGAAGAGACCCGATGTCACCCAGCCGGTACCCAAG

GCGGCGCTTCTGAACGCGATCAGAAAGCTTCATGTGGGCAAAGTCGGGGAGAAC

GGGTATGTGGAGATAGAGGATGACATTGGAAGGAGGGCAGAAATGAATGAACTT

ATGGAGCAGACCTCGGAGATCATCACGTTTGCCGAGTCAGGAACAGCCAGGAAG

ACGCTGCACTTCGAGATTTCCAAGGAAGGCAGTGACCTGTCAGTGGTGGAGCGT

GCAGAAGTCTGGCTCTTCCTAAAAGTCCCCAAGGCCAACAGGACCAGGACCAAA

GTCACCATCCGCCTCTTCCAGCAGCAGAAGCACCCGCAGGGCAGCTTGGACACA

GGGGAAGAGGCCGAGGAAGTGGGCTTAAAGGGGGAGAGGAGTGAACTGTTGCT

CTCTGAAAAAGTAGTAGACGCTCGGAAGAGCACCTGGCATGTCTTCCCTGTCTCC

AGCAGCATCCAGCGGTTGCTGGACCAGGGCAAGAGCTCCCTGGACGTTCGGATT

GCCTGTGAGCAGTGCCAGGAGAGTGGCGCCAGCTTGGTTCTCCTGGGCAAGAAG

AAGAAGAAAGAAGAGGAGGGGGAAGGGAAAAAGAAGGGCGGAGGTGAAGGTG

GGGCAGGAGCAGATGAGGAAAAGGAGCAGTCGCACAGACCTTTCCTCATGCTGC

AGGCCCGGCAGTCTGAAGACCACCCTCATCGCCGGCGTCGGCGGGGCTTGGAGT

GTGATGGCAAGGTCAACATCTGCTGTAAGAAACAGTTCTTTGTCAGTTTCAAGGA

CATCGGCTGGAATGACTGGATCATTGCTCCCTCTGGCTATCATGCCAACTACTGC

GAGGGTGAGTGCCCGAGCCATATAGCAGGCACGTCCGGGTCCTCACTGTCCTTCC

ACTCAACAGTCATCAACCACTACCGCATGCGGGGCCATAGCCCCTTTGCCAACCT

CAAATCGTGCTGTGTGCCCACCAAGCTGAGACCCATGTCCATGTTGTACTATGAT

GATGGTCAAAACATCATCAAAAAGGACATTCAGAACATGATCGTGGAGGAGTGT

GGGTGCTCATAGAGTTGCCCAGCCCAGGGGGAAAGGGAGCAAGAGTTGTCCAGA

GAAGACAGTGGCAAAATGAAGAAATTTTTAAGGTTTCTGAGTTAACCAGAAAAA

TAGAAATTAAAAACAAAACAAAAAAAAAAACAAAAAAAAACAAAAGTAAATTA

AAAACAAAACCTGATGAAACAGATGAAGGAAGATGTGGAAAAAATCCTTAGCC

AGGGCTCAGAGATGAAGCAGTGAAAGAGACAGGAATTGGGAGGGAAAGGGAGA

ATGGTGTACCCTTTATTTCTTCTGAAATCACACTGATGACATCAGTTGTTTAAACG

GGGTATTGTCCTTTCCCCCCTTGAGGTTCCCTTGTGAGCCTTGAATCAACCAATCT AGTCTGCAGTAGTGTGGACTAGAACAACCCAAATAGCATCTAGAAAGCCATGAG

TTTGAAAGGGCCCATCACAGGCACTTTCCTACCCAATTACCCAGGTCATAAGGTA

TGTCTGTGTGACACTTATCTCTGTGTATATCAGCATACACACACACACACACACA

CACACACACACACACAGGCATTTCCACACATTACATATATACACATACTGGTAAA

AGAACAATCGTGTGCAGGTGGTCACACTTCCTTTTTCTGTACCACTTTTGCAACA

AAACAA (SEQ ID NO: 11).

[00136] An exemplary human Inhibin- fib mRNA sequence is set forth as:

ACTCGGCTCGCCTCGCGGCGGGCGCCCTCGTCGCCAGCGGCGCACCATGGACGG

GCTGCCCGGTCGGGCGCTGGGGGCCGCCTGCCTTCTGCTGCTGGCGGCCGGCTGG

CTGGGGCCTGAGGCCTGGGGCTCACCCACGCCCCCGCCGACGCCTGCCGCGCCG

CCGCCACCCCCGCCACCCGGATCCCCGGGTGGCTCGCAGGACACCTGTACGTCGT

GCGGCGGCTTCCGGCGGCCAGAGGAGCTCGGCCGAGTGGACGGCGACTTCCTGG

AGGCGGTGAAGCGGCACATCTTGAGCCGCCTGCAGATGCGGGGCCGGCCCAACA

TCACGCACGCCGTGCCTAAGGCCGCCATGGTCACGGCCCTGCGCAAGCTGCACG

CGGGCAAGGTGCGCGAGGACGGCCGCGTGGAGATCCCGCACCTCGACGGCCACG

CCAGCCCGGGCGCCGACGGCCAGGAGCGCGTTTCCGAAATCATCAGCTTCGCCG

AGACAGATGGCCTCGCCTCCTCCCGGGTCCGCCTATACTTCTTCATCTCCAACGA

AGGCAACCAGAACCTGTTTGTGGTCCAGGCCAGCCTGTGGCTTTACCTGAAACTC

CTGCCCTACGTCCTGGAGAAGGGCAGCCGGCGGAAGGTGCGGGTCAAAGTGTAC

TTCCAGGAGCAGGGCCACGGTGACAGGTGGAACATGGTGGAGAAGAGGGTGGA

CCTCAAGCGCAGCGGCTGGCATACCTTCCCACTCACGGAGGCCATCCAGGCCTTG

TTTGAGCGGGGCGAGCGGCGACTCAACCTAGACGTGCAGTGTGACAGCTGCCAG

GAGCTGGCCGTGGTGCCGGTGTTCGTGGACCCAGGCGAAGAGTCGCACCGGCCC

TTTGTGGTGGTGCAGGCTCGGCTGGGCGACAGCAGGCACCGCATTCGCAAGCGA

GGCCTGGAGTGCGATGGCCGGACCAACCTCTGTTGCAGGCAACAGTTCTTCATTG

ACTTCCGCCTCATCGGCTGGAACGACTGGATCATAGCACCCACCGGCTACTACGG

GAACTACTGTGAGGGCAGCTGCCCAGCCTACCTGGCAGGGGTCCCCGGCTCTGCC

TCCTCCTTCCACACGGCTGTGGTGAACCAGTACCGCATGCGGGGTCTGAACCCCG

GCACGGTGAACTCCTGCTGCATTCCCACCAAGCTGAGCACCATGTCCATGCTGTA

CTTCGATGATGAGTACAACATCGTCAAGCGGGACGTGCCCAACATGATTGTGGA

GGAGTGCGGCTGCGCCTGACAGTGCAAGGCAGGGGCACGGTGGTGGGGCACGG

AGGGCAGTCCCGGGTGGGCTTCTTCCAGCCCCCGCGGGAACGGGGGTACACGGT GGGCTGAGTACAGTCATTCTGTTGGGCTGTGGAGATAGTGCCAGGGTGCGGCCTG

AGATATTTTTCTACAGCTTCATAGAGCAACCAGTCAAAACCAGAGCGAGAACCCT

CAACTGACATGAAATACTTTAAAATGCACACGTAGCCACGCACAGCCAGACGCA

TCCTGCCACCCACACAGCAGCCTCCAGGATACCAGCAAATGGATGCGGTGACAA

ATGGCAGCTTAGCTACAAATGCCTGTCAGTCGGAGAGAATGGGGTGAGCAGCCA

CCATTCCCACCAGCTGGCCCGGCCACTCTGAATTGCGCCTTCCGAGCACACATAA

AAGCACAAAGACAGAGACGCAGAGAGAGAGAGAGAGCCACGGAGAGGAAAAG

CAGATGCAGGGGTGGGGAGCGCAGCTCGGCGGAGGCTGCGTGTGCCCCGTGGCT

TTTACCAGGCCTGCTCTGCCTGGCTCGATGTCTGCTTCTTCCCCAGCCTGGGATCC

TTCGTGCTTCAAGGCCTGGGGAGCCTGTCCTTCCATGCCCTTGTCGAGGGAAAGA

GACCCAGAAAGGACACAACCCGTCAGAGACCTGGGAGCAGGGGCAATGACCGTT

TGACTGTTTGTGGCTTGGGCCTCTGACATGACTTATGTGTGTGTGTGTTTTTGGGG

TGGGGAGGGAGGGAGAGAAGAGGGGGCTAAATTTGATGCTTTAACTGATCTCCA

ACAGTTGACAGGTCATCCTTGCCAGTTGTATAACTGAAAAAGGACTTTTCTACCA

GGTATGACCTTTTAAGTGAAAATCTGAATTGTTCTAAATGGAAAGAAAAAAAGTT

GCAATCTGTGCCCTTCATTGGGGACATTCCTCTAGGACTGGTTTGGGGACGGGTG

GGAATGACCCCTAGGCAAGGGGATGAGACCGCAGGAGGAAATGGCGGGGAGGA

GGCATTCTTGAACTGCTGAGGATGGGGGGTGTCCCCTCAGCGGAGGCCAAGGGA

GGGGAGCAGCCTAGTTGGTCTTGGAGAGATGGGGAAGGCTTTCAGCTGATTTGC

AGAAGTTGCCCATGTGGGCCCCAGCCATCAGGGCTGGCCGTGGACGTGGCCCCT

GCCCACTCACCTGCCCGCCTGCCCGCCCGCCCGCATAGCACTTGCAGACCTGCCT

GAACGCACATGACATAGCACTTGCCGATCTGCGTGTGTCCAGAAGTGGCCCTTGG

CCGAGCGCCGAACTCGCTCGCCCTCTAGATGTCCAAGTGCCACGTGAACTATGCA

ATTTAAAGGGTTGACCCACACTAGACGAAACTGGACTCGTACGACTCTTTTTATA

TTTTTTATACTTGAAATGAAATCCTTTGCTTCTTTTTTAAGCGAATGATTGCTTTTA

ATGTTTGCACTGATTTAGTTGCATGATTAGTCAGAAACTGCCATTTGAAAAAAAG

TTATTTTTATAGCAGCAAAAAAAAAAAAAAAAGAATACAGTTAAATGTATTATA

CATAATTTTGGAACCAAAGAGGCCAACAGATCAGTTTTAATTTTATTAGACGGTG

AGGCCATCTGAGATGAGGTGGACGTTCTGAGCAGTCCCTTGAGTGGCCTGCCAAC

GTTTCAGGGTATGAATGGATTTTGTTTATTCGGTTTGATGTGTCTTTTCCATCCTT

ACACACCCAGAAGGTAGAGTAAAAATGACTATGATAGAATGCAGGTGTGTATCC

TTAAATCCTCATCTTTATGTTTATTTAATAAAGCTCCCCTTAGATTCTGTTTCATA

ATAATTTAAAACCAAACAATTTTCCCATAGACTTGCTGTTAAAGTATTGTACGTTT GTGTACAGTTTAAGAAAATAAAAGATTGAGTGCCACGGGAAAAAAAAAAAAAA A (SEQ ID NO: 12).

[00137] Activin receptor comprises two subunits selected from one of ActRIIA or ActRIIB and one of ALK2 or ALK4. An exemplary human ActRIIA mRNA sequence is set forth as one of:

AGGAGACCGAAAACGCGGCCGAGCCCGGAGCCCGGAGCTGGAGCCAGAGCCTG

GACCAGAACTTGGCCGCCGCCTGCACCGCCGCCGCCGCTGCCGCCCGCCGCCCCT

TCCCCGCGCCGCAGCCGCCTCGCCGCCACCGCCGCGAGCTCGGCCGCCAGTGGTC

CTCGGACTTTAGGTGTCTGGGTTGAAGGAGGTTTGTCTCCGAGGAAGACCCAGGG

AACTGGATATCTAGCGAGAACTTCCTCCGGATTCCCCGGCGCCTCGGGAAAATGG

GAGCTGCTGCAAAGTTGGCGTTTGCCGTCTTTCTTATCTCCTGTTCTTCAGGTGCT

ATACTTGGTAGATCAGAAACTCAGGAGTGTCTTTTCTTTAATGCTAATTGGGAAA

AAGACAGAACCAATCAAACTGGTGTTGAACCGTGTTATGGTGACAAAGATAAAC

GGCGGCATTGTTTTGCTACCTGGAAGAATATTTCTGGTTCCATTGAAATAGTGAA

ACAAGGTTGTTGGCTGGATGATATCAACTGCTATGACAGGACTGATTGTGTAGAA

AAAAAAGACAGCCCTGAAGTATATTTTTGTTGCTGTGAGGGCAATATGTGTAATG

AAAAGTTTTCTTATTTTCCGGAGATGGAAGTCACACAGCCCACTTCAAATCCAGT

TACACCTAAGCCACCCTATTACAACATCCTGCTCTATTCCTTGGTGCCACTTATGT

TAATTGCGGGGATTGTCATTTGTGCATTTTGGGTGTACAGGCATCACAAGATGGC

CTACCCTCCTGTACTTGTTCCAACTCAAGACCCAGGACCACCCCCACCTTCTCCAT

TACTAGGTTTGAAACCACTGCAGTTATTAGAAGTGAAAGCAAGGGGAAGATTTG

GTTGTGTCTGGAAAGCCCAGTTGCTTAACGAATATGTGGCTGTCAAAATATTTCC

AATACAGGACAAACAGTCATGGCAAAATGAATACGAAGTCTACAGTTTGCCTGG

AATGAAGCATGAGAACATATTACAGTTCATTGGTGCAGAAAAACGAGGCACCAG

TGTTGATGTGGATCTTTGGCTGATCACAGCATTTCATGAAAAGGGTTCACTATCA

GACTTTCTTAAGGCTAATGTGGTCTCTTGGAATGAACTGTGTCATATTGCAGAAA

CCATGGCTAGAGGATTGGCATATTTACATGAGGATATACCTGGCCTAAAAGATG

GCCACAAACCTGCCATATCTCACAGGGACATCAAAAGTAAAAATGTGCTGTTGA

AAAACAACCTGACAGCTTGCATTGCTGACTTTGGGTTGGCCTTAAAATTTGAGGC

TGGCAAGTCTGCAGGCGATACCCATGGACAGGTTGGTACCCGGAGGTACATGGC

TCCAGAGGTATTAGAGGGTGCTATAAACTTCCAAAGGGATGCATTTTTGAGGATA

GATATGTATGCCATGGGATTAGTCCTATGGGAACTGGCTTCTCGCTGTACTGCTG CAGATGGACCTGTAGATGAATACATGTTGCCATTTGAGGAGGAAATTGGCCAGC

ATCCATCTCTTGAAGACATGCAGGAAGTTGTTGTGCATAAAAAAAAGAGGCCTG

TTTTAAGAGATTATTGGCAGAAACATGCTGGAATGGCAATGCTCTGTGAAACCAT

TGAAGAATGTTGGGATCACGACGCAGAAGCCAGGTTATCAGCTGGATGTGTAGG

TGAAAGAATTACCCAGATGCAGAGACTAACAAATATTATTACCACAGAGGACAT

TGTAACAGTGGTCACAATGGTGACAAATGTTGACTTTCCTCCCAAAGAATCTAGT

CTATGATGGTTGCGCCATCTGTGCACACTAAGAAATGGGACTCTGAACTGGAGCT

GCTAAGCTAAAGAAACTGCTTACAGTTTATTTTCTGTGTAAAATGAGTAGGATGT

CTCTTGGAAATGTTAAGAAAGAAGACCCTTTGTTGAAAAATGTTGCTCTGGGAGA

CTTACTGCATTGCCGACAGCACAGATGTGAAGGACATGAGACTAAGAGAAACCT

TGCAAACTCTATAAAGAAACTTTTGAAAAAGTGTACATGAAGAATGTAGCCCTCT

CCAAATCAAGGATCTTTTGGACCTGGCTAATGGAGTGTTTGAAAACTGACATCAG

ATTTCTTAATGTCTGTCAGAAGACACTAATTCCTTAAATGAACTACTGCTATTTTT

TTTAAATCAAAAACTTTTCATTTCAGATTTTAAAAAGGGTAACTTGTTTTTATTGC

ATTTGCTGTTGTTTCTATAAATGACTATTGTAATGCCAATATGACACAGCTTGTGA

ATGTTTAGTGTGCTGCTGTTCTGTGTACATAAAGTCATCAAAGTGGGGTACAGTA

AAGAGGCTTCCAAGCATTACTTTAACCTCCCTCAACAAGGTATACCTCAGTTCCA

CGGTTGCTAAATTATAAAATTGAAAACACTAACAAAATTTGAATAATAAATCGAT

CCATGTTTTGTAACAAATTCACTGTGTTATTTAAGGAAAAAAAGGTAAGCTATGC

TTAGTGCCAACAATAAGTGGCCATTCGTAAAGCAGTGTTTTAGCATTTCTTGTGC

TGGCTTGTAATGTAGGGAAAAAAAGTGCTGTTTTTTGAAAAGATGGTGTCATTTC

CCCCTTCTTCCCATGTTTTAAAGCCCCATCTTATATCCAGTTCCCAAAATTTGCAT

ACTTACCTAAGTATTTTTTTTAGGTGTGCTGTGTTTGGGGAATATTTGAAAATTTA

AAGCATGATTTAAAATTTTTTAAAGTGAGCTGTGACACTGGAAAGCTCTTCATTT

TATCTTTTAAAATAGAGTTTTTTCTATTTATATATGTAAAATTGTAGTGTATTTCTT

TTCACCAAACAGTGTGTGGGACATTCTTTATCACTGTTTTAGGATCACCTCAGGA

AGTGTCGTTACCCAGAATTCCCCACTGTCTGCTATGAGACTTGTAACTTTATCACT

ATACTTCTGCTTGGTGCCATCTTGTCAGAGTAATATTTGATGTCTGTGATATGTAA

AGAATTATCCTAGGATAAAGATATTAAACTTTAAGCAGATTTCAGATGTTACTGC

TTTAAAACAAATCAGGGATAACAAATTAAACGTATAACTTAAAATATGCAATGA

CATTTAGAGGTAACCAATGTTGATATAGGTAGCATAGCCTAGCCTCCTCCCCAAA

ATTGCTTTTACAACTAACACTGATACTAATTTAGGATAGTTCATGCCTTATCCTTG

CTAAGAAAATGGAATTGATGGTAGGCAGGTGCTAAAGTGCTTTTCAAAACAATA TTACGTTAGAATACAATTGGATTCTTCCTCAAATTTATACAGGCCAAAAAGTAAA

ACATTAATTTTCTGAATTTCCAGATTACCAATCAATTAATCAACAAATAGCCAGT

ATTATGCTGTGTATTTCTGTCAGGTCATTTTAAAATCCATGTTAATTTTATAAAAG

AATTTTTTACATGTCACTGTCAGGAGCTCACTGTGAATGTGTTGTCTTCAAATGGT

TATTTAACCACACAGTACACTACATTTTACATATATGTACGTAATCTCTGGGAAT

AGTAAATTAATTATGTTATTTATAAACAATACATAGGTCAACAGACTTTAAGCAG

GGAGGAAAAGAAGAGTAATAGCGTCTGTGTGCTGCAGACCATTCAGAACTGTCA

CGTGTGTCCCCATGGTCTCATTCATTGTATTCCTAGCAATTCCCTTTTCAATGTTG

AGTTCACCTCTTTATTTCACAAAGTACTTGGTCTCTCAATTTCTTGATCTGGTTTTG

CTTCCATTTAAAAACTAATCAAGAAGGGAAAATATTGAGAATGTGCATACAAGA

AAATCATTAATTTCCTGAAGATGAATTTCTACCTGTTGTGAACATTTAACTTTCTT

TTTAAAAGTTAAACAAAAATAAACAAGGGATATTATGATGAATGTTTGGCTTATG

TGAGTACTAGAGATAAAATTTTTAAACCCAGTTATTCACAATATAAAATGTTTTC

AAGTTAGAAAAAATTTTTAGAAATCCTGGGTATTGTATTTAACTGTAGCTAACCA

ATTTTAAAACTTGTATTCTTTTGAGAACTATTATTAATAGAAAAACTTTTTATAAG

CAGTAAAATAAGAATGTTCCAGTGACTACCTGTCCTTATACCTAGTCTTGTTAAA

ACTTTCTTTTGCAGGGTATTTAGTGTTTGGTTTACAGTCAGTGCAGAGTGGGCAA

GTTAACAGAAAGTTTGAGCTAGAGATACTGGAAAAAAAAAAGATCAAAGAATG

AGAAAAATGGTGATCCATTTTGGGGCAAACTGAGACCCCCCAAATAACTCTTTCC

TCATGTGTATGGTGCTCCTCATGACTCGTCTTGTATTTTGCCTTTCTGATACCCAT

CAGAACTGCTGCTGCTCTAACTTATACTCTTTACCTTGCCCAGATCTCCGCGTAAG

GAATGCTTTATGATCAACTTGCCATAGGACTGATGGATTAACCAGTGTTCGGCTT

TATTTGAAGTCTATGCCCTGCACAGCTCTTGTATGTATTTTAGATGCTAGAAGTTT

TTTTAGCATGTGATGTGTGATTCTTGTTTGAATTCTAGGTACCTTGTGAATTCCAG

AAAAAGAGACTGTGCTTCACGATTGTTAGTCCCATGAACTTGCACTATCTATCTT

TCATGGTGATGTTTTGAAAATACAATCAGGAAAAAACCCAACACCTTTGGAATTT

AAAATAGAATCATATCATGAAATTTAAAAAGAATCTCTTCTGTTGCATTTCCTCA

CCCCTAAGTAACAGCTACATTTAAGTAAAATGCAGGTGGTAGGGGAAAAAAAAC

CATGGCGAGATGGTGGTTTAGTGGAATAAACTGATTACTGGTTTTTTTGTTTTTTT

TTTTTTTTTTAAAGAAAGAAGCTTCATCACAGATACTTTCCAGTTTCTCTTTTATA

CTTTTTTGAAAGATTACTTTTTAGGAACATTTGGTATGATATGCATAAAATTATTT

ATCCATTTATGGGCAAAATGATACAAGTAGCATCTTGATTGAACATCATTTACCT

CAGATATTCAACCAGCAGTACGTTTTTTATGCAGTCTCAACCCATATCCCATTTGT TACCTCTCAGAATATTGGTAAGCAGTTATTTTCGCTTTACTCTGTATTTCTTGTGTT TTGGGCACAGGTTATTGTACTACTGTCAAATCGTACTTGCTATTTTTTCTGCAAGT ATTTAACAGAAAGCTTAAAATCCCCATAAAACCCCACCTTGGATAAGTGATTGTT AAATATTGTACAAATAAAATGTATGCTATCCCCATTCCATCCCCAAGTTAAATAA AAAAATGAATACGGTATGAAAAAAAAAAA (SEQ ID NO: 13),

[00138] TGAGCGTTTTTTTTTTTTTTTTTTTTTTTTTTTGGTCTGGGCTTCCGAA

TATGTTTTATGACGGTTGATTTTACACCAGGAGGTTTGTCTCCGAGGAAGACCCA

GGGAACTGGATATCTAGCGAGAACTTCCTCCGGATTCCCCGGCGCCTCGGGAAA

ATGGGAGCTGCTGCAAAGTTGGCGTTTGCCGTCTTTCTTATCTCCTGTTCTTCAGG

TGCTATACTTGGTAGATCAGAAACTCAGGAGTGTCTTTTCTTTAATGCTAATTGG

GAAAAAGACAGAACCAATCAAACTGGTGTTGAACCGTGTTATGGTGACAAAGAT

AAACGGCGGCATTGTTTTGCTACCTGGAAGAATATTTCTGGTTCCATTGAAATAG

TGAAACAAGGTTGTTGGCTGGATGATATCAACTGCTATGACAGGACTGATTGTGT

AGAAAAAAAAGACAGCCCTGAAGTATATTTTTGTTGCTGTGAGGGCAATATGTGT

AATGAAAAGTTTTCTTATTTTCCGGAGATGGAAGTCACACAGCCCACTTCAAATC

CAGTTACACCTAAGCCACCCTATTACAACATCCTGCTCTATTCCTTGGTGCCACTT

ATGTTAATTGCGGGGATTGTCATTTGTGCATTTTGGGTGTACAGGCATCACAAGA

TGGCCTACCCTCCTGTACTTGTTCCAACTCAAGACCCAGGACCACCCCCACCTTCT

CCATTACTAGGTTTGAAACCACTGCAGTTATTAGAAGTGAAAGCAAGGGGAAGA

TTTGGTTGTGTCTGGAAAGCCCAGTTGCTTAACGAATATGTGGCTGTCAAAATAT

TTCCAATACAGGACAAACAGTCATGGCAAAATGAATACGAAGTCTACAGTTTGC

CTGGAATGAAGCATGAGAACATATTACAGTTCATTGGTGCAGAAAAACGAGGCA

CCAGTGTTGATGTGGATCTTTGGCTGATCACAGCATTTCATGAAAAGGGTTCACT

ATCAGACTTTCTTAAGGCTAATGTGGTCTCTTGGAATGAACTGTGTCATATTGCA

GAAACCATGGCTAGAGGATTGGCATATTTACATGAGGATATACCTGGCCTAAAA

GATGGCCACAAACCTGCCATATCTCACAGGGACATCAAAAGTAAAAATGTGCTG

TTGAAAAACAACCTGACAGCTTGCATTGCTGACTTTGGGTTGGCCTTAAAATTTG

AGGCTGGCAAGTCTGCAGGCGATACCCATGGACAGGTTGGTACCCGGAGGTACA

TGGCTCCAGAGGTATTAGAGGGTGCTATAAACTTCCAAAGGGATGCATTTTTGAG

GATAGATATGTATGCCATGGGATTAGTCCTATGGGAACTGGCTTCTCGCTGTACT

GCTGCAGATGGACCTGTAGATGAATACATGTTGCCATTTGAGGAGGAAATTGGC

CAGCATCCATCTCTTGAAGACATGCAGGAAGTTGTTGTGCATAAAAAAAAGAGG CCTGTTTTAAGAGATTATTGGCAGAAACATGCTGGAATGGCAATGCTCTGTGAAA

CCATTGAAGAATGTTGGGATCACGACGCAGAAGCCAGGTTATCAGCTGGATGTG

TAGGTGAAAGAATTACCCAGATGCAGAGACTAACAAATATTATTACCACAGAGG

ACATTGTAACAGTGGTCACAATGGTGACAAATGTTGACTTTCCTCCCAAAGAATC

TAGTCTATGATGGTTGCGCCATCTGTGCACACTAAGAAATGGGACTCTGAACTGG

AGCTGCTAAGCTAAAGAAACTGCTTACAGTTTATTTTCTGTGTAAAATGAGTAGG

ATGTCTCTTGGAAATGTTAAGAAAGAAGACCCTTTGTTGAAAAATGTTGCTCTGG

GAGACTTACTGCATTGCCGACAGCACAGATGTGAAGGACATGAGACTAAGAGAA

ACCTTGCAAACTCTATAAAGAAACTTTTGAAAAAGTGTACATGAAGAATGTAGC

CCTCTCCAAATCAAGGATCTTTTGGACCTGGCTAATGGAGTGTTTGAAAACTGAC

ATCAGATTTCTTAATGTCTGTCAGAAGACACTAATTCCTTAAATGAACTACTGCT

ATTTTTTTTAAATCAAAAACTTTTCATTTCAGATTTTAAAAAGGGTAACTTGTTTT

TATTGCATTTGCTGTTGTTTCTATAAATGACTATTGTAATGCCAATATGACACAGC

TTGTGAATGTTTAGTGTGCTGCTGTTCTGTGTACATAAAGTCATCAAAGTGGGGT

ACAGTAAAGAGGCTTCCAAGCATTACTTTAACCTCCCTCAACAAGGTATACCTCA

GTTCCACGGTTGCTAAATTATAAAATTGAAAACACTAACAAAATTTGAATAATAA

ATCGATCCATGTTTTGTAACAAATTCACTGTGTTATTTAAGGAAAAAAAGGTAAG

CTATGCTTAGTGCCAACAATAAGTGGCCATTCGTAAAGCAGTGTTTTAGCATTTC

TTGTGCTGGCTTGTAATGTAGGGAAAAAAAGTGCTGTTTTTTGAAAAGATGGTGT

CATTTCCCCCTTCTTCCCATGTTTTAAAGCCCCATCTTATATCCAGTTCCCAAAAT

TTGCATACTTACCTAAGTATTTTTTTTAGGTGTGCTGTGTTTGGGGAATATTTGAA

AATTTAAAGCATGATTTAAAATTTTTTAAAGTGAGCTGTGACACTGGAAAGCTCT

TCATTTTATCTTTTAAAATAGAGTTTTTTCTATTTATATATGTAAAATTGTAGTGT

ATTTCTTTTCACCAAACAGTGTGTGGGACATTCTTTATCACTGTTTTAGGATCACC

TCAGGAAGTGTCGTTACCCAGAATTCCCCACTGTCTGCTATGAGACTTGTAACTT

TATCACTATACTTCTGCTTGGTGCCATCTTGTCAGAGTAATATTTGATGTCTGTGA

TATGTAAAGAATTATCCTAGGATAAAGATATTAAACTTTAAGCAGATTTCAGATG

TTACTGCTTTAAAACAAATCAGGGATAACAAATTAAACGTATAACTTAAAATATG

CAATGACATTTAGAGGTAACCAATGTTGATATAGGTAGCATAGCCTAGCCTCCTC

CCCAAAATTGCTTTTACAACTAACACTGATACTAATTTAGGATAGTTCATGCCTT

ATCCTTGCTAAGAAAATGGAATTGATGGTAGGCAGGTGCTAAAGTGCTTTTCAAA

ACAATATTACGTTAGAATACAATTGGATTCTTCCTCAAATTTATACAGGCCAAAA

AGTAAAACATTAATTTTCTGAATTTCCAGATTACCAATCAATTAATCAACAAATA GCCAGTATTATGCTGTGTATTTCTGTCAGGTCATTTTAAAATCCATGTTAATTTTA

TAAAAGAATTTTTTACATGTCACTGTCAGGAGCTCACTGTGAATGTGTTGTCTTCA

AATGGTTATTTAACCACACAGTACACTACATTTTACATATATGTACGTAATCTCTG

GGAATAGTAAATTAATTATGTTATTTATAAACAATACATAGGTCAACAGACTTTA

AGCAGGGAGGAAAAGAAGAGTAATAGCGTCTGTGTGCTGCAGACCATTCAGAAC

TGTCACGTGTGTCCCCATGGTCTCATTCATTGTATTCCTAGCAATTCCCTTTTCAA

TGTTGAGTTCACCTCTTTATTTCACAAAGTACTTGGTCTCTCAATTTCTTGATCTG

GTTTTGCTTCCATTTAAAAACTAATCAAGAAGGGAAAATATTGAGAATGTGCATA

CAAGAAAATCATTAATTTCCTGAAGATGAATTTCTACCTGTTGTGAACATTTAAC

TTTCTTTTTAAAAGTTAAACAAAAATAAACAAGGGATATTATGATGAATGTTTGG

CTTATGTGAGTACTAGAGATAAAATTTTTAAACCCAGTTATTCACAATATAAAAT

GTTTTCAAGTTAGAAAAAATTTTTAGAAATCCTGGGTATTGTATTTAACTGTAGCT

AACCAATTTTAAAACTTGTATTCTTTTGAGAACTATTATTAATAGAAAAACTTTTT

ATAAGCAGTAAAATAAGAATGTTCCAGTGACTACCTGTCCTTATACCTAGTCTTG

TTAAAACTTTCTTTTGCAGGGTATTTAGTGTTTGGTTTACAGTCAGTGCAGAGTGG

GCAAGTTAACAGAAAGTTTGAGCTAGAGATACTGGAAAAAAAAAAGATCAAAG

AATGAGAAAAATGGTGATCCATTTTGGGGCAAACTGAGACCCCCCAAATAACTC

TTTCCTCATGTGTATGGTGCTCCTCATGACTCGTCTTGTATTTTGCCTTTCTGATAC

CCATCAGAACTGCTGCTGCTCTAACTTATACTCTTTACCTTGCCCAGATCTCCGCG

TAAGGAATGCTTTATGATCAACTTGCCATAGGACTGATGGATTAACCAGTGTTCG

GCTTTATTTGAAGTCTATGCCCTGCACAGCTCTTGTATGTATTTTAGATGCTAGAA

GTTTTTTTAGCATGTGATGTGTGATTCTTGTTTGAATTCTAGGTACCTTGTGAATT

CCAGAAAAAGAGACTGTGCTTCACGATTGTTAGTCCCATGAACTTGCACTATCTA

TCTTTCATGGTGATGTTTTGAAAATACAATCAGGAAAAAACCCAACACCTTTGGA

ATTTAAAATAGAATCATATCATGAAATTTAAAAAGAATCTCTTCTGTTGCATTTC

CTCACCCCTAAGTAACAGCTACATTTAAGTAAAATGCAGGTGGTAGGGGAAAAA

AAACCATGGCGAGATGGTGGTTTAGTGGAATAAACTGATTACTGGTTTTTTTGTT

TTTTTTTTTTTTTTTAAAGAAAGAAGCTTCATCACAGATACTTTCCAGTTTCTCTTT

TATACTTTTTTGAAAGATTACTTTTTAGGAACATTTGGTATGATATGCATAAAATT

ATTTATCCATTTATGGGCAAAATGATACAAGTAGCATCTTGATTGAACATCATTT

ACCTCAGATATTCAACCAGCAGTACGTTTTTTATGCAGTCTCAACCCATATCCCAT

TTGTTACCTCTCAGAATATTGGTAAGCAGTTATTTTCGCTTTACTCTGTATTTCTTG

TGTTTTGGGCACAGGTTATTGTACTACTGTCAAATCGTACTTGCTATTTTTTCTGC AAGTATTTAACAGAAAGCTTAAAATCCCCATAAAACCCCACCTTGGATAAGTGAT TGTTAAATATTGTACAAATAAAATGTATGCTATCCCCATTCCATCCCCAAGTTAA ATAAAAAAATGAATACGGTATGAAAAAAAAAAA ((SEQ ID NO: 14), or

[00139] AGGAGACCGAAAACGCGGCCGAGCCCGGAGCCCGGAGCTGGAGCC

AGAGCCTGGACCAGAACTTGGCCGCCGCCTGCACCGCCGCCGCCGCTGCCGCCC

GCCGCCCCTTCCCCGCGCCGCAGCCGCCTCGCCGCCACCGCCGCGAGCTCGGCCG

CCAGTGGTCCTCGGACTTTAGGTGTCTGGGTTGAAGACAGAACCAATCAAACTGG

TGTTGAACCGTGTTATGGTGACAAAGATAAACGGCGGCATTGTTTTGCTACCTGG

AAGAATATTTCTGGTTCCATTGAAATAGTGAAACAAGGTTGTTGGCTGGATGATA

TCAACTGCTATGACAGGACTGATTGTGTAGAAAAAAAAGACAGCCCTGAAGTAT

ATTTTTGTTGCTGTGAGGGCAATATGTGTAATGAAAAGTTTTCTTATTTTCCGGAG

ATGGAAGTCACACAGCCCACTTCAAATCCAGTTACACCTAAGCCACCCTATTACA

ACATCCTGCTCTATTCCTTGGTGCCACTTATGTTAATTGCGGGGATTGTCATTTGT

GCATTTTGGGTGTACAGGCATCACAAGATGGCCTACCCTCCTGTACTTGTTCCAA

CTCAAGACCCAGGACCACCCCCACCTTCTCCATTACTAGGTTTGAAACCACTGCA

GTTATTAGAAGTGAAAGCAAGGGGAAGATTTGGTTGTGTCTGGAAAGCCCAGTT

GCTTAACGAATATGTGGCTGTCAAAATATTTCCAATACAGGACAAACAGTCATGG

CAAAATGAATACGAAGTCTACAGTTTGCCTGGAATGAAGCATGAGAACATATTA

CAGTTCATTGGTGCAGAAAAACGAGGCACCAGTGTTGATGTGGATCTTTGGCTGA

TCACAGCATTTCATGAAAAGGGTTCACTATCAGACTTTCTTAAGGCTAATGTGGT

CTCTTGGAATGAACTGTGTCATATTGCAGAAACCATGGCTAGAGGATTGGCATAT

TTACATGAGGATATACCTGGCCTAAAAGATGGCCACAAACCTGCCATATCTCACA

GGGACATCAAAAGTAAAAATGTGCTGTTGAAAAACAACCTGACAGCTTGCATTG

CTGACTTTGGGTTGGCCTTAAAATTTGAGGCTGGCAAGTCTGCAGGCGATACCCA

TGGACAGGTTGGTACCCGGAGGTACATGGCTCCAGAGGTATTAGAGGGTGCTAT

AAACTTCCAAAGGGATGCATTTTTGAGGATAGATATGTATGCCATGGGATTAGTC

CTATGGGAACTGGCTTCTCGCTGTACTGCTGCAGATGGACCTGTAGATGAATACA

TGTTGCCATTTGAGGAGGAAATTGGCCAGCATCCATCTCTTGAAGACATGCAGGA

AGTTGTTGTGCATAAAAAAAAGAGGCCTGTTTTAAGAGATTATTGGCAGAAACA

TGCTGGAATGGCAATGCTCTGTGAAACCATTGAAGAATGTTGGGATCACGACGC

AGAAGCCAGGTTATCAGCTGGATGTGTAGGTGAAAGAATTACCCAGATGCAGAG ACTAACAAATATTATTACCACAGAGGACATTGTAACAGTGGTCACAATGGTGAC

AAATGTTGACTTTCCTCCCAAAGAATCTAGTCTATGATGGTTGCGCCATCTGTGC

ACACTAAGAAATGGGACTCTGAACTGGAGCTGCTAAGCTAAAGAAACTGCTTAC

AGTTTATTTTCTGTGTAAAATGAGTAGGATGTCTCTTGGAAATGTTAAGAAAGAA

GACCCTTTGTTGAAAAATGTTGCTCTGGGAGACTTACTGCATTGCCGACAGCACA

GATGTGAAGGACATGAGACTAAGAGAAACCTTGCAAACTCTATAAAGAAACTTT

TGAAAAAGTGTACATGAAGAATGTAGCCCTCTCCAAATCAAGGATCTTTTGGACC

TGGCTAATGGAGTGTTTGAAAACTGACATCAGATTTCTTAATGTCTGTCAGAAGA

CACTAATTCCTTAAATGAACTACTGCTATTTTTTTTAAATCAAAAACTTTTCATTT

CAGATTTTAAAAAGGGTAACTTGTTTTTATTGCATTTGCTGTTGTTTCTATAAATG

ACTATTGTAATGCCAATATGACACAGCTTGTGAATGTTTAGTGTGCTGCTGTTCTG

TGTACATAAAGTCATCAAAGTGGGGTACAGTAAAGAGGCTTCCAAGCATTACTTT

AACCTCCCTCAACAAGGTATACCTCAGTTCCACGGTTGCTAAATTATAAAATTGA

AAACACTAACAAAATTTGAATAATAAATCGATCCATGTTTTGTAACAAATTCACT

GTGTTATTTAAGGAAAAAAAGGTAAGCTATGCTTAGTGCCAACAATAAGTGGCC

ATTCGTAAAGCAGTGTTTTAGCATTTCTTGTGCTGGCTTGTAATGTAGGGAAAAA

AAGTGCTGTTTTTTGAAAAGATGGTGTCATTTCCCCCTTCTTCCCATGTTTTAAAG

CCCCATCTTATATCCAGTTCCCAAAATTTGCATACTTACCTAAGTATTTTTTTTAG

GTGTGCTGTGTTTGGGGAATATTTGAAAATTTAAAGCATGATTTAAAATTTTTTA

AAGTGAGCTGTGACACTGGAAAGCTCTTCATTTTATCTTTTAAAATAGAGTTTTTT

CTATTTATATATGTAAAATTGTAGTGTATTTCTTTTCACCAAACAGTGTGTGGGAC

ATTCTTTATCACTGTTTTAGGATCACCTCAGGAAGTGTCGTTACCCAGAATTCCCC

ACTGTCTGCTATGAGACTTGTAACTTTATCACTATACTTCTGCTTGGTGCCATCTT

GTCAGAGTAATATTTGATGTCTGTGATATGTAAAGAATTATCCTAGGATAAAGAT

ATTAAACTTTAAGCAGATTTCAGATGTTACTGCTTTAAAACAAATCAGGGATAAC

AAATTAAACGTATAACTTAAAATATGCAATGACATTTAGAGGTAACCAATGTTGA

TATAGGTAGCATAGCCTAGCCTCCTCCCCAAAATTGCTTTTACAACTAACACTGA

TACTAATTTAGGATAGTTCATGCCTTATCCTTGCTAAGAAAATGGAATTGATGGT

AGGCAGGTGCTAAAGTGCTTTTCAAAACAATATTACGTTAGAATACAATTGGATT

CTTCCTCAAATTTATACAGGCCAAAAAGTAAAACATTAATTTTCTGAATTTCCAG

ATTACCAATCAATTAATCAACAAATAGCCAGTATTATGCTGTGTATTTCTGTCAG

GTCATTTTAAAATCCATGTTAATTTTATAAAAGAATTTTTTACATGTCACTGTCAG

GAGCTCACTGTGAATGTGTTGTCTTCAAATGGTTATTTAACCACACAGTACACTA CATTTTACATATATGTACGTAATCTCTGGGAATAGTAAATTAATTATGTTATTTAT

AAACAATACATAGGTCAACAGACTTTAAGCAGGGAGGAAAAGAAGAGTAATAG

CGTCTGTGTGCTGCAGACCATTCAGAACTGTCACGTGTGTCCCCATGGTCTCATTC

ATTGTATTCCTAGCAATTCCCTTTTCAATGTTGAGTTCACCTCTTTATTTCACAAA

GTACTTGGTCTCTCAATTTCTTGATCTGGTTTTGCTTCCATTTAAAAACTAATCAA

GAAGGGAAAATATTGAGAATGTGCATACAAGAAAATCATTAATTTCCTGAAGAT

GAATTTCTACCTGTTGTGAACATTTAACTTTCTTTTTAAAAGTTAAACAAAAATAA

ACAAGGGATATTATGATGAATGTTTGGCTTATGTGAGTACTAGAGATAAAATTTT

TAAACCCAGTTATTCACAATATAAAATGTTTTCAAGTTAGAAAAAATTTTTAGAA

ATCCTGGGTATTGTATTTAACTGTAGCTAACCAATTTTAAAACTTGTATTCTTTTG

AGAACTATTATTAATAGAAAAACTTTTTATAAGCAGTAAAATAAGAATGTTCCAG

TGACTACCTGTCCTTATACCTAGTCTTGTTAAAACTTTCTTTTGCAGGGTATTTAG

TGTTTGGTTTACAGTCAGTGCAGAGTGGGCAAGTTAACAGAAAGTTTGAGCTAGA

GATACTGGAAAAAAAAAAGATCAAAGAATGAGAAAAATGGTGATCCATTTTGGG

GCAAACTGAGACCCCCCAAATAACTCTTTCCTCATGTGTATGGTGCTCCTCATGA

CTCGTCTTGTATTTTGCCTTTCTGATACCCATCAGAACTGCTGCTGCTCTAACTTA

TACTCTTTACCTTGCCCAGATCTCCGCGTAAGGAATGCTTTATGATCAACTTGCCA

TAGGACTGATGGATTAACCAGTGTTCGGCTTTATTTGAAGTCTATGCCCTGCACA

GCTCTTGTATGTATTTTAGATGCTAGAAGTTTTTTTAGCATGTGATGTGTGATTCT

TGTTTGAATTCTAGGTACCTTGTGAATTCCAGAAAAAGAGACTGTGCTTCACGAT

TGTTAGTCCCATGAACTTGCACTATCTATCTTTCATGGTGATGTTTTGAAAATACA

ATCAGGAAAAAACCCAACACCTTTGGAATTTAAAATAGAATCATATCATGAAAT

TTAAAAAGAATCTCTTCTGTTGCATTTCCTCACCCCTAAGTAACAGCTACATTTAA

GTAAAATGCAGGTGGTAGGGGAAAAAAAACCATGGCGAGATGGTGGTTTAGTGG

AATAAACTGATTACTGGTTTTTTTGTTTTTTTTTTTTTTTTTAAAGAAAGAAGCTTC

ATCACAGATACTTTCCAGTTTCTCTTTTATACTTTTTTGAAAGATTACTTTTTAGG

AACATTTGGTATGATATGCATAAAATTATTTATCCATTTATGGGCAAAATGATAC

AAGTAGCATCTTGATTGAACATCATTTACCTCAGATATTCAACCAGCAGTACGTT

TTTTATGCAGTCTCAACCCATATCCCATTTGTTACCTCTCAGAATATTGGTAAGCA

GTTATTTTCGCTTTACTCTGTATTTCTTGTGTTTTGGGCACAGGTTATTGTACTACT

GTCAAATCGTACTTGCTATTTTTTCTGCAAGTATTTAACAGAAAGCTTAAAATCCC

CATAAAACCCCACCTTGGATAAGTGATTGTTAAATATTGTACAAATAAAATGTAT

GCTATCCCCATTCCATCCCCAAGTTAAATAAAAAAATGAATACGGTATGAAAAA AAAAAA (SEQ ID NO: 15).

[00140] An exemplary human ActRIIB mRNA sequence is set forth as:

GTGCGCGGGGCGGCGCCGCGGAACATGACGGCGCCCTGGGTGGCCCTCGCCCTC

CTCTGGGGATCGCTGTGCGCCGGCTCTGGGCGTGGGGAGGCTGAGACACGGGAG

TGCATCTACTACAACGCCAACTGGGAGCTGGAGCGCACCAACCAGAGCGGCCTG

GAGCGCTGCGAAGGCGAGCAGGACAAGCGGCTGCACTGCTACGCCTCCTGGCGC

AACAGCTCTGGCACCATCGAGCTCGTGAAGAAGGGCTGCTGGCTAGATGACTTC

AACTGCTACGATAGGCAGGAGTGTGTGGCCACTGAGGAGAACCCCCAGGTGTAC

TTCTGCTGCTGTGAAGGCAACTTCTGCAACGAACGCTTCACTCATTTGCCAGAGG

CTGGGGGCCCGGAAGTCACGTACGAGCCACCCCCGACAGCCCCCACCCTGCTCA

CGGTGCTGGCCTACTCACTGCTGCCCATCGGGGGCCTTTCCCTCATCGTCCTGCTG

GCCTTTTGGATGTACCGGCATCGCAAGCCCCCCTACGGTCATGTGGACATCCATG

AGGACCCTGGGCCTCCACCACCATCCCCTCTGGTGGGCCTGAAGCCACTGCAGCT

GCTGGAGATCAAGGCTCGGGGGCGCTTTGGCTGTGTCTGGAAGGCCCAGCTCAT

GAATGACTTTGTAGCTGTCAAGATCTTCCCACTCCAGGACAAGCAGTCGTGGCAG

AGTGAACGGGAGATCTTCAGCACACCTGGCATGAAGCACGAGAACCTGCTACAG

TTCATTGCTGCCGAGAAGCGAGGCTCCAACCTCGAAGTAGAGCTGTGGCTCATCA

CGGCCTTCCATGACAAGGGCTCCCTCACGGATTACCTCAAGGGGAACATCATCAC

ATGGAACGAACTGTGTCATGTAGCAGAGACGATGTCACGAGGCCTCTCATACCT

GCATGAGGATGTGCCCTGGTGCCGTGGCGAGGGCCACAAGCCGTCTATTGCCCA

CAGGGACTTTAAAAGTAAGAATGTATTGCTGAAGAGCGACCTCACAGCCGTGCT

GGCTGACTTTGGCTTGGCTGTTCGATTTGAGCCAGGGAAACCTCCAGGGGACACC

CACGGACAGGTAGGCACGAGACGGTACATGGCTCCTGAGGTGCTCGAGGGAGCC

ATCAACTTCCAGAGAGATGCCTTCCTGCGCATTGACATGTATGCCATGGGGTTGG

TGCTGTGGGAGCTTGTGTCTCGCTGCAAGGCTGCAGACGGACCCGTGGATGAGTA

CATGCTGCCCTTTGAGGAAGAGATTGGCCAGCACCCTTCGTTGGAGGAGCTGCAG

GAGGTGGTGGTGCACAAGAAGATGAGGCCCACCATTAAAGATCACTGGTTGAAA

CACCCGGGCCTGGCCCAGCTTTGTGTGACCATCGAGGAGTGCTGGGACCATGATG

CAGAGGCTCGCTTGTCCGCGGGCTGTGTGGAGGAGCGGGTGTCCCTGATTCGGA

GGTCGGTCAACGGCACTACCTCGGACTGTCTCGTTTCCCTGGTGACCTCTGTCAC

CAATGTGGACCTGCCCCCTAAAGAGTCAAGCATCTAAGCCCAGGACATGAGTGT

CTGTCCAGACTCAGTGGATCTGAAGAAAAAAGGAAAAAAAGTTGTGTTTTGTTTT GGAAATCCCATAAAACCAACAAACACATAAAATGCAGCTGCTATTTTACCTTGAC

TTTTTATTATTATTATTATAATTATTATAATTATTATTATTAATATTATTTTTTGGA

TTGGATCAGTTTTTACCAGCATATTGCTCTACTGTATCACAAACAGCGGACACGT

CAGCAGGCGTTGAGGTGCTGAGCTGTGGATGCAGAACCAGCGCCATGCTGAAGA

GCCTCAGCCACCTCCTGTCCTTTGGGATTCGTTTTTCCCGCTTTCTCTTTGTTTGTC

GTCTCAGAATCTGTGACACAAAGAAACCCATCTCCTGTCTTAGGAAACCTAATGC

TGCAAACTCTACCTAGAGGAACCTTTGAAGACTGTTACATAAGAACATACCTTCC

TCAGAAGAGGAGTTTCCTCTGCCCTCTGCCCTTCTCCCCTGCCTCCCTCCCTCCCC

TCCTTTTATTTTGTTTTAGTGAGCTTAAGAAACAGCAGATGTGTCTTTCACGGATC

TAACGGGTGTTGTCCTGATCGAGAAAAAAACTGGGATGAGAATGGTTTGGACTG

GAGTTGGAAGGGGAGGACGGTACTGGGGGTAGGGTTTGGAACAGAGCTACACTG

GACTCGGGCACATTCGGAGCAGCATCCTTTAGTATGGAGGCTACTTCTCAGGTAA

CCAGGAATTGAGGGGAAGGACCTTGTGGAGGCCGAGCATTAACAGCAAGAGCG

GGGTTTGGAGAAAGTCTGAGATTGGGTGCAGCCCTGACTTACCTGCTGGCCCTGA

CCAGTTTCTTTTCACTAACTTGGCCTTGGGCATAGGATGAAACATTTTTTCTGCCC

TAATTTTAAAACTAGGTGAGGGTAGAATCATCACAGGTTAGGAATACATTCTTCA

TAAGACACGATGCTGTAAATACCCTTAATGGACGAAAAGTTGAAATACTTTTGTT

TCCTCTTGGAGCAGTTCAGGGAAATGCCCACAGGGGATTGTCCTGCACAGATAG

GGCAAGAGGATTTCCTGGGTGGAGTCTGCCAAGGCCTGCCTCGCTGGGGACCCC

AGAGTCCTGCACCTCTGGTTCCGCCCCAGGTGGTGACATTACTGTCCCCGTTCTGT

GGCTCGTGGACAAGACTTTCTCCAGACCCCTTAAAGTGGTACATATTCTAAAAAA

CTGTTTTTCTATTATGCCATAACCTTGCTCTAGTCAGTGAATGTTCCTAATGCTGC

TGTTTCAACATTTGAATTCTTTTTAATTTATGAAACATGCTAAATTTTTTTTTTCAA

ACAAAACACACACATCCACATATACACATGCTTCGCTATGTGGCTTCCAAGGTTT

AAATTTTGAAAAGTAAAAGAATTAAAACTTCACGACCACAGATCACCTCAAACC

AGAAATACCTCAGAATTTTCTACTTATGTAAGGTTTATTATATATTTTGTTAGTTG

TGTTGTCTTGTAGTAAGTATATTTTAATGTAAGTTGGCTTTTGTGACAAGGAAGTT

TAAAAGAAATAGAGAAAAAGAAAAAAGTTTGCATCTTCTAGGGAGTGCTACCAT

TTTTGTTTGATAACGCCCCCTTGTAAATAATTGTCATCAACTGTAGGTTGGCTGTC

TGGGCCAAGTCTGGGCATTTATCAGTCTTGTTTGTGAAGGCTTTTCCTTCTGGTTT

CTTTAGATCATTTTATTTAAAAACAGTGCATCTCTTCATCGTGAGGGTAGGCAAG

GCGGGGGCCGTGGGGAGAGGTTGACCTGGGTGAGAACTGAAGAGGCCGCCTCCT

CTTGGGTTGTTTGGAGCTTCACATGTAATTCACATGTAACATGTAACTTGATCGGT CAGTGTTCAGAATGACAAGTAACCCCGCTTAAACTTGGTAGAAGGATGGCCCTTA

GACCTGAATGGGGTGATTTTACTTGGGATTTAACTTCTTCAGCAAATTAACAGCA

ACGTTGGAAGAGATCTGTGGCGCCTCTGTGAAGCACACCGTGACTCAGGCCAGT

CTTTTAGTGCAGCGTGTCTGGGAGTGAAGGGTTTTGCCCTTGCTGGTCTTGGAGT

CCACAGTGTGAGGGGCACTGCACATGCCTGGGCATCTACCTAGTGTGCTATGTTC

AGTGTCTGGGGCTTACTGCCCCGGGGTCCTTTCCTCTGGGTGTTGGGGCACAGGG

TGCTATGGGAGGCCCATTTGCTTCCCTCTCGGAGCTCAGTTTTTGCTTCATGGGTC

AAAATGTGGGCTGGCCAAGTGGTTACAGGAACAGGGTTTCGGTAAGCTATGTTG

TCTTTTTTTTTTTTTTTTTTTTTTTTTTTAATGGTTTGATTTTGTGCTGTGGTATTTTT

TTTCCCTTAGAATAATTTTTAATGGCAAAACAGGCCTTACAGCAGTTGCTTTTCTT

TACCATTTATTTCTTTAAGAAGCTTTAAAATATTTATTGAAAAGTGCCATATCTAA

TTTCTTTAGCTTTCGCCTCAGGCAGTGCAGGCATCTTTACTTTTCATCCTCAGAAG

AAACAAACGACTAACAAATGTAGCAAATTTACTGCAGGAATAGTTAGGTCATGA

TACTACCTGAACACTAAACCCCAGCCTCTTTGTTTGGTTTTAGTTCCTCTGGGTGG

TTTTTCTTTTGTGTGCTGGCTTGATTCTTGTGAGAAGTTTTGACCTGGCCAAGGGA

GGGTTGAGCCATGGTTCTGGTGTGGGACTTTGCGGTCAAGACACAGTACAGACA

GGTCAGGCCTGCGTGCCTTTTCTCTGGGTGGCCTCCCCGTTAGGCCCACCGTACG

CTCAGCCACTATAGTGTCCCTGTGGGGCCTTGCCATCAGATTGTGTGTCAGGAGA

TGGTACCTTTTTGGTGTGGCTGGGGAGGAGTGTGGTCCATGCCAGTTCTTTGGGC

TTCAGGCCACTCTTCCCCTCATGCTGTGGTGTAAAGTGCACCCATCAGGTGGTAT

ATCTGGTTCTGATGGCAAGAAGAAGGTGGGGGATCTCCTTATAGGGCATGGGTCT

AGGAGCACAGATGGGCCTTTTGCCCCGGGTAAATGCTTGTCTGTTTGCTGTCATG

TGTTCTTTGAGGAGTGAGCCATCTCGAGCCCTGCTTTGAATTTACTGGGTCATAG

AGCCTCTGCCTGTGCTCTTTTCCATAATGACTTCATGTGACATGCACTTTTGGTGG

GCTCAGATAATTGGTTTCTTTTTGTTTTTGACCTCAGGCTCTGTGGCAGACTGGGG

AAAATGGGGCCTGGCATCATTTTCCCTGTCAATGGGAGGGGCTGTTCCATGCAGG

GTGGGAGGGGACCAAGTTAGCAGAGAGTAGCCAAGGATCCTTGCTTCTTCCTTTC

TAGTGTGCTGTCATCCAAGCAGGCTCCTGGCTGTAGGGATGGGCCTTGGGGAAG

AATCTTCTTTGAAAGCATCTATGATAACTGAGAAGTCATCCCTAGTTGGAGAAAT

CCAGTAATGAGCAGAAGGAGGAAGCAAGTGAGGACAGAGGCCATTGTATTACA

GTGTCACGCAGAGGGCCCTCAATGATGGGGCATTGGGGAAGGCTGTAGACATAG

TCATCAGAACATCCTGGCCTGGCATAAGCTGGGTTTTCTCCTGGGACCATTGGTC

CTCAGCAGGAGTTCTTTGCATGAGTTGCTCAGGGGCAAGGGCTGCAAGTGGGCT GTGCTTAGGAGAAAGTGACACCTGGCAGTGAGGGAAGATGGTGAGCATTATTAG

CCTTTGTTGTCCAGCATGGCCTTCTTGTCCTGTCTGCTCTGGAGAGGAGCCTGTGG

GACCAGTCCTGCCTGGGGAGGGCATACCCACACGTGCCAGCTGATTCTGACTCTG

AATACATCATGTCCGGACTTGGGGGTGTTTCTGCAGAAAAAGGAGGTTGTTTTTC

AGCCTTGAACATCTTCAGGAGGATAGAGACTCTTGCTCACATATTCTTAGCAAAG

GGAAGGGTCTCTCATCTCCAGGCCACAGAGATAGTTCTTCCATTGCCCTAAGAGG

CTAGGCTAACCCTCTTGACATAACTTAGACAGCAAAGCACTTCATCCTGTAGTTG

GGCTCTGTCACCTTTCTCTTCAGTTGGCCACATTCTCGTTTCCTCCATCCTGCTATG

CTTTGTGTGCTCGGGCTGTGTGTGGGGTTTTTCCCTGGTGGAAGGAAGCCCAGCT

GTGTATTGAATGTCCTTCATGTGTTGTGTGTGGCTCAGAAAGCCTGTCACTTGGCC

CCTGTGCTCTGAGCCGTGAGGGTGGGGAGGTGGCTGTTCCATTAAAGTGGGAGT

ATTGGATGGCCCTCTTGAAACTAGAATTTTGCCTTTTTTAGTATGCAGTATAAAGT

TTCCAGCATCTATTGGTAACACAAAGATTTGCTGGTTTTTAAAATAATACAGTAA

GCATAAGTATGTAAGTTTTTAGAATTGGTACTAGAAGTTGGACAGCTAGTTATTC

TCGAGAACTTTATTTCACTAGAAAAATATACTAATTGGAAAGCAGTTTCCAGGAG

TTAACTCAGTTTAATTTTCAGTCTCAGTTATTTTAGCCTGTTGAGTTTTTGATGGC

ACACCTTTGGAGAGATGGCCACGCCTGATTCCCATTTCAGGGGCATCAGACCATA

CCTTTTTAAGAAGCTCCGTGAATCTAGTCATCTACCCTTCATCCTGGGCGAACAG

CCAAAAAGAGAAGGGGACAAGGTGTCTTTTTCTCCTTCTCACTGGGGTGACATGA

ATTCTTTTAGTTAATGGCTGTTTGCAAATTCTAAACTAATGAAATACTTAGCAGCT

AACATGTTCAATCTAGTAATGATGAGTTTAAATCTCAATTGACAGTAATGTTTTA

GATAAACAGGCCCAGTAATTCAGTTGATGAACTGTATATCTTCTCAGTCTAGATT

TGTAAATGTTTAATGAATTCAGGGTTATAAGCATAGTTCTTTAAGTAAGATTCCA

GATAGTTGATTTGCAACCAGCAGTCTACCTATGAATGTATCCCAAACCTTTAGAA

GATTGGAAAAGATTTTTGAAATAATGATTTAGTTTTGTAGGAAAAACACCCCCTT

GAAAATTAATTCGGTTGACCCAGTAACATTTTTTAAAACAATTGGTGGCTCCAAA

AGGCCTGCCAACAAAGAAAAGTCCAAATTATCTAGTGGGACATTTTGAATGTTTT

ATGTTTATTTTGGGTCCACTGTAAACTTTGGTTCAAAAAAGAATTTGAATTTAAA

GAATTTACCATTATTTAAATTATTACCAAGTTTTTACATTTTCATGATGGTATTTT

CCAGGTATGAATGAAACATGACTTTTTGATTGTGGTACTTCCTGTATCCCCTGTAG

TGCCAAAACCAGTGATACTTTATTTGCTCCTATGGCAGCTCATAGAGGTAACCGA

AGTGATTTTTCCTCAGTAATTGAAACACATATTCTCTAAATGCCAATGTGTGGTG

ATGGGCCCTGCACTGCCTTCATTTCTCTAGGGCAGTGTCTTTGGATTGTCTAGGGC CTAGGTAATTCTGAGAACTACTGTAAACCAACCACAGGGCACTAAAGCAATGTA

CACACCACTCTTTGTGTGTATGGAAGGGGTTATATAAACCTGGGCTATGCTGGAC

ATCTACAGAAGAGTATTACATTCACTTGCAAAGTTTACATTTTTGAGCTCACAGT

TATGAAAAATATGACCCACAAGTTTTTCAGGCAGGTGAGGATGGGTCTTCTTGCA

AATGCATGAGTTCTGTCTTGAGTCCTGGGAACTTCTCTGTTGGTTGAGTGTGGGCT

CATTCCCTGACTCTCCTAATCATGTTTGCGTCAGAATGTTAGCATTGTAAATAAA

AGAATAGGTTGTATAATAGATACACAACACTTGAAACTTTACTTTAAAAAAATCG

ATAGTTCTACATATATATTTAGTTATATCACTTGACAGATTTCTTCTACACAGTGT

GGAGATTGTTTTATACCACAGATTATTTTTATAAAGTTAGTGAATTTGAATGATTT

TGTAATCAGAGCTAATGAGCTTTACCTTTCAAGAGAAACGTACACTGGAGCATGA

GTGGTGTGGAACTTTTACTTAGTGTTTATATGGATTCTTGTGATACACTGGCAGAC

TGGAGTCAATTTGCGGGTCTTTTTTGGCCAAAACTCCACTTGTGGTTGTGTAGGA

CAGTGATATTCAGCTCAGCTTCTTGTGGATTGGGAGGAGAGAGGGCCTGCAATGT

GTTTTACATTGGTGCTTCCTCCTGAGATTTCTGTTGAACAAAGGGTTCTGAGGTCA

AAAATTAGTTTGTAAGCCTTTGCCATAGGACATAGTCATGTGAGAGTGTTTGGGG

GAACAGAAATTGTATAGGGGTGCCTATTGGGGTGGGATGGGACTCGAATAAGAT

TCAGGTACAAAAACTTTGAAATGAGAATCTGGTGGTTTGAGTAATCCACCAGACT

GAATTATCTAAGATCACATTATCCAGGTTGGGGGGCAGAATTACCCAGTTAAGTA

ATTGTTCAGAAAAGTGGGGAGGGTGGCATGTGGATGCAGTGATCCAATTAAATG

GAGAGCTGCCAGGCACATTTTGTCCTCTCTGGTCAGTGAGAATGGTTGGGTTGGC

TCGCTGCTTCAATCTGTGGAATCAGCCAGGAGCCCAGTGAGGAAGCTCAGAACC

CCAGTAACAGCAGAGCATCTTTCAGATAGCTCCAGAGTTTTCCTGCTTTTCTGAG

GAAGCTCAGCATCACTGCCACAATACGGAAAGTGGTCTTCATTTTAGCCTATTTA

TTTTTAGGCAGAGAGTGGATGGTTATTTGTGTGGGACTTTTGGTGGCGATATATA

ATGAATAATTAAGTTAATTTCTGGTATGCATAATGGCCAGTCCTGAGGCCCAGCT

GAAGACCTGTCCCCCAGACCCTGCCCGCTGGCTTCAGGCTGCTGCTTCTAGACAG

AGGTGCACTGGACGGGATAGTTTTATCAAGAGAATCCCTAATGTGTCATTTTAAA

CCAGCTGTGCTTTTTATTCATTCTGGTTGAGCGTATAGGTTTACACTTTACCCTTTT

TATACTTGGAATAAATTTAGTTCCAGCAGATCTAGTAGCACTCCAGAAACCAACC

CCATCTGTTCCCCATAAAAAGAACATTTTCTCTGCTCTCCAGCCACGTGTCTTGGA

ATGTAATTCTGTTGTGCCTTTGTTTTTATCACTCTCTTCGCCCCAAAAGCAACTGC

TGTAAGCTTTTTTCTACTTGTCTTTTCTAGTCCCCAACCTCTACCTTTTTCCTTTTTC

CCAGCCCTAATTTCTGGATGCACTTCTGTGATCCAGGTATTTTAAGAACCAGTTA CCTCAGACCTCATGTTGAACAGTGTCGCCATCTGGGTCCTCTTGATACTGCAGAC

TTTTAACGTACACATGCAGGAACCCTGCTGAGCGTGGGCACTTGTTTTAAAGCAA

AACTCTTCCCAAGGACTGAAGAAAGGGCTTCTGGCAAGCTCGTCATGGCATTGTG

GTGGGATGGGTCTAGAGTGTCATCTGAATGGTGCTTCCTGTGTTCCTCTTTGAATT

CTGCCATTTTCAGTATTCTTGTGTGTCTGAATAGGCAAAGCGATTTAATTGGCTGG

TCTTGCACGCAAATTAGTTCCAAAGATAAGCTCTTTGTAACACATTTCCAGTCGC

TAATGCTCAAATGTAGAACATTCCTTTAAATGGCAGGATAAAAAACCCACTATCC

ACCATAGTGCATTTTGGGAAGATGTCTGTAGCATATGTTGCTGTGAAATTAGGCC

TTGTGGGATATGGCTGTTTGTCATTTTGATGTATTTTAAATAAATATATATATTTT

TTAAAGAGCCTTTTTTACCAGTTCAAAAAGTTTAATTAACCAGCAGTCACCGCAT

CTGAATTTTTGTCTCTGGGGCATAGATGGCAGACCAAGATTAAAAGTGGTAACTC

AGCTATACGAGCATGGGCTACCTTCCTGGGCTCTCCTGCAGTCCTGTAGACCTGC

TGTTCCGCAGACCATGGGACACAAGGTCAGTGTGTTCCCAGTGAGGGTCCCAAGT

CAGTCATCTTAAGTGTTTGTTCTCTGCCCCATTCAGTGGACTGTTGACTTCAGTCC

CTGCAAGTGCTTTAGCCCGAGTGGGGTTTTCTCAGAGCACTGCCACGAGTTAAGT

GTGTGTTTAGCCAAATAATTTCTCCGTAAGGGAAAAATGCAGTCACCCAAATTTT

ACCAACAATGACAGAGATGAGAGTAGAAAAGATTAGGCAACATCTGAGTTTTAA

CTTGAAAAGTGTCCAAGTCATCATGAAAGGCCGACTGGGAGCAAGTGATTATTA

GAGATTCTTCAGGAGACCTCATCTGAAAATGTTAAGACTGCCAGTGAGGGAAGG

AATTGTTAAAATGCCAGCGGCTTTTTTTTCCTCTTTTTTTCTGTAATTCTGTAAAA

ATGCAGAGAAAGTTGAGTGGTACTTCAGAATTGAGGGAGAGGGTTACCGCAGAG

TAGAAATATATTTCTAGATTTCAGTTCCACACCACAAATCCACAACAATGCCATT

TTTCAACTGTACAAAAATCTGCTTATGAACTGGACATGATCTTAATGGTAGTGTC

AAAGGCCAAGTTTTTCACCTGTTAATATTTTTCCACATTTGTCCTTGAATCTGAAT

AACTTTATACAGTACTGTAAATTTAACTTACATCGAGTTTGTTGTCAATTCTTATG

AAAAGAGCTTTCTGCATGTAACACATACGGTTAAAGAACACAGCAAAGGACAAA

ATTTGCAGGAACAGTTTTGGAACCAACAGAAAATGTCACCTTTTATTTGCCATCT

TATATATATCTATCAGTTTTACCAGCTACTTCTAAATTTGTACATTATTTGTAAGG

GAAAGAAGGAAAACCCTAAGACTTGTCTAACTTAGTGGAGAATGTGTGTGTTGG

GCTTAGGATGGATAGCTAAGTCTTATTGAGCTGTGTTACCTAACTTGTATATAAA

AATTGTAATTAAAAGTTTGGGTTCACCTGTTTCTCACAGTTTAAAATGATGAGTA

ATTGCAAACTCTGGAAATGTGACTAGTATATGATTTAAGGCTGTAGAAGCAAGG

AAGCTCTTTCAAGTGCTAAAACTAAAGACTTCTAGTTTTTGGCTCAAATAAGTAC TGTTTGTATACCAGGATATGTGAGATGTAAATGTAGTAGGTCACTTTTCACCCTT

GTAGCTATAAAATAAAAATTTTGTAGAACAGAAATAGCTTGTACTACTGAATTAA

CAAAAGTTATACTAAAGTATCATGTTTAAAAAAAATATATATATATATACAGAGT

TAAGCTTGTTGCTGTTACCCTGTCTGGATTTGAAAAGTGTGCTGATTTATATATAT

ATATTACACACACACACACACACACACACACACACACACACACACACACACACA

CACACACACACACACACACACACATACACCTAAAATGGCCTAAAGCAGACATCC

ATGTAATTACAGTTGCAAAATGAAAACATTTTGGAAAGAACATTGTATCATAGTT

CATTCATTTGCAGTGGATCTTTGTTCCTTTTTACTGTGGTAATTTTAGAAATGAGT

GTCAAGTTTGAAATTAGATCTGCTAAGTTGGGGTTTTGCTGCTTGAACTCTGCACT

GGGTCCTCAAATAAACCGATGTGAATGTAGTTTTTTCCCCCTGTGTGAAGAAGCA

GTTACACCCCAACAATAGGAGGAAAAATCTAGAACTATTTCAAGTTTTATCTTTT

TGTATATGAAAATAAAATAATAATAAAACAA (SEQ ID NO: 16).

[00141] An exemplary ALK2 mRNA sequence is set forth as one of:

GAAGAGATGTGGGCCTCTGGGGCCGCTGGATTCAGTAACTTCCGTCGGGTTCTAG

ACTGGCTCGGCTCTGTCCAGTTTGTGCCAGATAGTCTCCCACCCCCTCCCCACCCC

TCCTTTCCCCTGGAGATTTGAACGCTGCTTGCATGGGAGAAAAGCTACTTAGAGA

AGAAAACGTTCCACTTAGTAACAGAAGAAAAGTCTTGGTTAAAAAGTTGTCATG

AATTTGGCTTTTGGAGAGAGGCAGCAAGCCTGGAGCATTGGTAAGCGTCACACT

GCCAAAGTGAGAGCTGCTGGAGAACTCATAATCCCAGGAACGCCTCTTCTACTCT

CCGAGTACCCCAGTGACCAGAGTGAGAGAAGCTCTGAACGAGGGCACGCGGCTT

GAAGGACTGTGGGCAGATGTGACCAAGAGCCTGCATTAAGTTGTACAATGGTAG

ATGGAGTGATGATTCTTCCTGTGCTTATCATGATTGCTCTCCCCTCCCCTAGTATG

GAAGATGAGAAGCCCAAGGTCAACCCCAAACTCTACATGTGTGTGTGTGAAGGT

CTCTCCTGCGGTAATGAGGACCACTGTGAAGGCCAGCAGTGCTTTTCCTCACTGA

GCATCAACGATGGCTTCCACGTCTACCAGAAAGGCTGCTTCCAGGTTTATGAGCA

GGGAAAGATGACCTGTAAGACCCCGCCGTCCCCTGGCCAAGCCGTGGAGTGCTG

CCAAGGGGACTGGTGTAACAGGAACATCACGGCCCAGCTGCCCACTAAAGGAAA

ATCCTTCCCTGGAACACAGAATTTCCACTTGGAGGTTGGCCTCATTATTCTCTCTG

TAGTGTTCGCAGTATGTCTTTTAGCCTGCCTGCTGGGAGTTGCTCTCCGAAAATTT

AAAAGGCGCAACCAAGAACGCCTCAATCCCCGAGACGTGGAGTATGGCACTATC

GAAGGGCTCATCACCACCAATGTTGGAGACAGCACTTTAGCAGATTTATTGGATC

ATTCGTGTACATCAGGAAGTGGCTCTGGTCTTCCTTTTCTGGTACAAAGAACAGT GGCTCGCCAGATTACACTGTTGGAGTGTGTCGGGAAAGGCAGGTATGGTGAGGT

GTGGAGGGGCAGCTGGCAAGGGGAGAATGTTGCCGTGAAGATCTTCTCCTCCCG

TGATGAGAAGTCATGGTTCAGGGAAACGGAATTGTACAACACTGTGATGCTGAG

GCATGAAAATATCTTAGGTTTCATTGCTTCAGACATGACATCAAGACACTCCAGT

ACCCAGCTGTGGTTAATTACACATTATCATGAAATGGGATCGTTGTACGACTATC

TTCAGCTTACTACTCTGGATACAGTTAGCTGCCTTCGAATAGTGCTGTCCATAGCT

AGTGGTCTTGCACATTTGCACATAGAGATATTTGGGACCCAAGGGAAACCAGCC

ATTGCCCATCGAGATTTAAAGAGCAAAAATATTCTGGTTAAGAAGAATGGACAG

TGTTGCATAGCAGATTTGGGCCTGGCAGTCATGCATTCCCAGAGCACCAATCAGC

TTGATGTGGGGAACAATCCCCGTGTGGGCACCAAGCGCTACATGGCCCCCGAAG

TTCTAGATGAAACCATCCAGGTGGATTGTTTCGATTCTTATAAAAGGGTCGATAT

TTGGGCCTTTGGACTTGTTTTGTGGGAAGTGGCCAGGCGGATGGTGAGCAATGGT

ATAGTGGAGGATTACAAGCCACCGTTCTACGATGTGGTTCCCAATGACCCAAGTT

TTGAAGATATGAGGAAGGTAGTCTGTGTGGATCAACAAAGGCCAAACATACCCA

ACAGATGGTTCTCAGACCCGACATTAACCTCTCTGGCCAAGCTAATGAAAGAATG

CTGGTATCAAAATCCATCCGCAAGACTCACAGCACTGCGTATCAAAAAGACTTTG

ACCAAAATTGATAATTCCCTCGACAAATTGAAAACTGACTGTTGACATTTTCATA

GTGTCAAGAAGGAAGATTTGACGTTGTTGTCATTGTCCAGCTGGGACCTAATGCT

GGCCTGACTGGTTGTCAGAATGGAATCCATCTGTCTCCCTCCCCAAATGGCTGCT

TTGACAAGGCAGACGTCGTACCCAGCCATGTGTTGGGGAGACATCAAAACCACC

CTAACCTCGCTCGATGACTGTGAACTGGGCATTTCACGAACTGTTCACACTGCAG

AGACTAATGTTGGACAGACACTGTTGCAAAGGTAGGGACTGGAGGAACACAGAG

AAATCCTAAAAGAGATCTGGGCATTAAGTCAGTGGCTTTGCATAGCTTTCACAAG

TCTCCTAGACACTCCCCACGGGAAACTCAAGGAGGTGGTGAATTTTTAATCAGCA

ATATTGCCTGTGCTTCTCTTCTTTATTGCACTAGGAATTCTTTGCATTCCTTACTTG

CACTGTTACTCTTAATTTTAAAGACCCAACTTGCCAAAATGTTGGCTGCGTACTCC

ACTGGTCTGTCTTTGGATAATAGGAATTCAATTTGGCAAAACAAAATGTAATGTC

AGACTTTGCTGCATTTTACACATGTGCTGATGTTTACAATGATGCCGAACATTAG

GAATTGTTTATACACAACTTTGCAAATTATTTATTACTTGTGCACTTAGTAGTTTT

TACAAAACTGCTTTGTGCATATGTTAAAGCTTATTTTTATGTGGTCTTATGATTTT

ATTACAGAAATGTTTTTAACACTATACTCTAAAATGGACATTTTCTTTTATTATCA

GTTAAAATCACATTTTAAGTGCTTCACATTTGTATGTGTGTAGACTGTAACTTTTT

TTCAGTTCATATGCAGAACGTATTTAGCCATTACCCACGTGACACCACCGAATAT ATTACTGATTTAGAAGCAAAGATTTCAGTAGAATTTTAGTCCTGAACGCTACGGG GAAAATGCATTTTCTTCAGAATTATCCATTACGTGCATTTAAACTCTGCCAGAAA AAAATAACTATTTTGTTTTAATCTACTTTTTGTATTTAGTAGTTATTTGTATAAATT AAATAAACTGTTTTCAAGTCAAAAAAAAAAAAAAAAAAAA (SEQ ID NO: 17) or

[00142] CTGCAGCGCCCGGCTGCCTCGCACTCCGCCTCCCCCGGCTCAGCCC

CCGGCCGCGGCGGGACCCGAGCCTGGAGCATTGGTAAGCGTCACACTGCCAAAG

TGAGAGCTGCTGGAGAACTCATAATCCCAGGAACGCCTCTTCTACTCTCCGAGTA

CCCCAGTGACCAGAGTGAGAGAAGCTCTGAACGAGGGCACGCGGCTTGAAGGAC

TGTGGGCAGATGTGACCAAGAGCCTGCATTAAGTTGTACAATGGTAGATGGAGT

GATGATTCTTCCTGTGCTTATCATGATTGCTCTCCCCTCCCCTAGTATGGAAGATG

AGAAGCCCAAGGTCAACCCCAAACTCTACATGTGTGTGTGTGAAGGTCTCTCCTG

CGGTAATGAGGACCACTGTGAAGGCCAGCAGTGCTTTTCCTCACTGAGCATCAAC

GATGGCTTCCACGTCTACCAGAAAGGCTGCTTCCAGGTTTATGAGCAGGGAAAG

ATGACCTGTAAGACCCCGCCGTCCCCTGGCCAAGCCGTGGAGTGCTGCCAAGGG

GACTGGTGTAACAGGAACATCACGGCCCAGCTGCCCACTAAAGGAAAATCCTTC

CCTGGAACACAGAATTTCCACTTGGAGGTTGGCCTCATTATTCTCTCTGTAGTGTT

CGCAGTATGTCTTTTAGCCTGCCTGCTGGGAGTTGCTCTCCGAAAATTTAAAAGG

CGCAACCAAGAACGCCTCAATCCCCGAGACGTGGAGTATGGCACTATCGAAGGG

CTCATCACCACCAATGTTGGAGACAGCACTTTAGCAGATTTATTGGATCATTCGT

GTACATCAGGAAGTGGCTCTGGTCTTCCTTTTCTGGTACAAAGAACAGTGGCTCG

CCAGATTACACTGTTGGAGTGTGTCGGGAAAGGCAGGTATGGTGAGGTGTGGAG

GGGCAGCTGGCAAGGGGAGAATGTTGCCGTGAAGATCTTCTCCTCCCGTGATGA

GAAGTCATGGTTCAGGGAAACGGAATTGTACAACACTGTGATGCTGAGGCATGA

AAATATCTTAGGTTTCATTGCTTCAGACATGACATCAAGACACTCCAGTACCCAG

CTGTGGTTAATTACACATTATCATGAAATGGGATCGTTGTACGACTATCTTCAGC

TTACTACTCTGGATACAGTTAGCTGCCTTCGAATAGTGCTGTCCATAGCTAGTGG

TCTTGCACATTTGCACATAGAGATATTTGGGACCCAAGGGAAACCAGCCATTGCC

CATCGAGATTTAAAGAGCAAAAATATTCTGGTTAAGAAGAATGGACAGTGTTGC

ATAGCAGATTTGGGCCTGGCAGTCATGCATTCCCAGAGCACCAATCAGCTTGATG

TGGGGAACAATCCCCGTGTGGGCACCAAGCGCTACATGGCCCCCGAAGTTCTAG

ATGAAACCATCCAGGTGGATTGTTTCGATTCTTATAAAAGGGTCGATATTTGGGC

CTTTGGACTTGTTTTGTGGGAAGTGGCCAGGCGGATGGTGAGCAATGGTATAGTG GAGGATTACAAGCCACCGTTCTACGATGTGGTTCCCAATGACCCAAGTTTTGAAG

ATATGAGGAAGGTAGTCTGTGTGGATCAACAAAGGCCAAACATACCCAACAGAT

GGTTCTCAGACCCGACATTAACCTCTCTGGCCAAGCTAATGAAAGAATGCTGGTA

TCAAAATCCATCCGCAAGACTCACAGCACTGCGTATCAAAAAGACTTTGACCAA

AATTGATAATTCCCTCGACAAATTGAAAACTGACTGTTGACATTTTCATAGTGTC

AAGAAGGAAGATTTGACGTTGTTGTCATTGTCCAGCTGGGACCTAATGCTGGCCT

GACTGGTTGTCAGAATGGAATCCATCTGTCTCCCTCCCCAAATGGCTGCTTTGAC

AAGGCAGACGTCGTACCCAGCCATGTGTTGGGGAGACATCAAAACCACCCTAAC

CTCGCTCGATGACTGTGAACTGGGCATTTCACGAACTGTTCACACTGCAGAGACT

AATGTTGGACAGACACTGTTGCAAAGGTAGGGACTGGAGGAACACAGAGAAATC

CTAAAAGAGATCTGGGCATTAAGTCAGTGGCTTTGCATAGCTTTCACAAGTCTCC

TAGACACTCCCCACGGGAAACTCAAGGAGGTGGTGAATTTTTAATCAGCAATATT

GCCTGTGCTTCTCTTCTTTATTGCACTAGGAATTCTTTGCATTCCTTACTTGCACTG

TTACTCTTAATTTTAAAGACCCAACTTGCCAAAATGTTGGCTGCGTACTCCACTG

GTCTGTCTTTGGATAATAGGAATTCAATTTGGCAAAACAAAATGTAATGTCAGAC

TTTGCTGCATTTTACACATGTGCTGATGTTTACAATGATGCCGAACATTAGGAATT

GTTTATACACAACTTTGCAAATTATTTATTACTTGTGCACTTAGTAGTTTTTACAA

AACTGCTTTGTGCATATGTTAAAGCTTATTTTTATGTGGTCTTATGATTTTATTAC

AGAAATGTTTTTAACACTATACTCTAAAATGGACATTTTCTTTTATTATCAGTTAA

AATCACATTTTAAGTGCTTCACATTTGTATGTGTGTAGACTGTAACTTTTTTTCAG

TTCATATGCAGAACGTATTTAGCCATTACCCACGTGACACCACCGAATATATTAC

TGATTTAGAAGCAAAGATTTCAGTAGAATTTTAGTCCTGAACGCTACGGGGAAA

ATGCATTTTCTTCAGAATTATCCATTACGTGCATTTAAACTCTGCCAGAAAAAAA

TAACTATTTTGTTTTAATCTACTTTTTGTATTTAGTAGTTATTTGTATAAATTAAAT

AAACTGTTTTCAAGTCAAAAAAAAAAAAAAAAAAAA (SEQ ID NO: 18).

[00143] An exemplary ALK4 mRNA sequence is set forth as one of:

GGGGAGGCGCCGGGGGCGCGCGCGCGCGCGCTGGGCGCTGCTGGGCTGCGGCGG

CGGCGGCGGCGGCGGTGGTTACTATGGCGGAGTCGGCCGGAGCCTCCTCCTTCTT

CCCCCTTGTTGTCCTCCTGCTCGCCGGCAGCGGCGGGTCCGGGCCCCGGGGGGTC

CAGGCTCTGCTGTGTGCGTGCACCAGCTGCCTCCAGGCCAACTACACGTGTGAGA

CAGATGGGGCCTGCATGGTTTCCATTTTCAATCTGGATGGGATGGAGCACCATGT

GCGCACCTGCATCCCCAAAGTGGAGCTGGTCCCTGCCGGGAAGCCCTTCTACTGC CTGAGCTCGGAGGACCTGCGCAACACCCACTGCTGCTACACTGACTACTGCAACA

GGATCGACTTGAGGGTGCCCAGTGGTCACCTCAAGGAGCCTGAGCACCCGTCCA

TGTGGGGCCCGGTGGAGCTGGTAGGCATCATCGCCGGCCCGGTGTTCCTCCTGTT

CCTCATCATCATCATTGTTTTCCTTGTCATTAACTATCATCAGCGTGTCTATCACA

ACCGCCAGAGACTGGACATGGAAGATCCCTCATGTGAGATGTGTCTCTCCAAAG

ACAAGACGCTCCAGGATCTTGTCTACGATCTCTCCACCTCAGGGTCTGGCTCAGG

GTTACCCCTCTTTGTCCAGCGCACAGTGGCCCGAACCATCGTTTTACAAGAGATT

ATTGGCAAGGGTCGGTTTGGGGAAGTATGGCGGGGCCGCTGGAGGGGTGGTGAT

GTGGCTGTGAAAATATTCTCTTCTCGTGAAGAACGGTCTTGGTTCAGGGAAGCAG

AGATATACCAGACGGTCATGCTGCGCCATGAAAACATCCTTGGATTTATTGCTGC

TGACAATAAAGATAATGGCACCTGGACACAGCTGTGGCTTGTTTCTGACTATCAT

GAGCACGGGTCCCTGTTTGATTATCTGAACCGGTACACAGTGACAATTGAGGGG

ATGATTAAGCTGGCCTTGTCTGCTGCTAGTGGGCTGGCACACCTGCACATGGAGA

TCGTGGGCACCCAAGGGAAGCCTGGAATTGCTCATCGAGACTTAAAGTCAAAGA

ACATTCTGGTGAAGAAAAATGGCATGTGTGCCATAGCAGACCTGGGCCTGGCTG

TCCGTCATGATGCAGTCACTGACACCATTGACATTGCCCCGAATCAGAGGGTGGG

GACCAAACGATACATGGCCCCTGAAGTACTTGATGAAACCATTAATATGAAACA

CTTTGACTCCTTTAAATGTGCTGATATTTATGCCCTCGGGCTTGTATATTGGGAGA

TTGCTCGAAGATGCAATTCTGGAGGAGTCCATGAAGAATATCAGCTGCCATATTA

CGACTTAGTGCCCTCTGACCCTTCCATTGAGGAAATGCGAAAGGTTGTATGTGAT

CAGAAGCTGCGTCCCAACATCCCCAACTGGTGGCAGAGTTATGAGGCACTGCGG

GTGATGGGGAAGATGATGCGAGAGTGTTGGTATGCCAACGGCGCAGCCCGCCTG

ACGGCCCTGCGCATCAAGAAGACCCTCTCCCAGCTCAGCGTGCAGGAAGACGTG

AAGATCTAACTGCTCCCTCTCTCCACACGGAGCTCCTGGCAGCGAGAACTACGCA

CAGCTGCCGCGTTGAGCGTACGATGGAGGCCTACCTCTCGTTTCTGCCCAGCCCT

CTGTGGCCAGGAGCCCTGGCCCGCAAGAGGGACAGAGCCCGGGAGAGACTCGCT

CACTCCCATGTTGGGTTTGAGACAGACACCTTTTCTATTTACCTCCTAATGGCATG

GAGACTCTGAGAGCGAATTGTGTGGAGAACTCAGTGCCACACCTCGAACTGGTT

GTAGTGGGAAGTCCCGCGAAACCCGGTGCATCTGGCACGTGGCCAGGAGCCATG

ACAGGGGCGCTTGGGAGGGGCCGGAGGAACCGAGGTGTTGCCAGTGCTAAGCTG

CCCTGAGGGTTTCCTTCGGGGACCAGCCCACAGCACACCAAGGTGGCCCGGAAG

AACCAGAAGTGCAGCCCCTCTCACAGGCAGCTCTGAGCCGCGCTTTCCCCTCCTC

CCTGGGATGGACGCTGCCGGGAGACTGCCAGTGGAGACGGAATCTGCCGCTTTG TCTGTCCAGCCGTGTGTGCATGTGCCGAGGTGCGTCCCCCGTTGTGCCTGGTTCGT

GCCATGCCCTTACACGTGCGTGTGAGTGTGTGTGTGTGTCTGTAGGTGCGCACTT

ACCTGCTTGAGCTTTCTGTGCATGTGCAGGTCGGGGGTGTGGTCGTCATGCTGTC

CGTGCTTGCTGGTGCCTCTTTTCAGTAGTGAGCAGCATCTAGTTTCCCTGGTGCCC

TTCCCTGGAGGTCTCTCCCTCCCCCAGAGCCCCTCATGCCACAGTGGTACTCTGTG

TCTGGCAGGCTACTCTGCCCACCCCAGCATCAGCACAGCTCTCCTCCTCCATCTC

AGACTGTGGAACCAAAGCTGGCCCAGTTGTCCATGACAAAAGAGGCTTTTGGGC

CAAAATGTGAGGGTGGTGGGTGGGATGGGCAGGGAAGGAATCCTGGTGGAAGTC

TTGGGTGTTAGTGTCAGCCATGGGAAATGAGCCAGCCCAAGGGCATCATCCTCA

GCAGCATCGAGGAAGGGCCGAGGAATGTGAAGCCAGATCTCGGGACTCAGATTG

GAATGTTACATCTGTCTTTCATCTCCCAGATCCTGGAAACAGCAGTGTATATTTTT

GGTGGTGGTGGGTTTGGGGTGGGGAAGGGAAGGGCGGGCAAGGAGTGGGGAGG

GAGTCTGGGGTGGGAGGGAGGCATCTGCATGGGTCTTCTTTTACTGGACTGTCTG

ATCAGGGTGGAGGGAAGGTGAGAGGTTTGCATCCACTTCAGGAGCCCTACTGAA

GGGAACAGCCTGAGCCGAACATGTTATTTAACCTGAGTATAGTATTTAACGAAGC

CTAGAAGCACGGCTGTGGGTGGTGATTTGGTCAGCATATCTTAGGTATATAATAA

CTTTGAAGCCATAACTTTTAACTGGAGTGGTTTGATTTCTTTTTTTAATTTTATTGG

GAGGGTTTGGATTTTAACTTTTTTTAATGTTGTTAAATATTAAGTTTTTGTAAAAG

GAAAACCATCTCTGTGATTACCTCTCAATCTATTTGTTTTTAAAGAAATCCCTAAA

AAAAAAAATTATCCAATTGAACGCACATAGCTCAATCACACTGGAAATGTTTGTC

CTTGCACCTGAGCCTGTTCCCACTCAGCAGTGAGAGTTCCTCTTTGCCCTGAGGCT

CAGTCTCTCTCGTATTTTGTCCCCACCCCCAATTCCTTGAGTGGTTTTTGCTCTAG

GGCCCTTTCTTGCACTGTCCAGCTGGTTGTACCCTCTCCAGGCATTTATTCAACAA

ATGTGGGTGAAGTGCCTGCTGGGTGCCAGGTGCTGGGAATACATCTGTGGACAA

GACATGCTTGGGTCCTACTCCTGGAGCACTGTAAAAAGAGCTGATTCAAGTAAGT

AGATGCCTGTTTTGAGACCAGAAGGTTTCATAATTGGTTCTACGACCCTTTTGAG

CCTAGAATTATTGTTCTTATATAAGATCACTGAAGAAAGAGGAACCCCCACAACC

CCCTCCACAAAGAGACCAGGGGCGGGTGATGAGACCTGGGGTTTAGAACCCCAG

GTGAGACCTCAAATCACTGCATTCATTCTGAGCCCCCTTCCTGTCCCCAGGGGAG

GTGTATTGTGTATGTAGCCTTAGAGCATCTCTGCCTCCAACCCAGCAGTTCTCTGC

CAAAGCTTGTGGAGGAGGGAGAGCCCTGTCCCTGCCCTCAGGCTCCCCAGTGCTC

CTGGCCCTTCTATTTATTTGACTGATTATTGCTTCTTTCCTTGCATTAAAGGAGAT

CTTCCCCTAACCTTTGGGCCAATTTACTGGCCACTAATTTCGTTTAAATACCATTG TGTCATTGGGGGGACCGTCTTTACCCCTGCTGACCTCCCACCTATCCGCCCTGCA

GCAGAACCTTGGCGGTTTATAGGTAATGATGGAACTTAGACTCCTCTTCCCAGAG

TCACAAGTAGCCTCTGGGATCTGCCAACACACGTCCACTCCCAAGCCACTAGCCC

ACTCCCCAGTTGGCCCTTCTGCCCTTACCCCACACACAGTCCAACTCTTCCACCTC

TGGGGAAGATGGAGCAGGTCTTTGGGAAGCTCCCACACCCACCTCTGCCACTCTT

AACACTAAGTGAGAGTTGGGGAGAAACTGAAGCCGTGTTTTTGGCCCCCCGAGG

CTAACCCTGATCCATAGTGCTACCTGCACCTCTGGATTCTGGATTCACAGACCAA

GTCCAAGCCCGTTCTTACGTCGCCATAAAGGCCCCCGAACGGCATTCTCGGTACT

TCTGTTTGTTTTTGTACATTTTATTAGAAAGGACTGTAAAATAGCCACTTAGACAC

TTTACCTCTTCAGTATGCAAATGTAAATAAATTGTAATATAGGAAATCTTTTGTTT

TAATATAAGAATGAGCCTGTCCAATTTCTGCTGTACATTATTAAAAGTTTTATTCA

CAGAG (SEQ ID NO: 19),

[00144] AATGCTTCTCCTAAGCACCTCGTGTGTGTTCTTCGGCCTCACTGCTC

TGTGGCTTAGGTATCTGTGCTGTGGGGTTTGAGAAACATGGTGAAGGTGTATGAA

CAGAGCTTGACATTTGTGCTCTGCTGTGTGCGTGCACCAGCTGCCTCCAGGCCAA

CTACACGTGTGAGACAGATGGGGCCTGCATGGTTTCCATTTTCAATCTGGATGGG

ATGGAGCACCATGTGCGCACCTGCATCCCCAAAGTGGAGCTGGTCCCTGCCGGG

AAGCCCTTCTACTGCCTGAGCTCGGAGGACCTGCGCAACACCCACTGCTGCTACA

CTGACTACTGCAACAGGATCGACTTGAGGGTGCCCAGTGGTCACCTCAAGGAGC

CTGAGCACCCGTCCATGTGGGGCCCGGTGGAGCTGGTAGGCATCATCGCCGGCC

CGGTGTTCCTCCTGTTCCTCATCATCATCATTGTTTTCCTTGTCATTAACTATCATC

AGCGTGTCTATCACAACCGCCAGAGACTGGACATGGAAGATCCCTCATGTGAGA

TGTGTCTCTCCAAAGACAAGACGCTCCAGGATCTTGTCTACGATCTCTCCACCTC

AGGGTCTGGCTCAGGGTTACCCCTCTTTGTCCAGCGCACAGTGGCCCGAACCATC

GTTTTACAAGAGATTATTGGCAAGGGTCGGTTTGGGGAAGTATGGCGGGGCCGC

TGGAGGGGTGGTGATGTGGCTGTGAAAATATTCTCTTCTCGTGAAGAACGGTCTT

GGTTCAGGGAAGCAGAGATATACCAGACGGTCATGCTGCGCCATGAAAACATCC

TTGGATTTATTGCTGCTGACAATAAAGATAATGGCACCTGGACACAGCTGTGGCT

TGTTTCTGACTATCATGAGCACGGGTCCCTGTTTGATTATCTGAACCGGTACACA

GTGACAATTGAGGGGATGATTAAGCTGGCCTTGTCTGCTGCTAGTGGGCTGGCAC

ACCTGCACATGGAGATCGTGGGCACCCAAGGGAAGCCTGGAATTGCTCATCGAG

ACTTAAAGTCAAAGAACATTCTGGTGAAGAAAAATGGCATGTGTGCCATAGCAG ACCTGGGCCTGGCTGTCCGTCATGATGCAGTCACTGACACCATTGACATTGCCCC

GAATCAGAGGGTGGGGACCAAACGATACATGGCCCCTGAAGTACTTGATGAAAC

CATTAATATGAAACACTTTGACTCCTTTAAATGTGCTGATATTTATGCCCTCGGGC

TTGTATATTGGGAGATTGCTCGAAGATGCAATTCTGGAGGAGTCCATGAAGAATA

TCAGCTGCCATATTACGACTTAGTGCCCTCTGACCCTTCCATTGAGGAAATGCGA

AAGGTTGTATGTGATCAGAAGCTGCGTCCCAACATCCCCAACTGGTGGCAGAGTT

ATGAGGCACTGCGGGTGATGGGGAAGATGATGCGAGAGTGTTGGTATGCCAACG

GCGCAGCCCGCCTGACGGCCCTGCGCATCAAGAAGACCCTCTCCCAGCTCAGCGT

GCAGGAAGACGTGAAGATCTAACTGCTCCCTCTCTCCACACGGAGCTCCTGGCAG

CGAGAACTACGCACAGCTGCCGCGTTGAGCGTACGATGGAGGCCTACCTCTCGTT

TCTGCCCAGCCCTCTGTGGCCAGGAGCCCTGGCCCGCAAGAGGGACAGAGCCCG

GGAGAGACTCGCTCACTCCCATGTTGGGTTTGAGACAGACACCTTTTCTATTTAC

CTCCTAATGGCATGGAGACTCTGAGAGCGAATTGTGTGGAGAACTCAGTGCCAC

ACCTCGAACTGGTTGTAGTGGGAAGTCCCGCGAAACCCGGTGCATCTGGCACGT

GGCCAGGAGCCATGACAGGGGCGCTTGGGAGGGGCCGGAGGAACCGAGGTGTT

GCCAGTGCTAAGCTGCCCTGAGGGTTTCCTTCGGGGACCAGCCCACAGCACACCA

AGGTGGCCCGGAAGAACCAGAAGTGCAGCCCCTCTCACAGGCAGCTCTGAGCCG

CGCTTTCCCCTCCTCCCTGGGATGGACGCTGCCGGGAGACTGCCAGTGGAGACGG

AATCTGCCGCTTTGTCTGTCCAGCCGTGTGTGCATGTGCCGAGGTGCGTCCCCCG

TTGTGCCTGGTTCGTGCCATGCCCTTACACGTGCGTGTGAGTGTGTGTGTGTGTCT

GTAGGTGCGCACTTACCTGCTTGAGCTTTCTGTGCATGTGCAGGTCGGGGGTGTG

GTCGTCATGCTGTCCGTGCTTGCTGGTGCCTCTTTTCAGTAGTGAGCAGCATCTAG

TTTCCCTGGTGCCCTTCCCTGGAGGTCTCTCCCTCCCCCAGAGCCCCTCATGCCAC

AGTGGTACTCTGTGTCTGGCAGGCTACTCTGCCCACCCCAGCATCAGCACAGCTC

TCCTCCTCCATCTCAGACTGTGGAACCAAAGCTGGCCCAGTTGTCCATGACAAAA

GAGGCTTTTGGGCCAAAATGTGAGGGTGGTGGGTGGGATGGGCAGGGAAGGAAT

CCTGGTGGAAGTCTTGGGTGTTAGTGTCAGCCATGGGAAATGAGCCAGCCCAAG

GGCATCATCCTCAGCAGCATCGAGGAAGGGCCGAGGAATGTGAAGCCAGATCTC

GGGACTCAGATTGGAATGTTACATCTGTCTTTCATCTCCCAGATCCTGGAAACAG

CAGTGTATATTTTTGGTGGTGGTGGGTTTGGGGTGGGGAAGGGAAGGGCGGGCA

AGGAGTGGGGAGGGAGTCTGGGGTGGGAGGGAGGCATCTGCATGGGTCTTCTTT

TACTGGACTGTCTGATCAGGGTGGAGGGAAGGTGAGAGGTTTGCATCCACTTCA

GGAGCCCTACTGAAGGGAACAGCCTGAGCCGAACATGTTATTTAACCTGAGTAT AGTATTTAACGAAGCCTAGAAGCACGGCTGTGGGTGGTGATTTGGTCAGCATATC

TTAGGTATATAATAACTTTGAAGCCATAACTTTTAACTGGAGTGGTTTGATTTCTT

TTTTTAATTTTATTGGGAGGGTTTGGATTTTAACTTTTTTTAATGTTGTTAAATATT

AAGTTTTTGTAAAAGGAAAACCATCTCTGTGATTACCTCTCAATCTATTTGTTTTT

AAAGAAATCCCTAAAAAAAAAAATTATCCAATTGAACGCACATAGCTCAATCAC

ACTGGAAATGTTTGTCCTTGCACCTGAGCCTGTTCCCACTCAGCAGTGAGAGTTC

CTCTTTGCCCTGAGGCTCAGTCTCTCTCGTATTTTGTCCCCACCCCCAATTCCTTG

AGTGGTTTTTGCTCTAGGGCCCTTTCTTGCACTGTCCAGCTGGTTGTACCCTCTCC

AGGCATTTATTCAACAAATGTGGGTGAAGTGCCTGCTGGGTGCCAGGTGCTGGG

AATACATCTGTGGACAAGACATGCTTGGGTCCTACTCCTGGAGCACTGTAAAAAG

AGCTGATTCAAGTAAGTAGATGCCTGTTTTGAGACCAGAAGGTTTCATAATTGGT

TCTACGACCCTTTTGAGCCTAGAATTATTGTTCTTATATAAGATCACTGAAGAAA

GAGGAACCCCCACAACCCCCTCCACAAAGAGACCAGGGGCGGGTGATGAGACCT

GGGGTTTAGAACCCCAGGTGAGACCTCAAATCACTGCATTCATTCTGAGCCCCCT

TCCTGTCCCCAGGGGAGGTGTATTGTGTATGTAGCCTTAGAGCATCTCTGCCTCC

AACCCAGCAGTTCTCTGCCAAAGCTTGTGGAGGAGGGAGAGCCCTGTCCCTGCCC

TCAGGCTCCCCAGTGCTCCTGGCCCTTCTATTTATTTGACTGATTATTGCTTCTTTC

CTTGCATTAAAGGAGATCTTCCCCTAACCTTTGGGCCAATTTACTGGCCACTAATT

TCGTTTAAATACCATTGTGTCATTGGGGGGACCGTCTTTACCCCTGCTGACCTCCC

ACCTATCCGCCCTGCAGCAGAACCTTGGCGGTTTATAGGTAATGATGGAACTTAG

ACTCCTCTTCCCAGAGTCACAAGTAGCCTCTGGGATCTGCCAACACACGTCCACT

CCCAAGCCACTAGCCCACTCCCCAGTTGGCCCTTCTGCCCTTACCCCACACACAG

TCCAACTCTTCCACCTCTGGGGAAGATGGAGCAGGTCTTTGGGAAGCTCCCACAC

CCACCTCTGCCACTCTTAACACTAAGTGAGAGTTGGGGAGAAACTGAAGCCGTGT

TTTTGGCCCCCCGAGGCTAACCCTGATCCATAGTGCTACCTGCACCTCTGGATTCT

GGATTCACAGACCAAGTCCAAGCCCGTTCTTACGTCGCCATAAAGGCCCCCGAAC

GGCATTCTCGGTACTTCTGTTTGTTTTTGTACATTTTATTAGAAAGGACTGTAAAA

TAGCCACTTAGACACTTTACCTCTTCAGTATGCAAATGTAAATAAATTGTAATAT

AGGAAATCTTTTGTTTTAATATAAGAATGAGCCTGTCCAATTTCTGCTGTACATTA

TTAAAAGTTTTATTCACAGAG (SEQ ID NO: 20) or

[00145] GGGGAGGCGCCGGGGGCGCGCGCGCGCGCGCTGGGCGCTGCTGGG CTGCGGCGGCGGCGGCGGCGGCGGTGGTTACTATGGCGGAGTCGGCCGGAGCCT CCTCCTTCTTCCCCCTTGTTGTCCTCCTGCTCGCCGGCAGCGGCGGGTCCGGGCCC

CGGGGGGTCCAGGCTCTGCTGTGTGCGTGCACCAGCTGCCTCCAGGCCAACTACA

CGTGTGAGACAGATGGGGCCTGCATGGTTTCCATTTTCAATCTGGATGGGATGGA

GCACCATGTGCGCACCTGCATCCCCAAAGTGGAGCTGGTCCCTGCCGGGAAGCC

CTTCTACTGCCTGAGCTCGGAGGACCTGCGCAACACCCACTGCTGCTACACTGAC

TACTGCAACAGGATCGACTTGAGGGTGCCCAGTGGTCACCTCAAGGAGCCTGAG

CACCCGTCCATGTGGGGCCCGGTGGAGCTGGTAGGCATCATCGCCGGCCCGGTGT

TCCTCCTGTTCCTCATCATCATCATTGTTTTCCTTGTCATTAACTATCATCAGCGTG

TCTATCACAACCGCCAGAGACTGGACATGGAAGATCCCTCATGTGAGATGTGTCT

CTCCAAAGACAAGACGCTCCAGGATCTTGTCTACGATCTCTCCACCTCAGGGTCT

GGCTCAGGGTTACCCCTCTTTGTCCAGCGCACAGTGGCCCGAACCATCGTTTTAC

AAGAGATTATTGGCAAGGGTCGGTTTGGGGAAGTATGGCGGGGCCGCTGGAGGG

GTGGTGATGTGGCTGTGAAAATATTCTCTTCTCGTGAAGAACGGTCTTGGTTCAG

GGAAGCAGAGATATACCAGACGGTCATGCTGCGCCATGAAAACATCCTTGGATT

TATTGCTGCTGACAATAAAGCAGACTGCTCATTCCTCACATTGCCATGGGAAGTT

GTAATGGTCTCTGCTGCCCCCAAGCTGAGGAGCCTTAGACTCCAATACAAGGGA

GGAAGGGGAAGAGCAAGATTTTTATTCCCACTGAATAATGGCACCTGGACACAG

CTGTGGCTTGTTTCTGACTATCATGAGCACGGGTCCCTGTTTGATTATCTGAACCG

GTACACAGTGACAATTGAGGGGATGATTAAGCTGGCCTTGTCTGCTGCTAGTGGG

CTGGCACACCTGCACATGGAGATCGTGGGCACCCAAGGGAAGCCTGGAATTGCT

CATCGAGACTTAAAGTCAAAGAACATTCTGGTGAAGAAAAATGGCATGTGTGCC

ATAGCAGACCTGGGCCTGGCTGTCCGTCATGATGCAGTCACTGACACCATTGACA

TTGCCCCGAATCAGAGGGTGGGGACCAAACGATACATGGCCCCTGAAGTACTTG

ATGAAACCATTAATATGAAACACTTTGACTCCTTTAAATGTGCTGATATTTATGC

CCTCGGGCTTGTATATTGGGAGATTGCTCGAAGATGCAATTCTGGAGGAGTCCAT

GAAGAATATCAGCTGCCATATTACGACTTAGTGCCCTCTGACCCTTCCATTGAGG

AAATGCGAAAGGTTGTATGTGATCAGAAGCTGCGTCCCAACATCCCCAACTGGT

GGCAGAGTTATGAGGCACTGCGGGTGATGGGGAAGATGATGCGAGAGTGTTGGT

ATGCCAACGGCGCAGCCCGCCTGACGGCCCTGCGCATCAAGAAGACCCTCTCCC

AGCTCAGCGTGCAGGAAGACGTGAAGATCTAACTGCTCCCTCTCTCCACACGGA

GCTCCTGGCAGCGAGAACTACGCACAGCTGCCGCGTTGAGCGTACGATGGAGGC

CTACCTCTCGTTTCTGCCCAGCCCTCTGTGGCCAGGAGCCCTGGCCCGCAAGAGG

GACAGAGCCCGGGAGAGACTCGCTCACTCCCATGTTGGGTTTGAGACAGACACC TTTTCTATTTACCTCCTAATGGCATGGAGACTCTGAGAGCGAATTGTGTGGAGAA

CTCAGTGCCACACCTCGAACTGGTTGTAGTGGGAAGTCCCGCGAAACCCGGTGC

ATCTGGCACGTGGCCAGGAGCCATGACAGGGGCGCTTGGGAGGGGCCGGAGGA

ACCGAGGTGTTGCCAGTGCTAAGCTGCCCTGAGGGTTTCCTTCGGGGACCAGCCC

ACAGCACACCAAGGTGGCCCGGAAGAACCAGAAGTGCAGCCCCTCTCACAGGCA

GCTCTGAGCCGCGCTTTCCCCTCCTCCCTGGGATGGACGCTGCCGGGAGACTGCC

AGTGGAGACGGAATCTGCCGCTTTGTCTGTCCAGCCGTGTGTGCATGTGCCGAGG

TGCGTCCCCCGTTGTGCCTGGTTCGTGCCATGCCCTTACACGTGCGTGTGAGTGTG

TGTGTGTGTCTGTAGGTGCGCACTTACCTGCTTGAGCTTTCTGTGCATGTGCAGGT

CGGGGGTGTGGTCGTCATGCTGTCCGTGCTTGCTGGTGCCTCTTTTCAGTAGTGA

GCAGCATCTAGTTTCCCTGGTGCCCTTCCCTGGAGGTCTCTCCCTCCCCCAGAGCC

CCTCATGCCACAGTGGTACTCTGTGTCTGGCAGGCTACTCTGCCCACCCCAGCAT

CAGCACAGCTCTCCTCCTCCATCTCAGACTGTGGAACCAAAGCTGGCCCAGTTGT

CCATGACAAAAGAGGCTTTTGGGCCAAAATGTGAGGGTGGTGGGTGGGATGGGC

AGGGAAGGAATCCTGGTGGAAGTCTTGGGTGTTAGTGTCAGCCATGGGAAATGA

GCCAGCCCAAGGGCATCATCCTCAGCAGCATCGAGGAAGGGCCGAGGAATGTGA

AGCCAGATCTCGGGACTCAGATTGGAATGTTACATCTGTCTTTCATCTCCCAGAT

CCTGGAAACAGCAGTGTATATTTTTGGTGGTGGTGGGTTTGGGGTGGGGAAGGG

AAGGGCGGGCAAGGAGTGGGGAGGGAGTCTGGGGTGGGAGGGAGGCATCTGCA

TGGGTCTTCTTTTACTGGACTGTCTGATCAGGGTGGAGGGAAGGTGAGAGGTTTG

CATCCACTTCAGGAGCCCTACTGAAGGGAACAGCCTGAGCCGAACATGTTATTTA

ACCTGAGTATAGTATTTAACGAAGCCTAGAAGCACGGCTGTGGGTGGTGATTTGG

TCAGCATATCTTAGGTATATAATAACTTTGAAGCCATAACTTTTAACTGGAGTGG

TTTGATTTCTTTTTTTAATTTTATTGGGAGGGTTTGGATTTTAACTTTTTTTAATGT

TGTTAAATATTAAGTTTTTGTAAAAGGAAAACCATCTCTGTGATTACCTCTCAATC

TATTTGTTTTTAAAGAAATCCCTAAAAAAAAAAATTATCCAATTGAACGCACATA

GCTCAATCACACTGGAAATGTTTGTCCTTGCACCTGAGCCTGTTCCCACTCAGCA

GTGAGAGTTCCTCTTTGCCCTGAGGCTCAGTCTCTCTCGTATTTTGTCCCCACCCC

CAATTCCTTGAGTGGTTTTTGCTCTAGGGCCCTTTCTTGCACTGTCCAGCTGGTTG

TACCCTCTCCAGGCATTTATTCAACAAATGTGGGTGAAGTGCCTGCTGGGTGCCA

GGTGCTGGGAATACATCTGTGGACAAGACATGCTTGGGTCCTACTCCTGGAGCAC

TGTAAAAAGAGCTGATTCAAGTAAGTAGATGCCTGTTTTGAGACCAGAAGGTTTC

ATAATTGGTTCTACGACCCTTTTGAGCCTAGAATTATTGTTCTTATATAAGATCAC TGAAGAAAGAGGAACCCCCACAACCCCCTCCACAAAGAGACCAGGGGCGGGTG

ATGAGACCTGGGGTTTAGAACCCCAGGTGAGACCTCAAATCACTGCATTCATTCT

GAGCCCCCTTCCTGTCCCCAGGGGAGGTGTATTGTGTATGTAGCCTTAGAGCATC

TCTGCCTCCAACCCAGCAGTTCTCTGCCAAAGCTTGTGGAGGAGGGAGAGCCCTG

TCCCTGCCCTCAGGCTCCCCAGTGCTCCTGGCCCTTCTATTTATTTGACTGATTAT

TGCTTCTTTCCTTGCATTAAAGGAGATCTTCCCCTAACCTTTGGGCCAATTTACTG

GCCACTAATTTCGTTTAAATACCATTGTGTCATTGGGGGGACCGTCTTTACCCCTG

CTGACCTCCCACCTATCCGCCCTGCAGCAGAACCTTGGCGGTTTATAGGTAATGA

TGGAACTTAGACTCCTCTTCCCAGAGTCACAAGTAGCCTCTGGGATCTGCCAACA

CACGTCCACTCCCAAGCCACTAGCCCACTCCCCAGTTGGCCCTTCTGCCCTTACCC

CACACACAGTCCAACTCTTCCACCTCTGGGGAAGATGGAGCAGGTCTTTGGGAA

GCTCCCACACCCACCTCTGCCACTCTTAACACTAAGTGAGAGTTGGGGAGAAACT

GAAGCCGTGTTTTTGGCCCCCCGAGGCTAACCCTGATCCATAGTGCTACCTGCAC

CTCTGGATTCTGGATTCACAGACCAAGTCCAAGCCCGTTCTTACGTCGCCATAAA

GGCCCCCGAACGGCATTCTCGGTACTTCTGTTTGTTTTTGTACATTTTATTAGAAA

GGACTGTAAAATAGCCACTTAGACACTTTACCTCTTCAGTATGCAAATGTAAATA

AATTGTAATATAGGAAATCTTTTGTTTTAATATAAGAATGAGCCTGTCCAATTTCT

GCTGTACATTATTAAAAGTTTTATTCACAGAG (SEQ ID NO: 21).

[00146] Introduction of nucleic acid into target cells (e.g., host cells) can be carried out by methods known in the art such as osmotic shock (e.g., calcium phosphate), electroporation, microinjection, cell fusion, etc. Introduction of nucleic acid and polypeptide in vitro, ex vivo and in vivo can also be accomplished using other techniques. For example, a polymeric substance, such as polyesters, polyamine acids, hydrogel, polyvinyl pyrrolidone, ethylene-vinylacetate, methylcellulose, carboxymethylcellulose, protamine sulfate, or lactide/glycolide copolymers, polylactide/glycolide copolymers, or ethylenevinylacetate copolymers. A nucleic acid can be entrapped in microcapsules prepared by coacervation techniques or by interfacial polymerization, for example, by the use of hydroxymethylcellulose or gelatin-microcapsules, or poly (methylmethacrolate) microcapsules, respectively, or in a colloid system. Colloidal dispersion systems include macromolecule complexes, nano-capsules, microspheres, beads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes.

[00147] Liposomes for introducing various compositions into cells are known in the art and include, for example, phosphatidylcholine, phosphatidylserine, lipofectin and DOTAP (e.g., U.S. Patent Nos. 4,844,904, 5,000,959, 4,863,740, and 4,975,282; and GIBCO-BRL, Gaithersburg, MD). Piperazine based amphilic cationic lipids useful for gene therapy also are known (see, e.g., U.S. Patent No. 5,861,397). Cationic lipid systems also are known (see, e.g., U.S. Patent No. 5,459,127). Polymeric substances, microcapsules and colloidal dispersion systems such as liposomes are collectively referred to herein as "vesicles."

Therapeutic and Prophylactic Methods

[00148] In accordance with the invention, treatment methods and uses are provided that include therapeutic and prophylactic methods and uses. Such methods and uses can, for example, stimulate, induce, increase, enhance, or inhibit, decrease or reduce, an immune response in a subject. In one embodiment, a method includes administering to a subject in need of treatment an amount of activin or subsequence thereof, or an activin receptor activator or inhibitor, to treat the subject. In another embodiment, a method includes administering to a subject an amount of an activin receptor activator or inhibitor, or an activin or a subsequence thereof, sufficient to provide the subject with an immune response that is stimulated, induced, increased or enhanced, or inhibited, decreased or reduced.

[00149] Methods are applicable to immune responses, cell mediated and/or antibody mediated (e.g., a humoral immune response). Methods are applicable to immune responses, including undesirable or aberrant immune responses, such as undesirable or aberrant inflammatory responses or inflammation. Methods are also applicable to acute or chronic immune responses, and acute or chronic undesirable or aberrant immune responses, such as acute or chronic undesirable or aberrant inflammatory responses or inflammation.

[00150] As used herein, an "undesirable immune response" or "aberrant immune response" refers to any immune response, activity or function that is greater or less than desired or physiologically normal. An undesirable immune response, function or activity can be a normal response, function or activity. Thus, normal immune responses so long as they are undesirable, even if not considered abnormal, are included within the meaning of these terms. An undesirable immune response, function or activity can also be an abnormal response, function or activity. An abnormal (aberrant) immune response, function or activity deviates from normal. Undesirable and aberrant immune responses can be humoral, cell- mediated or a combination thereof, either chronic or acute.

[00151] One non-limiting example of an undesirable or aberrant immune response is where the immune response is hyper-responsive, such as in the case of an autoimmune disorder or disease. Another example of an undesirable or aberrant immune response is where an immune response leads to acute or chronic inflammatory response or inflammation in any tissue or organ, such as an allergy. Yet another example of an undesirable or aberrant immune response is where an immune response leads to destruction of cells, tissue or organ, such as a bone marrow transplant, as in graft vs. host disease (GVHD). Still another example of an undesirable or aberrant immune response is where the immune response is hypo- responsive, such as where response to an antigen is less than desired, e.g., tolerance has occurred.

[00152] The terms "immune disorder" and "immune disease" mean, an immune function or activity, that is greater than (e.g., autoimmunity) or less than (e.g., immunodeficiency) desired, and which is characterized by different physiological symptoms or abnormalities, depending upon the disorder or disease. Particular non-limiting examples of immune disorders and diseases to which the invention applies include autoimmune disorders. Autoimmune disorders are generally characterized as an undesirable or aberrant increased or inappropriate response, activity or function of the immune system. Disorders and diseases that can be treated in accordance with the invention include, but are not limited to, disorders and disease that cause cell or tissue/organ damage in the subject.

[00153] As used herein, the term "autoimmune disease" encompasses a condition, disorder, dysfunction or disease that results when the immune system attacks the body's own cells, tissues or organs. In particular, the term "autoimmune disease" includes a disorder wherein the immune system of a mammal mounts a humoral or cellular immune response to the mammal's own cells, tissues or organs. It is understood that more than one type of cell, tissue or organ may be attacked in the course of autoimmune disease.

[00154] Specific non-limiting examples of autoimmune diseases include rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, diabetes mellitus, multiple sclerosis, encephalomyelitis, myasthenia gravis, systemic lupus erythematous (SLE), autoimmune thyroiditis, atopic dermatitis, eczematous dermatitis, psoriasis, Sjogren's Syndrome, Crohn's disease, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis, asthma, allergic asthma, cutaneous lupus erythematous, scleroderma, vaginitis, proctitis, erythema nodosum leprosum, autoimmune uveitis, allergic encephalomyelitis, acute necrotizing hemorrhagic encephalopathy, idiopathic bilateral progressive sensorineural hearing loss, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's granulomatosis, chronic active hepatitis, Stevens- Johnson syndrome, idiopathic sprue, lichen planus, Graves' disease, sarcoidosis, primary biliary cirrhosis, uveitis posterior, interstitial lung fibrosis, Hashimoto's thyroiditis, autoimmune polyglandular syndrome, insulin-dependent diabetes mellitus, insulin-resistant diabetes mellitus, immune-mediated infertility, autoimmune Addison's disease, pemphigus vulgaris, pemphigus foliaceus, dermatitis herpetiformis, autoimmune alopecia, Vitiligo, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, pernicious anemia, Guillain-Barre syndrome, acute rheumatic fever, sympathetic ophthalmia, Goodpasture's syndrome, systemic necrotizing vasculitis, antiphospholipid syndrome and allergies.

[00155] An undesirable or aberrant inflammatory response or inflammation may cause, directly or indirectly, cell, tissue or organ damage, either to multiple cells, tissues or organs, or specifically to a single cell type, tissue type or organ. Exemplary tissues and organs that can exhibit damage include epidermal or mucosal tissue, gut, bowel, pancreas, thymus, liver, kidney, spleen, skin, or a skeletal joint (e.g., knee, ankle, hip, shoulder, wrist, finger, toe, or elbow). Treatment in accordance with the invention can result in reducing, inhibiting or preventing progression or worsening of tissue damage. Such treatments can in turn lead to regeneration or restoration of a damaged organ or tissue, e.g., skin, mucosum, liver.

[00156] In one embodiment, provided is a method of use of an anti ActRII antibody or antigen binding fragment thereof selected from

(i) an antibody or antigen binding fragment thereof that binds activin receptor, wherein said antibody or antigen binding fragment comprises a heavy chain variable region CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 22- 35; a heavy chain variable region CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 36-49; a heavy chain variable region CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 50-63; a light chain variable region CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 64-77; a light chain variable region CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 78-91; and a light chain variable region CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 92-105;

(ii) an antibody or antigen binding fragment thereof that binds activing receptor, wherein said antibody or antigen binding fragment comprises:

(a) a heavy chain variable region CDR1 of SEQ ID NO: 22; a heavy chain variable region CDR2 of SEQ ID NO: 36; a heavy chain variable region CDR3 of SEQ ID NO: 50; a light chain variable region CDR1 of SEQ ID NO: 64; a light chain variable region CDR2 of SEQ ID NO: 78; and a light chain variable region CDR3 of SEQ ID NO: 92,

(b) a heavy chain variable region CDR1 of SEQ ID NO: 23 a heavy chain variable region CDR2 of SEQ ID NO: 37; a heavy chain variable region CDR3 of SEQ ID NO: 51; a light chain variable region CDR1 of SEQ ID NO: 65; a light chain variable region CDR2 of SEQ ID NO: 79; and a light chain variable region CDR3 of SEQ ID NO: 93,

(c) a heavy chain variable region CDR1 of SEQ ID NO: 24; a heavy chain variable region CDR2 of SEQ ID NO: 38; a heavy chain variable region CDR3 of SEQ ID NO: 52; a light chain variable region CDR1 of SEQ ID NO: 66; a light chain variable region CDR2 of SEQ ID NO: 80; and a light chain variable region CDR3 of SEQ ID NO: 94,

(d) a heavy chain variable region CDR1 of SEQ ID NO: 25; a heavy chain variable region CDR2 of SEQ ID NO: 39; a heavy chain variable region CDR3 of SEQ ID NO: 53; a light chain variable region CDR1 of SEQ ID NO: 67; a light chain variable region CDR2 of SEQ ID NO: 81; and a light chain variable region CDR3 of SEQ ID NO: 95,

(e) a heavy chain variable region CDR1 of SEQ ID NO: 26; a heavy chain variable region CDR2 of SEQ ID NO: 40; a heavy chain variable region CDR3 of SEQ ID NO: 54; a light chain variable region CDR1 of SEQ ID NO: 68; a light chain variable region CDR2 of SEQ ID NO: 82; and a light chain variable region CDR3 of SEQ ID NO: 96,

(f) a heavy chain variable region CDR1 of SEQ ID NO: 27; a heavy chain variable region CDR2 of SEQ ID NO: 41; a heavy chain variable region CDR3 of SEQ ID NO: 55; a light chain variable region CDR1 of SEQ ID NO: 69; a light chain variable region CDR2 of SEQ ID NO: 62; and a light chain variable region CDR3 of SEQ ID NO: 97, (g) a heavy chain variable region CDR1 of SEQ ID NO: 28; a heavy chain variable region CDR2 of SEQ ID NO: 42; a heavy chain variable region CDR3 of SEQ ID NO: 56; a light chain variable region CDR1 of SEQ ID NO: 70; a light chain variable region CDR2 of SEQ ID NO: 84; and a light chain variable region CDR3 of SEQ ID NO: 98,

(h) a heavy chain variable region CDR1 of SEQ ID NO: 29; a heavy chain variable region CDR2 of SEQ ID NO: 43; a heavy chain variable region CDR3 of SEQ ID NO: 57; a light chain variable region CDR1 of SEQ ID NO: 71 a light chain variable region CDR2 of SEQ ID NO: 85; and a light chain variable region CDR3 of SEQ ID NO: 99,

(i) a heavy chain variable region CDR1 of SEQ ID NO: 30; a heavy chain variable region CDR2 of SEQ ID NO: 44; a heavy chain variable region CDR3 of SEQ ID NO: 58; a light chain variable region CDR1 of SEQ ID NO: 72; a light chain variable region CDR2 of SEQ ID NO: 86; and a light chain variable region CDR3 of SEQ ID NO: 100,

(j) a heavy chain variable region CDR1 of SEQ ID NO: 31; a heavy chain variable region CDR2 of SEQ ID NO: 45; a heavy chain variable region CDR3 of SEQ ID NO: 59; a light chain variable region CDR1 of SEQ ID NO: 73; a light chain variable region CDR2 of SEQ ID NO: 87; and a light chain variable region CDR3 of SEQ ID NO: 101,

(k) a heavy chain variable region CDR1 of SEQ ID NO: 32; a heavy chain variable region CDR2 of SEQ ID NO: 46; a heavy chain variable region CDR3 of SEQ ID NO: 60; a light chain variable region CDR1 of SEQ ID NO: 74; a light chain variable region CDR2 of SEQ ID NO: 88; and a light chain variable region CDR3 of SEQ ID NO: 102,

(1) a heavy chain variable region CDR1 of SEQ ID NO: 33; a heavy chain variable region CDR2 of SEQ ID NO: 47; a heavy chain variable region CDR3 of SEQ ID NO: 61; a light chain variable region CDR1 of SEQ ID NO: 75; a light chain variable region CDR2 of SEQ ID NO: 89; and a light chain variable region CDR3 of SEQ ID NO: 103,

(m) a heavy chain variable region CDR1 of SEQ ID NO: 34; a heavy chain variable region CDR2 of SEQ ID NO: 48; a heavy chain variable region CDR3 of SEQ ID NO: 62; a light chain variable region CDR1 of SEQ ID NO: 76; a light chain variable region CDR2 of SEQ ID NO: 90; and a light chain variable region CDR3 of SEQ ID NO: 104, or

(n) a heavy chain variable region CDR1 of SEQ ID NO: 35; a heavy chain variable region CDR2 of SEQ ID NO: 49; a heavy chain variable region CDR3 of SEQ ID NO: 63; a light chain variable region CDR1 of SEQ ID NO: 77; a light chain variable region CDR2 of SEQ ID NO: 91; and a light chain variable region CDR3 of SEQ ID NO: 105;

(iii) an antibody or antigen binding fragment thereof that binds activing receptor, wherein said antibody or antigen binding fragment comprises a VH polypeptide sequence having at least 95% sequence identity to at least one of SEQ ID NOs: 120-133 and a VL polypeptide sequence having at least 95% sequence identity to at least one of SEQ ID NOs: 106-119;

(iv) an antibody or antigen binding fragment thereof that binds activing receptor, wherein said antibody or antigen binding fragment comprises a full length heavy chain amino acid sequence having at least 95% sequence identity to at least one sequence selected from the group consisting of SEQ ID NOs:167-171 and 177-181 and a full length light chain amino acid sequence having at least 95% sequence identity to at least one sequence selected from the group consisting of SEQ ID NOs:162-166 and 172-176;

(v) an antibody or antigen binding fragment thereof that binds activing receptor, wherein said antibody or antigen binding fragment comprises

(a) the variable heavy chain sequence of SEQ ID NO: 120 and variable light chain sequence of SEQ ID NO: 106;

(b) the variable heavy chain sequence of SEQ ID NO: 121 and variable light chain sequence of SEQ ID NO: 107;

(c) the variable heavy chain sequence of SEQ ID NO: 122 and variable light chain sequence of SEQ ID NO: 108;

(d) the variable heavy chain sequence of SEQ ID NO: 123 and variable light chain sequence of SEQ ID NO: 109;

(e) the variable heavy chain sequence of SEQ ID NO: 124 and variable light chain sequence of SEQ ID NO: 110;

(f) the variable heavy chain sequence of SEQ ID NO: 125 and variable light chain sequence of SEQ ID NO: 111 ; (g) the variable heavy chain sequence of SEQ ID NO: 126 and variable light chain sequence of SEQ ID NO: 112;

(h) the variable heavy chain sequence of SEQ ID NO: 127 and variable light chain sequence of SEQ ID NO: 113;

(i) the variable heavy chain sequence of SEQ ID NO: 128 and variable light chain sequence of SEQ ID NO: 114;

(j) the variable heavy chain sequence of SEQ ID NO: 129 and variable light chain sequence of SEQ ID NO: 115;

(k) the variable heavy chain sequence of SEQ ID NO: 130 and variable light chain sequence of SEQ ID NO: 116;

(1) the variable heavy chain sequence of SEQ ID NO: 131 and variable light chain sequence of SEQ ID NO: 117;

(m) the variable heavy chain sequence of SEQ ID NO: 132 and variable light chain sequence of SEQ ID NO: 118; or

(n) the variable heavy chain sequence of SEQ ID NO: 133 and variable light chain sequence of SEQ ID NO: 119; or

(vi) an antibody or antigen binding fragment thereof that binds activing receptor, wherein said antigen binding fragment comprises

(a) the heavy chain sequence of SEQ ID NO: 167 and light chain sequence of SEQ ID NO: 162;

(b) the heavy chain sequence of SEQ ID NO: 168 and light chain sequence of SEQ ID NO: 163;

(c) the heavy chain sequence of SEQ ID NO: 169 and light chain sequence of SEQ ID NO: 164;

(d) the heavy chain sequence of SEQ ID NO: 170 and light chain sequence of SEQ ID NO: 165; (e) the heavy chain sequence of SEQ ID NO: 171 and light chain sequence of SEQ ID NO: 166;

(f) the heavy chain sequence of SEQ ID NO: 177 and light chain sequence of SEQ ID NO: 172;

(g) the heavy chain sequence of SEQ ID NO: 178 and light chain sequence of SEQ ID NO: 173;

(h) the heavy chain sequence of SEQ ID NO: 179 and light chain sequence of SEQ ID NO: 174;

(i) the heavy chain sequence of SEQ ID NO: 180 and light chain sequence of SEQ ID NO: 175; or

(j) the heavy chain sequence of SEQ ID NO: 181 and light chain sequence of SEQ ID NO: 176; or a pharmaceutical composition comprising such antibody or antigen binding fragment in the manufacture of a medicament for the treatment of an undesirable or aberrant immune response, inflammatory response or inflammation.

[00157] In a particular embodiment, provided is an anti ActRII antibody or antigen binding fragment thereof selected from:

(i) an antibody or antigen binding fragment thereof that binds activin receptor, wherein said antibody or antigen binding fragment comprises a heavy chain variable region CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 22- 35; a heavy chain variable region CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 36-49; a heavy chain variable region CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 50-63; a light chain variable region CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 64-77; a light chain variable region CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 78-91; and a light chain variable region CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 92-105; (ii) an antibody or antigen binding fragment thereof that binds activing receptor, wherein said antibody or antigen binding fragment comprises:

(a) a heavy chain variable region CDRl of SEQ ID NO: 22; a heavy chain variable region CDR2 of SEQ ID NO: 36; a heavy chain variable region CDR3 of SEQ ID NO: 50; a light chain variable region CDRl of SEQ ID NO: 64; a light chain variable region CDR2 of SEQ ID NO: 78; and a light chain variable region CDR3 of SEQ ID NO: 92,

(b) a heavy chain variable region CDRl of SEQ ID NO: 23 a heavy chain variable region CDR2 of SEQ ID NO: 37; a heavy chain variable region CDR3 of SEQ ID NO: 51; a light chain variable region CDRl of SEQ ID NO: 65; a light chain variable region CDR2 of SEQ ID NO: 79; and a light chain variable region CDR3 of SEQ ID NO: 93,

(c) a heavy chain variable region CDRl of SEQ ID NO: 24; a heavy chain variable region CDR2 of SEQ ID NO: 38; a heavy chain variable region CDR3 of SEQ ID NO: 52; a light chain variable region CDRl of SEQ ID NO: 66; a light chain variable region CDR2 of SEQ ID NO: 80; and a light chain variable region CDR3 of SEQ ID NO: 94,

(d) a heavy chain variable region CDRl of SEQ ID NO: 25; a heavy chain variable region CDR2 of SEQ ID NO: 39; a heavy chain variable region CDR3 of SEQ ID NO: 53; a light chain variable region CDRl of SEQ ID NO: 67; a light chain variable region CDR2 of SEQ ID NO: 81; and a light chain variable region CDR3 of SEQ ID NO: 95,

(e) a heavy chain variable region CDRl of SEQ ID NO: 26; a heavy chain variable region CDR2 of SEQ ID NO: 40; a heavy chain variable region CDR3 of SEQ ID NO: 54; a light chain variable region CDRl of SEQ ID NO: 68; a light chain variable region CDR2 of SEQ ID NO: 82; and a light chain variable region CDR3 of SEQ ID NO: 96,

(f) a heavy chain variable region CDRl of SEQ ID NO: 27; a heavy chain variable region CDR2 of SEQ ID NO: 41; a heavy chain variable region CDR3 of SEQ ID NO: 55; a light chain variable region CDRl of SEQ ID NO: 69; a light chain variable region CDR2 of SEQ ID NO: 62; and a light chain variable region CDR3 of SEQ ID NO: 97,

(g) a heavy chain variable region CDRl of SEQ ID NO: 28; a heavy chain variable region CDR2 of SEQ ID NO: 42; a heavy chain variable region CDR3 of SEQ ID NO: 56; a light chain variable region CDRl of SEQ ID NO: 70; a light chain variable region CDR2 of SEQ ID NO: 84; and a light chain variable region CDR3 of SEQ ID NO: 98, (h) a heavy chain variable region CDR1 of SEQ ID NO: 29; a heavy chain variable region CDR2 of SEQ ID NO: 43; a heavy chain variable region CDR3 of SEQ ID NO: 57; a light chain variable region CDR1 of SEQ ID NO: 71 a light chain variable region CDR2 of SEQ ID NO: 85; and a light chain variable region CDR3 of SEQ ID NO: 99,

(n) a heavy chain variable region CDR1 of SEQ ID NO: 35; a heavy chain variable region CDR2 of SEQ ID NO: 49; a heavy chain variable region CDR3 of SEQ ID NO: 63; a light chain variable region CDR1 of SEQ ID NO: 77; a light chain variable region CDR2 of SEQ ID NO: 91; and a light chain variable region CDR3 of SEQ ID NO: 105; antibody or antigen binding fragment thereof that binds activing receptor, wherein said antibody or antigen binding fragment comprises a VH polypeptide sequence having at least 95% sequence identity to at least one of SEQ ID NOs: 120-133 and a VL polypeptide sequence having at least 95% sequence identity to at least one of SEQ ID NOs: 106-119;

(f) the variable heavy chain sequence of SEQ ID NO: 125 and variable light chain sequence of SEQ ID NO: 111 ;

(g) the variable heavy chain sequence of SEQ ID NO: 126 and variable light chain sequence of SEQ ID NO: 112;

(h) the variable heavy chain sequence of SEQ ID NO: 127 and variable light chain sequence of SEQ ID NO: 113; (i) the variable heavy chain sequence of SEQ ID NO: 128 and variable light chain sequence of SEQ ID NO: 114;

(d) the heavy chain sequence of SEQ ID NO: 170 and light chain sequence of SEQ ID NO: 165;

(e) the heavy chain sequence of SEQ ID NO: 171 and light chain sequence of SEQ ID NO: 166;

(f) the heavy chain sequence of SEQ ID NO: 177 and light chain sequence of SEQ ID NO: 172; (g) the heavy chain sequence of SEQ ID NO: 178 and light chain sequence of SEQ ID NO: 173;

(j) the heavy chain sequence of SEQ ID NO: 181 and light chain sequence of SEQ ID NO: 176; or a pharmaceutical composition comprising such antibody or antigen binding fragment for use in the treatment of an undesirable or aberrant immune response, inflammatory response or inflammation.

[00158] Methods and uses of the invention include administering activin or subsequence thereof, or a activin receptor activator, in order to increase, stimulate enhance or promote an immune response in general. Such methods and uses can be used for treatment of chronic or acute immunosuppression or an immunocompromised subject, or an immunodeficiency.

[00159] Non- limiting examples of immunosuppression and immunodeficiency treatable in accordance with the invention include severe combined immunodeficiency (SCID) such as recombinase activating gene (RAG 1/2) deficiency, adenosine deaminase (ADA) deficiency, interleukin receptor γ chain deficiency, Janus-associated kinase 3 (JAK 3) deficiency and reticular dysgenesis; primary T cell immunodeficiency such as DiGeorge syndrome, Nude syndrome, T cell receptor deficiency, MHC class II deficiency, TAP-2 deficiency (MHC class I deficiency), ZAP70 tyrosine kinase deficiency and purine nucleotide phosphorylase (PNP) deficiency; predominantly antibody deficiencies such as X-linked agammaglobulinemia (Bruton's tyrosine kinase deficiency); autosomal recessive agammaglobulinemia such as Mu heavy chain deficiency; surrogate light chain (γ 5/14.1 ) deficiency; Hyper- IgM syndrome either X-linked (CD40 ligand deficiency) and others; Ig heavy chain gene deletion; IgA deficiency; deficiency of IgG subclasses (with or without IgA deficiency); common variable immunodeficiency (CVID); antibody deficiency with normal immunoglobulins; transient hypogammaglobulinemia of infancy; interferon γ receptor (IFNGR1, IFNGR2) deficiency; interleukin 1 and interleukin 12 receptor deficiency; immunodeficiency with thymoma; Wiskott-Aldrich syndrome (WAS protein deficiency); ataxia telangiectasia (ATM deficiency); X-linked lymphoproliferative syndrome (SH2D1 A/SAP deficiency); and hyper IgE syndrome). Exemplary immunodeficiencies also include disorders associated with or secondary to another disease (e.g., chromosomal instability or defective repair such as Bloom syndrome, Xeroderma pigmentosum, Fanconi anemia, ICF syndrome, Nijmegen breakage syndrome and Seckel syndrome; chromosomal defects such as Down syndrome (Trisomy 21), Turner syndrome and Deletions or rings of chromosome 18 (18p- and 18q-); skeletal abnormalities such as short-limbed skeletal dysplasia (short- limbed dwarfism) and cartilage-hair hypoplasia (metaphyseal chondroplasia); immunodeficiency associated with generalized growth retardation such as Schimke immuno-osseous dysplasia, Dubowitz syndrome, Kyphomelic dysplasia with SCID, Mulibrey's nannism, Growth retardation, facial anomalies and immunodeficiency and Progeria (Hutchinson-Gilford syndrome); immunodeficiency with dermatologic defects such as ectrodactyly-ectodermal dysplasia-clefting syndrome, immunodeficiency with absent thumbs, anosmia and ichthyosis, partial albinism, Dyskeratosis congenita, Netherton syndrome, Anhidrotic ectodermal dysplasia, Papillon-Lefevre syndrome and congenital ichthyosis; hereditary metabolic defects such as acrodermatitis enteropathica, transcobalamin 2 deficiency, type 1 hereditary orotic aciduria, intractable diarrhea, abnormal facies, trichorrhexis and immunodeficiency, methylmalonic acidemia, biotin dependent carboxylase deficiency, mannosidosis, glycogen storage disease, type lb, Chediak-Higashi syndrome; hypercatabolism of immunoglobulin such as familial hypercatabolism, intestinal lymphangiectasia; chronic muco-cutaneous candidiasis; hereditary or congenital hyposplenia or asplenia; and Ivermark syndrome.Methods and uses of the invention include administering activin or subsequence thereof, or a activin receptor activator, in order to increase, stimulate enhance or promote a response elicited by vaccination or immunization. Such methods and uses can be used in particular with any pathogen infection to which a vaccination or immunization may be desired.

[00160] Pathogens include, without limitation, bacteria, virus, fungi and parasites.

[00161] Non-limiting examples of a bacterial pathogen include Bordetella, Borellia, Brucella, Burkholderia, Campylobacter, Chlamydia, Cosotridia, Heliobacter, Legionella, Listeria, Mycobacterium, Mycoplasma, Neisseria, Pseudomonas, Rickettsia, Staphlyococcus, Streptococcus, Salmonella, Shigella, Treponema, Vibrio, and Yersenia.

[00162] Non-limiting examples of viral pathogens include a poxvirus, herpesvirus, hepatitis virus, immunodeficiency virus, flavi virus, papilloma virus (PV), polyoma virus, rhabdovirus, a myxovirus, an arenavirus, a coronavirus, adenovirus, reovirus, picornavirus, togavirus, bunyavirus, parvovirus and retrovirus.

[00163] Non-limiting examples of poxvirus include vaccinia virus, Molluscum contagiosum, variola major or variola minor smallpox virus, cow pox, camel pox, sheep pox, and monkey pox.

[00164] Non-limiting examples of herpesvirus include alpha-herpesvirus, beta- herpesvirus, gamma- herpesvirus, Epstein Bar Virus (EBV), Cytomegalovirus (CMV), varicella zoster virus (VZV/HHV- 3), and human herpes virus 1, 2, 4, 5, 6, 7, and 8 (HHV-8, Kaposi's sarcoma-associated virus).

[00165] Non-limiting examples of hepatitis virus include hepatitis A, B, C, D, E and G.

[00166] Non-limiting examples of immunodeficiency virus (HIV) include human HIV, such as HIV- 1 , HIV-2 and HIV-3.

[00167] Non-limiting examples of flavi virus include Yellow Fever virus, Dengue virus, Japanese Encephalitis and West Nile viruses.

[00168] Non-limiting examples of papilloma virus include a human papilloma virus (HPV), such as HPV strain 1, 6, 11, 16, 18, 30, 31, 42, 43, 44, 45, 51, 52, and 54.

[00169] Non-limiting examples of polyoma virus include BK virus (BKV) and JC virus (JCV).

[00170] Non-limiting examples of rhabdovirus include rabies virus and vesiculovirus.

[00171] Non-limiting examples of myxovirus include paramyxovirus and orthomyoxo virus. Non- limiting examples of paramyxovirus include measles, mumps, pneumovirus and respiratory syncytial virus (RSV).

[00172] Non-limiting examples of orthomyoxovirus include influenza virus, such as influenza A, influenza B and influenza C.

[00173] Non-limiting examples of arenavirus include lymphocytic choriomeningitis virus (LCMV), Junin virus, Lassa virus, Guanarito virus, Sabia virus and Machupo virus.

[00174] Non-limiting examples of corona virus include a virus that causes a common cold, and severe acute respiratory syndrome (SARS).

[00175] Non-limiting examples of adenovirus include viral infections of bronchii, lung, stomach, intestine (gastroenteritis), eye (conjunctivitis), bladder (cystitis) and skin.

[00176] Non-limiting examples of reo virus include a rotavirus, cypovirus and orbi virus.

[00177] Non-limiting examples of picornavirus include a rhinovirus, apthovirus, hepatovirus, enterovirus and cardiovirus. Rhinovirus can cause the common cold.

[00178] Non-limiting examples of togavirus include alphavirus, sindbus virus, and rubellavirus.

[00179] Non-limiting examples of bunyavirus include hantavirus, phlebo virus and nairo virus.

[00180] Non-limiting examples of retrovirus include an alpha, beta, delta, gamma, epsilon, lentivirus, spumavirus and human T-cell leukemia virus.

[00181] Non-limiting examples of lentivirus include an immunodeficiency virus, such as immunodeficiency virus (e.g., a bovine, porcine, equine, canine, feline or primate virus).

[00182] Non-limiting examples of human T-cell leukemia viruses include human T- cell leukemia virus 1 and 2 (HTLV-1 and HTLV-2).

[00183] Non-limiting examples of a fungal pathogen include yeasts and molds. More particular examples include Candida, Aspergillus, Cryptococcus, Histoplasma, Pneumocysti and Stachybotrys.

[00184] Non-limiting examples of a parasite pathogen include protozoa. More particular examples include Plasmodium, which causes malaria, Leishmania, Toxoplasma and Trypanosoma.

[00185] Pathogens and pathogen antigens, useful in accordance with the invention methods include any pathogen or pathogen antigen, or live or attenuated or weakened pathogen, suitable as a vaccine or immunizing agent, which typically can or is likely to provide protection against the pathogen.

[00186] Non-limiting examples include live pathogen, a pathogen antigen, pathogen extract, heat or ultraviolet light inactivated or attenuated or weakened pathogen.

[00187] Methods and uses of the invention include administering activin or subsequence thereof, or a activin receptor activator, in order to increase, stimulate enhance or promote a response elicited by vaccination or immunization. Such methods and uses can be used in particular with any cancer or tumor to which a vaccination, immunization or immunotherapy may be desired.

[00188] Non-limiting examples of cancer include Acute lymphoblastic leukemia (ALL); Acute myeloid leukemia; Adrenocortical carcinoma; AIDS-related cancers; AIDS- related lymphoma; Anal cancer; Appendix cancer; Astrocytoma; childhood cerebellar or cerebral; Basal-cell carcinoma; Bile duct cancer; extrahepatic (see Cholangiocarcinoma); Bladder cancer; Bone tumor; Osteosarcoma/Malignant fibrous histiocytoma; Brainstem glioma; Brain cancer; Brain tumor; cerebellar astrocytoma; Brain tumor; cerebral astrocytoma/malignant glioma; Brain tumor; ependymoma; Brain tumor; medulloblastoma; Brain tumor; supratentorial primitive neuroectodermal tumors; Brain tumor; visual pathway and hypothalamic glioma; Breast cancer; Bronchial adenomas/carcinoids; Burkitt's lymphoma; Carcinoid tumor, childhood; Carcinoid tumor, gastrointestinal; Carcinoma of unknown primary; Central nervous system lymphoma, primary; Cerebellar astrocytoma, childhood; Cerebral astrocytoma/Malignant glioma, childhood; Cervical cancer; Childhood cancers; Chronic lymphocytic leukemia; Chronic myelogenous leukemia; Chronic myeloproliferative disorders; Colon Cancer; Cutaneous T-cell lymphoma; Desmoplastic small round cell tumor; Endometrial cancer; Ependymoma; Esophageal cancer; Ewing's sarcoma in the Ewing family of tumors; Extracranial germ cell tumor, Childhood; Extragonadal Germ cell tumor; Extrahepatic bile duct cancer; Eye Cancer; Intraocular melanoma; Eye Cancer, Retinoblastoma; Gallbladder cancer; Gastric (Stomach) cancer; Gastrointestinal Carcinoid Tumor; Gastrointestinal stromal tumor (GIST); Germ cell tumor: extracranial, extragonadal, or ovarian; Gestational trophoblastic tumor; Glioma of the brain stem; Glioma, Childhood Cerebral Astrocytoma; Glioma, Childhood Visual Pathway and Hypothalamic; Gastric carcinoid; Hairy cell leukemia; Head and neck cancer; Heart cancer; Hepatocellular (liver) cancer; Hodgkin lymphoma; Hypopharyngeal cancer; Hypothalamic and visual pathway glioma, childhood; Intraocular Melanoma; Islet Cell Carcinoma (Endocrine Pancreas); Kaposi sarcoma; Kidney cancer (renal cell cancer); Laryngeal Cancer; Leukemias; Leukemia, acute lymphoblastic (also called acute lymphocytic leukemia); Leukemia, acute myeloid (also called acute myelogenous leukemia); Leukemia, chronic lymphocytic (also called chronic lymphocytic leukemia); Leukemia, chronic myelogenous (also called chronic myeloid leukemia); Leukemia, hairy cell; Lip and Oral Cavity Cancer; Liposarcoma; Liver Cancer (Primary); Lung Cancer, Non-Small Cell; Lung Cancer, Small Cell; Lymphomas; Lymphoma, AIDS-related; Lymphoma, Burkitt; Lymphoma, cutaneous T- Cell; Lymphoma, Hodgkin; Lymphomas, Non-Hodgkin (an old classification of all lymphomas except Hodgkin's); Lymphoma, Primary Central Nervous System; Macroglobulinemia, Waldenstrom; Malignant Fibrous Histiocytoma of Bone/Osteosarcoma; Medulloblastoma, Childhood; Melanoma; Melanoma, Intraocular (Eye); Merkel Cell Carcinoma; Mesothelioma, Adult Malignant; Mesothelioma, Childhood; Metastatic Squamous Neck Cancer with Occult Primary; Mouth Cancer; Multiple Endocrine Neoplasia Syndrome, Childhood; Multiple Myeloma/Plasma Cell Neoplasm; Mycosis Fungoides; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Myelogenous Leukemia, Chronic; Myeloid Leukemia, Adult Acute; Myeloid Leukemia, Childhood Acute; Myeloma, Multiple (Cancer of the Bone-Marrow); Myeloproliferative Disorders, Chronic; Nasal cavity and paranasal sinus cancer; Nasopharyngeal carcinoma; Neuroblastoma; Non- Hodgkin lymphoma; Non-small cell lung cancer; Oral Cancer; Oropharyngeal cancer; Osteosarcoma/malignant fibrous histiocytoma of bone; Ovarian cancer; Ovarian epithelial cancer (Surface epithelial- stromal tumor); Ovarian germ cell tumor; Ovarian low malignant potential tumor; Pancreatic cancer; Pancreatic cancer, islet cell; Paranasal sinus and nasal cavity cancer; Parathyroid cancer; Penile cancer; Pharyngeal cancer; Pheochromocytoma; Pineal astrocytoma; Pineal germinoma; Pineoblastoma and supratentorial primitive neuroectodermal tumors, childhood; Pituitary adenoma; Plasma cell neoplasia/Multiple myeloma; Pleuropulmonary blastoma; Primary central nervous system lymphoma; Prostate cancer; Rectal cancer; Renal cell carcinoma (kidney cancer); Renal pelvis and ureter, transitional cell cancer; Retinoblastoma; Rhabdomyosarcoma, childhood; Salivary gland cancer; Sarcoma, Ewing family of tumors; Sarcoma, Kaposi; Sarcoma, soft tissue; Sarcoma, uterine; Sezary syndrome; Skin cancer (nonmelanoma); Skin cancer (melanoma); Skin carcinoma, Merkel cell; Small cell lung cancer; Small intestine cancer; Soft tissue sarcoma; Squamous cell carcinoma; Squamous neck cancer with occult primary, metastatic; Stomach cancer; Supratentorial primitive neuroectodermal tumor, childhood; T-Cell lymphoma, cutaneous; Testicular cancer; Throat cancer; Thymoma, childhood; Thymoma and Thymic carcinoma; Thyroid cancer; Thyroid cancer, childhood; Transitional cell cancer of the renal pelvis and ureter; Trophoblastic tumor, gestational; Unknown primary site, carcinoma of, adult; Unknown primary site, cancer of, childhood; Ureter and renal pelvis, transitional cell cancer; Urethral cancer; Uterine cancer, endometrial; Uterine sarcoma; Vaginal cancer; Visual pathway and hypothalamic glioma, childhood; Vulvar cancer; Waldenstrom macroglobulinemia or Wilms tumor (kidney cancer), childhood.

[00189] Therapeutic and prophylactic methods of treating a subject with an activin receptor activator or inhibitor, or activin or a subsequence thereof, include, for example, treatment of a subject having or at risk of having an immune disorder, such as an undesirable or aberrant immune response, inflammatory response, or inflammation. Such methods can treat the immune disorder, thereby providing the subject with a benefit.

[00190] In methods and uses of the invention, any activin receptor activator or inhibitor, or activin or subsequence thereof, can be administered or used. Non-limiting examples include an activin or activin receptor antibody or subsequence thereof, or activin or subsequence thereof (e.g., of SEQ ID NO: 1-2), or an amino acid insertion, addition or substitution thereof.

[00191] In particular methods and embodiments, treatment methods will modulate an immune response. Such modulation can stimulate, induce, increase or enhance, or inhibit, decrease or reduce, as needed. For example, proliferation, survival, differentiation, or activity of immune responses or cells (e.g., T cells, B cells, macrophages, neutrophils, dendritic cells, etc.), can be modulated.

[00192] Methods of the invention include treatment methods, which result in any therapeutic or beneficial effect. In various methods embodiments, an immune response is stimulated, induced, increased or enhanced, or inhibited, decreased or reduced. Methods of the invention further include inhibiting, decreasing or reducing one or more adverse (e.g., physical) symptoms, disorders, illnesses, diseases or complications caused by or associated with the immune response, such as (e.g., swelling, fever, rash, headache, infiltration of tissue or organs with immune cells, muscle or joint pain, nausea, vomiting, loss of appetite, etc.).

[00193] A therapeutic or beneficial effect of treatment is therefore any objective or subjective measurable or detectable improvement or benefit provided to a particular subject. A therapeutic or beneficial effect can but need not be complete ablation of all or any particular adverse symptom, disorder, illness, disease or complication caused by or associated with an immune response in a subject. Thus, a satisfactory clinical endpoint is achieved when there is an incremental improvement or a partial reduction in an adverse symptom, disorder, illness, disease or complication caused by or associated with an immune response, or an inhibition, decrease, reduction, suppression, prevention, limit or control of worsening or progression of one or more adverse symptoms, disorders, illnesses, diseases or complications caused by or associated with the immune response, over a short or long duration (hours, days, weeks, months, etc.).

[00194] Accordingly, methods of the invention that include treatment of an inflammatory response or inflammation include reducing, inhibiting or preventing occurrence, progression, severity, frequency or duration of a symptom or characteristic of an inflammatory response or inflammation. At the whole body, regional or local level, an inflammatory response or inflammation is generally characterized by swelling, pain, headache, fever, nausea, skeletal joint stiffness or lack of mobility, rash, redness or other discoloration. At the cellular level, an inflammatory response or inflammation is characterized by one or more of cell infiltration of the region, production of antibodies (e.g., autoantibodies), production of cytokines, lymphokines, chemokines, interferons and interleukins, cell growth and maturation factors (e.g., differentiation factors), cell proliferation, cell differentiation, cell accumulation or migration and cell, tissue or organ damage. Thus, treatment will reduce, inhibit or prevent occurrence, progression, severity, frequency or duration of any one or more of such symptoms or characteristics of an inflammatory response or inflammation.

[00195] A therapeutic or beneficial effect also includes reducing or eliminating the need, dosage frequency or amount of a second active such as another drug or other agent (e.g., small molecule, protein) used for treating a subject having or at risk of having an undesirable or aberrant immune response. For example, reducing an amount of an adjunct therapy, for example, a reduction or decrease of a treatment for an undesirable or aberrant immune response, inflammatory response or inflammation is considered a beneficial effect. In addition, reducing or decreasing an amount of a pathogen (live or attenuated or weakened) or pathogen antigen used for vaccination or immunization of a subject to provide protection to the subject is considered a beneficial effect.

[00196] Methods and compositions of the invention also include increasing, stimulating, promoting, enhancing, augmenting or inducing an immune response in a subject. In one embodiment, a method includes administering to a subject an amount of an activin receptor activator, or activin or subsequence thereof sufficient to increase, stimulate, promote, enhance, augment or induce an immune response in the subject. In another embodiment, a method includes administering to a subject an amount of an activin receptor activator, or activin or subsequence thereof, and administering pathogen (live or attenuated or weakened) or pathogen antigen sufficient to increase, stimulate, promote, enhance, augment or induce anti-pathogen immune response in the subject.

[00197] Methods and compositions of the invention include administration of an activin receptor inhibitor (e.g., Follistatin, Follistatin-like 3, Inhibin, Betaglycan, Cripto, BAMBI) activin or activin receptor antibody or inhibitory nucleic acid sequence, such as antisense RNA), or activin or subsequence thereof, to a subject prior to an undesirable or aberrant immune response, inflammatory response or inflammation, administration prior to, substantially contemporaneously with or after a subject has been afflicted with an undesirable or aberrant immune response, inflammatory response or inflammation, and administration prior to, substantially contemporaneously with or after development of one or more adverse symptoms caused by or associated with an undesirable or aberrant immune response, inflammatory response or inflammation. A subject with an undesirable or aberrant immune response, inflammatory response or inflammation, may have a chronic or acute undesirable or aberrant immune response, inflammatory response or inflammation, for example, a period of days, months, or years.

[00198] Methods and compositions of the invention also include administration of an activin receptor activator or activin or subsequence thereof to a subject prior to, substantially contemporaneously with or following a pathogen infection, or an adverse symptom, disorder, illness or disease caused by or associated with a pathogen infection or pathology. A subject infected with a pathogen may have a chronic or acute infection, for example, an infection for a period of days, months, or years.

[00199] Invention compositions (e.g., activin subunit polypeptides or subsequences thereof) and methods can be combined with any compound, agent, drug, treatment or other therapeutic regimen or protocol having a desired therapeutic, beneficial, additive, synergistic or complementary activity or effect.

[00200] Exemplary combination compositions and treatments include second actives, such as anti-immune response, inflammatory response or inflammation compounds, agents and drugs, as well as agents that assist, promote, stimulate or enhance an immune response where desired. Such drugs, agents, treatments and therapies can be administered or performed prior to, substantially contemporaneously with or following any other method of the invention, for example, a therapeutic method of treating a subject for an undesirable or aberrant immune response, inflammatory response or inflammation, or a method of vaccination or immunization.

[00201] An activin receptor activator or inhibitor, or activin or subsequence thereof, can be administered as a combination composition, or administered separately, such as concurrently or in series or sequentially (prior to or following) administering a second active, to a subject. The invention therefore provides combinations in which a method of the invention is used in a combination with any compound, agent, drug, therapeutic regimen, treatment protocol, process, remedy or composition, such as an anti-immune response, inflammatory response or inflammation, or an immune response stimulating, increasing, enhancing or augmenting protocol, such as pathogen vaccination or immunization set forth herein or known to one of skill in the art. The compound, agent, drug, therapeutic regimen, treatment protocol, process, remedy or composition can be administered or performed prior to, substantially contemporaneously with or following administration of an activin receptor activator or inhibitor, or activin or subsequence or thereof, to a subject. Specific non-limiting examples of combination embodiments therefore include the foregoing or other compound, agent, drug, therapeutic regimen, treatment protocol, process, remedy or composition. [00202] Combination methods embodiments include, for example, second actives such as anti inflammatory or anti-inflammation agents and drugs and immune stimulating agents and drugs. Combination methods embodiments also include, for example, second actives such as anti-pathogen drugs (e.g., protease inhibitors, reverse transcriptase inhibitors, virus fusion inhibitors and virus entry inhibitors, antibodies to pathogen, live or attenuated or weakened pathogen, or a nucleic acid encoding all or a portion (e.g., an epitope) of any protein or proteinaceous pathogen antigen) immune stimulating agents and drugs, etc.

[00203] Particular non-limiting examples of anti-inflammatory, anti-inflammation and anti- autoimmune disease agents include immunosuppressive agents such as corticosteroids (steroid receptor agonists) including budesonide, prednisone, flunisolide, flunisolide hydrofluoroalkane, estrogen, progesterone, dexamethasone and loteprednol; beta-agonists (e.g., short or long-acting) such as bambuterol, formoterol, salmeterol, albuterol; anticholinergics such as ipratropium bromide, oxitropium bromide, cromolyn and calcium- channel blocking agents; antihistamines such as terfenadine, astemizole, hydroxyzine, tripelennamine, cetirizine, desloratadine, mizolastine, fexofenadine, olopatadine hydrochloride, norastemizole, levocetirizine, levocabastine, azelastine, ebastine and loratadine; antileukotrienes (e.g., anti-cysteinyl leukotrienes (CysLTs)) such as oxatomide, montelukast, zafirlukast and zileuton; phosphodiesterase inhibitors (e.g., PDE4 subtype) such as ibudilast, cilomilast, BAY 19-8004, theophylline (e.g., sustained-release) and other xanthine derivatives (e.g., doxofylline); thromboxane antagonists such as seratrodast, ozagrel hydrochloride and ramatroban; prostaglandin antagonists such as COX-1 and COX-2 inhibitors (e.g., celecoxib and rofecoxib), aspirin; potassium channel openers; and methotrexate (anti-metabolite), mycophenolate mofetil (purine biosynthesis inhibitor), and hydroxychloroquine (anti-malarial) .

[00204] Additional specific examples of anti-inflammatory and anti-inflammation agents include antibodies, receptors or receptor ligands, such as anti-IgE (e.g., rhuMAb-E25 omalizumab), -IgA and - IgG antibodies; antibodies and soluble receptors against cytokines such as IL-1, IL-4, IL-5, EL-6, IL-9, IL-13, L-16 and IL-21 or growth factors such as granulocyte/macrophage colony-stimulating factor; cytokines such as IL-10; mucolytics (depolymerize polymers of mucin or DNA/actin, or increase cough clearance) such as ambroxol and N-acetylcysteine; expectorants; and allergens (allergen immunotherapy). [00205] Methods of the invention also include, among other things, methods that result in a reduced need or use of another compound, agent, drug, therapeutic regimen, treatment protocol, process, or remedy. For example, for an undesirable or aberrant immune response, inflammatory response or inflammation, a method of the invention has a therapeutic benefit if in a given subject a less frequent or reduced dose or elimination of another anti-inflammatory or anti-inflammation compound, agent, drug, therapeutic regimen, treatment protocol, process, or remedy. For example, for vaccination or immunization, a method of the invention has a therapeutic benefit if in a given subject a less frequent or reduced dose or elimination of a vaccine. Thus, in accordance with the invention, methods of reducing need or use of another treatment or therapy are provided.

[00206] In invention methods in which there is a desired outcome, such as a therapeutic or prophylactic method that provides a benefit from treatment, vaccination or immunization with an activin receptor activator or inhibitor, or activin or subsequence thereof can be administered in a sufficient or effective amount. As used herein, a "sufficient amount" or "effective amount" or an "amount sufficient" or an "amount effective" refers to an amount that provides, in single or multiple doses, alone or in combination with one or more other compounds, treatments, therapeutic regimens or agents (e.g., a drug), a long term or a short term detectable or measurable improvement in a given subject or any objective or subjective benefit to a given subject of any degree or for any time period or duration (e.g., for minutes, hours, days, months, years, or cured).

[00207] An amount sufficient or an amount effective can but need not be provided in a single administration and can but need not be achieved by an activin receptor activator or inhibitor, or activin or subsequence thereof, alone, in a combination composition or method that includes a second active. In addition, an amount sufficient or an amount effective need not be sufficient or effective if given in single or multiple doses without a second or additional administration or dosage, since additional doses, amounts or duration above and beyond such doses, or additional antigens, compounds, drugs, agents, treatment or therapeutic regimens may be included in order to provide a given subject with a detectable or measurable improvement or benefit to the subject.

[00208] An amount sufficient or an amount effective need not be therapeutically or prophylactically effective in each and every subject treated, nor a majority of subjects treated in a given group or population. An amount sufficient or an amount effective means sufficiency or effectiveness in a particular subject, not a group of subjects or the general population. As is typical for such methods, different subjects will exhibit varied responses to treatment.

[00209] In the case of an undesirable or aberrant immune response, treatment methods include reducing or increasing numbers or an activity of immune cells (e.g., lymphocytes, T cells, antigen presenting cells, B cells, etc.) towards physiologically normal baseline levels. Similarly, a reduction or decrease of circulating antibodies (e.g., auto-antibodies) towards normal is considered a successful treatment outcome.

[00210] Additional examples of a therapeutic benefit for an undesirable or aberrant immune response, immune disorder or immune disease is an improvement in a histopathological change caused by or associated with the immune response, disorder or disease. For example, preventing further or reducing skeletal joint infiltration or tissue destruction, or pancreas, thymus, kidney, liver, spleen, epidermal (skin) or mucosal tissue, gut or bowel infiltration or tissue destruction.

[00211] The term "subject" refers to an animal, typically a mammalian animal (mammal), such as humans, non-human primates (apes, gibbons, gorillas, chimpanzees, orangutans, macaques), a domestic animal (dogs and cats), a farm animal (poultry such as chickens and ducks, horses, cows, goats, sheep, pigs), and experimental animals (mouse, rat, rabbit, guinea pig). Subjects include animal disease models, for example, mouse and other animal models of inflammation, undesirable and aberrant immune responses, inflammatory and autoimmune diseases and others known to those of skill in the art (e.g., CIA, BXSB, EAE and SC murine models).

[00212] Subjects appropriate for treatment include those having or at risk of having an undesirable or aberrant immune response, inflammatory response or inflammation, or vaccination or immunization, or a pathogen infection. Target subjects therefore include subjects that have an undesirable or aberrant immune response, inflammatory response or inflammation, or have been or are in need of vaccination or immunization, or have been exposed to or contacted with a pathogen, regardless of the type, timing or degree of onset, progression, severity, frequency, duration of the symptoms. [00213] The invention methods are therefore applicable to treating a subject who is at risk of undesirable or aberrant immune response, inflammatory response or inflammation, or vaccination or immunization, or a pathogen infection, but may not have a symptom of an undesirable or aberrant immune response, inflammatory response or inflammation, or a pathogen infection, or have been exposed to or contacted with the pathogen. Prophylactic methods are therefore included. Such subjects are considered in need of treatment due to being at risk.

[00214] Target subjects need not be at increased risk but may be from the general population in which it is desired to inhibit, decrease or reduce an undesirable or aberrant immune response, inflammatory response or inflammation, or vaccination or immunization, or a pathogen infection. For example, a child such as an infant or toddler in which it is desired to vaccinate or immunize against a pathogen can be administered an Actvin or activin receptor activator or inhibitor, or activin or subsequence thereof, alone or in combination with a pathogen antigen. In another non-limiting example, a subject that is not specifically at risk of an undesirable or aberrant immune response, inflammatory response or inflammation, or vaccination or immunization, or pathogen infection, exposure to or contact, but nevertheless desires protection from an undesirable or aberrant immune response, inflammatory response or inflammation, or a pathogen infection or pathology, can be administered an activin receptor activator or inhibitor, or activin or subsequence thereof. Such subjects are also considered in need of treatment.

[00215] Target subjects also include subjects having or at risk of having immunosuppression or are immunocompromised or have or are at risk of an immunodeficiency . Specific non- limiting examples of such subjects have or at risk of having an immunodeficiency, such as that caused by chemotherapy or radiotherapy (ionizing or chemical) or immune-suppressive therapy following a transplant (e.g., organ or tissue such as heart, liver, lung, bone marrow, etc.). Additional non- limiting examples include subjects having or at risk of having a graft vs. host disease, e.g., a subject that is a candidate for a transplant or a subject undergoing or having received a transplant.

[00216] At risk subjects appropriate for treatment also include subjects exposed to environments in which subjects are at risk of a pathogen infection. Subjects appropriate for treatment therefore include human subjects exposed to pathogens. [00217] "Prophylaxis" and grammatical variations thereof mean a method in which contact, administration or in vivo delivery to a subject is prior to an undesirable or aberrant immune response, inflammatory response or inflammation, or vaccination or immunization, or exposure to or contact with a pathogen. Administration or in vivo delivery to a subject can be performed prior to development of an adverse symptom, condition, complication, etc. caused by or associated with undesirable or aberrant immune response, inflammatory response or inflammation, or vaccination or immunization, or pathogen infection. In such case, a method can eliminate, prevent, inhibit, suppress, limit, decrease or reduce the probability of an undesirable or aberrant immune response, inflammatory response or inflammation, or a pathogen infection or susceptibility.

[00218] Administration of an activin receptor activator or inhibitor, or activin or subsequence thereof, for treatment of an undesirable or aberrant immune response, inflammatory response or inflammation, vaccination or immunization, or a pathogen infection can be at any time. Methods of the invention may be practiced by any mode of administration or delivery, or by any route, via systemic, regional and local administration or delivery. For example, an activin receptor activator or inhibitor, or a activin or subsequence, may be administered systemically, regionally or locally, intravenously, orally (e.g., ingestion or inhalation), intramuscularly, intraperitoneally, intradermally, subcutaneously, intracavity, intracranially, transdermally (topical), parenterally, e.g. transmucosally or rectally. Exemplary administration and delivery routes include intravenous (i.v.), intraperitoneal (i.p.), intrartenal, intramuscular, parenteral, subcutaneous, intra-pleural, topical, dermal, intradermal, transdermal, transmucosal, intra-cranial, intra-spinal, rectal, oral (alimentary), mucosal, inhalation, respiration, intranasal, intubation, intrapulmonary, intrapulmonary instillation, buccal, sublingual, intravascular, intrathecal, intracavity, iontophoretic, intraocular, ophthalmic, optical, intraglandular, intraorgan, intralymphatic.

[00219] An activin receptor activator or inhibitor, or activin or subsequence thereof, can be administered as a combination (e.g., with a second active), or separately concurrently or in sequence (sequentially or serially) in accordance with the methods as a single or multiple dose e.g., one or more times hourly, daily, weekly, monthly or annually or between about 1 to 10 weeks, or for as long as appropriate, for example, to achieve a desired effect or activity. Thus, a method can be practiced one or more times (e.g., 1-10, 1-5 or 1-3 times) an hour, day, week, month, or year. The skilled artisan will know when it is appropriate to delay or discontinue administration. A non- limiting dosage schedule is 1-7 times per week, for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or more weeks, and any numerical value or range or value within such ranges.

[00220] Doses can be based upon current existing protocols, empirically determined, using animal disease models or optionally in human clinical trials. Initial study doses can be based upon animal studies set forth herein, for a mouse, which weighs about 30 grams, and the amount of an activin receptor activator or inhibitor, or activin or subsequence thereof administered that is determined to be effective. Exemplary non-limiting amounts (doses) are in a range of about 0.1 mg/kg to about 100 mg/kg, and any numerical value or range or value within such ranges. Greater or lesser amounts (doses) can be administered, for example, 0.01-500 mg/kg, and any numerical value or range or value within such ranges. The dose can be adjusted according to the mass of a subject, and will generally be in a range from about 1- 10 ug/kg, 10-25 ug/kg, 25-50 ug/kg, 50-100 ug/kg, 100-500 ug/kg, 500-1,000 ug/kg, 1-5 mg/kg, 5-10 mg/kg, 10-20 mg/kg, 20-50 mg/kg, 50-100 mg/kg, 100-250 mg/kg, 250-500 mg/kg, or more, two, three, four, or more times per hour, day, week, month or annually. A typical range will be from about 0.3 mg/kg to about 50 mg/kg, 0-25 mg/kg, or 1.0-10 mg/kg, or any numerical value or range or value within such ranges.

[00221] Doses can vary and depend upon whether the treatment is prophylactic or therapeutic, the type, onset, progression, severity, frequency, duration, or probability of the undesirable or aberrant immune response, inflammatory response or inflammation, vaccination or immunization, or pathogen infection to which treatment is directed, the clinical endpoint desired, previous or simultaneous treatments, the general health, age, gender, race or immunological competency of the subject and other factors that will be appreciated by the skilled artisan. The skilled artisan will appreciate the factors that may influence the dosage and timing required to provide an amount sufficient for providing a therapeutic or prophylactic benefit.

[00222] Typically, for therapeutic treatment, an activin receptor activator or inhibitor, or activin or subsequence thereof will be administered as soon as practical, typically within 1- 2, 2-4, 4-12, 12-24 or 24-72 hours after a subject has a symptom or is exposed to or contacted with a pathogen, or within 1-2, 2-4, 4-12, 12-24 or 24-48 hours after onset or development of one or more adverse symptoms, conditions, pathologies, complications, etc., associated with or caused by. For prophylactic treatment in connection with vaccination or immunization, an activin receptor activator or inhibitor, or activin or subsequence thereof can be administered for a duration of 0-4 weeks, e.g., 2-3 weeks, prior to exposure to, contact or infection with pathogen, or at least within 1-2, 2-4, 4-12, 12-24, 24-48 or 48-72 hours prior to exposure to, contact or infection with pathogen. For an acute or chronic undesirable or aberrant immune response, inflammatory response or inflammation, or vaccination or immunization, or a pathogen infection, an activin receptor activator or inhibitor, or activin or subsequence thereof, is administered at any appropriate time.

[00223] The dose amount, number, frequency or duration may be proportionally increased or reduced, as indicated by the status of the subject. The dose amount, number, frequency or duration may also be proportionally increased or reduced, as indicated by any adverse side effects, complications or other risk factors of the treatment or therapy.

[00224] Activin Receptor activators, inhibitors, and activin and subsequences thereof can be incorporated into pharmaceutical compositions, e.g., a pharmaceutically acceptable carrier or excipient. Such pharmaceutical compositions are useful for, among other things, administration to a subject in vivo or ex vivo.

[00225] As used herein the term "pharmaceutically acceptable" and "physiologically acceptable" mean a biologically acceptable formulation, gaseous, liquid or solid, or mixture thereof, which is suitable for one or more routes of administration, in vivo delivery or contact. Such formulations include solvents (aqueous or non-aqueous), solutions (aqueous or non-aqueous), emulsions (e.g., oil- in-water or water-in-oil), suspensions, syrups, elixirs, dispersion and suspension media, coatings, isotonic and absorption promoting or delaying agents, compatible with pharmaceutical administration or in vivo contact or delivery. Aqueous and non-aqueous solvents, solutions and suspensions may include suspending agents and thickening agents. Such pharmaceutically acceptable carriers include tablets (coated or uncoated), capsules (hard or soft), microbeads, powder, granules and crystals. Supplementary active compounds (e.g., preservatives, antibacterial, antiviral and antifungal agents) can also be incorporated into the compositions.

[00226] Pharmaceutical compositions can be formulated to be compatible with a particular route of administration. Thus, pharmaceutical compositions include carriers, diluents, or excipients suitable for administration by various routes. Exemplary routes of administration for contact or in vivo delivery which a composition can optionally be formulated include inhalation, respiration, intranasal, intubation, intrapulmonary instillation, oral, buccal, intrapulmonary, intradermal, topical, dermal, parenteral, sublingual, subcutaneous, intravascular, intrathecal, intraarticular, intracavity, transdermal, iontophoretic, intraocular, opthalmic, optical, intravenous (i.v.), intramuscular, intraglandular, intraorgan, intralymphatic.

[00227] Formulations suitable for parenteral administration comprise aqueous and nonaqueous solutions, suspensions or emulsions of the active compound, which preparations are typically sterile and can be isotonic with the blood of the intended recipient. Non-limiting illustrative examples include water, saline, dextrose, fructose, ethanol, animal, vegetable or synthetic oils.

[00228] For transmucosal or transdermal administration (e.g., topical contact), penetrants can be included in the pharmaceutical composition. Penetrants are known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. For transdermal administration, the active ingredient can be formulated into aerosols, sprays, ointments, salves, gels, or creams as generally known in the art. For contact with skin, pharmaceutical compositions typically include ointments, creams, lotions, pastes, gels, sprays, aerosols, or oils.

[00229] Carriers which may be used include Vaseline, lanolin, polyethylene glycols, alcohols, transdermal enhancers, and combinations thereof.

[00230] Cosolvents and adjuvants may be added to the formulation. Non-limiting examples of cosolvents contain hydroxyl groups or other polar groups, for example, alcohols, such as isopropyl alcohol; glycols, such as propylene glycol, polyethyleneglycol, polypropylene glycol, glycol ether; glycerol; polyoxyethylene alcohols and polyoxyethylene fatty acid esters. Adjuvants include, for example, surfactants such as, soya lecithin and oleic acid; sorbitan esters such as sorbitan trioleate; and polyvinylpyrrolidone.

[00231] Supplementary compounds (e.g., preservatives, antioxidants, antimicrobial agents including biocides and biostats such as antibacterial, antiviral and antifungal agents) can also be incorporated into the compositions. Pharmaceutical compositions may therefore include preservatives, anti oxidants and antimicrobial agents.

[00232] Preservatives can be used to inhibit microbial growth or increase stability of ingredients thereby prolonging the shelf life of the pharmaceutical formulation. Suitable preservatives are known in the art and include, for example, EDTA, EGTA, benzalkonium chloride or benzoic acid or benzoates, such as sodium benzoate. Antioxidants include, for example, ascorbic acid, vitamin A, vitamin E, tocopherols, and similar vitamins or provitamins.

[00233] An antimicrobial agent or compound directly or indirectly inhibits, reduces, delays, halts, eliminates, arrests, suppresses or prevents contamination by or growth, infectivity, replication, proliferation, reproduction, of a pathogenic or non- pathogenic microbial organism. Classes of antimicrobials include, antibacterial, antiviral, antifungal and antiparasitics. Antimicrobials include agents and compounds that kill or destroy (-cidal) or inhibit (-static) contamination by or growth, infectivity, replication, proliferation, reproduction of the microbial organism.

[00234] Exemplary antibacterials (antibiotics) include penicillins (e.g., penicillin G, ampicillin, methicillin, oxacillin, and amoxicillin), cephalosporins (e.g., cefadroxil, ceforanid, cefotaxime, and ceftriaxone), tetracyclines (e.g., doxycycline, chlortetracycline, minocycline, and tetracycline), aminoglycosides (e.g., amikacin, gentamycin, kanamycin, neomycin, streptomycin, netilmicin, paromomycin and tobramycin), macrolides (e.g., azithromycin, clarithromycin, and erythromycin), fluoroquinolones (e.g., ciprofloxacin, lomefloxacin, and norfloxacin), and other antibiotics including chloramphenicol, clindamycin, cycloserine, isoniazid, rifampin, vancomycin, aztreonam, clavulanic acid, imipenem, polymyxin, bacitracin, amphotericin and nystatin.

[00235] Particular non-limiting classes of anti-virals include reverse transcriptase inhibitors; protease inhibitors; thymidine kinase inhibitors; sugar or glycoprotein synthesis inhibitors; structural protein synthesis inhibitors; nucleoside analogues; and viral maturation inhibitors. Specific non- limiting examples of anti-virals include nevirapine, delavirdine, efavirenz, saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, zidovudine (AZT), stavudine (d4T), larnivudine (3TC), didanosine (DDI), zalcitabine (ddC), abacavir, acyclovir, penciclovir, ribavirin, valacyclovir, ganciclovir, 1,-D- ribofuranosyl-l,2,4-triazole-3 carboxamide, 9->2-hydroxy-ethoxy methylguanine, adamantanamine, 5-iodo-2'- deoxyuridine, trifluorothymidine, interferon and adenine arabinoside.

[00236] Pharmaceutical formulations and delivery systems appropriate for the compositions and methods of the invention are known in the art (see, e.g., Remington: The Science and Practice of Pharmacy (2003) 20th ed., Mack Publishing Co., Easton, PA; Remington's Pharmaceutical Sciences (1990) 18 h ed., Mack Publishing Co., Easton, PA; The Merck Index (1996) 12th ed., Merck Publishing Group, Whitehouse, NJ; Pharmaceutical Principles of Solid Dosage Forms (1993), Technonic Publishing Co., Inc., Lancaster, Pa.; Ansel and Stoklosa, Pharmaceutical Calculations (2001) 11th ed., Lippincott Williams & Wilkins, Baltimore, MD; and Poznansky et al, Drug Delivery Systems (1980), R. L. Juliano, ed., Oxford, N.Y., pp. 253-315).

[00237] An activin receptor activator or inhibitor, or activin or subsequence thereof, along with any adjunct agent, compound drug, composition, whether active or inactive, etc., can be packaged in unit dosage form (capsules, tablets, troches, cachets, lozenges) for ease of administration and uniformity of dosage. A "unit dosage form" as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active ingredient optionally in association with a pharmaceutical carrier (excipient, diluent, vehicle or filling agent) which, when administered in one or more doses, is calculated to produce a desired effect (e.g., prophylactic or therapeutic effect). Unit dosage forms also include, for example, ampules and vials, which may include a composition in a freeze-dried or lyophilized state; a sterile liquid carrier, for example, can be added prior to administration or delivery in vivo. Unit dosage forms additionally include, for example, ampules and vials with liquid compositions disposed therein. Individual unit dosage forms can be included in multi-dose kits or containers. Pharmaceutical formulations can be packaged in single or multiple unit dosage form for ease of administration and uniformity of dosage.

[00238] The invention provides kits that include activin receptor activators, inhibitors, activin and subsequences thereof, optionally with a second active, and pharmaceutical formulations thereof, packaged into suitable packaging material. A kit typically includes a label or packaging insert including a description of the components or instructions for use in vitro, in vivo, or ex vivo, of the components therein. A kit can contain a collection of such components, e.g., activin or subsequence thereof and optionally a second active, such as another compound, agent, drug or composition.

[00239] The term "packaging material" refers to a physical structure housing the components of the kit. The packaging material can maintain the components sterilely, and can be made of material commonly used for such purposes (e.g., paper, corrugated fiber, glass, plastic, foil, ampules, vials, tubes, etc.).

[00240] Kits of the invention can include labels or inserts. Labels or inserts can include information identifying manufacturer, lot numbers, manufacturer location and date, expiration dates. Labels or inserts include "printed matter," e.g., paper or cardboard, or separate or affixed to a component, a kit or packing material (e.g., a box), or attached to an ampule, tube or vial containing a kit component. Labels or inserts can additionally include a computer readable medium, such as a bar-coded printed label, a disk, optical disk such as CD- or DVD-ROM/RAM, DVD, MP3, magnetic tape, or an electrical storage media such as RAM and ROM or hybrids of these such as magnetic/optical storage media, FLASH media or memory type cards.

[00241] Labels or inserts can include identifying information of one or more components therein, dose amounts, clinical pharmacology of the active ingredient(s) including mechanism of action, pharmacokinetics and pharmacodynamics. Labels or inserts can include information identifying manufacturer information, lot numbers, manufacturer location and date.

[00242] Labels or inserts can include information on a condition, disorder or disease (e.g., viral infection, vaccination or immunization) for which a kit component may be used. Labels or inserts can include instructions for the clinician or subject for using one or more of the kit components in a method, or treatment protocol or therapeutic regimen. Instructions can include dosage amounts, frequency or duration, and instructions for practicing any of the methods, treatment protocols or prophylactic or therapeutic regimes described herein. Exemplary instructions include, instructions for administering an activin receptor activator or inhibitor, or activin or subsequence thereof.

[00243] Labels or inserts can include information on any benefit that a component may provide, such as a prophylactic or therapeutic benefit. Labels or inserts can include information on potential adverse side effects, complications or reactions, such as warnings to the subject or clinician regarding situations where it would not be appropriate to use a particular composition. Adverse side effects or complications could also occur when the subject has, will be or is currently taking one or more other medications that may be incompatible with the composition, or the subject has, will be or is currently undergoing another treatment protocol or therapeutic regimen which would be incompatible with the composition and, therefore, instructions could include information regarding such incompatibilities.

[00244] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described herein.

[00245] All applications, publications, patents and other references, GenBank citations and ATCC citations cited herein are incorporated by reference in their entirety. In case of conflict, the specification, including definitions, will control.

[00246] All of the features disclosed herein may be combined in any combination. Each feature disclosed in the specification may be replaced by an alternative feature serving a same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, disclosed features (e.g., compound structures) are an example of a genus of equivalent or similar features.

[00247] As used herein, the singular forms "a", "and," and "the" include plural referents unless the context clearly indicates otherwise. Thus, for example, reference to "a first, second, third, fourth, fifth, etc. predictor gene" or a "positive or negative predictor gene" includes a plurality of such first, second, third, fourth, fifth, etc., genes, or a plurality of positive and/or negative predictor genes.

[00248] As used herein, all numerical values or numerical ranges include integers within such ranges and fractions of the values or the integers within ranges unless the context clearly indicates otherwise. Thus, to illustrate, reference to a range of 90-100%, includes 91%, 92%, 93%, 94%, 95%, 95%, 97%, etc., as well as 91.1%, 91.2%, 91.3%, 91.4%, 91.5%, etc., 92.1%, 92.2%, 92.3%, 92.4%, 92.5%, etc., and so forth.

[00249] Reference to a number with more (greater) or less than includes any number greater or less than the reference number, respectively. Thus, for example, a reference to less than 30,000, includes 29,999, 29,998, 29,997, etc. all the way down to the number one (1); and less than 20,000, includes 19,999, 19,998, 19,997, etc. all the way down to the number one (1).

[00250] As used herein, all numerical values or ranges include fractions of the values and integers within such ranges and fractions of the integers within such ranges unless the context clearly indicates otherwise. Thus, to illustrate, reference to a numerical range, such as a percentage range, 90-100%, includes 91%, 92%, 93%, 94%, 95%, 95%, 97%, etc., as well as 91.1%, 91.2%, 91.3%, 91.4%, 91.5%, etc., 92.1%, 92.2%, 92.3%, 92.4%, 92.5%, etc., and so forth. Reference to a range ofl-5 fold therefore includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, fold, etc., as well as 1.1, 1.2, 1.3, 1.4, 1.5, fold, etc., 2.1, 2.2, 2.3, 2.4, 2.5, fold, etc., and so forth.

[00251] Reference to a series of ranges includes ranges which combine the values of the boundaries of different ranges within the series. Thus, to illustrate reference to a series of ranges of 2-72 hours, 2-48 hours, 4-24 hours, 4-18 hours and 6-12 hours, includes ranges of 2-6 hours, 2, 2 hours, 2-18 hours, 2-24 hours, etc., and 4-27 hours, 4-48 hours, 4-6 hours, etc.

[00252] The invention is generally disclosed herein using affirmative language to describe the numerous embodiments and aspects. The invention also specifically includes embodiments in which particular subject matter is excluded, in full or in part, such as substances or materials, method steps and conditions, protocols, or procedures. For example, in certain embodiments or aspects of the invention, materials and/or method steps are excluded. Thus, even though the invention is generally not expressed herein in terms of what the invention does not include aspects that are not expressly excluded in the invention are nevertheless disclosed herein.

[00253] A number of embodiments of the invention have been described. Nevertheless, one skilled in the art, without departing from the spirit and scope of the invention, can make various changes and modifications of the invention to adapt it to various usages and conditions. Accordingly, the following examples are intended to illustrate but not limit the scope of the invention claimed.

EXAMPLES

[00254] Materials and Methods [00255] Human samples

[00256] Leukapheresis sample from a healthy donor was obtained from AllCells, Inc., after a prescreening of multiple donors. Fresh whole blood samples from healthy donors were obtained from the La Jolla Institute for Allergy and Immunology (LJI) in-house normal blood donor program (NBDP). Informed consent was obtained from all donors. Fresh human tonsils were obtained from the National Disease Resource Interchange. Tonsil preparation was previously described. Peripheral blood mononuclear cells (PBMCs) were isolated from both leukapheresis and whole blood samples by density-gradient centrifugation using Histopaque- 1077 (Sigma-Aldrich).

[00257] Flow cytometry and cell sorting

[00258] For surface staining, primary-staining panels used for phenotypic analysis or for cell sorting known in the art were used. For the intranuclear staining: cells were treated with the FoxP3 Fixation/Permeabilization kit (eBioscience) and stained in Permeabilization buffer (eBioscience). For cytokine staining: day 3 or day 5 in vitro differentiated cells (specified in the main text or in figure legends) cells were stimulated for 5 hours at 37 °C with Phorbol 12-myristate 13 -acetate (PMA, 25ng/ml) and lonomycin (lμg/ \) in the presence of Brefeldin A ^g/ml). Cells were fixed with PBS 2% FBS, 1% PFA and permeabilized with PBS 2% FBS, 0.5% Saponin (from quillaja bark, Sigma-Aldrich). Samples were analyzed on a LSR Fortessa Cell Analyzer (BD, Bioscience). Flow cytometry data were analyzed with FlowJo (Tree Star). For cell sorting, cells were sorted using sorted using a FACS Aria (BD, Bioscience).

[00259] Screening of "Secretomics" recombinant proteins

[00260] Naive CD4⁺ T cells were isolated from leukapheresis-derived mononuclear cells via CliniMACS negative selection (Miltenyi Biotec). The "secretomics" collection was previously described ¹⁹. An expanded secretomics set (Phasell), composed of 2688 unique proteins (total 1772 genes) was tested. Naive CD4⁺ T cells (1.25 x 10⁴ cells/well) were cultured with Secretomics proteins in the presence of Dynabeads Human T-Activator CD3/CD28 (0.5 μΐ/well, Life Technologies), recombinant human IL-7 (4ng/ml, Peprotech), and anti-human-TGF blocking mAb (10(^g/ml, clone 1D11.16.8, BioXcell) in RPMI medium (Cellgro), supplemented with 10% fetal bovine serum (Omega Scientific), GlutaMAX (Gibco) and Penicillin/Streptomycin (Gibco). Induction of CXCR5 and PD-1 was assessed after 5 days of in vitro culture using automated FACS acquisition via HTS on LSR Fortessa (BD Biosciences). For each 384 well plate, mean and standard deviation of PD- 1⁺CXCR5⁺ cell frequency induced by each individual recombinant proteins was determined and used to calculate the Z score. Z scores of replicate plates were analyzed independently.

[00261 ] In vitro differentiation

[00262] Unless differently specified, naive CD4⁺ T cells were enriched from PBMCs by magnetic bead negative selection with the Naive CD4⁺ T Cell Isolation Kit (Stem Cell Technologies). Purity (CD4⁺CD45RA⁺) was 90% or higher. Cells (7.5 x 10⁴ cells/well) were activated by Dynabeads Human T-Activator CD3/CD28 (2μ1Λνβ11, Life Technologies) and cultured with recombinant human/mouse/rat activin A (50ng/ml or lOOng/ml), recombinant human IL-12 (5ng/ml), recombinant human TGF (lng/ml), recombinant human IL-23 (lOng/ml) or recombinant human IL-35 (lOng/ml) in the presence of and recombinant human IL-7 (4ng/ml) in AIM-V medium (Life Technologies). All cytokines were from R&D System and Peprotech. The 14 kDa mature human beta A chain of human activin A shares 100% amino acid sequence identity with bovine, feline, mouse, porcine, and rat beta A. Phenotype was quantified after 3 or 5 days, as specified in the main text of Figure legends. Similar results were obtained when using Treg-depleted FACS sorted naive CD4 T cells, in which cells were sorted from total PBMCs by flow cytometry as CD 19 CD8 CD 14^"CD 16^" CD4⁺CD45RO^"CD25^" cells. For experiments quantifying supernatant CXCL13 concentration, cells were activated by plate-bound anti-human CD3 (5μg/ \, BD) and ICOS-L (5μg/ \, recombinant human B7-H2, R&D). CXCL13 concentrations were determined via human CXCL13 DuoSet ELISA (R&D) on supernatants harvested after 5 days of in vitro culture. For blocking experiments, cells were cultured with anti-activin A blocking mAb (5 μg/ml, clone 69403, R&D), anti-TGF mAb (100 μ^πιΐ, clone 1D11.16.8, BioXcell), or equivalent concentration of mouse IgGl isotype mAb (BioXcell). For blockade of IL-2, cells were cultured with anti-IL-2 blocking mAb (10 μg/ml, clone 5334, R&D) or mouse IgGl isotype mAb (BioXcell). For SMAD2/3 inhibition experiments, cells were cultured with different concentrations of SB 431542 (Sigma-Aldrich), Galunisertib (LY2157299, Selleck Chemicals) or vehicle (DMSO) for 5 days in AIM-V supplemented with 2% heat-inactivated FBS or in RPMI-1640 (Corning) supplemented with 10% heat-inactivated FBS, 1% GlutaMax, 1% PenStrep.

[00263] Confocal microscopy

[00264] Tonsils were fixed for 4 hours in freshly diluted 4% paraformaldehyde in PBS (Electron Microscopy Sciences, Hatfield, PA EMS Diasum), then washed 3 times in PBS and equilibrated in 30% w/v sucrose solution in PBS for 24 hours. Tissues were briefly washed in PBS, frozen in OCT and stored at -80 °C. Cryostat sections were cut at 12 μιη thickness, and air-dried for 30 minutes. Sections were rehydrated for 10 minutes in PBS and non-specific binding sites were saturated with 5% normal donkey serum (Jackson Immunoresearch) in the presence of 0.3% Triton X-100 in PBS for 1 hour. Tissues were incubated with rabbit polyclonal anti-INHBA Ab (HPA020031, Sigma-Aldrich), mouse anti-CD3 FITC (UCHT1, Tonbo Biosciences) and mouse anti-Bcl6 Alexa Fluor 647 (Kl 12-91, BD Biosciences) overnight at 4 °C. Following washing, sections were reacted with donkey anti-rabbit Alexa Fluor 568 and goat anti-FITC Alexa Fluor 488 secondary antibodies (Invitrogen) for 1 hour at room temperature. Slides were counterstained with 10 μg/ml Hoechst for 10 minutes, washed and mounted in Prolong Gold antifade reagent (Invitrogen) with a cover slip and examined with AxioScan Zl slide scanner equipped in 20x/0.8 NA air objective using appropriate filter sets. High resolution imaging of selected regions was done on a FluoView FVlOi confocal microscope (Olympus) using 60x/1.35 NA oil objective. To reduce blurriness epifluorescence images were processed with an extended depth of field algorithm (ZEN2, Zeiss). To improve feature visibility images were processed by contrast stretching using identical procedures (ZEN2 and Olympus FluoView software).

[00265] T-B co-culture

[00266] Naive CD4⁺ T cells were differentiated with activin A and/or IL-12. At day 3, live CD4⁺ T cells were sorted by FACS. Fresh autologous B cells were enriched from PBMCs by CD19 magnetic-bead positive selection (Miltenyi Biotec). Memory B cells were then FACS sorted as CD3^"CD14^"CD4^"CD19⁺IgD^"CD27⁺CD38^" cells and cultured (4 x 10⁵ cells/well) with the in vitro differentiated T cells (2.5 x 10³ cells/well) in the presence of staphylococcal enterotoxin B (SEB, 0.25 ng/ml, Toxin Technology) in AIM-V medium. B cell counts and plasmablast frequencies were measured after 7 days by FACS. Ig concentrations in the supernatants were determined by ELISA.

[00267] Mouse CD4 T cell differentiation

[00268] Naive CD4⁺ T cells were isolated from spleen using the Naive CD4⁺ T cell isolation kit (Stem Cell). Purity was 92% or higher. Naive CD4⁺ T cells (2 x 10⁵ cells/well) were cultured for 3 days with recombinant human/mouse/rat activin A (50 ng/ml, R&D Systems), recombinant mouse IL-12 (10 ng/ml, Peprotech), and/or recombinant mouse IL-6 (20 ng/ml, Peprotech) in the presence of plate -bound anti-mouse-CD3 mAb (8 μg/ml, clone 145-2C11, BioXcell) and anti-mouse-CD28 (8 μ^πιΐ, clone 37.51, BioXcell), in RPMI medium, supplemented with 10% fetal bovine serum, GlutaMAX, penicillin/streptomycin, and 2.5 μΜ β-mercaptoethanol. After 3 days, cells were removed from stimuli and further cultured for 2 additional days in IL-2 (50 U/mL,) and the same cytokine combination used at day 0. Phenotype was quantified by FACS at day 5 of the in vitro culture.

[00269] Non-human primate (NHP) differentiation

[00270] CD4⁺ T cells from rhesus macaque PBMCs were enriched using the Non- Human Primate CD4⁺ T Cell Isolation Kit (Miltenyi Biotec). Naive CD4⁺ T cells were isolated by FACS sorting as CD4⁺CD45RA⁺CD95^"CD28⁺CCR7⁺ cells. Naive CD4⁺ T cells (7.5 x 10⁴ cells/well) were activated by plate-bound anti-human-CD3 and anti-human-CD28 (both at 5 μg/ml, BD) and cultured with recombinant human/mouse/rat activin A (50 ng/ml) and/or recombinant human IL-12 (5 ng/ml) for 5 days. Phenotype was assessed by flow cytometry.

[00271 ] RNA sequencing

[00272] Differentiation of naive CD4⁺ T cells with activin A and/or IL-12 was described above. Naive CD4 T cells from 4 or more donors were cultured with the following conditions: beads only (beads), IL-12, activin A (100 ng/ml), activin A (100 ng/ml) + IL-12, TGF , TGF + IL-12. After 3 days of in vitro culture, live CD4⁺ T cells were sorted by FACS. Total RNA was purified using miRNAeasy Mini kit (Qiagen). Standard quality control steps were included to determine total RNA quality using Agilent Bioanalyzer (RNA integrity number (RIN) > 8.5; Agilent RNA 6000 Nano Kit, USA) and quantity using a nanoliter spectrophotometer (Nanodrop, Thermofisher, USA). For every sample, 500 ng of purified total RNA was prepared into mRNA libraries, according to manufacturer's instructions, using the Truseq Stranded mRNA Library Prep Kit (Illumina, RS-122-2103). The resulting libraries were deep sequenced, using the Illumina HiSeq2500 system in rapid run mode, to obtain between 6 to 7 millions of 50-bp length single-end reads per library.

[00273] Analysis of RNA-seq data

[00274] The single-end reads that passed Illumina filters were filtered for reads aligning to tRNA, rRNA, adapter sequences, and spike-in controls. The reads were then aligned to UCSC hgl9 reference genome using TopHat ⁵⁵ (v 1.4.1). DUST scores were calculated with PRINSEQ Lite ⁵⁶ (v 0.20.3) and low-complexity reads (DUST > 4) were removed from the BAM files. The alignment results were parsed via the SAMtools ⁵⁷ to generate SAM files. Read counts to each genomic feature were obtained with the htseq-count program 58 (v 0.6.0) using the "union" option. After removing absent features (zero counts in all samples), the raw counts were converted to RPKM value followed by quantile normalization via R library 'aroma.light' ⁵⁹. Then the quantile normalized RPKM values were filtered by setting a cutoff value of 1 and analyzed with the Multiplot module in GenePattern suite (http://www.broadinstitute.org/cancer/software/genepattern/) to generate the Volcano, Heatmap and Expression plots. Meanwhile the filtered raw counts were imported to R/Bioconductor package DESeq2⁶⁰ (v 3.1) to normalize counts and identify differentially expressed genes among conditions.

[00275] Gene Set Enrichment analysis (GSEA)

[00276] Gene Set Enrichment Analysis (v 2.2.0;

http://www.broadinstitute.org/gsea/index.jsp) was used to evaluate if a pre-defined tonsil GC- Tfh gene set showed statistically significant enrichment between two phenotypes when cells are given a particular stimulus. The tonsil GC Tfh gene set was generated from previously published microarray data 38 and defined by genes with more than two-fold higher expression in GC-Tfh cells (CD4⁺CD45RO⁺PD-l^hiCXCR5^hi) compared to non-Tfh cells (CD4⁺CD45RO⁺PD-l^"CXCR5^"). For RNA-seq profiles used as the query list, genes were ranked from the most up-regulated to the most down-regulated in cells stimulated with beads versus activin A + IL-12, IL-12 versus activin A + IL-12, and activin A versus activin A + IL-12 on the basis of the DESeq2 analysis results. The signal-to-noise metric was used for ranking the genes in the RNA-seq expression datasets and 10⁵ cycles of permutations on the phenotype labels were performed to determine the normalized enrichment score (NES).

[00277] Quantitative Real-Time PCR

[00278] RNA was isolated by QIAGEN RNeasy spin columns and reverse-transcribed into cDNA using Superscript II Reverse Transcriptase (Invitrogen). Quantitative real-time PCR of ACTB, LIF, and PRDM1 was performed using the following primers: ACTB forward, 5 ' - ACCTTCTACAATGAGCTGCG-3 ' , ACTB reverse, 5'-

CCTGGATAGCAACGTACATGG-3 ' ; LIF forward, 5'- ATACGCCACCCATGTCAC -3' , LIF reverse, 5 ' -CCAC ATAGCTTGTCCAGGTTG-3 ' ; and PRDM1 forward, 5'- TGTGGTATTGTCGGGACTTTG-3 ' , PRDM1 reverse 5 ' -CTTTGGGAC ATTCTTTGGGC- CTG-3' . Real-time PCR was set up with Applied Biosystem SYBR Green Master Mix.

[00279] Analysis of phosphorylated SMAD2/3

[00280] Fresh PBMCs and tonsil mononuclear cells were serum-starved over night in AIM-V medium. The following day, the cells (10^A<5 cells/condition) were stimulated for 10, 30, 60, 120 or 180 minutes with activin A (400 ng/ml) + vehicle (DMSO), activin A + SB 431542 (10 μΜ, Sigma- Aldrich), Galunisertib (10 μg/ml, Selleck Chemicals) or vehicle only in AIM-V medium. Following stimulation, the cells were fixed in BD Phosflow™ Fix Buffer I (BD Biosciences), then permeabilized using BD Phosflow™ Perm Buffer III (BD Biosciences) following manufacture's instruction.

[00281 ] Statistical Analysis

[00282] All the statistical analyses, unless differently specified, were done with two- tailed Wilcoxon matched-pairs signed ranked test, which does not assume Gaussian distribution of the data, but it allows the direct comparison of populations within donors. Independent experiments were repeated several times with controls. Prism 6.0 (GraphPad) was used for all analysis. [00283] Anti-activin A Type II receptor (ACVR2) blocking mAb

[00284] Naive CD4⁺ T cells were enriched from PBMCs by magnetic bead negative selection with the Naive CD4⁺ T Cell Isolation Kit (Stem Cell Technologies). Purity (CD4⁺CD45RA⁺) was 90% or higher. Cells (7.5 x 10⁴ cells/well) were activated by Dynabeads Human T- Activator CD3/CD28 (2 μΐ/well, Life Technologies) and cultured with recombinant human/mouse/rat activin A (50 ng/ml) or recombinant human IL-12 (5 ng/ml) in the presence of and recombinant human IL-7 (4 ng/ml) in AIM-V medium (Life Technologies). Phenotype was quantified after 5 days, by flow cytometry. For blocking experiments, cells were cultured with pan anti-activin A Type II receptor (ACVR2) blocking mAb (100 g/ml, clone MOR8806, Novartis, described previously in International Publication No. WO2010125003, published November 4, 2010, the contents of which are incorporated herein by reference.) or equivalent concentration of isotype mAb (Novartis).

[00285] Example 1: Summary of Initial Experiments

[00286] T follicular helper (Tfh) cells are CD4 T cells specialized in helping B cell responses. Tfh cells are characterized by the expression of signature surface molecules, including CXCR5 and PD-1. CXCR5 is chemokine receptor involved in the location of Tfh cells at the border with B cell follicle, while PD-1 is an inhibitory receptor controlling the expansion of Tfh cells. An unbiased high throughput human Tfh cell differentiation screen was conducted using recombinant proteins. Overall, over 3000 unique human proteins were tested for their ability to induce expression of the Tfh signature markers CXCR5 and PD-1 in human naive CD4 T cells upon activation. The screen identified TGF as regulator T cell differentiation and unexpectedly, the cytokine activin A emerged from the screen as a potent regulator of the human Tfh gene program.

[00287] To test the effect of activin A on the differentiation of Tfh cells, human naive CD4 T cells were isolated from PBMCs and stimulated in vitro with anti CD3/CD28 coated beads and activin A, with or without IL-12, a cytokine previously associated with Tfh cell differentiation. It was found that activin A alone was able to drive a massive PD-1 induction and some CXCR5 expression. Moreover, in combination with IL-12, activin A caused a dramatic increase in the coexpression of PD-1 and CXCR5, a feature of bona fide Tfh cells (Fig 8B). [00288] Bcl6 is a transcription factor playing a crucial role in the development of Tfh cells. Importantly, it was observed that activin A induced a significant expression of Bcl6, particularly when combined with IL-12 (Fig 8C). It has been shown that Bcl6 controls the down regulation of chemokine receptor CCR7, which is important for the localization of Tfh cells at the B cell follicle border in lymphoid tissues. Consistent with its ability to induce Bcl6 expression, it was found that activin A presence resulted in a decreased CCR7 expression (Fig 8D). Therefore, activin A regulates human Tfh differentiation.

[00289] Titration of recombinant activin A, with or without recombinant IL-12, and its effect on the induction of FoxP3⁺CXCR5⁺ cells was measured by flow cytometry. The effect of recombinant TGF with or without recombinant IL-12 was also measured. TGF but not activin A was found to induce high FoxP3 expression.

[00290] Titration of recombinant activin A, with or without recombinant TGF and its effect on the induction of FoxP3⁺CXCR5⁺ cells was measured by flow cytometry. It was found that TGF and activin A synergize in inducing FoxP3 upregulation.

[00291 ] Titration of recombinant activin A, with or without recombinant TGF and its effect on the induction of PD1⁺CXCR5⁺ cells was measured by flow cytometry. It was found that there was no synergy between TGF and activin A.

[00292] Example 2: A high throughput screen revealed activin A as a novel regulator of human CD4 T cell CXCR5 and PD-1 expression

[00293] To discover novel regulators of human Tfh cell differentiation, we performed an unbiased high throughput screen of a human extracellular proteome library consisting of over 2000 human proteins predicted or known to be cytokines, chemokines, morphogens, costimulatory receptors, or single pass transmembrane molecules ¹⁹. Each unique protein in this proteome, or "secretomics", library was produced as a secreted recombinant molecule and tested for its capacity to modulate the differentiation of activated naive CD4 T cells into Tfh cells in vitro. The Tfh screen experimental design and workflow is illustrated in Fig. 1A. Briefly, purified human naive CD4 T cells were stimulated by anti-CD3/CD28 beads in the presence of the human secretome library arrayed on 384 well plates. Each recombinant protein was tested in duplicate. Following 5 days, expression of the Tfh signature markers CXCR5 and PD-1 were measured on the cells by flow cytometry, in an automated fashion. The primary screen revealed multiple recombinant proteins that behaved either as an inducer or inhibitor of CXCR5 and PD-1 expression (Fig. IB). The product of the Inhibin beta A gene (INHBA) emerged as the most potent inducer of CXCR5 and PD-1 (Fig. IB and SIB). The primary screen results were next confirmed, showing that the product of INHBA from the secretomics collection was responsible for CXCR5 and PD-1 induction (Fig. 1C).

[00294] The product of INHBA forms the cytokine activin A as a homodimer. Activin A belongs to the family of activins/inhibins, a group of 5 distinct dimeric cytokines resulting from the combination of 3 different monomers: inhibin beta A, beta B, and alpha ^{20 21}. Activin A is a pleiotropic cytokine involved in multiple vital biological processes ^22~26. Activin A was the first cytokine discovered to sustain human pluripotent stem cells ²¹. Additionally, activin A has complex activities on human stem cells in combination with other factors ^28~30. However, the role of activin A in the immune system is not fully understood, with only a small number of studies providing evidence for involvement of activin A in T cell

, · , 26,31-34

biology

[00295] It was then asked whether activin A is present in sites where Tfh cell differentiation physiologically occurs. To this aim, human tonsils were stained, a tissue enriched in Tfh cells and GCs, for INHBA. Importantly, INHBA was found in T cell zones, including the T-B borders, of all the tonsils analyzed (Fig. ID and SIC), and the majority of INHBA production was in CD3^" cells. Therefore, the in vivo localization of INHBA subunit is compatible with an early role of activin A in human Tfh differentiation.

[00296] The role of activin A in in vitro Tfh differentiation was then independently confirmed by testing activin A from multiple commercial vendors (data not shown), and validated using primary naive CD4 T cells from numerous human donors (Fig. 2A-C). Furthermore, many uncharacterized proteins are present in serum used to supplement T cell cultures. Thus, serum-free medium was used as a critical control to rule out possible indirect or synergistic effects of undefined serum components. In stringent serum free conditions, activin A induces both PD- 1 and CXCR5 expression on activated naive CD4 T cells in a dose dependent fashion (Fig. 2A-C and S2A), demonstrating a direct effect of activin A on human Tfh differentiation. Overall, these data indicate that a high throughput screen of human proteins enables the identification of factors that can function as early regulators of human Tfh differentiation, with activin A identified as the top hit in the screen. [00297] Example 3: Activin A synergizes with IL-12

[00298] IL-12 is the strongest identified stimulus driving IL-21 production by human CD4 T cells " IL-12 can also modulate the induction of CXCR5 expression ³⁵ (Fig. 2A). Therefore, it was asked whether IL-12 might act in synergy with activin A. Activin A regulation of CXCR5 was enhanced by IL-12 (Fig. 2A-C), indicating the existence of a synergy between these two cytokines in promoting CXCR5 expression. Two additional cytokines of the IL-12 cytokine family, IL-23 and IL-35, were evaluated for their ability to synergize with activin A. While IL-23 had a modest but detectable synergistic activity with activin A, IL-35 had no relevant effect on CXCR5 and PD-1 expression in serum-free conditions. Expression of CXCR5 and PD-1 was retained by cells stimulated with activin A in combination with IL-12 (Fig 2C). These data point to IL-12 as an enhancer of activin A induction of CXCR5 and PD-1.

[00299] Treatment of activated CD4 T cells with an anti-activin A neutralizing monoclonal antibody (mAb) abolished activin A-mediated differentiation of PD-1⁺CXCR5⁺ cells (Fig 2D and Fig 18B). Thus, activin A acts directly on activated human CD4 T cells and regulates differentiation of PD-1⁺CXCR5⁺ cells in a specific manner.

[00300] Example 4: Activin A regulates human Tfh differentiation associated genes

[00301] The finding that activin A, combined with IL-12, induced the expression of multiple Tfh canonical receptors on in vitro activated naive CD4 T cells prompted investigation of whether additional molecules important for Tfh biology were under the control of activin A or activin A/IL-12 synergy. Activin A was sufficient to decrease CCR7 expression on activated CD4 T cells (Fig. 2E). Moreover, a fraction of CD4 T cells differentiated with activin A + IL-12 increased expression of BCL6 (Fig 2F and S4). Next, the global transcriptomic profile of the in vitro differentiated Tfh-like cells was ascertained by RNA sequencing (RNA-seq) gene expression analysis. A comparison of gene expression profiles of in vitro cultured CD4 T cells and bona fide human GC Tfh cells revealed that cells differentiated in presence of activin A or activin A + IL-12 were imprinted with bona fide GC Tfh signature genes (Fig. 2G-I). Activin A contributed more than IL-12 to driving expression of bona fide GC Tfh associated genes (Fig. 2H-I). Activin A + IL-12 resulted in a selective upregulation of 116 genes versus cells differentiated with beads only (Fig. 2J). Examination of the 116 upregulated genes confirmed the presence of numerous genes of interest, including SLAMF1, LIF, LTA, and TNF (Fig. 2K), in addition to CXCR5, and PDCD1 (PD-1). Interestingly, activin A emerged as the major factor regulating several Tfh-signature genes such as LIF, LTA, PDCD1, and TNF genes (Fig. 2K). Differential LIF and SLAMF1 expression were confirmed (Fig. 2L-M).

[00302] In addition to the upregulated genes, a set of 60 genes was suppressed by activin A + IL-12 (Fig. 2J and table S2). Activin A caused significant downregulation of PRDM1 (Fig. 2K and 2N). The transcription factor BLIMP1 (PRDM1) is a potent and well- established BCL6 antagonist that is expressed at low levels in bona fide Tfh cells ⁸. ΙΤΟβ7 was an additional target of interest downregulated in the presence of activin A (Fig 20). ΙΤΟβ7 is an integrin downregulated on human GC Tfh cells. Altogether, gene expression analysis of CD4 T cells cultured in the presence of activin A indicated that activin A is sufficient to regulate the expression of multiple molecules important for Tfh cell biology, including genes involved in migration, differentiation and proliferation.

[00303] Example 5: Activin A contributes to the generation of functionally competent Tfh-like cells

[00304] Tfh cells are defined by their specialized function as B cell helpers. To investigate whether activin A can modulate Tfh cell function, the production of Tfh canonical lymphokines by the in vitro differentiated cells was evaluated. First, the ability of the in vitro differentiated cells to secrete CXCL13 ,the chemokine ligand of CXCR5, was tested. CXCL13 is one of the defining factors secreted by human Tfh cells, in that it is constitutively produced in large quantities by human GC Tfh cells and selectively expressed by circulating memory Tfh cells upon restimulation ^36~38. In addition to its chemoattractant properties, CXCL13 also exhibits cytokine-type activity on B lymphocytes ³⁹. Here, it was found that activin A selectively induces CXCL13 expression by CD4 T cells in vitro (Fig. 3A).

[00305] IL-21 is a cytokine highly produced by GC Tfh cells and circulating memory Tfh cells, and is a potent mediator of GC B cell survival and plasma cell differentiation ²'³⁸·⁴⁰. It was observed that CD4 T cells cultured in vitro with IL-12 were capable of producing IL- 21 after a short re- stimulation with PMA/Ionomycin (Fig. 3B). Moreover, cells cultured with activin A + IL-12 retained full IL-21 production potential (Fig. 3B).

[00306] The RNA-seq data from CD4 T cells cultured in the presence of activin A indicated that expression of two cytokine encoding genes that are also highly expressed by human GC Tfh cells: TNF and LTA (Fig. 2K). Subsequent experiments confirmed a superior ability of CD4 T cells cultured with activin A to express TNFoc and LToc proteins upon restimulation (Fig 3C-D).

[00307] Finally, the capacity of activin A differentiated cells to provide help to B cells was evaluated. CD4 T cells differentiated with activin A + IL-12 were functionally competent B cell helpers, capable of supporting B cell proliferation and survival, plasmablast differentiation, and IgG production (Fig. 3E). Overall, the data indicate that activin A, in combination with IL-12, promotes the generation of Tfh-like cells that express high levels of CXCR5 and PD-1 and display Tfh functional properties, including B cell helper activity and production of CXCL13, IL-21, TNFoc and LToc.

[00308] Example 6: Activin A and TGFP have a similar capacity to drive human Tfh cell differentiation, but act independently of each other

[00309] TGF is a pleotropic cytokine involved in the differentiation of multiple CD4 T cell subsets in a context dependent fashion ⁴¹. A recent study showed that TGFP, in conjunction with IL-12 and other cytokines, played a role in human Tfh differentiation ¹⁵. An intriguing connection links activin A and ΤΟΡβ: while activin A and TGF use independent receptors, both cytokines can trigger the SMAD2/3 signaling pathway downstream of their respective receptors ^{41 44}. In stringent conditions using serum free media, TGF can synergize with IL-12 to induce CXCR5 and PD-1 expression. TGF and activin A displayed a similar capacity to regulate the differentiation of PD-1⁺CXCR5⁺ cells when combined with IL-12. To gain insight into the similarity between activin A and TGFP in the regulation of human CD4 T cells, the trascriptomes of cells cultured in vitro with activin A + IL-12 versus TGFP+IL-12 was compared. This comparison revealed a high degree of similarity (Fig. 4A- B), with only 35 genes differentially upregulated by activin A + IL-12 and 45 genes differentially upregulated by TGFP+ IL-12 (Fig. 4A). Similarly, "Volcano" plot analysis indicated that the majority of the genes that were selectively upregulated or downregulated by activin A + IL-12 compare to no exogenous cytokines, followed the same trend in TGFP+IL- 12 samples (Fig. 4B). Because TGF mirrored activin A in driving human Tfh differentiation, we next explored the possibility that activin A accounted for the TGFP- induced phenotype in vitro. This is possible because activated CD4 T cells are capable of secreting activin A following TCR stimulation ³⁴. However, activin A blockade did not alter the frequency of PD-1⁺CXCR5⁺ cells induced by TGF (Fig. 4C), indicating that activin A is not responsible for TGFP-induced Tfh cell differentiation. Conversely, anti-TGFP mAbs did not have any relevant effect on activin A mediated Tfh differentiation, indicating that TGF is not responsible for activin A-induced Tfh cell differentiation (Fig. 4D-E). Next, it was evaluated if these two cytokines could induce PD-1 and CXCR5 expression in an additive or synergistic fashion. However, neither PD-1 nor CXCR5 expression changed when activin A and TGFP were combined in vitro (Fig 4F-G). Interestingly, despite driving very similar gene programming, activin A and TGFP significantly differed in their ability to induce FoxP3 expression, with activin A being less potent than TGFP in driving the generation of FoxP3⁺ cells (Fig. 4H-I). Differential induction of FoxP3 may be important in vivo, since FoxP3 is the lineage defining transcription factor of regulatory T (Treg) cells. Thus, TGFP may preferentially bias cells toward a Treg phenotype and activin A may bias cells toward a Tfh phenotype. In summary, activin A and TGFP do not account for each other's ability to regulate Tfh cell biology, and TGFP preferentially induces FoxP3.

[00310] Example 7: Activin A and IL-2 directly compete in Tfh differentiation

[00311 ] While activin A-stimulated cells express less PRDM1 (Blimpl) (Fig. 2N), IL- 2 potently induces Blimpl in mouse CD4 T cells ⁸'^45"47. Blimpl is one of the strongest negative regulators of the Tfh gene program, both through its ability to antagonize BCL6 and directly suppress CXCR5 expression. Thus, it was hypothesized that activin A and IL-2 signaling may antagonize each other in the regulation of BLIMP1 expression and human Tfh differentiation. This was tested by evaluating the effect of IL-2 blockade on activin A differentiated CD4 T cells. In the presence of activin A alone, differentiation of PD- 1⁺CXCR5⁺ cells was dramatically increased when IL-2 was neutralized (Fig 5A-C). Thus, human IL-2 normally counteracts activin A signaling and impairs the human Tfh gene program. IL-2 blockade also modestly potentiated the expression of PD-1 and CXCR5 in cells cultured with activin A + IL-12 (Fig. 7S). Thus, IL-2 is a potent inhibitor of human Tfh differentiation, and activin A can directly induce human Tfh associated gene expression in the absence of any additional cytokines.

[00312] Example 8: Evolutionary divergence in the regulation of Tfh differentiation by activin A

[00313] To determine if the role of activin A in Tfh cell differentiation was conserved in mice, murine naive CD4 T cells were activated in the presence of activin A alone or combined with IL-12. Strikingly, activin A did not have any relevant effect on PD-1 and CXCR5 expression by mouse CD4 T cells (Fig. 6A-B). This was true for both C57BL/6 and BALB/c mouse strains (Fig. 6A-B). Even the presence of IL-6 did not result in activin A mediated promotion of in vitro mouse Tfh differentiation (Fig. 6B).

[00314] The lack of any measurable effect of activin A on Tfh associated gene expression by mouse CD4 T cells prompted investigation of whether the role of activin A in Tfh cell differentiation was unique to humans. Thus, the capacity of activin A to drive in vitro Tfh differentiation by a species in a different taxonomial family, macaca mulatta (rhesus macaques) of the non-human primate family Cercopithecidae was evaluated. Potent induction of PD-1⁺CXCR5⁺ cells was observed by activated m. mulatta naive CD4 T cells in response to activin A (Fig. 6C-D). These data demonstrate that the Tfh-like differentiation mediated by activin A in vitro is not preserved in mice, but is conserved between non-primate species and humans. This suggests the existence of a possible evolutionary divergence in activin A- mediated Tfh cell differentiation.

[00315] Example 9: Activin A-induced Tfh differentiation is mediated by a SMAD2/3 signaling pathway

[00316] SMAD2/3 is the canonical signaling pathway activated downstream of activin A binding to type IIA and/or IIB receptors and type I receptor ALK4 ⁴³'⁴⁴. Phosphorylation of SMAD2/3 in naive human CD4 T cells in response to activin A was observed (Fig. 7A-B). No relevant induction of SMAD-independent pathways downstream of activin A was observed at the time points analyzed. Therefore, it was hypothesized that SMAD2/3 activation is a central signaling pathway in activin A mediated induction of Tfh associated gene expression. In line with thishypothesis, the usage of a pharmacological inhibitor of ALK4, SB 431542, known to suppress SMAD2/3 activation but not the SMAD-independent

48

pathways , caused a strong reduction of activin A-mediated SMAD2/3 phosphorylation (Fig. 7A-B). Furthermore, it inhibited the differentiation of PD-1 CXCR5 cells in activin A containing culture conditions (Fig. 7C-D). To rule out the possibility of non-specific Tfh differentiation suppression by ALK inhibitors, the effect of Galunisertib⁴⁹, an alternative ALK4 inhibitor currently in clinical trials, was tested for its capacity to dampen activin A- mediated Tfh differentiation. Galunisertib mediated a potent suppression of PD-1⁺CXCR5⁺ cell generation in response to activin A (Fig 7E and S7C continued). Finally, it was found that naive CD4 T cells from tonsils, similarly to naive CD4 T cells from blood, quickly phosphorylated SMAD2/3 when cultured with activin A, and the phosphorylation was abolished by Galunisertib (Fig. 7F and G). Interestingly, PD-l^intCXCR5^int Tfh cells, a heterogeneous population of early Tfh and post-GC Tfh cells located at the T-B border (referred here to as marginal Tfh, mTfh) shown a moderate but specific P-SMAD induction in response to activinA, whereas fully mature GC Tfh cells did not. Altogether, these data point to SMAD2/3 as an important signaling pathway downstream activin A in the early regulation of human Tfh cell biology.

[00317] Example 10: Effect of anti-activin A Type II receptor (ACVR2) blocking mAb

[00318] Activin A belongs to the family of activins/inhibins, a group of 5 distinct dimeric cytokines resulting from the combination of 3 different monomers: inhibin beta A, beta B, and alpha (Gold and Risbridger, 2012; Thompson et al., 2004). Activin A is a pleiotropic cytokine involved in multiple vital biological processes (Aleman-Muench and Soldevila, 2012; Lotinun et al., 2012; Munz et al., 2001; Muttukrishna et al., 2004; Phillips et al., 2009). However, activin A' s role in the immune system is understudied, and a small number of studies provide evidence for involvement of activin A in T cell biology (Aleman- Muench and Soldevila, 2012; Huber et al., 2009; Jones et al., 2012; Ogawa et al., 2006; Semitekolou et al., 2009).

[00319] The data provided herein shows that activin A is responsible for induction of the Tfh signature markers CXCR5 and PD-1 on numerous human donors, and its activity is enhanced by IL12 (Fig. 18A).

[00320] Activin A primarily binds and signals through the type I receptor ALK4, in complex with the activin A receptor type IIA (ACVR2A) or IIB (ACVR2B). A monoclonal antibody against human Type II activin A receptors, capable of blocking activin A binding to ACVR2A and ACVR2B ("anti-ACVR2 pan Ab"), resulted in a severe decrease of PD-1 and CXCR5 induction driven by activin A (Fig. 18 B). Thus, activin A acts directly on activated human CD4 T cells and regulates differentiation of PD-1⁺CXCR5⁺ cells in a Type II activin A receptor-specific manner.

[00321 ] Example 11 : Discussion of Results

[00322] Tfh cells are crucial regulators of most humoral responses, and at least two biomedical fields could benefit from Tfh cell manipulation in vivo: vaccinations and autoimmune therapies. In vaccination, generating more Tfh cells could promote larger GC B cell responses and increased production of long-lived plasma cells and memory B cells. Therefore, it is highly desirable to foster Tfh cells in vivo from a vaccine design perspective, when the generation of a protective vaccine relies on the production of neutralizing Abs \ In contrast, dysregulated Ab responses may lead to auto-Ab mediated autoimmune diseases ¹. Direct studies of bona fide Tfh cells in autoimmune disease are often not possible because of unavailability of lymphoid organs. However, memory blood Tfh cells, that we and others

37 38 40 50

have described as the circulating counterpart of bona fide Tfh cells ' ' ' , or recently

38 50

activated blood Tfh cells ' have been found to be elevated in patients affected by rheumatoid arthritis, systemic lupus erythematous and juvenile dermatomyositis ⁵¹. Furthermore, the abundance of Tfh-related cells in blood correlated with disease score and/or serum auto-Ab levels ⁵¹. In this context, hampering Tfh in a targeted fashion may represent a promising therapeutic approach.

[00323] Activin A signals foster the early expression of Tfh associated molecules involved in localization and function

[00324] Herein, it is shown that the signals delivered by the cytokine activin A convert activated human naive CD4 T cells into Tfh-like cells. Early regulators of Tfh cell differentiation that are capable of imprinting the Tfh gene program are secreted by DCs or other myeloid APCs in the T cell area. In line with an early role of activin A in educating the initial stages of Tfh differentiation, DCs and other APCs have been shown to produce activin A following stimulation ²⁶ '. Moreover, B cells and activated T cells are also capable of producing activin A ²⁶. Consistent with this hypothesis, evidence is provided for the expression of activin A subunit INHBA in tonsillar T cell areas and it is shown that, in these areas, INHBA is mainly produced by non-T cells. In addition, a gradient in the capacity of tonsillar CD4 T cells to phosphorylate SMAD2/3 following activin A exposure was found, with naive CD4 T cells having the highest and GC Tfh cells the lowest capacity to sense and respond to activin A. Overall, these data indicate that activin A may behave as early regulator of human Tfh cell differentiation in vivo.

[00325] Proper localization is a key feature of Tfh biology. Activin A acts by dampening CCR7 while fostering CXCR5 expression. In addition, activin A also suppresses the expression of the gut homing receptor ΙΤΟβ7, thus adding another level of control in the Tfh localization process. Besides regulating localization, activin A also modulates the expression of Tfh functional regulators. Activin A regulates the production of CXCL13, a chemokine with cytokine-like activity highly expressed by bona fide tonsillar Tfh cells. CXCL13 likely amplifies GC reactions by recruiting B cells and newly generated Tfh cells to B cell follicles and by enhancing BCR-mediated B cell activation via CXCR5 binding. TNFoc, which was also highly induced by activin A, is a cytokine produced by GC Tfh cells that can act as co-stimulatory signal to mediate B cell activation and Ig production ⁵². Moreover, activin A also enhanced CD4 T cell expression of LIF and LToc, two cytokines highly expressed by bona fide GC Tfh cells. The roles of LIF and LToc in B cell help have not formally addressed. However, B cell hyperplasia and polyclonal hypergammaglobulemia is found in mice overexpressing LIF ⁵³, suggesting a role for LIF in regulating B cell responses. Disruption of lymphoid organ architecture caused by genetic depletion of LToc does not currently allow for interpretation of any T cell intrinsic role of LToc in the generation of affinity matured memory B cells and long-lived plasma cells. Thus, additional studies are required to address the role of LToc in B cell help. In T-B co-cultures, the B cell helper activity of the in vitro differentiated Tfh cells was driven entirely by IL-12. Although this assay is the best in vitro proxy to test the B cell helper activity of T cells, it has major limitations in that it mostly relies on CD40L (which is equally expressed by all activated cells), and IL-21, which is IL-12 dependent ¹¹. Therefore, additional Tfh features regulated by activin A (with or without IL-12) that are vital for B cell helper function in vivo, such as location (CXCR5, CCR7), the recruitment of additional Tfh and B cells (CXCL13), and the formation of stable contacts with cognate B cells (SLAM), are not emphasized in the in vitro help assay. [00326] Relationships between activin A and other cytokines in human Tfh differentiation

[00327] Activin A alone was sufficient for the regulation of many Tfh signature molecules. Nevertheless, the integration of activin A and IL-12 mediated signal was required to acquire a more complete Tfh-like phenotype, which also included high expression of IL- 21. This finding demonstrates that activin A is at the center of a cytokine network orchestrating human Tfh differentiation. The cytokine network controlling Tfh differentiation includes not only agonistic players such as IL-12, but also antagonistic signals. It is shown that IL-2 is an example of an antagonistic signal, as indicated by the remarkable enhancement of activin A-mediated CXCR5 induction when IL-2 is specifically blocked in vitro. The enhancement of activin A mediated CXCR5 induction under low IL-2 conditions relies at least partially on the capacity of activin A and IL-2 to exert opposing effects on the expression of BLIMP1, which can directly modulate CXCR5 and BCL6 expression. Thus, IL-2 blockade reduces BLIMP 1 levels and poises the activated CD4 T cells to become Tfh- like cells, while the simultaneous presence of activin A further suppresses BLIMP1 and amplifies Tfh differentiation.

[00328] TGF likely has similar interactions with IL-12 and IL-2 in Tfh programing. However, while activin A induced similar levels of CXCR5 and PD-1 expression compared to TGF , activin A induced less FoxP3 expression. Although activated human T cells can express FoxP3 in the absence of suppressive activity ⁵⁴, it is still considered controversial as to whether the acquisition of FoxP3 in vitro by human CD4 T cells confers them with the capacity to suppress immune responses. Nevertheless, the lower FoxP3 induction by activin A appears to be a favorable event when the ultimate goal is the induction induce human Tfh cells in vitro.

[00329] Evolutionary divergence in the regulation of Tfh differentiation

[00330] Mouse models represent important tools to investigate the biological relevance of molecular pathways involved in the regulation of Tfh cell differentiation and B cell responses in vivo. However, a significant limitation in the usage of rodent models results from the existence of evolutionary divergence in signaling pathways shaping Tfh cell biology. Fully mature mouse and human Tfh cells express a virtually identical set of signature molecules, including CXCR5, PD-1, BCL6, CD200, BTLA, TIGIT, SAP, IL-21 and IL-4, while lacking expression of CCR7, PSGL-1 and BLIMP1. This phenotypical similarity indicates that the majority of the target genes of the Tfh differentiation program have been conserved through evolution. Nevertheless, a growing body of evidence suggested that the mechanisms regulating this gene expression pattern are not the same in mice and humans and there are signaling pathways that are crucial for the regulation of human, but not mouse Tfh differentiation, such as IL-12 and TGFp. No relevant CXCR5 and PD-1 induction was found when mouse naive CD4 T cells were stimulated with activin A in vitro. By contrast, activin A was a potent CXCR5 and PD-1 inducer for both human and non-human primate activated naive CD4 T cells. This data demostrates the existence of a potential evolutionary divergence in the role that activin A plays in Tfh cell biology. Nevertheless, the inability of activin A to induce CXCR5 and PD-1 by mouse CD4 T cells may alternatively reflect an unknown inhibitor or cofactor. Thus far, a reproducible approach to generate robust PD-1⁺CXCR5⁺ cells in vitro starting from mouse naive CD4 T cells is still missing. Thus, a possible interpretation is that, in addition to TCR activation and costimulatory signals, activin A needs the presence of additional pathways in vitro in order to drive mouse Tfh cell differentiation.

[00331] Example 12: Additional Antibody Sequences For Sequence Listing

SEQ ID NO: 22

Gly Tyr Thr Phe Thr Ser Ser Tyr lie Asn

1 5 10

SEQ ID NO: 23

Gly Tyr Thr Phe Thr Ser Ser Tyr lie Asn

1 5 10

SEQ ID NO: 24

Gly Tyr Thr Phe Thr Ser Ser Tyr lie Asn

1 5 10

SEQ ID NO: 25

Gly Tyr Thr Phe Thr Ser Ser Tyr lie Asn

1 5 10 SEQ ID NO: 26

Gly Tyr Thr Phe Thr Ser Ser Tyr lie Asn 1 5 10

SEQ ID NO: 27

Gly Tyr Thr Phe Thr Ser Ser Tyr lie Asn 1 5 10

SEQ ID NO: 28

Gly Tyr Thr Phe Thr Ser Ser Tyr lie Asn 1 5 10

SEQ ID NO: 29

Gly Tyr Thr Phe Thr Ser Ser Tyr lie Asn 1 5 10

SEQ ID NO: 30

Gly Tyr Thr Phe Thr Ser Ser Tyr lie Asn 1 5 10

SEQ ID NO: 31

Gly Tyr Thr Phe Thr Ser Ser Tyr lie Asn 1 5 10

SEQ ID NO: 32

Gly Tyr Thr Phe Thr Ser Ser Tyr lie Asn 1 5 10

SEQ ID NO: 33

Gly Tyr Thr Phe Thr Ser Ser Tyr lie Asn 1 5 10

SEQ ID NO: 34

Gly Tyr Thr Phe Thr Ser Ser Tyr lie Asn 1 5 10

SEQ ID NO: 35

Gly Tyr Thr Phe Thr Ser Ser Tyr lie Asn 1 5 10 SEQ ID NO: 36

Thr He Asn Pro Val Ser Gly Asn Thr Ser Tyr Ala Gin Lys Phe Gin 1 5 10 15

Gly

SEQ ID NO: 37

Thr He Asn Pro Val Ser Gly Asn Thr Ser Tyr Ala Gin Lys Phe Gin 1 5 10 15

Gly

SEQ ID NO: 38

Thr He Asn Pro Val Ser Gly Asn Thr Ser Tyr Ala Gin Lys Phe Gin 1 5 10 15

Gly

SEQ ID NO: 39

Thr He Asn Pro Val Ser Gly Asn Thr Ser Tyr Ala Gin Lys Phe Gin 1 5 10 15

Gly

SEQ ID NO: 40

Met He Asn Ala Pro He Gly Thr Thr Arg Tyr Ala Gin Lys Phe Gin 1 5 10 15

Gly

SEQ ID NO: 41

Gin He Asn Ala Ala Ser Gly Met Thr Arg Tyr Ala Gin Lys Phe Gin 1 5 10 15

Gly

SEQ ID NO: 42 Met He Asn Ala Pro He Gly Thr Thr Arg Tyr Ala Gin Lys Phe Gin 1 5 10 15

Gly

SEQ ID NO: 43

Thr He Asn Pro Val Ser Gly Asn Thr Arg Tyr Ala Gin Lys Phe Gin 1 5 10 15

Gly

SEQ ID NO: 44

Thr He Asn Pro Val Ser Gly Ser Thr Ser Tyr Ala Gin Lys Phe Gin 1 5 10 15

Gly

SEQ ID NO: 45

Gin He Asn Ala Ala Ser Gly Met Thr Arg Tyr Ala Gin Lys Phe Gin 1 5 10 15

Gly

SEQ ID NO: 46

Asn He Asn Ala Ala Ala Gly He Thr Leu Tyr Ala Gin Lys Phe Gin 1 5 10 15

Gly

SEQ ID NO: 47

Thr He Asn Pro Pro Thr Gly Gly Thr Tyr Tyr Ala Gin Lys Phe Gin 1 5 10 15

Gly

SEQ ID NO: 48

Gly He Asn Pro Pro Ala Gly Thr Thr Ser Tyr Ala Gin Lys Phe Gin 1 5 10 15 Gly

SEQ ID NO: 49

Asn lie Asn Pro Ala Thr Gly His Ala Asp Tyr Ala Gin Lys Phe Gin 1 5 10 15

Gly

SEQ ID NO: 50

Gly Gly Trp Phe Asp Ty

1 5

SEQ ID NO: 51

Gly Gly Trp Phe Asp Ty

1 5

SEQ ID NO: 52

Gly Gly Trp Phe Asp Ty

1 5

SEQ ID NO: 53

Gly Gly Trp Phe Asp

1 5

SEQ ID NO: 54

Gly Gly Trp Phe Asp

1 5

SEQ ID NO: 55

Gly Gly Trp Phe Asp

1 5

SEQ ID NO: 56

Gly Gly Trp Phe Asp Tyr

1 5

SEQ ID NO: 57

Gly Gly Trp Phe Asp Tyr

1 5

SEQ ID NO: 58 Gly Gly Trp Phe Asp Tyr

1 5

SEQ ID NO: 59

Gly Gly Trp Phe Asp

1 5

SEQ ID NO: 60

Gly Gly Trp Phe Asp Tyr

1 5

SEQ ID NO: 61

Gly Gly Trp Phe Asp

1 5

SEQ ID NO: 62

Gly Gly Trp Phe Asp

1 5

SEQ ID NO: 63

Gly Gly Trp Phe Asp Tyr

1 5

SEQ ID NO: 64

Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Tyr Val Asn 1 5 10

SEQ ID NO: 65

Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Tyr Val Asn 1 5 10

SEQ ID NO: 66

Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Tyr Val Asn 1 5 10

SEQ ID NO: 67

Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Tyr Val Asn 1 5 10

SEQ ID NO: 68 Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Tyr Val Asn 1 5 10

SEQ ID NO: 69

Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Tyr Val Asn 1 5 10

SEQ ID NO: 70

Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Tyr Val Asn 1 5 10

SEQ ID NO: 71

Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Tyr Val Asn 1 5 10

SEQ ID NO: 72

Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Tyr Val Asn 1 5 10

SEQ ID NO: 73

Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Tyr Val Asn 1 5 10

SEQ ID NO: 74

Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Tyr Val Asn 1 5 10

SEQ ID NO: 75

Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Tyr Val Asn 1 5 10

SEQ ID NO: 76

Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Tyr Val Asn 1 5 10

SEQ ID NO: 77

Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr Asn Tyr Val Asn 1 5 10

SEQ ID NO: 78 Leu Met He Tyr Gly Val Ser Lys Arg Pro Ser 1 5 10

SEQ ID NO: 79

Leu Met He Tyr Gly Val Ser Lys Arg Pro Ser 1 5 10

SEQ ID NO: 80

Leu Met He Tyr Gly Val Ser Lys Arg Pro Ser 1 5 10

SEQ ID NO: 81

Leu Met He Tyr Gly Val Ser Lys Arg Pro Ser 1 5 10

SEQ ID NO: 82

Leu Met He Tyr Gly Val Ser Lys Arg Pro Ser 1 5 10

SEQ ID NO: 83

Leu Met He Tyr Gly Val Ser Lys Arg Pro Ser 1 5 10

SEQ ID NO: 84

Leu Met He Tyr Gly Val Ser Lys Arg Pro Ser 1 5 10

SEQ ID NO: 85

Leu Met He Tyr Gly Val Ser Lys Arg Pro Ser 1 5 10

SEQ ID NO: 86

Leu Met He Tyr Gly Val Ser Lys Arg Pro Ser 1 5 10

SEQ ID NO: 87

Leu Met He Tyr Gly Val Ser Lys Arg Pro Ser 1 5 10

SEQ ID NO: Leu Met lie Tyr Gly Val Ser Lys Arg Pro Ser 1 5 10

SEQ ID NO: 89

Leu Met lie Tyr Gly Val Ser Lys Arg Pro Ser 1 5 10

SEQ ID NO: 90

Leu Met lie Tyr Gly Val Ser Lys Arg Pro Ser 1 5 10

SEQ ID NO: 91

Leu Met lie Tyr Gly Val Ser Lys Arg Pro Ser 1 5 10

SEQ ID NO: 92

Gin Ala Trp Thr Ser Lys Met Ala Gly

1 5

SEQ ID NO: 93

Ser Ser Tyr Thr Arg Met Gly His Pro

1 5

SEQ ID NO: 94

Ala Thr Tyr Gly Gly Val Thr Pro Pro 1 10

SEQ ID NO: 95

Gly Thr Phe Ala Gly Gly Ser Tyr Tyr Gly 1 5 10

SEQ ID NO: 96

Gin Ala Trp Thr Ser Lys Met Ala Gly

1 5

SEQ ID NO: 97

Gin Ala Trp Thr Ser Lys Met Ala Gly

1 5

SEQ ID NO:

Gly Thr Phe Ala Gly Gly Ser Tyr Tyr Gly 1 5 10

SEQ ID NO: 99

Gly Thr Phe Ala Gly Gly Ser Tyr Tyr Gly 1 5 10 SEQ ID NO: 100

Gly Thr Phe Ala Gly Gly Ser Tyr Tyr Gly

1 5 10

SEQ ID NO: 101

Gly Thr Phe Ala Gly Gly Ser Tyr Tyr Gly

1 5 10

SEQ ID NO: 102

Gly Thr Phe Ala Gly Gly Ser Tyr Tyr Gly

1 5 10

SEQ ID NO: 103

Gly Thr Phe Ala Gly Gly Ser Tyr Tyr Gly

1 5 10

SEQ ID NO: 104

Gly Thr Phe Ala Gly Gly Ser Tyr Tyr Gly

1 5 10

SEQ ID NO: 105

Gly Thr Phe Ala Gly Gly Ser Tyr Tyr Gly

1 5 10

SEQ ID NO: 106

Asp lie Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15

Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr

20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu

35 40 45

Met lie Tyr Gly Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gin Ala Trp Thr Ser Lys

85 90 95 Met Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gin 100 105 110

SEQ ID NO: 107

Asp lie Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15

Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr

20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu

35 40 45

Met lie Tyr Gly Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Arg Met

85 90 95

Gly His Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gin

100 105 110

SEQ ID NO: 108

Asp lie Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15

Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr

20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu

35 40 45

Met lie Tyr Gly Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Tyr Gly Lys Gly

85 90 95 Val Thr Pro Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 110

Gin

SEQ ID NO: 109

Asp lie Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15

Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr

20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu

35 40 45

Met lie Tyr Gly Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Phe Ala Gly Gly

85 90 95

Ser Tyr Tyr Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly

100 105 110

Gin

SEQ ID NO: 110

Asp lie Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15

Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr

20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu

35 40 45

Met lie Tyr Gly Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gin Ala Trp Thr Ser Lys

85 90 95

Met Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gin

100 105 110

SEQ ID NO: ill

Asp lie Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15

Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr

20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu

35 40 45

Met lie Tyr Gly Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gin Ala Trp Thr Ser Lys

85 90 95

Met Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gin

100 105 110

SEQ ID NO: 112

Asp lie Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15

Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr

20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu

35 40 45

Met lie Tyr Gly Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Phe Ala Gly Gly

85 90 95

Ser Tyr Tyr Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly

100 105 110

Gin

SEQ ID NO: 113

Asp lie Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15

Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr

20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu

35 40 45

Met lie Tyr Gly Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Phe Ala Gly Gly

85 90 95

Ser Tyr Tyr Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly

100 105 110

Gin

SEQ ID NO: 114

Asp lie Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15

Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr

20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45

Met lie Tyr Gly Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Phe Ala Gly Gly

85 90 95

Ser Tyr Tyr Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly

100 105 110

Gin

SEQ ID NO: 115

Asp lie Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15

Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr

20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu

35 40 45

Met lie Tyr Gly Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Phe Ala Gly Gly

85 90 95

Ser Tyr Tyr Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly

100 105 110

Gin

SEQ ID NO: 116

Asp lie Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15 Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr 20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu

35 40 45

Met lie Tyr Gly Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Phe Ala Gly Gly

85 90 95

Ser Tyr Tyr Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly

100 105 110

Gin

SEQ ID NO: 117

Asp lie Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15

Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr

20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu

35 40 45

Met lie Tyr Gly Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Phe Ala Gly Gly

85 90 95

Ser Tyr Tyr Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly

100 105 110

Gin SEQ ID NO: 118

Asp lie Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15

Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr

20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu

35 40 45

Met lie Tyr Gly Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Phe Ala Gly Gly

85 90 95

Ser Tyr Tyr Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly

100 105 110

Gin

SEQ ID NO: 119

Asp lie Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15

Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr

20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu

35 40 45

Met lie Tyr Gly Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Phe Ala Gly Gly

85 90 95 Ser Tyr Tyr Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 110

Gin

SEQ ID NO: 120

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser

20 25 30

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45

Gly Thr lie Asn Pro Val Ser Gly Asn Thr Ser Tyr Ala Gin Lys Phe 50 55 60

Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr

100 105 110

Val Ser Ser

115

SEQ ID NO: 121

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser

20 25 30

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45

Gly Thr lie Asn Pro Val Ser Gly Asn Thr Ser Tyr Ala Gin Lys Phe 50 55 60 Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr

100 105 110

Val Ser Ser

115

SEQ ID NO: 122

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser

20 25 30

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45

Gly Thr lie Asn Pro Val Ser Gly Asn Thr Ser Tyr Ala Gin Lys Phe 50 55 60

Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr

100 105 110

Val Ser Ser

115

SEQ ID NO: 123

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser 20 25 30

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45

Gly Thr lie Asn Pro Val Ser Gly Asn Thr Ser Tyr Ala Gin Lys Phe 50 55 60

Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr

100 105 110

Val Ser Ser

115

SEQ ID NO: 124

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser

20 25 30

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45

Gly Met lie Asn Ala Pro lie Gly Thr Thr Arg Tyr Ala Gin Lys Phe 50 55 60

Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr

100 105 110

Val Ser Ser 115

SEQ ID NO: 125

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser

20 25 30

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45

Gly Gin lie Asn Ala Ala Ser Gly Met Thr Arg Tyr Ala Gin Lys Phe 50 55 60

Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr

100 105 110

Val Ser Ser

115

SEQ ID NO: 126

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser

20 25 30

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45

Gly Met lie Asn Ala Pro lie Gly Thr Thr Arg Tyr Ala Gin Lys Phe 50 55 60

Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95

Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr

100 105 110

Val Ser Ser

115

SEQ ID NO: 127

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser

20 25 30

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45

Gly Thr lie Asn Pro Val Ser Gly Asn Thr Arg Tyr Ala Gin Lys Phe 50 55 60

Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr

100 105 110

Val Ser Ser

115

SEQ ID NO: 128

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser

20 25 30

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45 Gly Thr lie Asn Pro Val Ser Gly Ser Thr Ser Tyr Ala Gin Lys Phe 50 55 60

Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr

100 105 110

Val Ser Ser

115

SEQ ID NO: 129

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser

20 25 30

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45

Gly Gin lie Asn Ala Ala Ser Gly Met Thr Arg Tyr Ala Gin Lys Phe 50 55 60

Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr

100 105 110

Val Ser Ser

115

SEQ ID NO: 130

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45

Gly Asn lie Asn Ala Ala Ala Gly lie Thr Leu Tyr Ala Gin Lys Phe 50 55 60

Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr

100 105 110

Val Ser Ser

115

SEQ ID NO: 131

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser

20 25 30

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45

Gly Thr lie Asn Pro Pro Thr Gly Gly Thr Tyr Tyr Ala Gin Lys Phe 50 55 60

Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr

100 105 110 Val Ser Ser

115

SEQ ID NO: 132

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser

20 25 30

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45

Gly Gly lie Asn Pro Pro Ala Gly Thr Thr Ser Tyr Ala Gin Lys Phe 50 55 60

Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr

100 105 110

Val Ser Ser

115

SEQ ID NO: 133

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser

20 25 30

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45

Gly Asn lie Asn Pro Ala Thr Gly His Ala Asp Tyr Ala Gin Lys Phe 50 55 60

Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr

100 105 110

Val Ser Ser

115

SEQ ID NO: 134

gatatcgcac tgacccagcc agcttcagtg agcggctcac caggtcagag cattaccatc 60 tcgtgtacgg gtactagcag cgatgttggt tcttataatt atgtgaattg gtaccagcag 120 catcccggga aggcgccgaa acttatgatt tatggtgttt ctaagcgtcc ctcaggcgtg 180 agcaaccgtt ttagcggatc caaaagcggc aacaccgcga gcctgaccat tagcggcctg 240 caagcggaag acgaagcgga ttattattgc caggcttgga cttctaagat ggctggtgtg 300 tttggcggcg gcacgaagtt aaccgttctt ggccag 336

SEQ ID NO: 135

gatatcgcac tgacccagcc agcttcagtg agcggctcac caggtcagag cattaccatc 60 tcgtgtacgg gtactagcag cgatgttggt tcttataatt atgtgaattg gtaccagcag 120 catcccggga aggcgccgaa acttatgatt tatggtgttt ctaagcgtcc ctcaggcgtg 180 agcaaccgtt ttagcggatc caaaagcggc aacaccgcga gcctgaccat tagcggcctg 240 caagcggaag acgaagcgga ttattattgc tcttcttata ctcgtatggg tcatcctgtg 300 tttggcggcg gcacgaagtt aaccgttctt ggccag 336

SEQ ID NO: 136

gatatcgcac tgacccagcc agcttcagtg agcggctcac caggtcagag cattaccatc 60 tcgtgtacgg gtactagcag cgatgttggt tcttataatt atgtgaattg gtaccagcag 120 catcccggga aggcgccgaa acttatgatt tatggtgttt ctaagcgtcc ctcaggcgtg 180 agcaaccgtt ttagcggatc caaaagcggc aacaccgcga gcctgaccat tagcggcctg 240 caagcggaag acgaagcgga ttattattgc gctacttatg gtaagggtgt tactcctcct 300 gtgtttggcg gcggcacgaa gttaaccgtt cttggccag 339 SEQ ID NO: 137

gatatcgcac tgacccagcc agcttcagtg agcggctcac caggtcagag cattaccatc 60 tcgtgtacgg gtactagcag cgatgttggt tcttataatt atgtgaattg gtaccagcag 120 catcccggga aggcgccgaa acttatgatt tatggtgttt ctaagcgtcc ctcaggcgtg 180 agcaaccgtt ttagcggatc caaaagcggc aacaccgcga gcctgaccat tagcggcctg 240 caagcggaag acgaagcgga ttattattgc ggtacttttg ctggtggttc ttattatggt 300 gtgtttggcg gcggcacgaa gttaaccgtt cttggccag 339

SEQ ID NO: 138

SEQ ID NO: 139

SEQ ID NO: 140

gatatcgcac tgacccagcc agcttcagtg agcggctcac caggtcagag cattaccatc 60 tcgtgtacgg gtactagcag cgatgttggt tcttataatt atgtgaattg gtaccagcag 120 catcccggga aggcgccgaa acttatgatt tatggtgttt ctaagcgtcc ctcaggcgtg 180 agcaaccgtt ttagcggatc caaaagcggc aacaccgcga gcctgaccat tagcggcctg 240 caagcggaag acgaagcgga ttattattgc ggtacttttg ctggtggttc ttattatggt 300 gtgtttggcg gcggcacgaa gttaaccgtt cttggccag 339 SEQ ID NO: 141

SEQ ID NO: 142

SEQ ID NO: 143

SEQ ID NO: 144

gatatcgcac tgacccagcc agcttcagtg agcggctcac caggtcagag cattaccatc 60 tcgtgtacgg gtactagcag cgatgttggt tcttataatt atgtgaattg gtaccagcag 120 catcccggga aggcgccgaa acttatgatt tatggtgttt ctaagcgtcc ctcaggcgtg 180 agcaaccgtt ttagcggatc caaaagcggc aacaccgcga gcctgaccat tagcggcctg 240 caagcggaag acgaagcgga ttattattgc ggtacttttg ctggtggttc ttattatggt 300 gtgtttggcg gcggcacgaa gttaaccgtt cttggccag 339 SEQ ID NO: 145

gatatcgcac tgacccagcc agcttcagtg agcggctcac caggtcagag cattaccatc 60 tcgtgtactg gtactagcag cgatgttggt tcttataatt atgtgaattg gtaccagcag 120 catcccggga aggcgccgaa acttatgatt tatggtgttt ctaagcgtcc ctcaggcgtg 180 agcaaccgtt ttagcggatc caaaagcggc aacaccgcga gcctgaccat tagcggcctg 240 caagcggaag acgaagcgga ttattattgc ggtacttttg ctggtggttc ttattatggt 300 gtgtttggcg gcggcacgaa gttaaccgtt cttggccag 339

SEQ ID NO: 146

SEQ ID NO: 147

SEQ ID NO: 148

caggtgcaat tggttcagag cggcgcggaa gtgaaaaaac cgggcgcgag cgtgaaagtg 60 agctgcaaag cctccggata tacctttact tcttcttata ttaattgggt ccgccaagcc 120 cctgggcagg gtctcgagtg gatgggcact atcaatccgg tttctggcaa tacgtcttac 180 gcgcagaagt ttcagggccg ggtgaccatg acccgtgata ccagcattag caccgcgtat 240 atggaactga gcagcctgcg tagcgaagat acggccgtgt attattgcgc gcgtggtggt 300 tggtttgatt attggggcca aggcaccctg gtgacggtta gctca 345

SEQ ID NO: 149

SEQ ID NO: 150

SEQ ID NO: 151

SEQ ID NO: 152

caggtgcaat tggttcagag cggcgcggaa gtgaaaaaac cgggcgcgag cgtgaaagtg 60 agctgcaaag cctccggata tacctttact tcttcttata ttaattgggt ccgccaagcc 120 cctgggcagg gtctcgagtg gatgggcatg attaatgctc ctattggtac tactcgttat 180 gctcagaagt ttcagggtcg ggtgaccatg acccgtgata ccagcattag caccgcgtat 240 atggaactga gcagcctgcg tagcgaagat acggccgtgt attattgcgc gcgtggtggt 300 tggtttgatt attggggcca aggcaccctg gtgacggtta gctca 345

SEQ ID NO: 153

caggtgcaat tggttcagag cggcgcggaa gtgaaaaaac cgggcgcgag cgtgaaagtg 60 agctgcaaag cctccggata tacctttact tcttcttata ttaattgggt ccgccaagcc 120 cctgggcagg gtctcgagtg gatgggccag attaatgctg cttctggtat gactcgttat 180 gctcagaagt ttcagggtcg ggtgaccatg acccgtgata ccagcattag caccgcgtat 240 atggaactga gcagcctgcg tagcgaagat acggccgtgt attattgcgc gcgtggtggt 300 tggtttgatt attggggcca aggcaccctg gtgacggtta gctca 345

SEQ ID NO: 154

SEQ ID NO: 155

caggtgcaat tggttcagag cggcgcggaa gtgaaaaaac cgggcgcgag cgtgaaagtg 60 agctgcaaag cctccggata tacctttact tcttcttata ttaattgggt ccgccaagcc 120 cctgggcagg gtctcgagtg gatgggcact atcaatccgg tttctggcaa tacgcgttac 180 gcgcagaagt ttcagggccg ggtgaccatg acccgtgata ccagcattag caccgcgtat 240 atggaactga gcagcctgcg tagcgaagat acggccgtgt attattgcgc gcgtggtggt 300 tggtttgatt attggggcca aggcaccctg gtgacggtta gctca 345

SEQ ID NO: 156

caggtgcaat tggttcagag cggcgcggaa gtgaaaaaac cgggcgcgag cgtgaaagtg 60 agctgcaaag cctccggata tacctttact tcttcttata ttaattgggt ccgccaagcc 120 cctgggcagg gtctcgagtg gatgggcact atcaatccgg tttctggctc tacgtcttac 180 gcgcagaagt ttcagggccg ggtgaccatg acccgtgata ccagcattag caccgcgtat 240 atggaactga gcagcctgcg tagcgaagat acggccgtgt attattgcgc gcgtggtggt 300 tggtttgatt attggggcca aggcaccctg gtgacggtta gctca 345

SEQ ID NO: 157

caggtgcaat tggttcagag cggcgcggaa gtgaaaaaac cgggcgcgag cgtgaaagtg 60 agctgcaaag cctccggata tacctttact tcttcttata ttaattgggt ccgccaagcc 120 cctgggcagg gtctcgagtg gatgggccag attaatgctg cttctggtat gactcgttat 180 gctcagaagt ttcagggtcg ggtcaccatg acccgtgata ccagcattag caccgcgtat 240 atggaactga gcagcctgcg tagcgaagat acggccgtgt attattgcgc gcgtggtggt 300 tggtttgatt attggggcca aggcaccctg gtgacggtta gctca 345

SEQ ID NO: 158

caggtgcaat tggttcagag cggcgcggaa gtgaaaaaac cgggcgcgag cgtgaaagtg 60 agctgcaaag cctccggata tacctttact tcttcttata ttaattgggt ccgccaagcc 120 cctgggcagg gtctcgagtg gatgggcaat attaatgctg ctgctggtat tactctttat 180 gctcagaagt ttcagggtcg ggtcaccatg acccgtgata ccagcattag caccgcgtat 240 atggaactga gcagcctgcg tagcgaagat acggccgtgt attattgcgc gcgtggtggt 300 tggtttgatt attggggcca aggcaccctg gtgacggtta gctca 345

SEQ ID NO: 159

caggtgcaat tggttcagag cggcgcggaa gtgaaaaaac cgggcgcgag cgtgaaagtg 60 agctgcaaag cctccggata tacctttact tcttcttata ttaattgggt ccgccaagcc 120 cctgggcagg gtctcgagtg gatgggcact attaatcctc ctactggagg tacttattat 180 gctcagaagt ttcagggtcg ggtgaccatg acccgtgata ccagcattag caccgcgtat 240 atggaactga gcagcctgcg tagcgaagat acggccgtgt attattgcgc gcgtggtggt 300 tggtttgatt attggggcca aggcaccctg gtgacggtta gctca 345

SEQ ID NO: 160

caggtgcaat tggttcagag cggcgcggaa gtgaaaaaac cgggcgcgag cgtgaaagtg 60 agctgcaaag cctccggata tacctttact tcttcttata ttaattgggt ccgccaagcc 120 cctgggcagg gtctcgagtg gatgggcggt attaatcctc ctgctggtac tacttcttat 180 gctcagaagt ttcagggtcg ggtcaccatg acccgtgata ccagcattag caccgcgtat 240 atggaactga gcagcctgcg tagcgaagat acggccgtgt attattgcgc gcgtggtggt 300 tggtttgatt attggggcca aggcaccctg gtgacggtta gctca 345

SEQ ID NO: 161

caggtgcaat tggttcagag cggcgcggaa gtgaaaaaac cgggcgcgag cgtgaaagtg 60 agctgcaaag cctccggata tacctttact tcttcttata ttaattgggt ccgccaagcc 120 cctgggcagg gtctcgagtg gatgggcaat attaatcctg ctactggtca tgctgattat 180 gctcagaagt ttcagggtcg ggtgaccatg acccgtgata ccagcattag caccgcgtat 240 atggaactga gcagcctgcg tagcgaagat acggccgtgt attattgcgc gcgtggtggt 300 tggtttgatt attggggcca aggcaccctg gtgacggtta gctca 345

SEQ ID NO: 162

Gin Ser Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin

1 5 10 15

Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr

20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu

35 40 45

Met lie Tyr Gly Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe

50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu

65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Phe Ala Gly Gly

85 90 95

Ser Tyr Tyr Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly

100 105 110

Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu

115 120 125

Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu lie Ser Asp Phe

130 135 140

Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val

145 150 155 160 Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser Asn Asn Lys 165 170 175

Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin Trp Lys Ser

180 185 190

His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser Thr Val Glu

195 200 205

Thr Val Ala Pro Thr Glu Cys Ser

210 215

SEQ ID NO: 163

Gin Ser Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15

Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr

20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu

35 40 45

Met lie Tyr Gly Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Phe Ala Gly Gly

85 90 95

Ser Tyr Tyr Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly

100 105 110

Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu

115 120 125

Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu lie Ser Asp Phe 130 135 140

Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val 145 150 155 160 Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser Asn Asn Lys 165 170 175

Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin Trp Lys Ser

180 185 190

His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser Thr Val Glu

195 200 205

Thr Val Ala Pro Thr Glu Cys Ser

210 215

SEQ ID NO: 164

Gin Ser Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15

Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr

20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu

35 40 45

Met lie Tyr Gly Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Phe Ala Gly Gly

85 90 95

Ser Tyr Tyr Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly

100 105 110

Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu

115 120 125

Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu lie Ser Asp Phe 130 135 140

Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin Trp Lys Ser

180 185 190

His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser Thr Val Glu

195 200 205

Thr Val Ala Pro Thr Glu Cys Ser

210 215

SEQ ID NO: 165

Gin Ser Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15

Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr

20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu

35 40 45

Met lie Tyr Gly Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Phe Ala Gly Gly

85 90 95

Ser Tyr Tyr Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly

100 105 110

Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu

115 120 125

Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu lie Ser Asp Phe 130 135 140

Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val 145 150 155 160

Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser Asn Asn Lys 165 170 175

Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin Trp Lys Ser

180 185 190

His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser Thr Val Glu

195 200 205

Thr Val Ala Pro Thr Glu Cys Ser

210 215

SEQ ID NO: 166

Gin Ser Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15

Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr

20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu

35 40 45

Met lie Tyr Gly Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Phe Ala Gly Gly

85 90 95

Ser Tyr Tyr Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly

100 105 110

Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu

115 120 125

Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu lie Ser Asp Phe 130 135 140

Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val 145 150 155 160

Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser Asn Asn Lys

165 170 175 Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin Trp Lys Ser 180 185 190

His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser Thr Val Glu

195 200 205

Thr Val Ala Pro Thr Glu Cys Ser

210 215

SEQ ID NO: 167

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser

20 25 30

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45

Gly Thr lie Asn Pro Val Ser Gly Ser Thr Ser Tyr Ala Gin Lys Phe 50 55 60

Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr

100 105 110

Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro

115 120 125

Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 130 135 140

Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 145 150 155 160

Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser Ser Gly

165 170 175 Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 180 185 190

Thr Gin Thr Tyr lie Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys

195 200 205

Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 210 215 220

Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu 225 230 235 240

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser Arg Thr Pro Glu

245 250 255

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys

260 265 270

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys

275 280 285

Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 290 295 300

Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 305 310 315 320

Val Ser Asn Lys Ala Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys

325 330 335

Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser

340 345 350

Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys

355 360 365

Gly Phe Tyr Pro Ser Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin 370 375 380

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 385 390 395 400

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin

405 410 415 Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 420 425 430

His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

SEQ ID NO: 168

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser

20 25 30

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45

Gly Gin lie Asn Ala Ala Ser Gly Met Thr Arg Tyr Ala Gin Lys Phe 50 55 60

Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr

100 105 110

Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro

115 120 125

Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 130 135 140

Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 145 150 155 160

Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser Ser Gly

165 170 175

Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly

180 185 190

Thr Gin Thr Tyr lie Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys 195 200 205

Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 210 215 220

Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu 225 230 235 240

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser Arg Thr Pro Glu

245 250 255

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys

260 265 270

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys

275 280 285

Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 290 295 300

Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 305 310 315 320

Val Ser Asn Lys Ala Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys

325 330 335

Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser

340 345 350

Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys

355 360 365

Gly Phe Tyr Pro Ser Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin 370 375 380

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 385 390 395 400

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin

405 410 415

Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn

420 425 430

His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445

SEQ ID NO: 169

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser

20 25 30

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45

Gly Asn lie Asn Ala Ala Ala Gly lie Thr Leu Tyr Ala Gin Lys Phe 50 55 60

Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr

100 105 110

Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro

115 120 125

Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 130 135 140

Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 145 150 155 160

Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser Ser Gly

165 170 175

Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly

180 185 190

Thr Gin Thr Tyr lie Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys

195 200 205

Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 210 215 220 Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu 225 230 235 240

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser Arg Thr Pro Glu

245 250 255

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys

260 265 270

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys

275 280 285

Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 290 295 300

Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 305 310 315 320

Val Ser Asn Lys Ala Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys

325 330 335

Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser

340 345 350

Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys

355 360 365

Gly Phe Tyr Pro Ser Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin 370 375 380

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 385 390 395 400

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin

405 410 415

Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn

420 425 430

His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

SEQ ID NO: 170 Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser

20 25 30

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45

Gly Gly lie Asn Pro Pro Ala Gly Thr Thr Ser Tyr Ala Gin Lys Phe 50 55 60

Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr

100 105 110

Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro

115 120 125

Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 130 135 140

Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 145 150 155 160

Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser Ser Gly

165 170 175

Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly

180 185 190

Thr Gin Thr Tyr lie Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys

195 200 205

Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 210 215 220

Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu 225 230 235 240 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser Arg Thr Pro Glu 245 250 255

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys

260 265 270

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys

275 280 285

Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 290 295 300

Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 305 310 315 320

Val Ser Asn Lys Ala Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys

325 330 335

Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser

340 345 350

Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys

355 360 365

Gly Phe Tyr Pro Ser Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin 370 375 380

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 385 390 395 400

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin

405 410 415

Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn

420 425 430

His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

SEQ ID NO: 171

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45

Gly Asn lie Asn Pro Ala Thr Gly His Ala Asp Tyr Ala Gin Lys Phe 50 55 60

Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr

100 105 110

Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro

115 120 125

Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val 130 135 140

Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 145 150 155 160

Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser Ser Gly

165 170 175

Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly

180 185 190

Thr Gin Thr Tyr lie Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys

195 200 205

Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 210 215 220

Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu 225 230 235 240

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met lie Ser Arg Thr Pro Glu

245 250 255 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys 260 265 270

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys

275 280 285

Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu 290 295 300

Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 305 310 315 320

Val Ser Asn Lys Ala Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys

325 330 335

Ala Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser

340 345 350

Arg Glu Glu Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys

355 360 365

Gly Phe Tyr Pro Ser Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin 370 375 380

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 385 390 395 400

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin

405 410 415

Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn

420 425 430

His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440 445

SEQ ID NO: 172

Gin Ser Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15

Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr

20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu 35 40 45

Met lie Tyr Gly Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Phe Ala Gly Gly

85 90 95

Ser Tyr Tyr Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly

100 105 110

Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu

115 120 125

Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu lie Ser Asp Phe 130 135 140

Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val 145 150 155 160

Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser Asn Asn Lys

165 170 175

Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin Trp Lys Ser

180 185 190

His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser Thr Val Glu

195 200 205

Thr Val Ala Pro Thr Glu Cys Ser

210 215

SEQ ID NO: 173

Gin Ser Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15

Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr

20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu

35 40 45 Met lie Tyr Gly Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Phe Ala Gly Gly

85 90 95

Ser Tyr Tyr Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly

100 105 110

Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu

115 120 125

Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu lie Ser Asp Phe 130 135 140

Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val 145 150 155 160

Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser Asn Asn Lys

165 170 175

Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin Trp Lys Ser

180 185 190

His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser Thr Val Glu

195 200 205

Thr Val Ala Pro Thr Glu Cys Ser

210 215

SEQ ID NO: 174

Gin Ser Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15

Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr

20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Phe Ala Gly Gly

85 90 95

Ser Tyr Tyr Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly

100 105 110

Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu

115 120 125

Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu lie Ser Asp Phe 130 135 140

Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val 145 150 155 160

Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser Asn Asn Lys

165 170 175

Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin Trp Lys Ser

180 185 190

His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser Thr Val Glu

195 200 205

Thr Val Ala Pro Thr Glu Cys Ser

210 215

SEQ ID NO: 175

Gin Ser Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15

Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr

20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Phe Ala Gly Gly

85 90 95

Ser Tyr Tyr Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly

100 105 110

Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu

115 120 125

Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu lie Ser Asp Phe 130 135 140

Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val 145 150 155 160

Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser Asn Asn Lys

165 170 175

Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin Trp Lys Ser

180 185 190

His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser Thr Val Glu

195 200 205

Thr Val Ala Pro Thr Glu Cys Ser

210 215

SEQ ID NO: 176

Gin Ser Ala Leu Thr Gin Pro Ala Ser Val Ser Gly Ser Pro Gly Gin 1 5 10 15

Ser lie Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ser Tyr

20 25 30

Asn Tyr Val Asn Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu

35 40 45

Met lie Tyr Gly Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu 65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Phe Ala Gly Gly

85 90 95

Ser Tyr Tyr Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly

100 105 110

Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu

115 120 125

Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu lie Ser Asp Phe 130 135 140

Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val 145 150 155 160

Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin Ser Asn Asn Lys

165 170 175

Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin Trp Lys Ser

180 185 190

His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser Thr Val Glu

195 200 205

Thr Val Ala Pro Thr Glu Cys Ser

210 215

SEQ ID NO: 177

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser

20 25 30

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45

Gly Thr lie Asn Pro Val Ser Gly Ser Thr Ser Tyr Ala Gin Lys Phe 50 55 60 Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr

100 105 110

Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro

115 120 125

Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val 130 135 140

Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 145 150 155 160

Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser Ser Gly

165 170 175

Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly

180 185 190

Thr Gin Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys

195 200 205

Val Asp Lys Thr Val Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys 210 215 220

Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 225 230 235 240

Pro Lys Asp Thr Leu Met lie Ser Arg Thr Pro Glu Val Thr Cys Val

245 250 255

Val Val Asp Val Ser His Glu Asp Pro Glu Val Gin Phe Asn Trp Tyr

260 265 270

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu

275 280 285

Gin Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His 290 295 300 Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 305 310 315 320

Gly Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys Thr Lys Gly Gin

325 330 335

Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met

340 345 350

Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro

355 360 365

Ser Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn 370 375 380

Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu 385 390 395 400

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val

405 410 415

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin

420 425 430

Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440

SEQ ID NO: 178

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser

20 25 30

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45

Gly Gin lie Asn Ala Ala Ser Gly Met Thr Arg Tyr Ala Gin Lys Phe 50 55 60

Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95

Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr

100 105 110

Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro

115 120 125

Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val 130 135 140

Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 145 150 155 160

Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser Ser Gly

165 170 175

Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly

180 185 190

Thr Gin Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys

195 200 205

Val Asp Lys Thr Val Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys 210 215 220

Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 225 230 235 240

Pro Lys Asp Thr Leu Met lie Ser Arg Thr Pro Glu Val Thr Cys Val

245 250 255

Val Val Asp Val Ser His Glu Asp Pro Glu Val Gin Phe Asn Trp Tyr

260 265 270

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu

275 280 285

Gin Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His 290 295 300

Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 305 310 315 320 Gly Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys Thr Lys Gly Gin 325 330 335

Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met

340 345 350

Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro

355 360 365

Ser Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn 370 375 380

Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu 385 390 395 400

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val

405 410 415

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin

420 425 430

Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440

SEQ ID NO: 179

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser

20 25 30

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45

Gly Asn lie Asn Ala Ala Ala Gly lie Thr Leu Tyr Ala Gin Lys Phe 50 55 60

Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys

85 90 95 Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr 100 105 110

Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro

115 120 125

Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val 130 135 140

Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 145 150 155 160

Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser Ser Gly

165 170 175

Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly

180 185 190

Thr Gin Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys

195 200 205

Val Asp Lys Thr Val Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys 210 215 220

Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 225 230 235 240

Pro Lys Asp Thr Leu Met lie Ser Arg Thr Pro Glu Val Thr Cys Val

245 250 255

Val Val Asp Val Ser His Glu Asp Pro Glu Val Gin Phe Asn Trp Tyr

260 265 270

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu

275 280 285

Gin Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His 290 295 300

Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 305 310 315 320

Gly Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys Thr Lys Gly Gin

325 330 335 Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met 340 345 350

Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro

355 360 365

Ser Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn 370 375 380

Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu 385 390 395 400

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val

405 410 415

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin

420 425 430

Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440

SEQ ID NO: 180

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser

20 25 30

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45

Gly Gly lie Asn Pro Pro Ala Gly Thr Thr Ser Tyr Ala Gin Lys Phe 50 55 60

Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr

100 105 110

Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 115 120 125

Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val 130 135 140

Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 145 150 155 160

Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser Ser Gly

165 170 175

Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly

180 185 190

Thr Gin Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys

195 200 205

Val Asp Lys Thr Val Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys 210 215 220

Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 225 230 235 240

Pro Lys Asp Thr Leu Met lie Ser Arg Thr Pro Glu Val Thr Cys Val

245 250 255

Val Val Asp Val Ser His Glu Asp Pro Glu Val Gin Phe Asn Trp Tyr

260 265 270

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu

275 280 285

Gin Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His 290 295 300

Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 305 310 315 320

Gly Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys Thr Lys Gly Gin

325 330 335

Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met

340 345 350

Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 355 360 365

Ser Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn 370 375 380

Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu 385 390 395 400

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val

405 410 415

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin

420 425 430

Lys Ser Leu Ser Leu Ser Pro Gly Lys

435 440

SEQ ID NO: 181

Gin Val Gin Leu Val Gin Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser

20 25 30

Tyr lie Asn Trp Val Arg Gin Ala Pro Gly Gin Gly Leu Glu Trp Met

35 40 45

Gly Asn lie Asn Pro Ala Thr Gly His Ala Asp Tyr Ala Gin Lys Phe 50 55 60

Gin Gly Arg Val Thr Met Thr Arg Asp Thr Ser lie Ser Thr Ala Tyr 65 70 75 80

Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys

85 90 95

Ala Arg Gly Gly Trp Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr

100 105 110

Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro

115 120 125

Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val 130 135 140 Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 145 150 155 160

Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser Ser Gly

165 170 175

Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly

180 185 190

Thr Gin Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys

195 200 205

Val Asp Lys Thr Val Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys 210 215 220

Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 225 230 235 240

Pro Lys Asp Thr Leu Met lie Ser Arg Thr Pro Glu Val Thr Cys Val

245 250 255

Val Val Asp Val Ser His Glu Asp Pro Glu Val Gin Phe Asn Trp Tyr

260 265 270

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu

275 280 285

Gin Phe Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His 290 295 300

Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 305 310 315 320

Gly Leu Pro Ala Pro lie Glu Lys Thr lie Ser Lys Thr Lys Gly Gin

325 330 335

Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met

340 345 350

Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro

355 360 365

Ser Asp lie Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn 370 375 380 Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu

385 390 395 400

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val

405 410 415

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gin

420 425 430

Lys Ser Leu Ser Leu Ser Pro Gly Lys

SEQ ID NO: 182

cagagcgccc tgacccagcc cgccagcgtg tccggcagcc caggccagtc tatcacaatc 60 agctgcaccg gcacctccag cgacgtgggc agctacaact acgtgaactg gtatcagcag 120 caccccggca aggcccccaa gctgatgatc tacggcgtga gcaagaggcc cagcggcgtg 180 tccaacaggt tcagcggcag caagagcggc aacaccgcca gcctgacaat cagtgggctg 240 caggctgagg acgaggccga ctactactgc ggcacctttg ccggcggatc atactacggc 300 gtgttcggcg gagggaccaa gctgaccgtg ctgggccagc ctaaggctgc ccccagcgtg 360 accctgttcc cccccagcag cgaggagctg caggccaaca aggccaccct ggtgtgcctg 420 atcagcgact tctacccagg cgccgtgacc gtggcctgga aggccgacag cagccccgtg 480 aaggccggcg tggagaccac cacccccagc aagcagagca acaacaagta cgccgccagc 540 agctacctga gcctgacccc cgagcagtgg aagagccaca ggtcctacag ctgccaggtg 600 acccacgagg gcagcaccgt ggaaaagacc gtggccccaa ccgagtgcag c 651

SEQ ID NO: 183

SEQ ID NO: 184

cagagcgcac tgacccagcc agcttcagtg agcggctcac caggtcagag cattaccatc 60 tcgtgtacgg gtactagcag cgatgttggt tcttataatt atgtgaattg gtaccagcag 120 catcccggga aggcgccgaa acttatgatt tatggtgttt ctaagcgtcc ctcaggcgtg 180 agcaaccgtt ttagcggatc caaaagcggc aacaccgcga gcctgaccat tagcggcctg 240 caagcggaag acgaagcgga ttattattgc ggtacttttg ctggtggttc ttattatggt 300 gtgtttggcg gcggcacgaa gttaaccgtc ctaggtcagc ccaaggctgc cccctcggtc 360 actctgttcc cgccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc 420 ataagtgact tctacccggg agccgtgaca gtggcctgga aggcagatag cagccccgtc 480 aaggcgggag tggagaccac cacaccctcc aaacaaagca acaacaagta cgcggccagc 540 agctatctga gcctgacgcc tgagcagtgg aagtcccaca gaagctacag ctgccaggtc 600 acgcatgaag ggagcaccgt ggagaagaca gtggccccta cagaatgttc a 651

SEQ ID NO: 185

SEQ ID NO: 186

SEQ ID NO: 187

caggtgcagc tggtgcagag cggagctgag gtgaagaagc caggcgccag cgtcaaggtg 60 tcctgcaagg ccagcggcta caccttcacc agcagctaca tcaactgggt ccgccaggct 120 cctgggcagg gactggagtg gatgggcacc atcaaccccg tgtccggcag caccagctac 180 gcccagaagt tccagggcag agtcaccatg accagggaca ccagcatcag caccgcctac 240 atggagctgt ccaggctgag aagcgacgac accgccgtgt actactgcgc caggggcggc 300 tggttcgact actggggcca gggcaccctg gtgaccgtgt cctcagctag caccaagggc 360 cccagcgtgt tccccctggc ccccagcagc aagagcacct ccggcggcac agccgccctg 420 ggctgcctgg tgaaggacta cttccccgag cccgtgaccg tgtcctggaa cagcggagcc 480 ctgaccagcg gcgtgcacac cttccccgcc gtgctgcaga gcagcggcct gtacagcctg 540 tccagcgtgg tgacagtgcc cagcagcagc ctgggcaccc agacctacat ctgcaacgtg 600 aaccacaagc ccagcaacac caaggtggac aagagagtgg agcccaagag ctgcgacaag 660 acccacacct gccccccctg cccagccccc gaagctgcag gcggcccttc cgtgttcctg 720 ttccccccca agcccaagga caccctgatg atcagcagga cccccgaggt gacctgcgtg 780 gtggtggacg tgagccacga ggacccagag gtgaagttca actggtacgt ggacggcgtg 840 gaggtgcaca acgccaagac caagcccaga gaggagcagt acaacagcac ctacagggtg 900 gtgtccgtgc tgaccgtgct gcaccaggac tggctgaacg gcaaagaata caagtgcaag 960 gtctccaaca aggccctgcc tgcccccatc gaaaagacca tcagcaaggc caagggccag 1020 ccacgggagc cccaggtgta caccctgccc ccttctcggg aggagatgac caagaaccag 1080 gtgtccctga cctgtctggt gaagggcttc taccccagcg acatcgccgt ggagtgggag 1140 agcaacggcc agcccgagaa caactacaag accacccccc cagtgctgga cagcgacggc 1200 agcttcttcc tgtacagcaa gctgaccgtg gacaagagca ggtggcagca gggcaacgtg 1260 ttcagctgca gcgtgatgca cgaggccctg cacaaccact acacccagaa gagcctgagc 1320 ctgtcacccg gcaag 1335

SEQ ID NO: 188

caggtgcagc tggtgcagag cggagctgag gtgaagaagc caggcgccag cgtcaaggtg 60 tcctgcaagg ccagcggcta caccttcacc agcagctaca tcaactgggt gcgccaggct 120 ccagggcagg gactggagtg gatgggccag atcaacgccg ccagcggcat gaccagatac 180 gcccagaagt tccagggcag agtcacaatg accagggaca cctctatcag caccgcctac 240 atggagctgt ccaggctgag aagcgacgac accgccgtgt actactgcgc caggggcggc 300 tggttcgact actggggcca gggcaccctg gtgaccgtgt cctcagctag caccaagggc 360 cccagcgtgt tccccctggc ccccagcagc aagagcacct ccggcggcac agccgccctg 420 ggctgcctgg tgaaggacta cttccccgag cccgtgaccg tgtcctggaa cagcggagcc 480 ctgaccagcg gcgtgcacac cttccccgcc gtgctgcaga gcagcggcct gtacagcctg 540 tccagcgtgg tgacagtgcc cagcagcagc ctgggcaccc agacctacat ctgcaacgtg 600 aaccacaagc ccagcaacac caaggtggac aagagagtgg agcccaagag ctgcgacaag 660 acccacacct gccccccctg cccagccccc gaagctgcag gcggcccttc cgtgttcctg 720 ttccccccca agcccaagga caccctgatg atcagcagga cccccgaggt gacctgcgtg 780 gtggtggacg tgagccacga ggacccagag gtgaagttca actggtacgt ggacggcgtg 840 gaggtgcaca acgccaagac caagcccaga gaggagcagt acaacagcac ctacagggtg 900 gtgtccgtgc tgaccgtgct gcaccaggac tggctgaacg gcaaagaata caagtgcaag 960 gtctccaaca aggccctgcc tgcccccatc gaaaagacca tcagcaaggc caagggccag 1020 ccacgggagc cccaggtgta caccctgccc ccttctcggg aggagatgac caagaaccag 1080 gtgtccctga cctgtctggt gaagggcttc taccccagcg acatcgccgt ggagtgggag 1140 agcaacggcc agcccgagaa caactacaag accacccccc cagtgctgga cagcgacggc 1200 agcttcttcc tgtacagcaa gctgaccgtg gacaagagca ggtggcagca gggcaacgtg 1260 ttcagctgca gcgtgatgca cgaggccctg cacaaccact acacccagaa gagcctgagc 1320 ctgtcacccg gcaag 1335 SEQ ID NO: 189

caggtgcaat tggttcagag cggcgcggaa gtgaaaaaac cgggcgcgag cgtgaaagtg 60 agctgcaaag cctccggata tacctttact tcttcttata ttaattgggt ccgccaagcc 120 cctgggcagg gtctcgagtg gatgggcaat attaatgctg ctgctggtat tactctttat 180 gctcagaagt ttcagggtcg ggtcaccatg acccgtgata ccagcattag caccgcgtat 240 atggaactga gccgcctgcg tagcgatgat acggccgtgt attattgcgc gcgtggtggt 300 tggtttgatt attggggcca aggcaccctg gtgacggtta gctcagcctc caccaagggt 360 ccatcggtct tccccctggc accctcctcc aagagcacct ctgggggcac agcggccctg 420 ggctgcctgg tcaaggacta cttccccgaa ccggtgacgg tgtcgtggaa ctcaggcgcc 480 ctgaccagcg gcgtgcacac cttcccggct gtcctacagt cctcaggact ctactccctc 540 agcagcgtgg tgaccgtgcc ctccagcagc ttgggcaccc agacctacat ctgcaacgtg 600 aatcacaagc ccagcaacac caaggtggac aagagagttg agcccaaatc ttgtgacaaa 660 actcacacat gcccaccgtg cccagcacct gaagcagcgg ggggaccgtc agtcttcctc 720 ttccccccaa aacccaagga caccctcatg atctcccgga cccctgaggt cacatgcgtg 780 gtggtggacg tgagccacga agaccctgag gtcaagttca actggtacgt ggacggcgtg 840 gaggtgcata atgccaagac aaagccgcgg gaggagcagt acaacagcac gtaccgggtg 900 gtcagcgtcc tcaccgtcct gcaccaggac tggctgaatg gcaaggagta caagtgcaag 960 gtctccaaca aagccctccc agcccccatc gagaaaacca tctccaaagc caaagggcag 1020 ccccgagaac cacaggtgta caccctgccc ccatcccggg aggagatgac caagaaccag 1080 gtcagcctga cctgcctggt caaaggcttc tatcccagcg acatcgccgt ggagtgggag 1140 agcaatgggc agccggagaa caactacaag accacgcctc ccgtgctgga ctccgacggc 1200 tccttcttcc tctacagcaa gctcaccgtg gacaagagca ggtggcagca ggggaacgtc 1260 ttctcatgct ccgtgatgca tgaggctctg cacaaccact acacgcagaa gagcctctcc 1320 ctgtctccgg gtaaa 1335

SEQ ID NO: 190

caggtgcaat tggttcagag cggcgcggaa gtgaaaaaac cgggcgcgag cgtgaaagtg 60 agctgcaaag cctccggata tacctttact tcttcttata ttaattgggt ccgccaagcc 120 cctgggcagg gtctcgagtg gatgggcggt attaatcctc ctgctggtac tacttcttat 180 gctcagaagt ttcagggtcg ggtcaccatg acccgtgata ccagcattag caccgcgtat 240 atggaactga gccgcctgcg tagcgatgat acggccgtgt attattgcgc gcgtggtggt 300 tggtttgatt attggggcca aggcaccctg gtgacggtta gctcagcctc caccaagggt 360 ccatcggtct tccccctggc accctcctcc aagagcacct ctgggggcac agcggccctg 420 ggctgcctgg tcaaggacta cttccccgaa ccggtgacgg tgtcgtggaa ctcaggcgcc 480 ctgaccagcg gcgtgcacac cttcccggct gtcctacagt cctcaggact ctactccctc 540 agcagcgtgg tgaccgtgcc ctccagcagc ttgggcaccc agacctacat ctgcaacgtg 600 aatcacaagc ccagcaacac caaggtggac aagagagttg agcccaaatc ttgtgacaaa 660 actcacacat gcccaccgtg cccagcacct gaagcagcgg ggggaccgtc agtcttcctc 720 ttccccccaa aacccaagga caccctcatg atctcccgga cccctgaggt cacatgcgtg 780 gtggtggacg tgagccacga agaccctgag gtcaagttca actggtacgt ggacggcgtg 840 gaggtgcata atgccaagac aaagccgcgg gaggagcagt acaacagcac gtaccgggtg 900 gtcagcgtcc tcaccgtcct gcaccaggac tggctgaatg gcaaggagta caagtgcaag 960 gtctccaaca aagccctccc agcccccatc gagaaaacca tctccaaagc caaagggcag 1020 ccccgagaac cacaggtgta caccctgccc ccatcccggg aggagatgac caagaaccag 1080 gtcagcctga cctgcctggt caaaggcttc tatcccagcg acatcgccgt ggagtgggag 1140 agcaatgggc agccggagaa caactacaag accacgcctc ccgtgctgga ctccgacggc 1200 tccttcttcc tctacagcaa gctcaccgtg gacaagagca ggtggcagca ggggaacgtc 1260 ttctcatgct ccgtgatgca tgaggctctg cacaaccact acacgcagaa gagcctctcc 1320 ctgtctccgg gtaaa 1335

SEQ ID NO: 191

caggtgcaat tggttcagag cggcgcggaa gtgaaaaaac cgggcgcgag cgtgaaagtg 60 agctgcaaag cctccggata tacctttact tcttcttata ttaattgggt ccgccaagcc 120 cctgggcagg gtctcgagtg gatgggcaat attaatcctg ctactggtca tgctgattat 180 gctcagaagt ttcagggtcg ggtgaccatg acccgtgata ccagcattag caccgcgtat 240 atggaactga gccgcctgcg tagcgatgat acggccgtgt attattgcgc gcgtggtggt 300 tggtttgatt attggggcca aggcaccctg gtgacggtta gctcagcctc caccaagggt 360 ccatcggtct tccccctggc accctcctcc aagagcacct ctgggggcac agcggccctg 420 ggctgcctgg tcaaggacta cttccccgaa ccggtgacgg tgtcgtggaa ctcaggcgcc 480 ctgaccagcg gcgtgcacac cttcccggct gtcctacagt cctcaggact ctactccctc 540 agcagcgtgg tgaccgtgcc ctccagcagc ttgggcaccc agacctacat ctgcaacgtg 600 aatcacaagc ccagcaacac caaggtggac aagagagttg agcccaaatc ttgtgacaaa 660 actcacacat gcccaccgtg cccagcacct gaagcagcgg ggggaccgtc agtcttcctc 720 ttccccccaa aacccaagga caccctcatg atctcccgga cccctgaggt cacatgcgtg 780 gtggtggacg tgagccacga agaccctgag gtcaagttca actggtacgt ggacggcgtg 840 gaggtgcata atgccaagac aaagccgcgg gaggagcagt acaacagcac gtaccgggtg 900 gtcagcgtcc tcaccgtcct gcaccaggac tggctgaatg gcaaggagta caagtgcaag 960 gtctccaaca aagccctccc agcccccatc gagaaaacca tctccaaagc caaagggcag 1020 ccccgagaac cacaggtgta caccctgccc ccatcccggg aggagatgac caagaaccag 1080 gtcagcctga cctgcctggt caaaggcttc tatcccagcg acatcgccgt ggagtgggag 1140 agcaatgggc agccggagaa caactacaag accacgcctc ccgtgctgga ctccgacggc 1200 tccttcttcc tctacagcaa gctcaccgtg gacaagagca ggtggcagca ggggaacgtc 1260 ttctcatgct ccgtgatgca tgaggctctg cacaaccact acacgcagaa gagcctctcc 1320 ctgtctccgg gtaaa 1335

SEQ ID NO: 192

SEQ ID NO: 193

SEQ ID NO: 194

SEQ ID NO: 195

SEQ ID NO: 196

SEQ ID NO: 197

caggtgcagc tggtgcagag cggagctgag gtgaagaagc caggcgccag cgtcaaggtg 60 tcctgcaagg ccagcggcta caccttcacc agcagctaca tcaactgggt ccgccaggct 120 cctgggcagg gactggagtg gatgggcacc atcaaccccg tgtccggcag caccagctac 180 gcccagaagt tccagggcag agtcaccatg accagggaca ccagcatcag caccgcctac 240 atggagctgt ccaggctgag aagcgacgac accgccgtgt actactgcgc caggggcggc 300 tggttcgact actggggcca gggcaccctg gtgaccgtgt cctcagctag caccaagggc 360 cccagcgtgt tccccctggc cccctgcagc agaagcacca gcgagagcac agccgccctg 420 ggctgcctgg tgaaggacta cttccccgag ccagtgaccg tgtcctggaa cagcggagcc 480 ctgaccagcg gcgtgcacac cttccccgcc gtgctgcaga gcagcggcct gtacagcctg 540 tccagcgtgg tgaccgtgcc cagcagcaac ttcggcaccc agacctacac ctgcaacgtg 600 gaccacaagc ccagcaacac caaggtggac aagaccgtgg agaggaagtg ctgcgtggag 660 tgccccccct gcccagcccc cccagtggcc ggaccctccg tgttcctgtt cccccccaag 720 cccaaggaca ccctgatgat cagcaggacc cccgaggtga cctgcgtggt ggtggacgtg 780 agccacgagg acccagaggt gcagttcaac tggtacgtgg acggcgtgga ggtgcacaac 840 gccaagacca agcccagaga ggaacagttt aacagcacct tcagggtggt gtccgtgctg 900 accgtggtgc accaggactg gctgaacggc aaagagtaca agtgcaaggt ctccaacaag 960 ggcctgccag cccccatcga gaaaaccatc agcaagacca agggccagcc acgggagccc 1020 caggtgtaca ccctgccccc cagccgggag gaaatgacca agaaccaggt gtccctgacc 1080 tgtctggtga agggcttcta ccccagcgac atcgccgtgg agtgggagag caacggccag 1140 cccgagaaca actacaagac cacccccccc atgctggaca gcgacggcag cttcttcctg 1200 tacagcaagc tgacagtgga caagagcagg tggcagcagg gcaacgtgtt cagctgcagc 1260 gtgatgcacg aggccctgca caaccactac acccagaaga gcctgagcct gtcccccggc 1320 aag 1323

SEQ ID NO: 198

caggtgcagc tggtgcagag cggagctgag gtgaagaagc caggcgccag cgtcaaggtg 60 tcctgcaagg ccagcggcta caccttcacc agcagctaca tcaactgggt gcgccaggct 120 ccagggcagg gactggagtg gatgggccag atcaacgccg ccagcggcat gaccagatac 180 gcccagaagt tccagggcag agtcacaatg accagggaca cctctatcag caccgcctac 240 atggagctgt ccaggctgag aagcgacgac accgccgtgt actactgcgc caggggcggc 300 tggttcgact actggggcca gggcaccctg gtgaccgtgt cctcagctag caccaagggc 360 cccagcgtgt tccccctggc cccctgcagc agaagcacca gcgagagcac agccgccctg 420 ggctgcctgg tgaaggacta cttccccgag ccagtgaccg tgtcctggaa cagcggagcc 480 ctgaccagcg gcgtgcacac cttccccgcc gtgctgcaga gcagcggcct gtacagcctg 540 tccagcgtgg tgaccgtgcc cagcagcaac ttcggcaccc agacctacac ctgcaacgtg 600 gaccacaagc ccagcaacac caaggtggac aagaccgtgg agaggaagtg ctgcgtggag 660 tgccccccct gcccagcccc cccagtggcc ggaccctccg tgttcctgtt cccccccaag 720 cccaaggaca ccctgatgat cagcaggacc cccgaggtga cctgcgtggt ggtggacgtg 780 agccacgagg acccagaggt gcagttcaac tggtacgtgg acggcgtgga ggtgcacaac 840 gccaagacca agcccagaga ggaacagttt aacagcacct tcagggtggt gtccgtgctg 900 accgtggtgc accaggactg gctgaacggc aaagagtaca agtgcaaggt ctccaacaag 960 ggcctgccag cccccatcga gaaaaccatc agcaagacca agggccagcc acgggagccc 1020 caggtgtaca ccctgccccc cagccgggag gaaatgacca agaaccaggt gtccctgacc 1080 tgtctggtga agggcttcta ccccagcgac atcgccgtgg agtgggagag caacggccag 1140 cccgagaaca actacaagac cacccccccc atgctggaca gcgacggcag cttcttcctg 1200 tacagcaagc tgacagtgga caagagcagg tggcagcagg gcaacgtgtt cagctgcagc 1260 gtgatgcacg aggccctgca caaccactac acccagaaga gcctgagcct gtcccccggc 1320 aag 1323

SEQ ID NO: 199

caggtgcaat tggttcagag cggcgcggaa gtgaaaaaac cgggcgcgag cgtgaaagtg 60 agctgcaaag cctccggata tacctttact tcttcttata ttaattgggt ccgccaagcc 120 cctgggcagg gtctcgagtg gatgggcaat attaatgctg ctgctggtat tactctttat 180 gctcagaagt ttcagggtcg ggtcaccatg acccgtgata ccagcattag caccgcgtat 240 atggaactga gccgcctgcg tagcgatgat acggccgtgt attattgcgc gcgtggtggt 300 tggtttgatt attggggcca aggcaccctg gtgacggtta gctcagcttc caccaagggc 360 cccagcgtgt tccccctggc cccctgcagc agaagcacca gcgagagcac agccgccctg 420 ggctgcctgg tgaaggacta cttccccgag cccgtgaccg tgagctggaa cagcggagcc 480 ctgaccagcg gcgtgcacac cttccccgcc gtgctgcaga gcagcggcct gtacagcctg 540 agcagcgtgg tgaccgtgcc cagcagcaac ttcggcaccc agacctacac ctgcaacgtg 600 gaccacaagc ccagcaacac caaggtggac aagaccgtgg agcggaagtg ctgcgtggag 660 tgccccccct gccctgcccc tcctgtggcc ggaccctccg tgttcctgtt cccccccaag 720 cccaaggaca ccctgatgat cagccggacc cccgaggtga cctgcgtggt ggtggacgtg 780 agccacgagg accccgaggt gcagttcaac tggtacgtgg acggcgtgga ggtgcacaac 840 gccaagacca agccccggga ggaacagttc aacagcacct tccgggtggt gtccgtgctg 900 accgtggtgc accaggactg gctgaacggc aaagaataca agtgcaaggt gtccaacaag 960 ggcctgcctg cccccatcga gaaaaccatc agcaagacaa agggccagcc cagggaaccc 1020 caggtgtaca ccctgccccc cagccgggag gaaatgacca agaaccaggt gtccctgacc 1080 tgtctggtga agggcttcta ccccagcgac atcgccgtgg agtgggagag caacggccag 1140 cccgagaaca actacaagac cacccccccc atgctggaca gcgacggcag cttcttcctg 1200 tacagcaagc tgacagtgga caagagccgg tggcagcagg gcaacgtgtt cagctgcagc 1260 gtgatgcacg aggccctgca caaccactac acccagaaga gcctgagcct gtcccccggc 1320 aaa 1323

SEQ ID NO: 200 caggtgcaat tggttcagag cggcgcggaa gtgaaaaaac cgggcgcgag cgtgaaagtg 60 agctgcaaag cctccggata tacctttact tcttcttata ttaattgggt ccgccaagcc 120 cctgggcagg gtctcgagtg gatgggcggt attaatcctc ctgctggtac tacttcttat 180 gctcagaagt ttcagggtcg ggtcaccatg acccgtgata ccagcattag caccgcgtat 240 atggaactga gccgcctgcg tagcgatgat acggccgtgt attattgcgc gcgtggtggt 300 tggtttgatt attggggcca aggcaccctg gtgacggtta gctcagcttc caccaagggc 360 cccagcgtgt tccccctggc cccctgcagc agaagcacca gcgagagcac agccgccctg 420 ggctgcctgg tgaaggacta cttccccgag cccgtgaccg tgagctggaa cagcggagcc 480 ctgaccagcg gcgtgcacac cttccccgcc gtgctgcaga gcagcggcct gtacagcctg 540 agcagcgtgg tgaccgtgcc cagcagcaac ttcggcaccc agacctacac ctgcaacgtg 600 gaccacaagc ccagcaacac caaggtggac aagaccgtgg agcggaagtg ctgcgtggag 660 tgccccccct gccctgcccc tcctgtggcc ggaccctccg tgttcctgtt cccccccaag 720 cccaaggaca ccctgatgat cagccggacc cccgaggtga cctgcgtggt ggtggacgtg 780 agccacgagg accccgaggt gcagttcaac tggtacgtgg acggcgtgga ggtgcacaac 840 gccaagacca agccccggga ggaacagttc aacagcacct tccgggtggt gtccgtgctg 900 accgtggtgc accaggactg gctgaacggc aaagaataca agtgcaaggt gtccaacaag 960 ggcctgcctg cccccatcga gaaaaccatc agcaagacaa agggccagcc cagggaaccc 1020 caggtgtaca ccctgccccc cagccgggag gaaatgacca agaaccaggt gtccctgacc 1080 tgtctggtga agggcttcta ccccagcgac atcgccgtgg agtgggagag caacggccag 1140 cccgagaaca actacaagac cacccccccc atgctggaca gcgacggcag cttcttcctg 1200 tacagcaagc tgacagtgga caagagccgg tggcagcagg gcaacgtgtt cagctgcagc 1260 gtgatgcacg aggccctgca caaccactac acccagaaga gcctgagcct gtcccccggc 1320 aaa 1323

SEQ ID NO: 201

caggtgcaat tggttcagag cggcgcggaa gtgaaaaaac cgggcgcgag cgtgaaagtg 60 agctgcaaag cctccggata tacctttact tcttcttata ttaattgggt ccgccaagcc 120 cctgggcagg gtctcgagtg gatgggcaat attaatcctg ctactggtca tgctgattat 180 gctcagaagt ttcagggtcg ggtgaccatg acccgtgata ccagcattag caccgcgtat 240 atggaactga gccgcctgcg tagcgatgat acggccgtgt attattgcgc gcgtggtggt 300 tggtttgatt attggggcca aggcaccctg gtgacggtta gctcagcttc caccaagggc 360 cccagcgtgt tccccctggc cccctgcagc agaagcacca gcgagagcac agccgccctg 420 ggctgcctgg tgaaggacta cttccccgag cccgtgaccg tgagctggaa cagcggagcc 480 ctgaccagcg gcgtgcacac cttccccgcc gtgctgcaga gcagcggcct gtacagcctg 540 agcagcgtgg tgaccgtgcc cagcagcaac ttcggcaccc agacctacac ctgcaacgtg 600 gaccacaagc ccagcaacac caaggtggac aagaccgtgg agcggaagtg ctgcgtggag 660 tgccccccct gccctgcccc tcctgtggcc ggaccctccg tgttcctgtt cccccccaag 720 cccaaggaca ccctgatgat cagccggacc cccgaggtga cctgcgtggt ggtggacgtg 780 agccacgagg accccgaggt gcagttcaac tggtacgtgg acggcgtgga ggtgcacaac 840 gccaagacca agccccggga ggaacagttc aacagcacct tccgggtggt gtccgtgctg 900 accgtggtgc accaggactg gctgaacggc aaagaataca agtgcaaggt gtccaacaag 960 ggcctgcctg cccccatcga gaaaaccatc agcaagacaa agggccagcc cagggaaccc 1020 caggtgtaca ccctgccccc cagccgggag gaaatgacca agaaccaggt gtccctgacc 1080 tgtctggtga agggcttcta ccccagcgac atcgccgtgg agtgggagag caacggccag 1140 cccgagaaca actacaagac cacccccccc atgctggaca gcgacggcag cttcttcctg 1200 tacagcaagc tgacagtgga caagagccgg tggcagcagg gcaacgtgtt cagctgcagc 1260 gtgatgcacg aggccctgca caaccactac acccagaaga gcctgagcct gtcccccggc 1320 aaa 1323

REFERENCES

1. Crotty, S. T Follicular Helper Cell Differentiation, Function, and Roles in Disease.

Immunity 41, 529-542 (2014).

2. Crotty, S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 29, 621-663 (2011).

3. Victora, G. D. & Nussenzweig, M. C. Germinal centers. Annu Rev Immunol 30, 429- 457 (2012).

4. Crotty, S. A brief history of T cell help to B cells. Nat. Rev. Immunol. 15, 185-189 Gitlin, A. D., Shulman, Z. & Nussenzweig, M. C. Clonal selection in the germinal centre by regulated proliferation and hypermutation. Nature 509, 637-640 (2014). Vinuesa, C. G. & Cyster, J. G. How T cells earn the follicular rite of passage. Immunity 35, 671-680 (2011). Ueno, H., Banchereau, J. & Vinuesa, C. G. Pathophysiology of T follicular helper cells in humans and mice. Nat Immunol 16, 142-152 (2015). Johnston, R. J. et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 325, 1006-1010 (2009). Nurieva, R. I. et al. Bcl6 mediates the development of T follicular helper cells. Science 325, 1001-1005 (2009). Yu, D. et al. The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. Immunity 31, 457-468 (2009). Suto, A. et al. Development and characterization of IL-21 -producing CD4+ T cells. J Exp Med 205, 1369-1379 (2008). Nurieva, R. I. et al. Generation of T follicular helper cells is mediated by interleukin- 21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 29, 138-149 (2008). Eto, D. et al. IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation. PLoS < N£ 6, el7739 (2011). Choi, Y. S., Eto, D., Yang, J. A., Lao, C. & Crotty, S. Cutting edge: STAT1 is required for IL-6-mediated Bcl6 induction for early follicular helper cell differentiation. J Immunol 190, 3049-3053 (2013). Schmitt, Ν. et al. The cytokine TGF-β co-opts signaling via STAT3-STAT4 to promote the differentiation of human TFH cells. Nat Immunol (2014). doi: 10.1038/ni.2947 Ma, C. S. et al. Early commitment of naive human CD4(+) T cells to the T follicular helper (T(FH)) cell lineage is induced by IL-12. Immunol Cell Biol 87, 590-600 (2009). Schmitt, N. et al. Human dendritic cells induce the differentiation of interleukin-21- producing T follicular helper-like cells through interleukin-12. Immunity 31, 158-169

(2009) . Nakayamada, S. et al. Early Thl cell differentiation is marked by a Tfh cell-like transition. Immunity 35, 919-931 (2011). Gonzalez, R. et al. Screening the mammalian extracellular proteome for regulators of embryonic human stem cell pluripotency. Proc Natl Acad Sci USA 107, 3552-3557

(2010) . Thompson, T. B., Cook, R. W., Chapman, S. C, Jardetzky, T. S. & Woodruff, T. K. Beta A versus beta B : is it merely a matter of expression? Mol. Cell. Endocrinol. 225, 9-17 (2004). Gold, E. & Risbridger, G. Activins and activin antagonists in the prostate and prostate cancer. Mol. Cell. Endocrinol. 359, 107-112 (2012). Muttukrishna, S., Tannetta, D., Groome, N. & Sargent, I. Activin and follistatin in female reproduction. Mol. Cell. Endocrinol. 225, 45-56 (2004). Munz, B. et al. The roles of activins in repair processes of the skin and the brain. Mol. Cell. Endocrinol. 180, 169-177 (2001). Phillips, D. J., de Kretser, D. M. & Hedger, M. P. Activin and related proteins in inflammation: not just interested bystanders. Cytokine Growth Factor Rev. 20, 153- 164 (2009). Lotinun, S., Pearsall, R. S., Home, W. C. & Baron, R. Activin receptor signaling: a potential therapeutic target for osteoporosis. Curr Mol Pharmacol 5, 195-204 (2012). Aleman-Muench, G. R. & Soldevila, G. When versatility matters: activins/inhibins as key regulators of immunity. Immunol Cell Biol 90, 137-148 (2012). Dalton, S. Signaling networks in human pluripotent stem cells. Curr. Opin. Cell Biol. 25, 241-246 (2013). Beattie, G. M. et al. Activin A maintains pluripotency of human embryonic stem cells in the absence of feeder layers. Stem Cells 23, 489-495 (2005). Vallier, L., Alexander, M. & Pedersen, R. A. Activin/Nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. /. Cell. Sci. 118, 4495-4509 (2005). Sulzbacher, S., Schroeder, I. S., Truong, T. T. & Wobus, A. M. Activin A-induced differentiation of embryonic stem cells into endoderm and pancreatic progenitors-the influence of differentiation factors and culture conditions. Stem Cell Rev 5, 159-173 (2009). Jones, C. P., Gregory, L. G., Causton, B., Campbell, G. A. & Lloyd, C. M. Activin A and TGF-β promote T(H)9 cell-mediated pulmonary allergic pathology. /. Allergy Clin. Immunol. 129, 1000-10.e3 (2012). Semitekolou, M. et al. Activin-A induces regulatory T cells that suppress T helper cell immune responses and protect from allergic airway disease. J Exp Med 206, 1769- 1785 (2009). Huber, S. et al. Activin a promotes the TGF-beta-induced conversion of CD4+CD25- T cells into Foxp3+ induced regulatory T cells. J Immunol 182, 4633-4640 (2009). Ogawa, K., Funaba, M., Chen, Y. & Tsujimoto, M. Activin A functions as a Th2 cytokine in the promotion of the alternative activation of macrophages. J Immunol 177, 6787-6794 (2006). Schmitt, N. et al. IL-12 receptor βΐ deficiency alters in vivo T follicular helper cell response in humans. Blood 121, 3375-3385 (2013). Kroenke, M. A. et al. Bcl6 and Maf Cooperate To Instruct Human Follicular Helper CD4 T Cell Differentiation. J Immunol 188, 3734-3744 (2012). Chevalier, N. et al. CXCR5 Expressing Human Central Memory CD4 T Cells and Their Relevance for Humoral Immune Responses. J Immunol 186, 5556-5568 (2011). Locci, M. et al. Human circulating PD-⁺1CXCR3^~CXCR5⁺ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 39, 758-769 (2013). Saez de Guinoa, J., Barrio, L., Mellado, M. & Carrasco, Y. R. CXCL13/CXCR5 signaling enhances BCR-triggered B-cell activation by shaping cell dynamics. Blood 118, 1560-1569 (2011). Morita, R. et al. Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 34, 108-121 (2011). Travis, M. A. & Sheppard, D. TGF-β Activation and Function in Immunity. Annu Rev Immunol (2013). doi: 10.1146/annurev-immunol-032713-120257 Tsuchida, K. et al. Activin isoforms signal through type I receptor serine/threonine kinase ALK7. Mol. Cell. Endocrinol. 220, 59-65 (2004). Abe, Y., Minegishi, T. & Leung, P. C. K. Activin receptor signaling. Growth Factors 22, 105-110 (2004). Tsuchida, K. et al. Activin signaling as an emerging target for therapeutic interventions. Cell Commun. Signal 7, 15 (2009). Johnston, R. J., Choi, Y. S., Diamond, J. A., Yang, J. A. & Crotty, S. STAT5 is a potent negative regulator of TFH cell differentiation. J Exp Med 209, 243-250 (2012). Ballesteros-Tato, A. et al. Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. Immunity 36, 847-856 (2012). Oestreich, K. J., Mohn, S. E. & Weinmann, A. S. Molecular mechanisms that control the expression and activity of Bcl-6 in THl cells to regulate flexibility with a TFH-like gene profile. Nat Immunol 13, 405-411 (2012). Inman, G. J. et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 62, 65-74 (2002). Herbertz, S. et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther 9, 4479-4499 (2015). Bentebibel, S.-E. et al. Induction of ICOS+CXCR3+CXCR5+ TH Cells Correlates with Antibody Responses to Influenza Vaccination. Sci Transl Med 5, 176ra32- 176ra32 (2013). Ma, C. S. & Deenick, E. K. Human T follicular helper (Tfh) cells and disease. Immunol Cell Biol 92, 64-71 (2014). Moens, L. & Tangye, S. G. Cytokine-Mediated Regulation of Plasma Cell Generation: IL-21 Takes Center Stage. Front Immunol 5, 65 (2014). Shen, M. M. et al. Expression of LIF in transgenic mice results in altered thymic epithelium and apparent intercon version of thymic and lymph node morphologies. EMBO J 13, 1375-1385 (1994). Tran, D. Q., Ramsey, H. & Shevach, E. M. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 110, 2983- 2990 (2007). Trapnell, C, Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105-1111 (2009). Schmieder, R. & Edwards, R. Quality control and preprocessing of metagenomic datasets. Bioinformatics 27, 863-864 (2011). Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009). Anders, S., Pyl, P. T. & Huber, W. HTSeq— a Python framework to work with high- throughput sequencing data. Bioinformatics 31, 166-169 (2015). Bengtsson, H., Ray, A., Spellman, P. & Speed, T. P. A single-sample method for normalizing and combining full-resolution copy numbers from multiple platforms, labs and analysis methods. Bioinformatics 25, 861-867 (2009). Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).

Claims

WHAT IS CLAIMED IS:

1. A method for stimulating, inducing, increasing or enhancing Tfh (follicular helper) cell differentiation comprising contacting a cell with activin or a subsequence thereof or an activator of activin receptor in an amount effective to stimulate, induce, increase or enhance Tfh (follicular helper) cell differentiation.

2. A method for stimulating, inducing, increasing or enhancing Tfh (follicular helper) cell differentiation, germinal center B cell development or an antibody response, comprising administering activin or a subsequence thereof or an activator of activin receptor to a subject in amount effective to stimulate induce, increase or enhance Tfh (follicular helper) cell differentiation, germinal center B cell development or an antibody response in the subject.

3. A method for stimulating, inducing, increasing or enhancing an immune response, comprising administering activin or a subsequence thereof or an activator of activin receptor to a subject in an amount effective to stimulate, induce, increase or enhance an immune response in the subject.

4. A method for stimulating or increasing an immune response induced by a vaccine, comprising administering activin or a subsequence thereof or an activator of activin receptor to a subject in an amount effective to stimulate, induce or increase an immune response induced by the vaccine in the subject.

5. The method of claim 3 or claim 4, wherein the immune response comprises a cell- mediated or humoral immune response.

6. The method of claim 3 or claim 4, wherein the immune response stimulated, induced or increased is against a bacterial, viral, fungal or parasite pathogen.

7. The method of claim 3 or claim 4, wherein the immune response stimulated, induced or increased is against cancer.

8. The method of claim 4, wherein the vaccine comprises a bacterial, viral, fungal, parasite or cancer antigen.

9. The method of claim 4, wherein the vaccine is administered prior to, during or following administration of an activator of activin receptor or activin or subsequence thereof.

10. The method of any one of claims 1 to 9, wherein the subject is immunosuppressed or immunocompromised or has an immunodeficiency syndrome.

11. A method for vaccinating a subject against a pathogen or cancer, comprising administering activin or a subsequence thereof or an activator of activin receptor and a pathogen or pathogen antigen or cancer antigen to a subject in an amount effective to vaccinate the subject against the pathogen or cancer.

12. The method of claim 11, wherein the pathogen comprises a bacterial, viral, fungal or parasite pathogen.

13. The method of claim 11 or claim 12, wherein the method provides the subject with protection against one or more physiological conditions, disorders, illness, diseases or symptoms caused by or associated with pathogen infection or pathology or cancer.

14. The method of any one of claims claim 11 to 13, wherein activin or a subsequence thereof or activator of activin receptor is administered prior to, substantially contemporaneously with or following administration of the subject with the pathogen or pathogen antigen or cancer antigen.

15. The method any one of claims 11 to 14, wherein activin or a subsequence thereof or activator of activin receptor is administered within 2-72 hours, 2-48 hours, 4-24 hours, 4-18 hours, or 6-12 hours of administration of the subject with the pathogen or pathogen antigen or cancer antigen.

16. A method for inhibiting, decreasing or reducing Tfh (follicular helper) cell differentiation, germinal center B cell development or an antibody response, comprising administering an inhibitor of activin or activin receptor to a subject in an amount effective to inhibit, decrease or reduce Tfh (follicular helper) cell differentiation, germinal center B cell development or an antibody response in the subject.

17. A method for inhibiting or reducing an undesirable or aberrant immune response, comprising administering an inhibitor of activin or activin receptor to a subject in an amount effective to inhibit or reduce an undesirable or aberrant immune response in the subject.

18. A method for inhibiting or reducing an undesirable or aberrant inflammatory response or inflammation, comprising administering an inhibitor of activin or activin receptor to a subject in an amount effective to inhibit or reduce an undesirable or aberrant inflammatory response or inflammation in the subject.

19. The method of any one of claims 16 to 18, wherein the inhibitor binds to activin or activin Receptor.

20. The method of any one of claims 16 to 18, wherein the inhibitor comprises Follistatin.

21. The method of any one of claims 16 to 18, wherein the inhibitor comprises an antibody or an antigen binding fragment thereof that binds to activin or activin receptor, or an antisense nucleic acid sequence of activin or activin receptor.

22. The method of claim 21, wherein the antibody or fragment thereof comprises an Fab, Fab', F(ab') 2, Fv, Fd, single-chain Fv (scFv), disulfide-linked Fvs (sdFv), V , VH, trispecific (Fab ), bispecific (Fab2), diabody ((VL-VH)2 or (V -V )2), triabody (trivalent), tetrabody (tetravalent), minibody ((scFv -CH3)2), bispecific single-chain Fv (Bis-scFv), IgGdeltaCH2, scFv-Fc or (scFv)2-Fc fragment.

23. The method of claim 21, wherein the antibody is human or humanized.

24. The method of claim 21, wherein the antibody comprises one or more of M244B, M248, LS Bio LS-C195902, R&D Systems Clone 132815, R&D Systems Clone 69403, R&D Systems AF338, Novus Biologicals MM0074-7L18, GeneTex 7L18, or Ray Biotech ACVR1B.

25. The method of claim 21, wherein the inhibitor is an antibody or antigen binding fragment thereof that binds activin receptor, wherein said antibody or antigen binding fragment comprises a heavy chain variable region CDRl comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 22-35; a heavy chain variable region CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 36- 49; a heavy chain variable region CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 50-63; a light chain variable region CDRl comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 64-77; a light chain variable region CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 78-91; and a light chain variable region CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 92-105.

26. The method of claim 25 wherein the antibody or antigen binding fragment comprises:

(n) a heavy chain variable region CDR1 of SEQ ID NO: 35; a heavy chain variable region CDR2 of SEQ ID NO: 49; a heavy chain variable region CDR3 of SEQ ID NO: 63; a light chain variable region CDR1 of SEQ ID NO: 77; a light chain variable region CDR2 of SEQ ID NO: 91; and a light chain variable region CDR3 of SEQ ID NO: 105.

27. The method of claim 25 wherein the antibody or antigen binding fragment comprises a VH polypeptide sequence having at least 95% sequence identity to at least one of SEQ ID NOs: 120-133 and a VL polypeptide sequence having at least 95% sequence identity to at least one of SEQ ID NOs: 106-119.

28. The method of claim 25 wherein the antibody or antigen binding fragment comprises a full length heavy chain amino acid sequence having at least 95% sequence identity to at least one sequence selected from the group consisting of SEQ ID NOs: 167-171 and 177-181 and a full length light chain amino acid sequence having at least 95% sequence identity to at least one sequence selected from the group consisting of SEQ ID NOs: 162-166 and 172-176.

29. The method of claim 25 wherein the antibody or antigen binding fragment comprises

(n) the variable heavy chain sequence of SEQ ID NO: 133 and variable light chain sequence of SEQ ID NO: 119.

30. The method of claim 25 wherein the antibody or antigen binding fragment comprises

(g) the heavy chain sequence of SEQ ID NO: 178 and light chain sequence of SEQ ID NO: 173; (h) the heavy chain sequence of SEQ ID NO: 179 and light chain sequence of SEQ ID NO: 174;

(j) the heavy chain sequence of SEQ ID NO: 181 and light chain sequence of SEQ ID NO: 176.

31. The method of claim 21, wherein the antisense binds to a nucleic acid encoding a mammalian activin or activin receptor.

32. The method of claim 21, wherein the antisense binds to a nucleic acid encoding a human activin or activin receptor.

33. The method of claim 21, wherein the antisense binds to a nucleic acid encoding all or a portion of a human activin sequence.

34. The method of claim 21, wherein the antisense binds to a nucleic acid encoding all or a portion of a human activin receptor sequence.

35. The method of claim 17 or claim 18, wherein the undesirable or aberrant immune response or undesirable or aberrant inflammatory response or inflammation is acute or chronic.

36. The method of claim 17 or claim 18, wherein the undesirable or aberrant immune response or undesirable or aberrant inflammatory response or inflammation comprises an autoimmune disease.

37. The method of claim 36, wherein the autoimmune disease comprises: rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, diabetes mellitus, multiple sclerosis, encephalomyelitis, myasthenia gravis, systemic lupus erythematosus (SLE), autoimmune thyroiditis, atopic dermatitis, eczematous dermatitis, psoriasis, Sjogren's Syndrome, Crohn's disease, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis, asthma, allergic asthma, cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis, erythema nodosum leprosum, autoimmune uveitis, allergic encephalomyelitis, acute necrotizing hemorrhagic encephalopathy, idiopathic bilateral progressive sensorineural hearing loss, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome, idiopathic sprue, lichen planus, Graves' disease, sarcoidosis, primary biliary cirrhosis, uveitis posterior, interstitial lung fibrosis, Hashimoto's thyroiditis, autoimmune polyglandular syndrome, insulin-dependent diabetes mellitus, insulin-resistant diabetes mellitus, immune-mediated infertility, autoimmune Addison's disease, pemphigus vulgaris, pemphigus foliaceus, dermatitis herpetiformis, autoimmune alopecia, Vitiligo, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, pernicious anemia, Guillain-Barre syndrome, acute rheumatic fever, sympathetic ophthalmia, Goodpasture's syndrome, systemic necrotizing vasculitis, antiphospholipid syndrome or an allergy.

38. The method of claim 17 or claim 18, wherein the undesirable or aberrant immune response or undesirable or aberrant inflammatory response or inflammation comprises a cell mediated or humoral immune response.

39. The method of any one of claims 16 to 18, wherein production or one or more antibodies is reduced, decreased, inhibited or suppressed.

40. The method of any one of claims 1 to 39, wherein the subject is a mammal.

41. The method of any one of claims 1 to 40, wherein the subject is a human.

42. The method of any one of claims 16 to 41, wherein the activin inhibitor binds to a mammalian activin or activin receptor.

43. The method of any one of 16 to 42, wherein the activin inhibitor binds to a human activin or activin receptor sequence.

44. The method of any one of claims 1 to 43, wherein the activin comprises a dimer, comprising two polypeptides each selected from inhibin-βΑ or inhibin-βΒ.

45. The method of any one of claims 1 to 44, wherein the activin is mammalian.

46. The method of any one of claims 1 to 45, wherein the activin is human.

47. The method of any one of claims 1 to 46, wherein the activin comprises all or a portion of a human activin sequence.

48. The method of any one of claims 1 to 43, wherein the activin receptor comprises one of ActRIIA or ActRIIB

49. The method of any one of claims 1 to 48, wherein the activin receptor further comprises one of ALK2 or ALK4.

50. A peptide comprising or consisting of a subsequence of human activin sequence wherein the subsequence stimulates, induces, increases or enhances development of Tfh (follicular helper) cell differentiation, germinal center B cell development, an antibody response, an immune response or an immune response induced by a vaccine.

51. The peptide of claim 50, wherein the polypeptide is isolated or purified.

52. The peptide of claim 50, wherein the subsequence is from about 5 to 425 amino acids in length provided that the subsequence is at least one amino acid less in length than the full length activin sequence.

53. The peptide of claim 50, wherein the subsequence is from 5 to 15, 20 to 25, 25 to 50,

50 to 100, 100 to 150, 150 to 200, 200 to 300 or 300 to 425 amino acids in length provided that the subsequence or portion is at least one amino acid less in length than a full length activin sequence.

54. A pharmaceutical composition comprising the peptide of any one of claims 50 to 53.

55. The pharmaceutical composition of claim 54, wherein the composition is a vaccine

56. The pharmaceutical composition of claim 54 or claim 55, further comprising an adjuvant.

57. Use of an anti ActRII antibody or antigen binding fragment thereof selected from

(i) an antibody or antigen binding fragment thereof that binds activin receptor, wherein said antibody or antigen binding fragment comprises a heavy chain variable region CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 22- 35; a heavy chain variable region CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 36-49; a heavy chain variable region CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 50-63; a light chain variable region CDRl comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 64-77; a light chain variable region CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 78-91; and a light chain variable region CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 92-105;

(f) a heavy chain variable region CDRl of SEQ ID NO: 27; a heavy chain variable region CDR2 of SEQ ID NO: 41; a heavy chain variable region CDR3 of SEQ ID NO: 55; a light chain variable region CDR1 of SEQ ID NO: 69; a light chain variable region CDR2 of SEQ ID NO: 62; and a light chain variable region CDR3 of SEQ ID NO: 97,

(g) a heavy chain variable region CDR1 of SEQ ID NO: 28; a heavy chain variable region CDR2 of SEQ ID NO: 42; a heavy chain variable region CDR3 of SEQ ID NO: 56; a light chain variable region CDR1 of SEQ ID NO: 70; a light chain variable region CDR2 of SEQ ID NO: 84; and a light chain variable region CDR3 of SEQ ID NO: 98,

(m) a heavy chain variable region CDR1 of SEQ ID NO: 34; a heavy chain variable region CDR2 of SEQ ID NO: 48; a heavy chain variable region CDR3 of SEQ ID NO: 62; a light chain variable region CDR1 of SEQ ID NO: 76; a light chain variable region CDR2 of SEQ ID NO: 90; and a light chain variable region CDR3 of SEQ ID NO: 104, or (n) a heavy chain variable region CDR1 of SEQ ID NO: 35; a heavy chain variable region CDR2 of SEQ ID NO: 49; a heavy chain variable region CDR3 of SEQ ID NO: 63; a light chain variable region CDR1 of SEQ ID NO: 77; a light chain variable region CDR2 of SEQ ID NO: 91; and a light chain variable region CDR3 of SEQ ID NO: 105;

58. The use of claim 57 wherein the undesirable or aberrant immune response, inflammatory response or inflammation is an autoimmune disease, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, diabetes mellitus, multiple sclerosis, encephalomyelitis, myasthenia gravis, systemic lupus erythematosus (SLE), autoimmune thyroiditis, atopic dermatitis, eczematous dermatitis, psoriasis, Sjogren's Syndrome, Crohn's disease, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis, asthma, allergic asthma, cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis, erythema nodosum leprosum, autoimmune uveitis, allergic encephalomyelitis, acute necrotizing hemorrhagic encephalopathy, idiopathic bilateral progressive sensorineural hearing loss, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome, idiopathic sprue, lichen planus, Graves' disease, sarcoidosis, primary biliary cirrhosis, uveitis posterior, interstitial lung fibrosis, Hashimoto's thyroiditis, autoimmune polyglandular syndrome, insulin-dependent diabetes mellitus, insulin-resistant diabetes mellitus, immune-mediated infertility, autoimmune Addison's disease, pemphigus vulgaris, pemphigus foliaceus, dermatitis herpetiformis, autoimmune alopecia, Vitiligo, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, pernicious anemia, Guillain-Barre syndrome, acute rheumatic fever, sympathetic ophthalmia, Goodpasture's syndrome, systemic necrotizing vasculitis, antiphospholipid syndrome or an allergy.

59. An anti ActRII antibody or antigen binding fragment thereof selected from

(c) a heavy chain variable region CDR1 of SEQ ID NO: 24; a heavy chain variable region CDR2 of SEQ ID NO: 38; a heavy chain variable region CDR3 of SEQ ID NO: 52; a light chain variable region CDRl of SEQ ID NO: 66; a light chain variable region CDR2 of SEQ ID NO: 80; and a light chain variable region CDR3 of SEQ ID NO: 94,

(g) a heavy chain variable region CDRl of SEQ ID NO: 28; a heavy chain variable region CDR2 of SEQ ID NO: 42; a heavy chain variable region CDR3 of SEQ ID NO: 56; a light chain variable region CDRl of SEQ ID NO: 70; a light chain variable region CDR2 of SEQ ID NO: 84; and a light chain variable region CDR3 of SEQ ID NO: 98,

(h) a heavy chain variable region CDRl of SEQ ID NO: 29; a heavy chain variable region CDR2 of SEQ ID NO: 43; a heavy chain variable region CDR3 of SEQ ID NO: 57; a light chain variable region CDRl of SEQ ID NO: 71 a light chain variable region CDR2 of SEQ ID NO: 85; and a light chain variable region CDR3 of SEQ ID NO: 99,

(i) a heavy chain variable region CDRl of SEQ ID NO: 30; a heavy chain variable region CDR2 of SEQ ID NO: 44; a heavy chain variable region CDR3 of SEQ ID NO: 58; a light chain variable region CDRl of SEQ ID NO: 72; a light chain variable region CDR2 of SEQ ID NO: 86; and a light chain variable region CDR3 of SEQ ID NO: 100,

(j) a heavy chain variable region CDRl of SEQ ID NO: 31; a heavy chain variable region CDR2 of SEQ ID NO: 45; a heavy chain variable region CDR3 of SEQ ID NO: 59; a light chain variable region CDRl of SEQ ID NO: 73; a light chain variable region CDR2 of SEQ ID NO: 87; and a light chain variable region CDR3 of SEQ ID NO: 101, (k) a heavy chain variable region CDR1 of SEQ ID NO: 32; a heavy chain variable region CDR2 of SEQ ID NO: 46; a heavy chain variable region CDR3 of SEQ ID NO: 60; a light chain variable region CDR1 of SEQ ID NO: 74; a light chain variable region CDR2 of SEQ ID NO: 88; and a light chain variable region CDR3 of SEQ ID NO: 102,

(v) an antibody or antigen binding fragment thereof that binds activing receptor, wherein said antibody or antigen binding fragment comprises (a) the variable heavy chain sequence of SEQ ID NO: 120 and variable light chain sequence of SEQ ID NO: 106;

(m) the variable heavy chain sequence of SEQ ID NO: 132 and variable light chain sequence of SEQ ID NO: 118; or (n) the variable heavy chain sequence of SEQ ID NO: 133 and variable light chain sequence of SEQ ID NO: 119; or

60. The antibody or antigen binding fragment of claim 59 for use in treatment wherein the undesirable or aberrant immune response, inflammatory response or inflammation is an autoimmune disease, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, diabetes mellitus, multiple sclerosis, encephalomyelitis, myasthenia gravis, systemic lupus erythematosus (SLE), autoimmune thyroiditis, atopic dermatitis, eczematous dermatitis, psoriasis, Sjogren's Syndrome, Crohn's disease, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis, asthma, allergic asthma, cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis, erythema nodosum leprosum, autoimmune uveitis, allergic encephalomyelitis, acute necrotizing hemorrhagic encephalopathy, idiopathic bilateral progressive sensorineural hearing loss, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome, idiopathic sprue, lichen planus, Graves' disease, sarcoidosis, primary biliary cirrhosis, uveitis posterior, interstitial lung fibrosis, Hashimoto's thyroiditis, autoimmune polyglandular syndrome, insulin-dependent diabetes mellitus, insulin-resistant diabetes mellitus, immune-mediated infertility, autoimmune Addison's disease, pemphigus vulgaris, pemphigus foliaceus, dermatitis herpetiformis, autoimmune alopecia, Vitiligo, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, pernicious anemia, Guillain-Barre syndrome, acute rheumatic fever, sympathetic ophthalmia, Goodpasture's syndrome, systemic necrotizing vasculitis, antiphospholipid syndrome or an allergy.